Any feedback?
Information on EC 3.4.24.69 - bontoxilysin
for references in articles please use BRENDA:EC3.4.24.69Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.24.69 bontoxilysinSpecify your search results
Word Map
- 3.4.24.69
- pain
- nerve
- spastic
- dystonias
-
bonts
-
facial
- palsy
- bladder
-
overact
- limb
- botulism
- paralysis
- neuromuscular
- spasm
-
placebo
-
double-blinded
- headache
- detrusor
- migraine
- incontinence
-
cosmetic
-
relief
-
rehabilitation
-
placebo-controlled
-
neurogenic
-
sphincter
-
satisfaction
-
aesthetic
- dysphagia
- snap-25
- ptosis
-
involuntary
-
anticholinergic
- eyelid
- strabismus
-
intravesical
-
wrinkle
-
urodynamic
-
electromyography
- flexor
- masseter
- voice
-
rectus
- fissure
-
filler
- adductor
- antitoxin
-
physiotherapy
-
pneumatic
- baclofen
- molecular biology
- medicine
- drug development
- analysis
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevin (also known as neuronal vesicle-associated membrane protein, VAMP), synaptosome-associated protein of 25 kDa (SNAP25) or syntaxin. No detected action on small molecule substrates
Synonyms
botulinum toxin, botulinum toxin type a, bont-a, bont/a, onabotulinumtoxina, botulinum neurotoxin, bonta, incobotulinumtoxina, bont/b, abobotulinumtoxina, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
BoNT
-
-
-
-
BoNT/B
-
-
-
-
BoNT/C1
-
-
-
-
BoNT/D
-
-
-
-
BoNT/E
-
-
-
-
BoNT/F
-
-
-
-
BoNT/G
-
-
-
-
Bontoxilysin C1
-
-
-
-
Botulinum neurotoxin
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of peptide bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
107231-12-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abducens Nerve Diseases
A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre.
Abducens Nerve Diseases
Augmented vertical recti transposition with intraoperative botulinum toxin for complete and chronic sixth nerve palsy.
Abducens Nerve Diseases
Botulinum toxin A in the early treatment of sixth nerve palsy in type 2 diabetes.
Abducens Nerve Diseases
Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.
Abducens Nerve Diseases
Botulinum toxin for sixth nerve palsies in children with brain tumors.
Abducens Nerve Diseases
Botulinum toxin in the treatment of strabismus. A review of its use and effects.
Abducens Nerve Diseases
Botulinum toxin injection with and without electromyographic assistance for treatment of abducens nerve palsy: a pilot study.
Abducens Nerve Diseases
Botulinum toxin treatment for acute traumatic complete sixth nerve palsy.
Abducens Nerve Diseases
Botulinum toxin treatment of the sixth nerve palsy: an experience of 5-year duration in Thailand.
Abducens Nerve Diseases
Dissociated effects of botulinum toxin chemodenervation on ocular deviation and saccade dynamics in chronic lateral rectus palsy.
Abducens Nerve Diseases
Early and late botulinum toxin treatment of acute sixth nerve palsy.
Abducens Nerve Diseases
Interventions for eye movement disorders due to acquired brain injury.
Abducens Nerve Diseases
Long-term outcomes after surgical management of chronic sixth nerve palsy.
Abducens Nerve Diseases
Long-term results of vertical rectus muscle transposition and botulinum toxin for sixth nerve palsy.
Abducens Nerve Diseases
Nishida procedure associated with botulinum toxin in a long-standing complete bilateral sixth cranial nerve palsy.
Abducens Nerve Diseases
Ocular Neuromyotonia Noted after Recent Botulinum Toxin Injection for Sixth Nerve Palsy Following Resection of a Posterior Fossa Skull Base Meningioma.
Abducens Nerve Diseases
Results of a prospective randomized trial of botulinum toxin therapy in acute unilateral sixth nerve palsy.
Abducens Nerve Diseases
Sixth Nerve Palsy Following Botulinum Toxin injection for Facial Rejuvenation.
Abducens Nerve Diseases
The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine.
Abducens Nerve Diseases
The efficacy of botulinum neurotoxin A for the treatment of complete and partially recovered chronic sixth nerve palsy.
Abducens Nerve Diseases
The influence of adaptation on visual motion detection in chronic sixth nerve palsy after treatment with botulinum toxin.
Abducens Nerve Diseases
Treatment of sixth nerve palsy in adults with combined botulinum toxin chemodenervation and surgery.
Abducens Nerve Diseases
Using Botulinum Toxin A as an Adjunct in the Surgery of Large-Angle Sensory Exotropia and Abducens Nerve Palsy.
Abducens Nerve Diseases
Vertical rectus muscle transposition and botulinum toxin (Oculinum) to medial rectus for abducens palsy.
Abducens Nerve Diseases
Vertical rectus muscle transposition and botulinum toxin for complete sixth nerve palsy.
Abducens Nerve Diseases
Vertical rectus muscle transposition with intraoperative botulinum injection for treatment of chronic sixth nerve palsy.
Abducens Nerve Diseases
[Treatment of sixth nerve palsy of traumatic or tumor etiology using botulinum toxin]
Abducens Nerve Injury
Botulinum toxin augmentation as a sequential procedure for residual esotropia in traumatic sixth nerve palsy.
Abducens Nerve Injury
Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis.
Abducens Nerve Injury
Subtenon injection of botulinum toxin for treatment of traumatic sixth nerve palsy.
Abscess
A Case of Sub-Diaphragmatic Abscess after Injection of Botulinum Toxin to Treat Achalasia.
Abscess
Analgesic injection of botulinum toxin in anal fissures is efficient and can be performed safely in patients actively receiving chemotherapy.
Abscess
Comparison of the effectiveness of two treatment modalities for chronic anal fissure: Botox versus sphincterotomy.
Abscess
Extensive abscess formation after repeated paravertebral injections for the treatment of chronic back pain.
Abscess
Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures.
Acne Vulgaris
The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post-acne.
Acne Vulgaris
The use of botulinum toxin as primary or adjunctive treatment for post acne and traumatic scarring.
Acne Vulgaris
Topographic computer analysis for acne scar treatment on face accompanying biopsy study after dermal injection of hydrotoxin mixture.
Acne Vulgaris
[Long-term effect of botulinum toxin type A injection on hypertrophic acne scar].
Acquired Immunodeficiency Syndrome
A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.
Acquired Immunodeficiency Syndrome
Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection.
Acquired Immunodeficiency Syndrome
Botulinum toxin A in the treatment of hemiplegic spastic foot drop--clinical and functional outcomes.
Acquired Immunodeficiency Syndrome
Management of ophthalmic complications in surgery of the brain stem.
Acquired Immunodeficiency Syndrome
Recovery of gait and other motor functions after stroke: novel physical and pharmacological treatment strategies.
Acquired Immunodeficiency Syndrome
[Botulinum toxin to treat sweat caused sequelae in patients with hearing aids, active middle ear implants and cochlear implants.]
Acute Kidney Injury
[French Association of Urology. COVID-19: Recommendations for functional urology].
Adenocarcinoma
Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
Adenocarcinoma
Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan.
Adenocarcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Adenoma, Pleomorphic
Botulinum toxoid in the management of gustatory sweating (Frey's syndrome) after superficial parotidectomy.
Airway Obstruction
Botulinum toxin for relief of bilateral abductor paralysis of the larynx: histologic study in an animal model.
Airway Obstruction
Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia.
Airway Obstruction
Establishment of a rabbit model of obstructive sleep apnea by paralyzing the genioglossus.
Airway Obstruction
Laryngeal Botulinum Toxin Injection: Can It Be a Cause of Obstructive Sleep Apnea as an Adverse Effect?
Airway Obstruction
Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
Airway Obstruction
[Botulinum toxin type A-induced "rebalancing" in bilateral vocal cord paralysis?]
Albinism
Presence of fusion in albinism after strabismus surgery augmented with botulinum toxin (type a) injection.
Albinism, Oculocutaneous
Inadvertent Globe Penetration and Subretinal injection of Botulinum Toxin in an Oculocutaneous Albinism Patient.
Alopecia
A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males.
Alopecia
A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients.
Alopecia
Author's Reply to the comment 'The Effect of Intradermal Botulinum Toxin on Androgenetic Alopecia and Its Possible Mechanism'.
Alopecia
Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp.
Alopecia
Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia.
Alopecia
Frontal Alopecia after Repeated Botulinum Toxin Type A Injections for Forehead Wrinkles: An Underestimated Entity?
Alopecia
Is there a therapeutic effect of botulinum toxin on scalp alopecia? Physiopathology and reported cases: A systematic review of the literature.
Alopecia
Reply to: « The Effect of Intradermal Botulinum Toxin on Androgenetic Alopecia and Its Possible Mechanism ».
Alopecia
The Effect of Intradermal Botulinum Toxin on Androgenetic Alopecia and Its Possible Mechanism.
Alopecia Areata
Treatment effects of intradermal botulinum toxin type A injection on alopecia areata.
Amblyopia
Consecutive strabismus after infantile nystagmus syndrome surgery and potential risk factors.
Amyotrophic Lateral Sclerosis
Acute Deterioration of Bulbar Function After Botulinum Toxin Treatment for Sialorrhoea in Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis
ALS dysphagia pathophysiology: differential botulinum toxin response.
Amyotrophic Lateral Sclerosis
Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.
Amyotrophic Lateral Sclerosis
Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Amyotrophic Lateral Sclerosis
Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Amyotrophic Lateral Sclerosis
Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
Amyotrophic Lateral Sclerosis
Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Botulinum toxin therapy improves masseter spasticity in Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Amyotrophic Lateral Sclerosis
Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis
Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: A clinical and neurophysiological study.
Amyotrophic Lateral Sclerosis
Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Botulinum toxin-A injections vs radiotherapy for drooling in ALS.
Amyotrophic Lateral Sclerosis
Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection.
Amyotrophic Lateral Sclerosis
Imaging three-dimensional innervation zone distribution in muscles from M-wave recordings.
Amyotrophic Lateral Sclerosis
Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.
Amyotrophic Lateral Sclerosis
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Manually guided botulinum toxin type A submandibular injections for the treatment of sialorrhea in tube-fed patients with advanced amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Parotid gland injections of botulinum toxin a are effective in treating sialorrhea in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study.
Amyotrophic Lateral Sclerosis
Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.
Amyotrophic Lateral Sclerosis
Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
The Role of Radiation Therapy and Botulinum Toxin Injections in the Management of Sialorrhea in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review.
Amyotrophic Lateral Sclerosis
Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: Efficacy and possible mechanisms.
Amyotrophic Lateral Sclerosis
Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy.
Amyotrophic Lateral Sclerosis
[Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis.]
Anaphylaxis
Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection.
Anaphylaxis
Separation of slow reacting substance of anaphylaxis (SRS-A) from human lung into four biologically active fractions.
Anaphylaxis
Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Aneurysm
Hemifacial Spasm due to Compression of the Posterior Inferior Cerebellar Artery Aneurysm Treated with Botulinum Toxin Type-A: A Case Report.
Aneurysm
Horner's syndrome and sixth nerve paresis secondary to a petrous internal carotid artery aneurysm.
Aneurysm, False
Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia.
Aneurysm, False
Pseudoaneurysm of the superficial temporal artery: a complication of botulinum toxin injection.
Aneurysm, Infected
Mycotic aneurysm of the distal thoracic aorta after botulinum toxin injection for esophageal dysmotility.
Angiomatosis
A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use.
Anisometropia
Consecutive strabismus after infantile nystagmus syndrome surgery and potential risk factors.
Ankylosis
Effect of Preoperative Intramuscular Injection of Botulinum Toxin A on Pain and Mouth Opening After Surgical Intervention in Temporomandibular Joint Ankylosis Cases: A Controlled Clinical Trial.
Ankylosis
Intramuscular injection of botulinum toxin as an adjunct to total joint replacement in temporomandibular joint ankylosis: preliminary reports.
Ankylosis
Myositis ossificans traumatica of the temporalis muscle: a case report and diagnostic considerations.
Anthrax
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
Anthrax
Application of NMR methods to identify detection reagents for use in development of robust nanosensors.
Anthrax
Bioterrorism in Canada: An economic assessment of prevention and postattack response.
Anthrax
Clostridium difficile toxins A and B: Receptors, pores, and translocation into cells.
Anthrax
Current therapy and the development of therapeutic options for the treatment of diseases due to bacterial agents of potential biowarfare and bioterrorism.
Anthrax
Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences.
Anthrax
Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.
Anthrax
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Anthrax
Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Anthrax
Neurological aspects of biological and chemical terrorism: a review for neurologists.
Anthrax
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Anthrax
Technological advancements for the detection of and protection against biological and chemical warfare agents.
Anthrax
Terrorism-Related Chemical, Biological, Radiation, and Nuclear Attacks: A Historical Global Comparison Influencing the Emergence of Counter-Terrorism Medicine.
Anthrax
Ultrasensitive detection of protease activity of anthrax and botulinum toxins by a new PCR-based assay.
Anthrax
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis.
Aortic Rupture
Mycotic aneurysm of the distal thoracic aorta after botulinum toxin injection for esophageal dysmotility.
Aphasia
Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features.
Aphasia
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Aphasia
[Botulinum toxin injection into the cricopharyngeal muscle for dysphagia: report of 2 successful cases]
Aphonia
Botulinum toxin injection for failed tracheo-oesophageal voice in laryngectomees: the Sunderland experience.
Apnea
Establishment of a rabbit model of obstructive sleep apnea by paralyzing the genioglossus.
Apraxias
Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Apraxias
Botulinum toxin for treating unilateral apraxia of eyelid opening in a patient with congenital myotonia.
Apraxias
Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening.
Apraxias
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Apraxias
Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases.
Apraxias
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Apraxias
Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.
Apraxias
Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.
Apraxias
Levator aponeurosis dehiscence in a patient treated with botulinum toxin for blepharospasms and eyelid apraxia.
Apraxias
Polytetrafluoroethylene frontalis suspension in blepharospasm with eyelid apraxia: an effective and well-tolerated adjunct to botulinum toxin therapy.
Apraxias
Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.
Apraxias
Reply: Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Apraxias
What is new in the era of focal dystonia treatment? Botulinum injections and more.
Arrhythmias, Cardiac
Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia?
Arthralgia
Anti-inflammatory Effects of Botulinum Toxin Type A in a Complete Freund's Adjuvant-Induced Arthritic Knee Joint of Hind Leg on Rat Model.
Arthralgia
Botulinum Toxin Injection of a Patient with Intractable Acromio-Clavicular Joint Pain due to Distal Clavicular Osteolysis.
Arthralgia
Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study.
Arthralgia
Clinical effectiveness of botulinum toxin A compared to a mixture of steroid and local anesthetics as a treatment for sacroiliac joint pain.
Arthralgia
Does Adjunctive Botulinum Toxin A Reduce Pain Scores When Combined With Temporomandibular Joint Arthroscopy for the Treatment of Concomitant Temporomandibular Joint Arthralgia and Myofascial Pain?
Arthralgia
Effect of intra-articular Botulinum toxin injections on temporo-mandibular joint pain.
Arthralgia
Efficacy of Intra-articular Botulinum Toxin in Osteo-articular Joint Pain: A Meta-analysis of Randomized Controlled Trials.
Arthralgia
Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases.
Arthralgia
Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
Arthralgia
Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: A randomized, double-blinded, placebo-controlled clinical trial.
Arthralgia
Intra-articular Botulinum Toxin Type A: A new approach to treat arthritis joint pain.
Arthralgia
Intra-articular injections of botulinum toxin a for refractory joint pain: A systematic review and meta-analysis.
Arthralgia
Intramuscular botulinum toxin injection additional to arthrocentesis in the management of temporomandibular joint pain.
Arthralgia
Long term effects of intra-articular botulinum toxin A for refractory joint pain.
Arthralgia
Multimodal treatment including lumbar facet joint denervation for severe low back pain in patients with neuromuscular disorders.
Arthralgia
Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain.
Arthralgia
The analgesic effect of intraarticular OnabotulinumtoxinA in a female murine model of collagenase induced chronic degenerative monoarthritis.
Arthralgia
The Use of Botulinum Toxin for the Treatment of Chronic Joint Pain: Clinical and Experimental Evidence.
Arthralgia
Therapeutic Effects of Intra-articular Botulinum Neurotoxin Versus Physical Therapy in Knee Osteoarthritis.
Arthralgia
[Clinical assessment of the effectiveness of botulinum toxin A in the treatment of temporomandibular joint pain dysfunction syndrome].
Arthritis
Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain.
Arthritis
Botulinum toxin type A ameliorates adjuvant-arthritis pain by inhibiting microglial activation-mediated neuroinflammation and intracellular molecular signaling.
Arthritis
Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats.
Arthritis
Effects of intra-articular botulinum toxin type A (Botox) in dogs with chronic osteoarthritis.
Arthritis
Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study.
Arthritis
Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
Arthritis
Intra-articular Botulinum Toxin Type A: A new approach to treat arthritis joint pain.
Arthritis
Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats.
Arthritis
Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis.
Arthritis
Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain.
Arthritis
The analgesic effect of intraarticular OnabotulinumtoxinA in a female murine model of collagenase induced chronic degenerative monoarthritis.
Arthritis, Experimental
Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis.
Arthritis, Rheumatoid
Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis.
Arthritis, Rheumatoid
Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases.
Arthrogryposis
Partial tarsal arthrodesis and botulinum toxin A injection for correction of tarsal arthrogryposis in a cat.
Asthma
Abnormal vocal cord movement treated with botulinum toxin in patients with asthma resistant to optimised management.
Asthma
Development of a novel enzyme-linked immunosorbent assay for blood and urinary eosinophil-derived neurotoxin: a preliminary study in patients with bronchial asthma.
Asthma
Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker.
Asthma
Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma.
Asthma
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Asthma
Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics.
Astigmatism
The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm.
Ataxia
An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders.
Ataxia
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Ataxia
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Ataxia
Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
Ataxia
Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
Ataxia
Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review.
Ataxia
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.
Ataxia
Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Ataxia
Comparing a transrectal ultrasound-guided with a cystoscopy-guided botulinum toxin a injection in treating detrusor external sphincter dyssynergia in spinal cord injury.
Ataxia
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA).
Ataxia
Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury.
Ataxia
Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia.
Ataxia
Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results.
Ataxia
Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update.
Ataxia
Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Ataxia
Is botulinum toxin type a intraprostatic injections really effective in patients with urinary retention?
Ataxia
OnabotulinumtoxinA injections in detrusor facilitate self-catheterisation in a patient with paraplegia and bladder outlet dyssynergia.
Ataxia
Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury.
Ataxia
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.
Ataxia
Re: Goel S et al. Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis. Urology. 2020. doi:10.1016/j.urology.2020.03.007.
Ataxia
Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.
Ataxia
Surgical decision-making in the management of children with intractable functional constipation: What are we doing and are we doing it right?
Ataxia
The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.
Ataxia
The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
Ataxia
Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Ataxia
Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia.
Ataxia
Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Ataxia
Transcutaneous needle-free injection of botulinum toxin: a novel treatment of childhood constipation and anal fissure.
Ataxia
Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance.
Ataxia
Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury.
Ataxia
Treatment of Detrusor External Sphincter Dyssynergia Using Ultrasound-Guided Trocar Catheter Transurethral Botulinum Toxin A Injection in Men With Spinal Cord Injury.
Ataxia
Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin.
Ataxia
Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis.
Ataxia
[Botulinum A toxin and detrusor sphincter dyssynergia: retrospective study of 47 patients].
Ataxia
[Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia]
Ataxia
[What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?]
Atrial Fibrillation
Acute delayed gastric emptying after ablation of atrial fibrillation: treatment with botulinum toxin injection.
Atrial Fibrillation
Botulinum toxin injection in epicardial autonomic Ganglia temporarily suppresses vagally mediated atrial fibrillation.
Atrial Fibrillation
Botulinum toxin injection in epicardial fat pads can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot study.
Atrial Fibrillation
Botulinum toxin injection in the autonomic ganglion plexi to prevent postoperative atrial fibrillation: More than a cosmetic treatment.
Atrial Fibrillation
Botulinum Toxin Injection into Epicardial Fat Pads: A Promising Potential Modality for Prevention of Postoperative Atrial Fibrillation After Cardiac Surgery.
Atrial Fibrillation
Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models.
Atrial Fibrillation
Cholinergic activity regulates the secretome of epicardial adipose tissue: Association with atrial fibrillation.
Atrial Fibrillation
Effect of botulinum toxin on inducibility and maintenance of atrial fibrillation in ovine myocardial tissue.
Atrial Fibrillation
Effect of botulinum toxin on inducibility and maintenance of atrial fibrillation in ovine myocardial tissue: Response to letter to the editor.
Atrial Fibrillation
Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open-heart surgery.
Atrial Fibrillation
Letter by Pearman et al. regarding article "Effect of botulinum toxin on inducibility and maintenance of atrial fibrillation in ovine myocardial tissue".
Atrial Fibrillation
Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One-Year Follow-Up of a Randomized Pilot Study.
Atrial Fibrillation
Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: Three-year follow-up of a randomized study.
Atrial Fibrillation
Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery.
Atrial Fibrillation
Temporary Suppression of Cardiac Ganglionated Plexi Leads to Long-Term Suppression of Atrial Fibrillation: Evidence of Early Autonomic Intervention to Break the Vicious Cycle of "AF Begets AF".
Autonomic Dysreflexia
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Autonomic Dysreflexia
Effect of intravesical botulinum toxin injection on symptoms of autonomic dysreflexia in a patient with chronic spinal cord injury: a case report.
Autonomic Dysreflexia
Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor.
Autonomic Dysreflexia
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Autonomic Dysreflexia
Intradetrusor OnabotulinumtoxinA Injections Ameliorate Autonomic Dysreflexia while Improving Lower Urinary Tract Function and Urinary Incontinence-Related Quality of Life in Individuals with Cervical and Upper Thoracic Spinal Cord Injury.
Autonomic Dysreflexia
Intravesical Botulinum Toxin for Persistent Autonomic Dysreflexia in a Pediatric Patient.
Autonomic Dysreflexia
Long-term neurogenic lower urinary tract dysfunction: A case of cardiovascular nightmares.
Autonomic Dysreflexia
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
Autonomic Nervous System Diseases
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system.
Autonomic Nervous System Diseases
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.
Autonomic Nervous System Diseases
Clinical comparison of botulinum toxin in motor and autonomic disorders: Similarities and differences.
Autonomic Nervous System Diseases
[Therapeutic use of botulinum toxin in otorhinolaryngology. 2. Movement disorders of craniocervical musculature (except for mimetic musculature) and disorders of the autonomic nervous system]
Bacterial Infections
Eutrophication and bacterial pathogens as risk factors for avian botulism outbreaks in wetlands receiving effluents from urban wastewater treatment plants.
Bacteriuria
Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity.
Bacteriuria
Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A.
Bacteriuria
Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?
Bacteriuria
The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.
Bell Palsy
Abobotulinum Toxin A (Dysport) and Botulinum Toxin Type A (Botox) for Purposeful Induction of Eyelid Ptosis.
Bell Palsy
Bell's palsy: management of sequelae using EMG rehabilitation, botulinum toxin, and surgery.
Bell Palsy
[Botulinum toxin injection effective for post-peripheral facial nerve palsy synkinesis]
Birth Injuries
Botulinum toxin type A as an adjunct to the surgical treatment of the medial rotation deformity of the shoulder in birth injuries of the brachial plexus.
Birth Injuries
Effectiveness and safety of early intramuscular botulinum toxin injections to prevent shoulder deformity in babies with brachial plexus birth injury (POPB-TOX), a randomised controlled trial: study protocol.
Birth Injuries
Outcomes of Botulinum Toxin Injection for Shoulder Internal Rotation Contractures in Infants with Brachial Plexus Birth Injury.
Birth Injuries
The Use of Botulinum Toxin Injection for Brachial Plexus Birth Injuries: A Systematic Review of the Literature.
Blepharoptosis
Abobotulinum Toxin A (Dysport) and Botulinum Toxin Type A (Botox) for Purposeful Induction of Eyelid Ptosis.
Blepharoptosis
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Blepharoptosis
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Blepharoptosis
Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options.
Blepharoptosis
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Blepharoptosis
Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Blepharoptosis
Eyelid Make-Up to Manage Transient Blepharoptosis After Botulinum Toxin Injection.
Blepharoptosis
GaAs laser treatment of bilateral eyelid ptosis due to complication of botulinum toxin type A injection.
Blepharoptosis
How to avoid eyelid ptosis when injecting botulinum toxin into the corrugators.
Blepharoptosis
Safe botulinum toxin type A injection in patients with history of eyelid ptosis.
Blepharoptosis
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
Blepharoptosis
Safety Profile of Combined Same-Day Treatment for Botulinum Toxin With Full Face Nonablative Fractionated Laser Resurfacing.
Blepharoptosis
Temporary management of upper lid ptosis, lid malposition, and eyelid fissure asymmetry with botulinum toxin type A.
Blepharoptosis
The "Ram's Horns Sign": A Case Report of an Unusual Side Effect of OnabotulinumtoxinA in a Chronic Migraine Patient.
Blepharoptosis
[Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review.]
Blepharospasm
A case of thrombosis of subcutaneous anterior chest veins (Mondor's disease) as an unusual complication of botulinum type A injection.
Blepharospasm
A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Blepharospasm
A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin.
Blepharospasm
A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Blepharospasm
A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Blepharospasm
A five-year analysis of botulinum toxin type A injections: some unusual features.
Blepharospasm
A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin(®): A new botulinum neurotoxin A.
Blepharospasm
A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
Blepharospasm
A Survey of Current Blepharospasm Treatment Patterns Among Oculoplastic Surgeons.
Blepharospasm
Acute angle closure following periorbital botulinum toxin injection in a patient with retinitis pigmentosa.
Blepharospasm
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm.
Blepharospasm
Advancement of the frontalis muscle for ptosis of the brow associated with essential blepharospasm.
Blepharospasm
Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery.
Blepharospasm
An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm.
Blepharospasm
Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
Blepharospasm
Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients.
Blepharospasm
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Blepharospasm
Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment.
Blepharospasm
Associative stimulation of the supraorbital nerve fails to induce timing-specific plasticity in the human blink reflex.
Blepharospasm
Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature.
Blepharospasm
Blepharospasm and Apraxia of Eyelid Opening Associated with Anti-Hu Paraneoplastic Antibodies A Case Report.
Blepharospasm
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
Blepharospasm
Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
Blepharospasm
Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.
Blepharospasm
Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin.
Blepharospasm
Blepharospasm plus Cervical Dystonia with Predominant Anterocollis: A Distinctive Subphenotype of Segmental Craniocervical Dystonia?
Blepharospasm
Blepharospasm with non-satisfactory response to treatment: Our experience with IncobotulinumtoxinA.
Blepharospasm
Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.
Blepharospasm
Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin.
Blepharospasm
Botulinum isn't just a poison anymore. Botulinum toxin in treatment of strabismus and essential blepharospasm.
Blepharospasm
Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Payment policy perspectives.
Blepharospasm
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Blepharospasm
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Blepharospasm
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
Blepharospasm
Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Blepharospasm
Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Blepharospasm
Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.
Blepharospasm
Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm.
Blepharospasm
Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
Blepharospasm
Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach.
Blepharospasm
Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
Blepharospasm
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Blepharospasm
Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening.
Blepharospasm
Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
Blepharospasm
Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
Blepharospasm
Botulinum toxin in the management of blepharospasm: current evidence and recent developments.
Blepharospasm
Botulinum toxin in the treatment of paralytic strabismus and essential blepharospasm.
Blepharospasm
Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report.
Blepharospasm
Botulinum toxin injections for treatment of blepharospasm and hemifacial spasm.
Blepharospasm
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
Blepharospasm
Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia.
Blepharospasm
Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
Blepharospasm
Botulinum toxin therapy for strabismus and blepharospasm: Bascom Palmer Eye Institute experience.
Blepharospasm
Botulinum toxin treatment for blepharospasm associated with myasthenia gravis.
Blepharospasm
Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion.
Blepharospasm
Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
Blepharospasm
Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
Blepharospasm
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Blepharospasm
Botulinum toxin type A purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force.
Blepharospasm
Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.
Blepharospasm
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Blepharospasm
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
Blepharospasm
Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm.
Blepharospasm
Can methylphenidate objectively provide relief in patients with uncontrolled blepharospasm? A pilot study using surface electromyography.
Blepharospasm
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Blepharospasm
Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Blepharospasm
Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Blepharospasm
Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China.
Blepharospasm
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Blepharospasm
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Blepharospasm
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
Blepharospasm
Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience.
Blepharospasm
Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
Blepharospasm
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
Blepharospasm
Cluster Headache Associated with Secondary Unilateral Blepharospasm: A Case Report and Review of the Literature.
Blepharospasm
Cognitive performance after facial botulinum toxin treatment in a cohort of neurological patients - an exploratory study.
Blepharospasm
Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.
Blepharospasm
Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm.
Blepharospasm
Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial.
Blepharospasm
Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis.
Blepharospasm
Comparison of pain scores with 30-gauge and 32-gauge needles for periocular botulinum toxin type a injections.
Blepharospasm
Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
Blepharospasm
Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Blepharospasm
Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Blepharospasm
Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.
Blepharospasm
Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm.
Blepharospasm
Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Blepharospasm
Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essential Blepharospasm: A Randomized Controlled Trial.
Blepharospasm
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Blepharospasm
Content of botulinum neurotoxin in botox(r)/vistabel(r), dysport(r)/azzalure(r), and xeomin(r)/bocouture(r).
Blepharospasm
Correction: Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
Blepharospasm
Cortical gray matter changes in primary blepharospasm: A voxel-based morphometry study.
Blepharospasm
Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study.
Blepharospasm
Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin.
Blepharospasm
Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Blepharospasm
Differential section of the seventh nerve as a tertiary procedure for the treatment of benign essential blepharospasm.
Blepharospasm
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm.
Blepharospasm
Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
Blepharospasm
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
Blepharospasm
Effect of Botulinum Toxin A Treatment on Eyelid Pressure in Eyes with Blepharospasm.
Blepharospasm
Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity.
Blepharospasm
Effect of upper eyelid myectomy on subsequent chemodenervation in the management of benign essential blepharospasm.
Blepharospasm
Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.
Blepharospasm
Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin.
Blepharospasm
Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Blepharospasm
Effects of Repeated Eyelid Injections with Botulinum Toxin A on Innervation of Treated Muscles in Patients with Blepharospasm.
Blepharospasm
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
Blepharospasm
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial.
Blepharospasm
Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review.
Blepharospasm
Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.
Blepharospasm
Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
Blepharospasm
Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm.
Blepharospasm
Efficacy of botulinum toxin in benign essential Blepharospasm: Desirable & undesirable effects.
Blepharospasm
Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
Blepharospasm
Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Blepharospasm
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options.
Blepharospasm
Efficacy of Repetitive Transcranial Magnetic Stimulation Combined with Botulinum Toxin Type A for Benign Essential Blepharospasm Patients Accompanied by Anxiety and Depression.
Blepharospasm
Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type a in patients with blepharospasm.
Blepharospasm
Electrophysiological studies in patients with blepharospasm before and after botulinum toxin A therapy.
Blepharospasm
Epidemiology of primary focal dystonias in the western area of tottori prefecture in Japan: Comparison with prevalence evaluated in 1993.
Blepharospasm
Erratum to: 'Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial'.
Blepharospasm
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Blepharospasm
Exploratory structural assessment in craniocervical dystonia: Global and differential analyses.
Blepharospasm
Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin.
Blepharospasm
FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.
Blepharospasm
Fifteen-year experience in treating blepharospasm with botox or dysport: same toxin, two drugs.
Blepharospasm
Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Blepharospasm
Follow-up of patients with essential blepharospasm who underwent eyelid protractor myectomy at the Mayo Clinic from 1980 through 1995.
Blepharospasm
Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therapy. First results.
Blepharospasm
Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results.
Blepharospasm
Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.
Blepharospasm
Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
Blepharospasm
Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm.
Blepharospasm
Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm.
Blepharospasm
High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?
Blepharospasm
Histologic features of human orbicularis oculi treated with botulinum A toxin.
Blepharospasm
Human herpesvirus type 8-positive facial angiosarcoma developing at the site of botulinum toxin injection for blepharospasm.
Blepharospasm
Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Blepharospasm
Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
Blepharospasm
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Blepharospasm
IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
Blepharospasm
Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
Blepharospasm
Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy.
Blepharospasm
Levator aponeurosis dehiscence in a patient treated with botulinum toxin for blepharospasms and eyelid apraxia.
Blepharospasm
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Blepharospasm
Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome.
Blepharospasm
Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
Blepharospasm
Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm.
Blepharospasm
Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
Blepharospasm
Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
Blepharospasm
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Blepharospasm
Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
Blepharospasm
Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.
Blepharospasm
Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections.
Blepharospasm
Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Blepharospasm
Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.
Blepharospasm
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia.
Blepharospasm
Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.
Blepharospasm
Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Blepharospasm
Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.
Blepharospasm
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
Blepharospasm
Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.
Blepharospasm
Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle.
Blepharospasm
Motor nerve sprouting in human orbicularis muscle after botulinum A injection.
Blepharospasm
Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox.
Blepharospasm
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
Blepharospasm
Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm.
Blepharospasm
Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm.
Blepharospasm
Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Blepharospasm
Orbicularis Oculi Myectomy as a Treatment for Blepharospasm in a Case of Schwartz Jampel Syndrome.
Blepharospasm
Orbicularis oculi myo-osseous fixation: a new treatment for benign essential blepharospasm and blepharospasm associated with diffuse facial dystonia (meige syndrome).
Blepharospasm
Patient-Reported Benefit From Botulinum Toxin Treatment for Essential Blepharospasm: Using 2 Assessment Scales.
Blepharospasm
Periorbital injections of botulinum toxin a: a novel therapeutic option for convergence spasm in neuropsychiatric disorders.
Blepharospasm
Personality traits associated with blepharospasm: A comparison with healthy subjects, patients with facial hemispasm and patients with hyperhidrosis.
Blepharospasm
Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.
Blepharospasm
Polytetrafluoroethylene frontalis suspension in blepharospasm with eyelid apraxia: an effective and well-tolerated adjunct to botulinum toxin therapy.
Blepharospasm
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Blepharospasm
Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.
Blepharospasm
Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients.
Blepharospasm
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.
Blepharospasm
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.
Blepharospasm
Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Blepharospasm
Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm.
Blepharospasm
Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
Blepharospasm
Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
Blepharospasm
Regional Diffusion of Botulinum Toxin in Facial Muscles: A Rando-mised Double-blind Study and a Consideration for Clinical Studies with Split-face Design.
Blepharospasm
Relationship between various clinical outcome assessments in patients with blepharospasm.
Blepharospasm
Reply: Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Blepharospasm
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Blepharospasm
Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections.
Blepharospasm
Scientific skepticism and new discoveries: an analysis of a report of zinc/phytase supplementation and the efficacy of botulinum toxins in treating cosmetic facial rhytides, hemifacial spasm and benign essential blepharospasm.
Blepharospasm
Serial SFEMG studies of orbicularis oculi muscle after the first administration of botulinum toxin.
Blepharospasm
Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm.
Blepharospasm
Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology.
Blepharospasm
Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm.
Blepharospasm
Surgical technique for patients with the apractic type of essential blepharospasm: case report.
Blepharospasm
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
Blepharospasm
Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
Blepharospasm
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm.
Blepharospasm
Tardive Blepharospasm May Respond to Bilateral Pallidal Deep Brain Stimulation.
Blepharospasm
Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Blepharospasm
The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm.
Blepharospasm
The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
Blepharospasm
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Blepharospasm
The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment.
Blepharospasm
The good toxin: 10?years of experience with botulinum toxin A in the treatment of benign essential blepharospasm.
Blepharospasm
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
Blepharospasm
The orbicularis stripping operation for intractable blepharospasm: surgical results in eighteen patients.
Blepharospasm
The pupillary effects of retrobulbar injection of botulinum toxin A (oculinum) in albino rats.
Blepharospasm
The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
Blepharospasm
The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog.
Blepharospasm
The use of botulinum toxin in the medical management of benign essential blepharospasm.
Blepharospasm
Treatment Effects of Botulinum Toxin Injection and Acupuncture on Blepharospasm Assessed by the Change in Lower Eyelid Tension.
Blepharospasm
Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study.
Blepharospasm
Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Blepharospasm
Treatment of Blepharospasm in Schwartz-Jampel Syndrome: Botulinum Toxin A Injection or Surgery.
Blepharospasm
Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Blepharospasm
Treatment of blepharospasm with medication, surgery and type A botulinum toxin.
Blepharospasm
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.
Blepharospasm
Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
Blepharospasm
Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis.
Blepharospasm
Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study.
Blepharospasm
Unilateral pallidotomy for blepharospasm refractory to botulinum toxin injections.
Blepharospasm
Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening.
Blepharospasm
Upper lid orbicularis oculi muscle strip and sequential brow suspension with autologous fascia lata is beneficial for selected patients with essential blepharospasm.
Blepharospasm
Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
Blepharospasm
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
Blepharospasm
Use of botulinum toxin injections to treat peripheral stimulator induced facial muscle twitching: a case report.
Blepharospasm
Use of botulinum toxin to treat blepharospasm in a 16-year-old with a dystonic syndrome.
Blepharospasm
Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children.
Blepharospasm
Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?
Blepharospasm
Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection.
Blepharospasm
What is new in the era of focal dystonia treatment? Botulinum injections and more.
Blepharospasm
[Ameliorating strabismus, preventing blepharospasm: botulinum toxin can do more than smooth wrinkles]
Blepharospasm
[Botulinum toxin in blepharospasm, in hemifacial spasm, and in cervical dystonia: results in 33 patients]
Blepharospasm
[Botulinum toxin type A (BOTOX) for treatment of blepharospasm: an open label, dose-response study]
Blepharospasm
[Clinical and psychological factors influencing the efficacy of botulinum toxin in the treatment of hemifacial spasm and blepharospasm]
Blepharospasm
[Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
Blepharospasm
[Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm]
Blepharospasm
[Diplopia following subcutaneous injections of botulinum toxin for cosmetic or medical use].
Blepharospasm
[Efficacy and side-effects of the botulinum toxin A treatment in patients with focal dystonia.]
Blepharospasm
[Essential blepharospasm : Practice-oriented therapy with botulinum toxin employing reduced treatment intervals].
Blepharospasm
[Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review.]
Blepharospasm
[Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment]
Blepharospasm
[Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients]
Blepharospasm
[Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A]
Blepharospasm
[Long-term treatment with botulinum toxin: dosage, treatment schedules and costs]
Blepharospasm
[Our experience with English botulinum toxin in the treatment of blepharospasm]
Blepharospasm
[Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A]
Blepharospasm
[Torticollis spasmodicus, blepharospasm and hemifacial spasm. Subjective evaluation of therapy by patients]
Blepharospasm
[Treatment of blepharospasm and facial hemispasm by injection of botulinum toxin]
Blepharospasm
[Treatment of blepharospasm and facial hemispasm with botulinum toxin.Apropos of 58 injections in 22 patients]
Blepharospasm
[Treatment of blepharospasm: injection of botulinum toxin or surgical treatment?]
Blepharospasm
[Treatment of dystonic blepharospasm and hemifacial spasm with botulinum toxin: preliminary studies]
Blepharospasm
[What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?]
Blindness
Acute angle closure following periorbital botulinum toxin injection in a patient with retinitis pigmentosa.
Blindness
Botulinum toxin for temporary corneal protection after surgery for vestibular schwannoma.
Blindness
Transverse facial artery: Its role in blindness after cosmetic filler and botulinum toxin injections.
Blister
A Vector Force Model of Upper Eyelid Position in the Setting of a Trabeculectomy Bleb.
Blister
Microbotulinum: A Quantitative Evaluation of Aesthetic Skin Improvement in 62 Patients.
Blister
The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
Bluetongue
Development of a comparative risk ranking system for agents posing a bioterrorism threat to human or animal populations.
Bone Cysts
Practice pearl: a novel use of botulinum toxin for unicameral bone cyst ablation.
Bone Diseases, Metabolic
A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia.
Bone Diseases, Metabolic
Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice.
Bone Diseases, Metabolic
Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review.
Bone Diseases, Metabolic
Disuse osteopenia induced by botulinum toxin is similar in skeletally mature young and aged female C57BL/6J mice.
Bone Diseases, Metabolic
Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study.
Bone Diseases, Metabolic
Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling.
Bone Diseases, Metabolic
Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.
Bone Diseases, Metabolic
Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.
Bone Resorption
Masseter muscle atrophy impairs bone quality of the mandibular condyle but not the alveolar process early after induction.
Bone Resorption
Muscle Paralysis Induces Bone Marrow Inflammation and Predisposition to Formation of Giant Osteoclasts.
Botulism
A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.
Botulism
A capillary electrophoresis method to assay catalytic activity of botulinum neurotoxin serotypes: implications for substrate specificity.
Botulism
A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity.
Botulism
A case of infant botulism with a possible link to infant formula milk powder: evidence for the presence of more than one strain of Clostridium botulinum in clinical specimens and food.
Botulism
A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.
Botulism
A monoclonal antibody based capture ELISA for botulinum neurotoxin serotype B: toxin detection in food.
Botulism
A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
Botulism
A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.
Botulism
A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins.
Botulism
A novel multiplex PCR method for Clostridium botulinum neurotoxin type A gene cluster typing.
Botulism
A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin.
Botulism
A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins.
Botulism
A penicillin- and metronidazole-resistant Clostridium botulinum strain responsible for an infant botulism case.
Botulism
A Quantum Dot Nanobiosensor for Rapid Detection of Botulinum Neurotoxin Serotype E.
Botulism
A Rapid, Sensitive, and Portable Biosensor Assay for the Detection of Botulinum Neurotoxin Serotype A in Complex Food Matrices.
Botulism
A sensitive and useful radioimmunoassay for neurotoxin and its haemagglutinin complex from Clostridium botulinum.
Botulism
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.
Botulism
A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.
Botulism
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
Botulism
A two-stage multiplex method for quantitative analysis of botulinum neurotoxins type A, B, E, and F by MALDI-TOF mass spectrometry.
Botulism
A unique restriction site in the flaA gene allows rapid differentiation of group I and group II Clostridium botulinum strains by PCR-restriction fragment length polymorphism analysis.
Botulism
Accelerated intoxication of GABAergic synapses by botulinum neurotoxin A disinhibits stem cell-derived neuron networks prior to network silencing.
Botulism
Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization.
Botulism
Adeno-associated virus transfer of a gene encoding SNAP-25 resistant to botulinum toxin A attenuates neuromuscular paralysis associated with botulism.
Botulism
An adenoviral vector-based mucosal vaccine is effective in protection against botulism.
Botulism
An epitopic approach to designing and characterization of a multiple antigenic polypeptide against Botulinum neurotoxins A and E
Botulism
An innovative molecular detection tool for tracking and tracing Clostridium botulinum types A, B, E, F and other botulinum neurotoxin producing Clostridia based on the GeneDisc cycler.
Botulism
An Integrated Pharmacophore/Docking/3D-QSAR Approach to Screening a Large Library of Products in Search of Future Botulinum Neurotoxin A Inhibitors.
Botulism
Analysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype.
Botulism
Analysis of Clostridium botulinum serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing.
Botulism
Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.
Botulism
Analysis of the Neurotoxin Complex Genes in Clostridium botulinum A1-A4 and B1 Strains: BoNT/A3, /Ba4 and /B1 Clusters Are Located within Plasmids.
Botulism
Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.
Botulism
Antimicrobial susceptibility of 260 Clostridium botulinum types A, B, Ba and Bf strains and a neurotoxigenic Clostridium baratii type F strain isolated from California infant botulism patients.
Botulism
Application of nested polymerase chain reaction for the rapid diagnosis of infant botulism type B.
Botulism
Application of PCR to a clinical and environmental investigation of a case of equine botulism.
Botulism
Attempts to quantity Clostridium botulinum type A toxin and antitoxin in serum of two cases of infant botulism in Japan.
Botulism
Barbiturate ingestion in three adult captive tigers (Panthera tigris) and concomitant fatal botulism of one.
Botulism
Beltless translocation domain of botulinum neurotoxin A embodies a minimum ion-conductive channel.
Botulism
Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism.
Botulism
BotR/A and TetR are alternative RNA polymerase sigma factors controlling the expression of the neurotoxin and associated protein genes in Clostridium botulinum type A and Clostridium tetani.
Botulism
Botulinum Endopeptidase: SAXS Experiments and MD Simulations Reveal Extended Solution Structures That Account for Its Biochemical Properties.
Botulism
Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission.
Botulism
Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design.
Botulism
Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
Botulism
Botulinum neurotoxin serotypes detected by electrochemical impedance spectroscopy.
Botulism
Botulinum Neurotoxin Type A is Internalized and Translocated from Small Synaptic Vesicles at the Neuromuscular Junction.
Botulism
Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins.
Botulism
Botulinum Neurotoxins B and E Translocate at Different Rates and Exhibit Divergent Responses to GT1b and Low pH.
Botulism
Botulinum toxin A complex exploits intestinal M cells to enter the host and exert neurotoxicity.
Botulism
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review).
Botulism
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Botulism
Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.
Botulism
Botulism challenge studies of a modified atmosphere package for fresh mussels: inoculated pack studies.
Botulism
Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation.
Botulism
Botulism in Brazil, 2000-2008: epidemiology, clinical findings and laboratorial diagnosis.
Botulism
Brain functional changes in patients with botulism after illegal cosmetic injections of botulinum toxin: A resting-state fMRI study.
Botulism
Ca2(+)-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain.
Botulism
Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Botulism
Characterization of botulinum neurotoxin a subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.
Botulism
Characterization of the neurotoxin isolated from a Clostridium baratii strain implicated in infant botulism.
Botulism
Chronic botulism in a Saxony dairy farm: sources, predisposing factors, development of the disease and treatment possibilities.
Botulism
Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT).
Botulism
Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin.
Botulism
Clostridium botulinum and the ophthalmologist: a review of botulism, including biological warfare ramifications of botulinum toxin.
Botulism
Clostridium botulinum and the safety of minimally heated, chilled foods: an emerging issue?
Botulism
Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E.
Botulism
Comparison of oral toxicological properties of botulinum neurotoxin serotypes A and B.
Botulism
Cosmetic Injection of Botulinum Toxin Unmasking Subclinical Myasthenia Gravis: A Case Report and Literature Review.
Botulism
Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C.
Botulism
Crystallization and preliminary X-ray analysis of a novel haemagglutinin component of the toxin complex of serotype C Clostridium botulinum.
Botulism
Delayed Antitoxin Treatment of Two Adult Patients with Botulism after Cosmetic Injection of Botulinum Type A Toxin.
Botulism
Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.
Botulism
Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk.
Botulism
Detection of Clostridium botulinum neurotoxin genes (A-F) in dairy farms from Northern Germany using PCR: A case-control study.
Botulism
Detection of the genes encoding botulinum neurotoxin types A to E by the polymerase chain reaction.
Botulism
Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry.
Botulism
Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.
Botulism
Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Botulism
Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Botulism
Development and preclinical evaluation of a new F(ab')? antitoxin against botulinum neurotoxin serotype A.
Botulism
Development of An Innovative and Quick Method for the Isolation of Clostridium botulinum Strains Involved in Avian Botulism Outbreaks.
Botulism
Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies.
Botulism
Differences in the Vulnerability of Waterbird Species to Botulism Outbreaks in Mediterranean Wetlands: an Assessment of Ecological and Physiological Factors.
Botulism
Differentiation of Clostridium botulinum serotype A strains by multiple-locus variable-number tandem-repeat analysis.
Botulism
Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism.
Botulism
Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C.
Botulism
Distinguishing highly-related outbreak-associated Clostridium botulinum type A(B) strains.
Botulism
Diversity of the Genomes and Neurotoxins of Strains of Clostridium botulinum Group I and Clostridium sporogenes Associated with Foodborne, Infant and Wound Botulism.
Botulism
Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
Botulism
Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.
Botulism
Draft Genome Sequence of Clostridium botulinum Type B Strain Osaka05, Isolated from an Infant Patient with Botulism in Japan.
Botulism
Dynamin inhibition blocks botulinum neurotoxin type-A endocytosis in neurons and delays botulism.
Botulism
Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
Botulism
Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F.
Botulism
Effect of adjuvants on antibody titer of synthetic recombinant light chain of botulinum neurotoxin type B and its diagnostic potential for botulism.
Botulism
Effects of antibiotics on the viability of and toxin production by Clostridium botulinum.
Botulism
Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literature.
Botulism
Emergency response to a cluster of suspected food-borne botulism in Abuja, Nigeria: challenges with diagnosis and treatment in a resource-poor setting.
Botulism
Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease.
Botulism
Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.
Botulism
Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.
Botulism
Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates.
Botulism
Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.
Botulism
Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.
Botulism
Equine botulism and acute pasture myodystrophy: new soil-borne emerging diseases in Switzerland?
Botulism
Ethyl acetate extract from black tea prevents neuromuscular blockade by botulinum neurotoxin type A in vitro.
Botulism
Evaluation of lateral flow assays for the detection of botulinum neurotoxin type A and their application in laboratory diagnosis of botulism.
Botulism
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Botulism
Evidence for a natural humoral response in dairy cattle affected by persistent botulism sustained by non-chimeric type C strains.
Botulism
Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine.
Botulism
Experimental botulism in chickens: the cecum as the site of production and absorption of botulinum toxin.
Botulism
Finished Whole-Genome Sequences of Clostridium butyricum Toxin Subtype E4 and Clostridium baratii Toxin Subtype F7 Strains.
Botulism
Foodborne Botulinum Type E Intoxication Associated with Dried Bean Curd: First Case Report in Taiwan.
Botulism
Foodborne botulinum type e intoxication associated with dried bean curd: first case report in taiwan.
Botulism
Foodborne Botulism Outbreak Associated with Commercial Nacho Cheese Sauce from a Gas Station Market.
Botulism
Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant.
Botulism
Functional dissection of the Clostridium botulinum type B hemagglutinin complex: identification of the carbohydrate and E-cadherin binding sites.
Botulism
Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons.
Botulism
Generalized botulism: diagnostic problems in a patient treated with botulinum toxin type A.
Botulism
Generation and characterization of monoclonal antibodies against botulinum neurotoxin type A (BoNT/A).
Botulism
Genetic analysis of type E botulinum toxin-producing Clostridium butyricum strains.
Botulism
Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan.
Botulism
Genetic diversity among Clostridium botulinum strains harboring bont/A2 and bont/A3 genes.
Botulism
Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes.
Botulism
Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins.
Botulism
Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin.
Botulism
Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
Botulism
Horizontal gene transfer of toxin genes in Clostridium botulinum: Involvement of mobile elements and plasmids.
Botulism
Host-cell specificity and transcytosis of nontoxic nonhemagglutinin protein of botulinum neurotoxin serotype D.
Botulism
Iatrogenic botulism after the therapeutic use of botulinum toxin-a: a case report and review of the literature.
Botulism
Iatrogenic Botulism Due to Therapeutic Botulinum Toxin A Injection in a Pediatric Patient.
Botulism
Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Botulism
Identification and characterization of Clostridium botulinum group III field strains by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS).
Botulism
Identification of Cross Reactive Antigens of C. botulinum Types A, B, E & F by Immunoproteomic Approach.
Botulism
Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency.
Botulism
In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
Botulism
In Vivo Neutralization of Botulinum Neurotoxins Serotype E with Heavy-chain Camelid Antibodies (VHH).
Botulism
In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.
Botulism
Inability of non-proteolytic Clostridium botulinum to grow in mussels inoculated via immersion and packaged in high oxygen atmospheres.
Botulism
Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.
Botulism
Infant botulism due to C. butyricum type E toxin: a novel environmental association with pet terrapins.
Botulism
Infant botulism with prolonged faecal excretion of botulinum neurotoxin and Clostridium botulinum for 7 months.
Botulism
Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1.
Botulism
Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
Botulism
Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
Botulism
Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome.
Botulism
Intestinal toxicoinfection by Clostridium botulinum type F in an adult. Case associated with Guillain-Barré syndrome.
Botulism
Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores.
Botulism
Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.
Botulism
Investigation of a type C/D botulism outbreak in free-range laying hens in France.
Botulism
Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.
Botulism
Is botulism type C transmissible to human by consumption of contaminated poultry meat? Analysis of a suspect outbreak in French Guyana.
Botulism
Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Botulism
Isolation and Functional Characterization of the Novel Clostridium botulinum Neurotoxin A8 Subtype.
Botulism
Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism.
Botulism
Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.
Botulism
Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis.
Botulism
Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.
Botulism
Meta-analysis of D-values of proteolytic Clostridium botulinum and its surrogate strain Clostridium sporogenes PA 3679.
Botulism
Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin.
Botulism
Mild Botulism From Illicitly Brewed Alcohol in a Large Prison Outbreak in Mississippi.
Botulism
Modification and validation of the Endopep-mass spectrometry method for botulinum neurotoxin detection in liver samples with application to samples collected during animal botulism outbreaks.
Botulism
Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.
Botulism
Molecular characterization and comparison of Clostridium botulinum type C avian strains.
Botulism
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
Botulism
Molecular properties of a hemagglutinin purified from type A Clostridium botulinum.
Botulism
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
Botulism
Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.
Botulism
Multi-locus variable number tandem repeat analysis for Clostridium botulinum type B isolates in Japan: Comparison with other isolates and genotyping methods.
Botulism
Multiplex PCR assay for detection and identification of Clostridium botulinum types A, B, E, and F in food and fecal material.
Botulism
National outbreak of type a foodborne botulism associated with a widely distributed commercially canned hot dog chili sauce.
Botulism
Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.
Botulism
Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.
Botulism
Novel Clostridium botulinum Toxin Gene Arrangement with Subtype A5 and Partial Subtype B3 Botulinum Neurotoxin Genes.
Botulism
Novel Lytic Enzyme of Prophage Origin from Clostridium botulinum E3 Strain Alaska E43 with Bactericidal Activity against Clostridial Cells.
Botulism
Occurrence of avian botulism in Korea during the period from June to September 2012.
Botulism
On the first systematic descriptions of botulism and botulinum toxin by Justinus Kerner (1786-1862).
Botulism
Optimization of peptide substrates for botulinum neurotoxin E improves detection sensitivity in the Endopep-MS assay.
Botulism
Optimization of the BoNT/A-Hc expression in recombinant Escherichia coli using Taguchi statistical method.
Botulism
Outbreak of type A botulism caused by a commercial food product in Taiwan: clinical and epidemiological investigations.
Botulism
Pan-Genomic Analysis of Clostridium botulinum Group II (Non-Proteolytic C. botulinum) Associated with Foodborne Botulism and Isolated from the Environment.
Botulism
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Botulism
Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Botulism
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
Botulism
Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.
Botulism
Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
Botulism
Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations.
Botulism
Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine.
Botulism
Preliminary study on the isolation of Clostridium butyricum strains from natural sources in the UK and screening the isolates for presence of the type E botulinal toxin gene.
Botulism
Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum.
Botulism
Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
Botulism
Presence of Clostridium botulinum and botulinum toxin in milk and udder tissue of dairy cows with suspected botulism.
Botulism
Prevalence of botulinum neurotoxin C1 and its corresponding gene in environmental samples from low and high risk avian botulism areas.
Botulism
Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain.
Botulism
Profiling gene expression reveals insights into pulmonary response to aerosolized botulinum toxin type A exposure in mice.
Botulism
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.
Botulism
Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Botulism
Quantification of botulinum neurotoxin serotypes A and B from serum using mass spectrometry.
Botulism
Quantification of Clostridium botulinum toxin gene expression by competitive reverse transcription-PCR.
Botulism
Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism.
Botulism
Quantities of Clostridium botulinum organisms and toxin in feces and presence of Clostridium botulinum toxin in the serum of an infant with botulism.
Botulism
RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake.
Botulism
Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly.
Botulism
Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers.
Botulism
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Botulism
Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains.
Botulism
Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
Botulism
Reoccurrence of botulinum neurotoxin subtype A3 inducing food-borne botulism, Slovakia, 2015.
Botulism
Repeated low-level exposure of the round goby (Neogobius melanostomas) to Clostridium botulinum type E neurotoxin.
Botulism
Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues.
Botulism
Resistance of mice with limited intestinal flora to enteric colonization by Clostridium botulinum.
Botulism
Role of csp genes in NaCl, pH, and ethanol stress response and motility in Clostridium botulinum ATCC 3502.
Botulism
Role of neurotoxin associated proteins in the low pH induced structural changes in the botulinum neurotoxin complex.
Botulism
Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.
Botulism
Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins.
Botulism
Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.
Botulism
Separation of the components of type A botulinum neurotoxin complex by electrophoresis.
Botulism
Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins.
Botulism
SERS detection of Clostridium botulinum neurotoxin serotypes A and B in buffer and serum: Towards the development of a biodefense test platform.
Botulism
Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.
Botulism
Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum.
Botulism
Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors.
Botulism
Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D.
Botulism
Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.
Botulism
Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.
Botulism
Subtyping botulinum neurotoxins by sequential multiple endoproteases in-gel digestion coupled with mass spectrometry.
Botulism
Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
Botulism
Temperature dependency of Clostridium botulinum C and D toxin production from anaerobically enriched bovine gastrointestinal samples.
Botulism
The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex.
Botulism
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
Botulism
The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.
Botulism
The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Botulism
The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.
Botulism
The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
Botulism
The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
Botulism
The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples.
Botulism
Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Botulism
Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction.
Botulism
Tonsils--place of botulinum toxin production: results of routine laboratory diagnosis in farm animals.
Botulism
Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
Botulism
Two cases of adult botulism caused by botulinum neurotoxin producing Clostridium baratii.
Botulism
Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells.
Botulism
Type E Botulinum Neurotoxin-Producing Clostridium butyricum Strains Are Aerotolerant during Vegetative Growth.
Botulism
Type F Infant Botulism: Investigation of Recent Clusters and Overview of This Exceedingly Rare Disease.
Botulism
Utilizing Ayurvedic literature for the identification of novel phytochemical inhibitors of botulinum neurotoxin A.
Botulism
Wound Botulism Caused by Botulinum Neurotoxin Type A in a Chronic Parenteral Drug Abuser.
Botulism
[Biological effects of toosendanin, an active ingredient of herbal vermifuge in Chinese traditional medicine]
Botulism
[Isolation and determination of an antidote for botulinum neurotoxin from black tea extract]
Botulism
[Morphological and histochemical reactions of an organism to the administration of Clostridium botulinum toxin. IX. Reactions of the neurons of the abducens nerve nucleus and of the Darkshevich's nucleus to the administration of C. botulinum type B toxin]
Botulism
[Rapid diagnosis of botulism in cattle using heated microcomplement fixation reactions]
Botulism
[THE SIGNIFICANCE OF TYPE E BOTULINUM TOXIN ACTIVATION IN THE LABORATORY DIAGNOSIS OF BOTULISM.]
Brachial Plexus Neuritis
Brachial Neuritis After Botulinum Toxin Injections for Cervical Dystonia: A Need for a Reappraisal?
Brachial Plexus Neuritis
Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp.
Brachial Plexus Neuropathies
Botulinum toxin for treatment of cocontractions related to obstetrical brachial plexopathy.
Brachial Plexus Neuropathies
Brachial plexopathy after botulinum toxin administration for cervical dystonia.
Brachial Plexus Neuropathies
Brachial plexopathy after Botulinum toxin administration for cervical dystonia.
Bradycardia
Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart.
Brain Diseases
Botulinum toxin in the treatment of spasticity in HIV-infected children affected with progressive encephalopathy.
Brain Diseases
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Brain Diseases
[Course and treatment of progressive subacute encephalopathy caused by human immunodeficiency virus in children. The value of Botulinum toxin]
Brain Injuries
A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury.
Brain Injuries
Botulinum toxin in the treatment of drooling in tetraplegic patients with brain injury.
Brain Injuries
Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques.
Brain Injuries
Botulinum toxin injection for bruxism associated with brain injury: case report.
Brain Injuries
Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.
Brain Injuries
Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury.
Brain Injuries
Care management of spasticity with botulinum toxin-A in patients with severe acquired brain injury: a 1-year follow-up prospective study.
Brain Injuries
Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis.
Brain Injuries
European consensus table on the use of botulinum toxin type A in adult spasticity.
Brain Injuries
High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
Brain Injuries
Influence of intrathecal baclofen on the level of consciousness and mental functions after extremely severe traumatic brain injury: Brief report.
Brain Injuries
Investigating Inducible Muscle Overactivity in Acquired Brain Injury and the Impact of Botulinum Toxin A.
Brain Injuries
Long-Term Resolution of Severe Ankle Contractures Using Botulinum Toxin, Serial Casting, Splinting, and Motor Retraining.
Brain Injuries
Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes.
Brain Injuries
Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A.
Brain Injuries
Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications.
Brain Injuries
Novel approach to the application of botulinum toxin to the flexor digitorum superficialis muscle in acquired brain injury.
Brain Injuries
Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb.
Brain Injuries
The process of developing a non-medical (advanced allied health) botulinum toxin A prescribing and injecting model of care in a public rehabilitation setting.
Brain Injuries
[Treatment of spasticity after traumatic brain injury in children: the role of botulinum toxin therapy].
Brain Injuries, Traumatic
Botulinum toxin B increases mouth opening in patients with spastic trismus.
Brain Injuries, Traumatic
Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial.
Brain Injuries, Traumatic
Botulinum toxin injection for bruxism associated with brain injury: case report.
Brain Injuries, Traumatic
Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity.
Brain Injuries, Traumatic
Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury.
Brain Injuries, Traumatic
Clinical trials of botulinum toxin in the treatment of spasticity.
Brain Injuries, Traumatic
Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity.
Brain Injuries, Traumatic
Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.
Brain Injuries, Traumatic
Efficacy and safety of Botulinum Toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.
Brain Injuries, Traumatic
Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity.
Brain Injuries, Traumatic
Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury.
Brain Injuries, Traumatic
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Brain Injuries, Traumatic
Kinematic changes following botulinum toxin injection after traumatic brain injury.
Brain Injuries, Traumatic
Long-Term Resolution of Severe Ankle Contractures Using Botulinum Toxin, Serial Casting, Splinting, and Motor Retraining.
Brain Injuries, Traumatic
Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.
Brain Injuries, Traumatic
Patient Registry of Spasticity Care World: Data Analysis Based on Physician Experience.
Brain Injuries, Traumatic
Peri-incisional botulinum toxin for chronic post craniotomy headache following traumatic brain injury: A case series.
Brain Injuries, Traumatic
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Brain Injuries, Traumatic
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Brain Injuries, Traumatic
The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury.
Brain Injuries, Traumatic
[Treatment of spasticity after traumatic brain injury in children: the role of botulinum toxin therapy].
Brain Neoplasms
Botulinum Toxin Type A Injection for Neuropathic Pain in a Patient With a Brain Tumor: A Case Report.
Breast Neoplasms
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Breast Neoplasms
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
Breast Neoplasms
Botulinum Toxin Type A as a Tool for Correcting Capsular Contracture after Reconstructive Breast Surgery.
Breast Neoplasms
Effect of Botulinum Toxin A on Proliferation and Apoptosis in the T47D Breast Cancer Cell Line.
Breast Neoplasms
Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial.
Breast Neoplasms
Knockdown of RAC1 and VASP gene expression inhibits breast cancer cell migration.
Breast Neoplasms
The effectiveness of Botulinum Toxin A for treatment of upper limb impairments and dysfunctions in breast cancer survivors: A randomised controlled trial.
Breast Neoplasms
The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells.
Bronchial Hyperreactivity
Endobronchial injection of botulinum toxin for the reduction of bronchial hyperreactivity induced by methacholine inhalation in dogs.
Bronchitis
Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.
Bronchitis
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Bronchopneumonia
Barbiturate ingestion in three adult captive tigers (Panthera tigris) and concomitant fatal botulism of one.
Brown-Sequard Syndrome
Delayed onset of Brown-Sequard syndrome involving upper extremity pain.
Brucellosis
Effects of vaccination against brucellosis and clostridia on the intake, performance, feeding behavior, blood parameters, and immune responses of dairy heifers calves.
Brucellosis
The threat of biological terrorism: a public health and infection control reality.
Bruxism
A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism.
Bruxism
Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw.
Bruxism
Application of botulinum toxin in maxillofacial field: Part II. Wrinkle, intraoral ulcer, and cranio-maxillofacial pain.
Bruxism
Application of botulinum toxin in maxillofacial field: Part III. Ancillary treatment for maxillofacial surgery and summary.
Bruxism
Application of Botulinum Toxin in Patients with Secondary Otalgia Caused by Bruxism.
Bruxism
Awake Bruxism Treated with Pregabaline in a Patient with Generalized Anxiety Disorder.
Bruxism
Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin.
Bruxism
Botulinum toxin in masticatory muscles of the adult rat induces bone loss at the condyle and alveolar regions of the mandible associated with a bone proliferation at a muscle enthesis.
Bruxism
Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study.
Bruxism
Botulinum Toxin Type A as Preoperative Treatment for Immediately Loaded Dental Implants Placed in Fresh Extraction Sockets for Full-Arch Restoration of Patients With Bruxism.
Bruxism
Botulinum toxin type A for controlling bruxism assessed with computerized occlusal analysis: A pilot study.
Bruxism
Cerebral palsy and bruxism: Effects of botulinum toxin injections-A randomized controlled trial.
Bruxism
Clinical outcomes of botulinum toxin type A injections in the management of primary bruxism in adults: A systematic review.
Bruxism
Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects.
Bruxism
Different approaches to dental management of self-inflicted oral trauma: oral shield, botulinum toxin type A neuromuscular block, and oral surgery.
Bruxism
Effect of Botulinum Toxin Injection on Nocturnal Bruxism: A Randomized Controlled Trial.
Bruxism
Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism.
Bruxism
Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study.
Bruxism
Fulminant thymomatous AMPAR-antibody limbic encephalitis with hypertonic coma, bruxism, an isoelectric electroencephalogram and temporal cortical atrophy, with recovery.
Bruxism
Important uncertainty regarding the effects of botulinum toxin in patients with temporomandibular disorders or bruxism owing to serious limitations of a systematic review.
Bruxism
Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?
Bruxism
Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review.
Bruxism
Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX - A)for treatment of temporomandibular disorder.
Bruxism
The use of botulinum toxin in the treatment of the consequences of bruxism on cervical spine musculature.
Bruxism
The use of botulinum toxin-a in the treatment of severe bruxism in a patient with autism: a case report.
Bruxism
Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study.
Bruxism
[Series: Medicaments and oral healthcare. Medicaments and addictive substances, potentially inducing or ameliorating bruxism].
Bulbar Palsy, Progressive
Botulinum toxin as a biological weapon: medical and public health management.
Bursitis
A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder.
Bursitis
Clinical Effectiveness of Botulinum Toxin Type B in the Treatment of Subacromial Bursitis or Shoulder Impingement Syndrome.
Bursitis
Treatment of frozen shoulder with intra-articular injection of botulinum toxin in shoulder joints.
Callosities
A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma.
Carcinoma
Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells.
Carcinoma
Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors.
Carcinoma
Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin.
Carcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Carcinoma
Parotid fistula complicating surgical excision of a Basal cell carcinoma: successful treatment with botulinum toxin type a.
Carcinoma
Primary treatment of early fistula of parotid duct with botulinum toxin type A injection.
Carcinoma
RAC2 promotes abnormal proliferation of quiescent cells by enhanced JUNB expression via the MAL-SRF pathway.
Carcinoma
Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers.
Carcinoma
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Carcinoma
Resveratrol suppresses malignant progression of oral squamous cell carcinoma cells by inducing the ZNF750/RAC1 signaling pathway.
Carcinoma
The use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinoma.
Carcinoma
Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Carcinoma
Unique use of botulinum toxin to decrease adductor tone and allow surgical excision of vulvar carcinoma.
Carcinoma
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
Carcinoma, Basal Cell
Parotid fistula complicating surgical excision of a Basal cell carcinoma: successful treatment with botulinum toxin type a.
Carcinoma, Embryonal
CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C.
Carcinoma, Embryonal
Neurotransmitter Vesicle Release from Human Model Neurons (NT2) is Sensitive to Botulinum Toxin A.
Carcinoma, Hepatocellular
Alteration of the cytoskeleton of mammalian cells cultured in vitro by Clostridium botulinum C2 toxin and C3 ADP-ribosyltransferase.
Carcinoma, Non-Small-Cell Lung
Use of Botulinum Toxin A to Treat Chemotherapy-Induced Raynaud's Phenomenon.
Carcinoma, Squamous Cell
Prevention of esophageal strictures after endoscopic submucosal dissection with the injection of botulinum toxin type A.
Carcinoma, Squamous Cell
Primary treatment of early fistula of parotid duct with botulinum toxin type A injection.
Carcinoma, Squamous Cell
The Effect of Botulinum Toxin on an Iatrogenic Sialo-Cutaneous Fistula.
Cardiomyopathy, Hypertrophic
[Inhibiting contractility without necrosis: would it be helpful for hypertrophic cardiomyopathy? Experimental model of intramyocardial botulinum toxin and wortmannin].
Carotid Artery, Internal, Dissection
Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A.
Carpal Tunnel Syndrome
Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome.
Carpal Tunnel Syndrome
Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience.
Cataract
Prospective evaluation of anesthetic protocols during pediatric ophthalmic surgery.
Central Nervous System Diseases
Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology.
Central Nervous System Diseases
Medical management of oral motor disorders: dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions.
Central Nervous System Diseases
Negative effects of submandibular botulinum neurotoxin A injections on oral motor function in children with drooling due to central nervous system disorders.
Central Nervous System Diseases
[Treatment of spasticity with botulinum toxin: implications for molecular targeting therapy for CNS diseases]
Cerebral Infarction
Salivagram after gland injection of botulinum neurotoxin A in patients with cerebral infarction and cerebral palsy.
Cerebral Infarction
Ultrasound-guided botulinum toxin injections and EMG biofeedback therapy the lower limb muscle spasm after cerebral infarction.
Cerebral Infarction
[Botulinum toxin injection into the cricopharyngeal muscle for dysphagia: report of 2 successful cases]
Cerebral Palsy
'Why do children with cerebral palsy discontinue therapy with botulinum toxin A?'.
Cerebral Palsy
A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research.
Cerebral Palsy
A dose-response relationship research on botulinum toxin type A local intramuscular injections of lower extremity spasticity in children with cerebral palsy.
Cerebral Palsy
A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
Cerebral Palsy
A major improvement in social participation of two children with cerebral palsy by a single botulinum toxin injection.
Cerebral Palsy
A novel compound heterozygous mutation in the arginase-1 gene identified in a Chinese patient with argininemia: A case report.
Cerebral Palsy
A Pilot Study of Two Different Constraint-Induced Movement Therapy Interventions in Children With Hemiplegic Cerebral Palsy After Botulinum Toxin Injection During Preschool Education.
Cerebral Palsy
A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use.
Cerebral Palsy
A Randomized Control Trial of Botulinum Toxin A Administration under Ultrasound Guidance against Manual Palpation in Spastic Cerebral Palsy.
Cerebral Palsy
A randomized controlled trial to compare two botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy.
Cerebral Palsy
A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures.
Cerebral Palsy
A rectally administered combination of midazolam and ketamine was easy, effective and feasible for procedural pain in children with cerebral palsy.
Cerebral Palsy
A risk-stratified approach toward safely resuming OnabotulinumtoxinA injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19).
Cerebral Palsy
A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM.
Cerebral Palsy
AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections.
Cerebral Palsy
AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial.
Cerebral Palsy
Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation.
Cerebral Palsy
Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography.
Cerebral Palsy
Acute sialadenitis secondary to submandibular calculi after botulinum neurotoxin injection for sialorrhea in a child with cerebral palsy.
Cerebral Palsy
Additional effect of botulinum toxin a treatment on upper limb functional skills in children with hemiparetic cerebral palsy.
Cerebral Palsy
Adjunct therapies to improve outcomes after botulinum toxin injection in children: A systematic review.
Cerebral Palsy
Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase.
Cerebral Palsy
Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy.
Cerebral Palsy
Adverse events following botulinum toxin type A treatment in children with cerebral palsy.
Cerebral Palsy
Analgesia and sedation modalities used with botulinum toxin injections in children with cerebral palsy: a literature review.
Cerebral Palsy
Analgesic effect of botulinum toxin in children with cerebral palsy: A systematic review.
Cerebral Palsy
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.
Cerebral Palsy
Application of botulinum toxin in treatment of spasticity and functional improvements for children suffering from cerebral palsy.
Cerebral Palsy
Architectural changes of the gastrocnemius muscle after botulinum toxin type A injection in children with cerebral palsy.
Cerebral Palsy
Atrophy and hypertrophy following injections of botulinum toxin in children with cerebral palsy.
Cerebral Palsy
Automatic classification of gait patterns in children with cerebral palsy using fuzzy clustering method.
Cerebral Palsy
Best clinical practice in botulinum toxin treatment for children with cerebral palsy.
Cerebral Palsy
Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy.
Cerebral Palsy
Botulinum neurotoxin treatment in children with cerebral palsy: A population-based study in Norway.
Cerebral Palsy
Botulinum neurotoxin treatment in children with cerebral palsy: validation of a needle placement protocol using passive muscle stretching and relaxing.
Cerebral Palsy
Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes.
Cerebral Palsy
Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review.
Cerebral Palsy
Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy.
Cerebral Palsy
Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE).
Cerebral Palsy
Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy.
Cerebral Palsy
Botulinum Toxin A for Nonambulatory Children with Cerebral Palsy: A Double Blind Randomized Controlled Trial.
Cerebral Palsy
Botulinum toxin A in conjunction with occupational therapy reduces spasticity and improves upper limb function and goal attainment in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
Cerebral Palsy
Botulinum toxin A in the management of upper limb spasticity in cerebral palsy.
Cerebral Palsy
Botulinum Toxin A Injection in Treatment of Upper Limb Spasticity in Children with Cerebral Palsy: A Systematic Review of Randomized Controlled Trials.
Cerebral Palsy
Botulinum toxin a injection into calf muscles for treatment of spastic equinus in cerebral palsy: a controlled trial comparing sonography and electric stimulation-guided injection techniques: a preliminary report.
Cerebral Palsy
Botulinum toxin A injections and occupational therapy in children with unilateral spastic cerebral palsy: a randomized controlled trial.
Cerebral Palsy
Botulinum toxin A injections do not improve surface EMG patterns during gait in children with cerebral palsy--a randomized controlled study.
Cerebral Palsy
Botulinum Toxin A Injections to the Upper Limbs in Children With Cerebral Palsy: Duration of Effect.
Cerebral Palsy
Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.
Cerebral Palsy
Botulinum toxin a treatment in children with cerebral palsy: its effects on walking and energy expenditure.
Cerebral Palsy
Botulinum toxin A treatment of the lower extremities in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.
Cerebral Palsy
Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.
Cerebral Palsy
Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy.
Cerebral Palsy
Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat?
Cerebral Palsy
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement.
Cerebral Palsy
Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.
Cerebral Palsy
Botulinum toxin effect on salivary flow rate in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques.
Cerebral Palsy
Botulinum toxin for spasticity and athetosis in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.
Cerebral Palsy
Botulinum toxin for the treatment of early-onset esotropia in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin injection as primary treatment for esotropia in patients with cerebral palsy.
Cerebral Palsy
Botulinum Toxin Injection in Children with Hemiplegic Cerebral Palsy: Correction of Growth through Comparison of Treated and Unaffected Limbs.
Cerebral Palsy
Botulinum toxin injections minimally affect modelled muscle forces during gait in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option.
Cerebral Palsy
Botulinum toxin treatment in cerebral palsy: intervention with poor evaluation?
Cerebral Palsy
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Cerebral Palsy
Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques.
Cerebral Palsy
Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Cerebral Palsy
Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites.
Cerebral Palsy
Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.
Cerebral Palsy
Botulinum Toxin Treatment on Upper Limb Function in School Age Children With Bilateral Spastic Cerebral Palsy: One Year Follow-up.
Cerebral Palsy
Botulinum toxin type A and dynamic equinus in children with cerebral palsy: new indication. Better than repeat casts.
Cerebral Palsy
Botulinum toxin type A enhances the inhibitory spontaneous postsynaptic currents on the substantia gelatinosa neurons of the subnucleus caudalis in immature mice.
Cerebral Palsy
Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy.
Cerebral Palsy
Botulinum toxin type A for spastic cerebral palsy: Is it time to change praxis?
Cerebral Palsy
Botulinum toxin type a for the treatment of the spastic equinus foot in cerebral palsy.
Cerebral Palsy
Botulinum toxin type A improved ankle function in children with cerebral palsy and dynamic equinus foot deformity.
Cerebral Palsy
Botulinum Toxin Type A in Children and Adolescents With Severe Cerebral Palsy: A Retrospective Chart Review.
Cerebral Palsy
Botulinum toxin type A in the management of cerebral palsy: low or high dose?
Cerebral Palsy
Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation.
Cerebral Palsy
Botulinum Toxin Type A in the Spasticity of Cerebral Palsy Related to Congenital Zika Syndrome: An Observational Study.
Cerebral Palsy
Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy.
Cerebral Palsy
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy.
Cerebral Palsy
Botulinum toxin type A in the treatment of spasticity in cerebral palsy: theoretical and practical foundations of effective therapy.
Cerebral Palsy
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.
Cerebral Palsy
Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review.
Cerebral Palsy
Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.
Cerebral Palsy
Botulinum toxin type A injection increases range of motion in hip, knee and ankle joint contractures of children with cerebral palsy.
Cerebral Palsy
Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy.
Cerebral Palsy
Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response.
Cerebral Palsy
Botulinum Toxin Type A Injections Impact Hamstring Muscles and Gait Parameters in Children with Flexed Knee Gait.
Cerebral Palsy
Botulinum toxin type A injections in the psoas muscle of children with cerebral palsy: muscle atrophy after motor end plate-targeted injections.
Cerebral Palsy
Botulinum toxin type A injections into the calf muscles for treatment of spastic equinus in cerebral palsy: a randomized trial comparing single and multiple injection sites.
Cerebral Palsy
Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy.
Cerebral Palsy
Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy.
Cerebral Palsy
Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
Cerebral Palsy
Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial.
Cerebral Palsy
Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.
Cerebral Palsy
Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study.
Cerebral Palsy
Botulinum toxin type A treatment in children with cerebral palsy: Evaluation of treatment success or failure by means of goal attainment scaling.
Cerebral Palsy
Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Cerebral Palsy
Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses.
Cerebral Palsy
Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose-escalation pilot study.
Cerebral Palsy
Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment.
Cerebral Palsy
Botulinum toxin, physical and occupational therapy, and neuromuscular electrical stimulation to treat spastic upper limb of children with cerebral palsy: a pilot study.
Cerebral Palsy
Botulinum toxin-a in children with congenital spastic hemiplegia does not improve upper extremity motor-related function over rehabilitation alone: a randomized controlled trial.
Cerebral Palsy
Botulinum toxin-induced paralysis leads to slower myosin heavy chain isoform composition and reduced titin content in juvenile rat gastrocnemius muscle.
Cerebral Palsy
Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.
Cerebral Palsy
BTX-A has notable effects contradicting some treatment aims in the rat triceps surae compartment, which are not confined to the muscles injected.
Cerebral Palsy
Budget Impact Analysis of Botulinum Toxin Type A Treatment for Cerebral Palsy In The Russian Federation.
Cerebral Palsy
Can we identify predictors of multilevel botulinum toxin A injections in children with cerebral palsy who walk with a flexed knee pattern?
Cerebral Palsy
Casting Protocols Following BoNT-A Injections to Treat Spastic Hypertonia of the Triceps Surae in Children with Cerebral Palsy and Equinus Gait: A Randomized Controlled Trial.
Cerebral Palsy
Categorization of gait patterns in adults with cerebral palsy: A clustering approach.
Cerebral Palsy
Cerebral palsy and bruxism: Effects of botulinum toxin injections-A randomized controlled trial.
Cerebral Palsy
Cerebral palsy hip deformities: is there a consensus? II. Botulinum toxin A: a clinical experiment.
Cerebral Palsy
Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment.
Cerebral Palsy
Change of dynamic gastrocnemius and soleus muscle length after block of spastic calf muscle in cerebral palsy.
Cerebral Palsy
Changes in Muscle Mass after Botulinum Toxin Injection in Children with Spastic Hemiplegic Cerebral Palsy.
Cerebral Palsy
Changes in spastic muscle stiffness after botulinum toxin A injections as part of rehabilitation therapy in patients with spastic cerebral palsy.
Cerebral Palsy
Changes of kinematics parameters of pelvis during walking under the influence of means facilitates treatment of cerebral palsied children.
Cerebral Palsy
Children undergoing treatment with botulinum toxin: the role of the physical therapist.
Cerebral Palsy
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Cerebral Palsy
Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy.
Cerebral Palsy
Clinical outcomes of botulinum toxin injection in patients with cerebral palsy and esotropia.
Cerebral Palsy
Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review.
Cerebral Palsy
Clown-care reduces pain in children with cerebral palsy undergoing recurrent botulinum toxin injections- A quasi-randomized controlled crossover study.
Cerebral Palsy
Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
Cerebral Palsy
Comparative assessment of therapeutic response to physiotherapy with or without botulinum toxin injection using diffusion tensor tractography and clinical scores in term diplegic cerebral palsy children.
Cerebral Palsy
Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy.
Cerebral Palsy
Comparison between botulinum toxin type A injection and selective posterior rhizotomy in improving gait performance in children with cerebral palsy.
Cerebral Palsy
Comparison of botulinum toxin type A injection and soft-tissue surgery to treat hip subluxation in children with cerebral palsy.
Cerebral Palsy
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Cerebral Palsy
Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial.
Cerebral Palsy
Comparison of treatment effects between children with spastic cerebral palsy under and over five years after botulinum toxin type a injection.
Cerebral Palsy
Computerized gait analysis of botulinum toxin treatment in children with cerebral palsy.
Cerebral Palsy
Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review.
Cerebral Palsy
Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak
Cerebral Palsy
Constipation as an adverse event after botulinum toxin A treatment in children with cerebral palsy.
Cerebral Palsy
Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy--is it worth it?
Cerebral Palsy
Coordination of the upper and lower extremities during walking in children with cerebral palsy.
Cerebral Palsy
Correspondence on ''Outcome measures used in studies of botulinum toxin in childhood cerebral palsy: a systematic review''.
Cerebral Palsy
Cortical somatosensory evoked potentials and spasticity assessment after botulinum toxin type A injection in children with cerebral palsy.
Cerebral Palsy
Cost Comparison of Botulinum Toxin Injections Versus Surgical Treatment in Pediatric Patients With Cerebral Palsy: A Markov Model.
Cerebral Palsy
Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy.
Cerebral Palsy
Cost-Effectiveness Analysis of Botulinum Toxin Type a Treatment for Cerebral Palsy.
Cerebral Palsy
Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial.
Cerebral Palsy
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Cerebral Palsy
Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.
Cerebral Palsy
Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review.
Cerebral Palsy
Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy.
Cerebral Palsy
Determining the technical and clinical factors associated with pain for children undergoing botulinum toxin injections under nitrous oxide and anesthetic cream.
Cerebral Palsy
Development of a framework to define the functional goals and outcomes of botulinum toxin A spasticity treatment relevant to the child and family living with cerebral palsy using the International Classification of Functioning, Disability and Health for Children and Youth.
Cerebral Palsy
Development of an inventory of goals using the International Classification of Functioning, Disability and Health in a population of non-ambulatory children and adolescents with cerebral palsy treated with botulinum toxin A.
Cerebral Palsy
Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy.
Cerebral Palsy
Do gait parameters improve after botulinum toxin injections in post stroke patients? A prospective study.
Cerebral Palsy
Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.
Cerebral Palsy
Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.
Cerebral Palsy
Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.
Cerebral Palsy
Edwards P, Sakzewski L, Copeland L, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics. 136(5):895-904.
Cerebral Palsy
Effect of botulinum toxin A-induced paralysis and exercise training on mechanosensing and signalling gene expression in juvenile rat gastrocnemius muscle.
Cerebral Palsy
Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
Cerebral Palsy
Effect of botulinum toxin on equinus foot deformity in cerebral palsy patients: A systematic review and network meta-analysis.
Cerebral Palsy
Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
Cerebral Palsy
Effect of botulinum toxin type a on morphology of salivary glands in patients with cerebral palsy.
Cerebral Palsy
Effect of botulinum toxin type A treatment in children with cerebral palsy: Sequential physical changes for 3?months after the injection.
Cerebral Palsy
Effect of botulinum toxin type-A in spasticity and functional outcome of upper limbs in cerebral palsy.
Cerebral Palsy
Effect of combined rehabilitation program with botulinum toxin type A injections on gross motor function scores in children with spastic cerebral palsy.
Cerebral Palsy
Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
Cerebral Palsy
Effect of multilevel lower-limb botulinum injections & intensive physical therapy on children with cerebral palsy.
Cerebral Palsy
Effect of multisite botulinum toxin injections on gait quality in adults with cerebral palsy.
Cerebral Palsy
Effect of physiotherapeutic intervention on the gait after the application of botulinum toxin in children with cerebral palsy: systematic review.
Cerebral Palsy
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Cerebral Palsy
Effectiveness of botulinum toxin A in the treatment of spasticity of the lower extremities in adults - preliminary report.
Cerebral Palsy
Effectiveness of Botulinum Toxin A Injection in Managing Mobility-Related Outcomes in Adult Patients With Cerebral Palsy: Systematic Review.
Cerebral Palsy
Effectiveness of electrical stimulation after administration of botulinum toxin in children with spastic diplegic cerebral palsy: A prospective, randomized clinical study.
Cerebral Palsy
Effectiveness of Multilevel Botulinum Toxin A Injection with Integrated Treatment Program on Spasticity Reduction in Non-Ambulatory Young Children with Cerebral Palsy.
Cerebral Palsy
Effectiveness of multiple botulinum toxin sessions and the duration of effects in spasticity therapy in children with cerebral palsy.
Cerebral Palsy
Effectiveness of nitrous oxide and analgesic cream (lidocaine and prilocaine) for prevention of pain during intramuscular botulinum toxin injections in children.
Cerebral Palsy
Effectiveness of sedation using nitrous oxide compared with enteral midazolam for botulinum toxin A injections in children.
Cerebral Palsy
Effects of botulinum toxin A and/or bimanual task-oriented therapy on upper extremity activities in unilateral Cerebral Palsy: a clinical trial.
Cerebral Palsy
Effects of botulinum toxin A and/or bimanual task-oriented therapy on upper extremity impairments in unilateral Cerebral Palsy: An explorative study.
Cerebral Palsy
Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial.
Cerebral Palsy
Effects of Botulinum Toxin A Injection on Ambulation Capacity in Patients with Cerebral Palsy.
Cerebral Palsy
Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review.
Cerebral Palsy
Effects of botulinum toxin A on functional outcome during distraction osteogenesis.
Cerebral Palsy
Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy.
Cerebral Palsy
Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy.
Cerebral Palsy
Effects of botulinum toxin serotype A on sleep problems in children with cerebral palsy and on mothers sleep quality and depression.
Cerebral Palsy
Effects of Botulinum Toxin Treatment in Nonambulatory Children and Adolescents With Cerebral Palsy: Understanding Parents' Perspectives.
Cerebral Palsy
Effects of botulinum toxin type A and a programme of functional activity to improve manual ability in children and adolescents with cerebral palsy.
Cerebral Palsy
Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review.
Cerebral Palsy
Effects of different dilutions of botulinum toxin type A treatment for children with cerebral palsy with spastic ankle plantarflexor: a randomized controlled trial.
Cerebral Palsy
Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review.
Cerebral Palsy
Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy.
Cerebral Palsy
Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study.
Cerebral Palsy
Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy.
Cerebral Palsy
Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review.
Cerebral Palsy
Efficacy of radial extracorporeal shock wave therapy compared with botulinum toxin type A injection in treatment of lower extremity spasticity in subjects with cerebral palsy: A randomized, controlled, cross-over study.
Cerebral Palsy
Efficacy of Repeat AbobotulinumtoxinA (Dysport®) Injections in Improving Gait in Children with Spastic Cerebral Palsy.
Cerebral Palsy
Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cerebral Palsy-A Secondary Analysis of the Randomized Clinical Trial.
Cerebral Palsy
Electrical Stimulation Following Botulinum Toxin A in Children With Spastic Diplegia: A Within-Participant Randomized Pilot Study.
Cerebral Palsy
Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy.
Cerebral Palsy
European consensus table 2006 on botulinum toxin for children with cerebral palsy.
Cerebral Palsy
Evaluating Functional Outcomes of Botulinum Toxin Type A Injection Combined with Occupational Therapy in the Upper Limbs of Children with Cerebral Palsy: A 9-Month Follow-Up from the Perspectives of Both Child and Caregiver.
Cerebral Palsy
Evaluation of botulinum toxin therapy of spastic equinus in paediatric patients with cerebral palsy.
Cerebral Palsy
Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance.
Cerebral Palsy
Evaluation of the effects of Botulinum toxin A injections when used to improve ease of care and comfort in children with cerebral palsy whom are non-ambulant: a double blind randomized controlled trial.
Cerebral Palsy
Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy.
Cerebral Palsy
Expert Consensus on Physical Therapist Intervention after Botulinum Toxin A Injection for Children with Cerebral Palsy.
Cerebral Palsy
Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
Cerebral Palsy
Factors predicting the efficacy of botulinum toxin-A treatment of the lower limb in children with cerebral palsy.
Cerebral Palsy
Feasibility of a day-camp model of modified constraint-induced movement therapy with and without botulinum toxin A injection for children with hemiplegia.
Cerebral Palsy
Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects.
Cerebral Palsy
Functional electrical stimulation to lower limb muscles after botox in children with cerebral palsy.
Cerebral Palsy
Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results.
Cerebral Palsy
Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy.
Cerebral Palsy
Functional outcome of botulinum toxin injection of gastrocnemius and adductors in spastic hemiplegic cerebral palsied children.
Cerebral Palsy
Functional outcomes of botulinum neurotoxin-A injection followed by reciprocal electrical stimulation in children with cerebral palsy: A randomized controlled trial.
Cerebral Palsy
Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.
Cerebral Palsy
Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial.
Cerebral Palsy
Functional Outcomes of Multilevel Botulinum Toxin and Comprehensive Rehabilitation in Cerebral Palsy.
Cerebral Palsy
Future needs of young people receiving botulinum toxin A in paediatric rehabilitation services of New South Wales: focus on transition.
Cerebral Palsy
Gait training using a hybrid assistive limb after botulinum toxin treatment for cerebral palsy: a case report.
Cerebral Palsy
Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats.
Cerebral Palsy
Hemiplegic cerebral palsy: role of repeat botulinum toxin A injections as an adjunct to occupational therapy.
Cerebral Palsy
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Cerebral Palsy
High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy.
Cerebral Palsy
High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
Cerebral Palsy
High-density electromyographic data during isometric contractions of the ankle joint in children with cerebral palsy pre and post BoNT-A treatment.
Cerebral Palsy
Hip Adductor Intramuscular Nerve Distribution Pattern of Children: A Guide for BTX-A Treatment to Muscle Spasticity in Cerebral Palsy.
Cerebral Palsy
Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up.
Cerebral Palsy
Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A.
Cerebral Palsy
Iatrogenic Botulism Due to Therapeutic Botulinum Toxin A Injection in a Pediatric Patient.
Cerebral Palsy
Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Cerebral Palsy
Impairment, Disability, and Satisfaction Outcomes After Lower-Extremity Botulinum Toxin A Injections for Children with Cerebral Palsy.
Cerebral Palsy
IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.
Cerebral Palsy
IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study.
Cerebral Palsy
IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy - a retrospective case series focusing on dosing and tolerability.
Cerebral Palsy
Influence of botulinum toxin therapy on postural control and lower limb intersegmental coordination in children with spastic cerebral palsy.
Cerebral Palsy
Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.
Cerebral Palsy
Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial.
Cerebral Palsy
Intensive therapy following upper limb botulinum toxin A injection in young children with unilateral cerebral palsy: a randomized trial.
Cerebral Palsy
Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial.
Cerebral Palsy
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy.
Cerebral Palsy
Intramuscular nerve distribution patterns of anterior forearm muscles in children: a guide for botulinum toxin injection.
Cerebral Palsy
Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
Cerebral Palsy
Intrinsic properties and functional changes in spastic muscle after application of BTX-A in children with cerebral palsy: systematic review.
Cerebral Palsy
Is botulinum toxin type A more effective and safer than other treatments for the management of lower limb spasticity in children with cerebral palsy? A Cochrane Review summary with commentary.
Cerebral Palsy
Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?
Cerebral Palsy
Joint and Muscle Assessments of the Separate Effects of Botulinum NeuroToxin-A and Lower-Leg Casting in Children With Cerebral Palsy.
Cerebral Palsy
Ketamine-based procedural sedation and analgesia for botulinum toxin A injections in children with cerebral palsy.
Cerebral Palsy
Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy.
Cerebral Palsy
Laryngeal dystonia causing inspiratory stridor in children with cerebral palsy.
Cerebral Palsy
Letter to the editor on 'Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials'.
Cerebral Palsy
Letter to the editor: Re: Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Cerebral Palsy
Literature Review and Comparison of Two Statistical Methods to Evaluate the Effect of Botulinum Toxin Treatment on Gait in Children with Cerebral Palsy.
Cerebral Palsy
Long lasting benefits following the combination of static night upper extremity splinting with botulinum toxin A injections in cerebral palsy children.
Cerebral Palsy
Long-term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy.
Cerebral Palsy
Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan.
Cerebral Palsy
Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy: a prospective study.
Cerebral Palsy
Long-term effects of repeated botulinum neurotoxin A, bimanual training, and splinting in young children with cerebral palsy.
Cerebral Palsy
Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy.
Cerebral Palsy
Long-term use of botulinum toxin type A in children with cerebral palsy: Treatment consistency.
Cerebral Palsy
Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy.
Cerebral Palsy
Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy.
Cerebral Palsy
Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A.
Cerebral Palsy
Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications.
Cerebral Palsy
Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: preliminary report.
Cerebral Palsy
Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy.
Cerebral Palsy
Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure.
Cerebral Palsy
Migration percentage and odds of recurrence/subsequent surgery after treatment for hip subluxation in pediatric cerebral palsy: a meta-analysis and systematic review.
Cerebral Palsy
Modified constraint-induced movement therapy or bimanual occupational therapy following injection of Botulinum toxin-A to improve bimanual performance in young children with hemiplegic cerebral palsy: a randomised controlled trial methods paper.
Cerebral Palsy
Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy.
Cerebral Palsy
Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy.
Cerebral Palsy
MRI changes in calf muscles of two children with cerebral palsy following Botulinum Toxin Type A injections: a preliminary report.
Cerebral Palsy
Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study.
Cerebral Palsy
Muscle disuse caused by botulinum toxin injection leads to increased central gain of the stretch reflex in the rat.
Cerebral Palsy
Muscle histopathology in children with spastic cerebral palsy receiving botulinum toxin type A.
Cerebral Palsy
Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.
Cerebral Palsy
Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.
Cerebral Palsy
Negative effects of submandibular botulinum neurotoxin A injections on oral motor function in children with drooling due to central nervous system disorders.
Cerebral Palsy
Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
Cerebral Palsy
Neurophysiological changes induced by the botulinum toxin type A injection in children with cerebral palsy.
Cerebral Palsy
Neurorehabilitation with versus without resistance training after botulinum toxin treatment in children with cerebral palsy: a randomized pilot study.
Cerebral Palsy
No change in calf muscle passive stiffness after botulinum toxin injection in children with cerebral palsy.
Cerebral Palsy
No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy.
Cerebral Palsy
Off label use of botulinum toxin in children under two years of age: a systematic review.
Cerebral Palsy
Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy.
Cerebral Palsy
Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: an ICIDH-2 approach.
Cerebral Palsy
Outcome Measures Used in Studies of Botulinum Toxin in Childhood Cerebral Palsy: A Systematic Review.
Cerebral Palsy
Outcomes of Botulinum Toxin Type A Injection Followed by Rehabilitation in Cases of Cerebral Palsy With Upper Extremity Involvement.
Cerebral Palsy
Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy.
Cerebral Palsy
Parent evaluation of spasticity treatment in cerebral palsy using botulinum toxin type A.
Cerebral Palsy
Parent-proxy ratings of pain before and after botulinum toxin type A treatment for children with spasticity and cerebral palsy.
Cerebral Palsy
Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy.
Cerebral Palsy
Pedobarometric evaluation of equinus foot disorder after injection of botulinum toxin A in children with cerebral palsy: a pilot study.
Cerebral Palsy
Pelvic-Spinal Analysis and the Impact of Onabotulinum toxin A Injections on Spinal Balance in one Child With Cerebral Palsy.
Cerebral Palsy
Periodic botulinum toxin injections for paradoxical vocal fold motion in a child with cerebral palsy: a case study.
Cerebral Palsy
Phenol Versus Botulinum Toxin A Injection in Ambulatory Cerebral Palsy Spastic Diplegia: A Comparative Study.
Cerebral Palsy
Physical therapy intervention for children with cerebral palsy who receive botulinum toxin a injections.
Cerebral Palsy
Physiological anatomy of botulinum toxin effect on the spastic muscle of children with cerebral palsy.
Cerebral Palsy
Physiotherapy assessment and treatment for an ambulant child with cerebral palsy after botox a to the lower limbs: a case report.
Cerebral Palsy
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Cerebral Palsy
Planovalgus foot deformity in cerebral palsy corrected by botulinum toxin injection in the peroneus longus: Clinical and radiological evaluations in young children.
Cerebral Palsy
Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party.
Cerebral Palsy
Poster 485 Safety and Tolerability of AbobotulinumtoxinA (Dysport) in Children (2-17 Years) with Lower Limb Spasticity Due to Cerebral Palsy: A Pooled Analysis of 8 Clinical Trials.
Cerebral Palsy
Posture-Dependent Dysphagia After Botulinum Toxin Type A Injection at Sternocleidomastoid in a Patient With Athetoid Cerebral Palsy.
Cerebral Palsy
Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Cerebral Palsy
Predicting the Response to Botulinum Toxin Treatment in Children With Cerebral Palsy.
Cerebral Palsy
Preoperative botulinum neurotoxin A for children with bilateral cerebral palsy undergoing major hip surgery: a randomized double-blind placebo-controlled trial.
Cerebral Palsy
Preoperative botulinum toxin test injections before muscle lengthening in cerebral palsy.
Cerebral Palsy
Preoperative treatment of spasticity with botulinum neurotoxin A to reduce pain in cerebral palsy: is it worthwhile?
Cerebral Palsy
Preoperative treatment with botulinum toxin to facilitate cervical fusion in dystonic cerebral palsy. Report of two cases.
Cerebral Palsy
Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity.
Cerebral Palsy
Prospective study examining remote effects of botulinum toxin a in children with cerebral palsy.
Cerebral Palsy
Protocol for The Toxin Study: Understanding clinical and patient reported response of children and young people with cerebral palsy to intramuscular lower limb Botulinum neurotoxin-A injections, exploring all domains of the ICF. A pragmatic longitudinal observational study using a prospective one-group repeated measures design.
Cerebral Palsy
Quality of life of children with cerebral palsy treated with botulinum toxin: are well-being measures appropriate?
Cerebral Palsy
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study.
Cerebral Palsy
Quantitative assessment of muscle stiffness with acoustic radiation force impulse elastography after botulinum toxin A injection in children with cerebral palsy.
Cerebral Palsy
Quantitative effects on proximal joints of botulinum toxin treatment for gastrocnemius spasticity: a 4-year-old case study.
Cerebral Palsy
Quantitative evaluation for spasticity of calf muscle after botulinum toxin injection in patients with cerebral palsy: a pilot study.
Cerebral Palsy
Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy.
Cerebral Palsy
Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
Cerebral Palsy
Randomized double-blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
Cerebral Palsy
Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.
Cerebral Palsy
Rationale for Using Botulinum Toxin A as an Adjunct to Upper Limb Rehabilitation in Children With Cerebral Palsy.
Cerebral Palsy
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
Cerebral Palsy
Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: A review.
Cerebral Palsy
Reliability and validity of the Upper Limb Physician's Rating Scale in children with cerebral palsy.
Cerebral Palsy
Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial.
Cerebral Palsy
Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy.
Cerebral Palsy
Repeated botulinum toxin A injections in the treatment of spastic equinus foot.
Cerebral Palsy
Risk of systemic adverse events after botulinum neurotoxin A treatment in cerebral palsy.
Cerebral Palsy
Robotic therapy and botulinum toxin type A: a novel intervention approach for cerebral palsy.
Cerebral Palsy
Role for botulinum toxin in back pain treatment in adults with cerebral palsy: report of a case.
Cerebral Palsy
Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection.
Cerebral Palsy
Role of motor end plate-targeted Botulinum toxin type A injections in children with cerebral palsyitle.
Cerebral Palsy
Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019.
Cerebral Palsy
Safety and efficacy of a propofol and ketamine based procedural sedation protocol in children with cerebral palsy undergoing botulinum toxin A injections.
Cerebral Palsy
Safety and efficacy of Botulinum toxin type A preparations in cerebral palsy - an evidence-based review.
Cerebral Palsy
Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy.
Cerebral Palsy
Safety of botulinum toxin a in children and adolescents with cerebral palsy in a pragmatic setting.
Cerebral Palsy
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Cerebral Palsy
Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy.
Cerebral Palsy
Safety of combined salivary gland and multilevel intramuscular onabotulinumtoxinA injections with and without ethanol in pediatric patients with cerebral palsy: A retrospective study.
Cerebral Palsy
Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
Cerebral Palsy
Salivagram after gland injection of botulinum neurotoxin A in patients with cerebral infarction and cerebral palsy.
Cerebral Palsy
Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review.
Cerebral Palsy
Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy.
Cerebral Palsy
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities.
Cerebral Palsy
Severe Dysphagia after botulinum toxin B injection to the lower limbs and lumbar paraspinal muscles.
Cerebral Palsy
Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections.
Cerebral Palsy
Short-term effect of botulinum toxin a injection on spastic equinovarus foot in cerebral palsy patients: a study using the foot pressure measurement system.
Cerebral Palsy
Short-term effects of "botulinum toxin a" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint.
Cerebral Palsy
Short-term effects of combined serial casting and botulinum toxin injection for spastic equinus in ambulatory children with cerebral palsy.
Cerebral Palsy
Should botulinum toxin A injections be repeated in children with cerebral palsy? A systematic review.
Cerebral Palsy
Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences.
Cerebral Palsy
Single-event multilevel surgery, but not botulinum toxin injections normalize joint loading in cerebral palsy patients.
Cerebral Palsy
Sonoelastographic Evaluation of Medial Gastrocnemius Muscles Intrinsic Stiffness After Rehabilitation Therapy With Botulinum Toxin A Injection in Spastic Cerebral Palsy.
Cerebral Palsy
Sonographic and clinical effects of botulinum toxin Type A combined with extracorporeal shock wave therapy on spastic muscles of children with cerebral palsy.
Cerebral Palsy
Sonography-guided injection of botulinum toxin A in children with cerebral palsy.
Cerebral Palsy
Sonography-guided injection of botulinum toxin in children with cerebral palsy.
Cerebral Palsy
Spread of Botulinum Neurotoxin Type A at Standard Doses Is Inherent to the Successful Treatment of Spastic Equinus Foot in Cerebral Palsy: Short-Term Neurophysiological and Clinical Study.
Cerebral Palsy
Study protocol: precision of a protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle in the lower extremity during BTX-A treatment in children with spastic cerebral palsy, as verified by means of electrical stimulation.
Cerebral Palsy
Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy.
Cerebral Palsy
Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study.
Cerebral Palsy
Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
Cerebral Palsy
Surgery versus botulinum neurotoxin A to reduce drooling and improve daily life for children with neurodevelopmental disabilities: a randomized controlled trial.
Cerebral Palsy
Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation.
Cerebral Palsy
Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
Cerebral Palsy
Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
Cerebral Palsy
Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy.
Cerebral Palsy
The change of intrinsic stiffness in gastrocnemius after intensive rehabilitation with botulinum toxin a injection in spastic diplegic cerebral palsy.
Cerebral Palsy
The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial.
Cerebral Palsy
The effect of botulinum toxin A (Botox) injections used to treat limb spasticity on speech patterns in children with dysarthria and cerebral palsy: A report of two cases.
Cerebral Palsy
The effect of botulinum toxin A injections in the spine muscles for cerebral palsy scoliosis, examined in a prospective, randomized triple-blinded study.
Cerebral Palsy
The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response.
Cerebral Palsy
The Effect of Botulinum Toxin Injections on Gross Motor Function for Lower Limb Spasticity in Children with Cerebral Palsy.
Cerebral Palsy
The effect of botulinum toxin type A injection into the gastrocnemius muscle on sit-to-stand transfer in children with spastic diplegic cerebral palsy.
Cerebral Palsy
The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling.
Cerebral Palsy
The effect of botulinum toxin type-A injection on spasticity, range of motion and gait patterns in children with spastic diplegic cerebral palsy: an Egyptian study.
Cerebral Palsy
The effect of injections of botulinum toxin type A combined with casting on the equinus gait of children with cerebral palsy.
Cerebral Palsy
The Effect of Treatment on Stereognosis in Children With Hemiplegic Cerebral Palsy.
Cerebral Palsy
The effects of botulinum toxin (BTX-A) on spasticity of the lower limb and on gait in cerebral palsy.
Cerebral Palsy
The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study.
Cerebral Palsy
The effects of botulinum toxin type A on improvement and dynamic spastic equinus correction in children with cerebral palsy - preliminary results.
Cerebral Palsy
The effects of COVID-19 pandemic countermeasures on patients receiving botulinum toxin therapy and on their caregivers: a study from an Italian cohort.
Cerebral Palsy
The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy.
Cerebral Palsy
The efficacy of botulinum toxin A lower limb injections in addition to physiotherapy approaches in children with cerebral palsy: A systematic review.
Cerebral Palsy
The emerging role of therapeutic botulinum toxin in the treatment of cerebral palsy.
Cerebral Palsy
The expanding role of botulinum toxin type A injections in the management of children with cerebral palsy.
Cerebral Palsy
The impact of botulinum toxin A and abduction bracing on long-term hip development in children with cerebral palsy.
Cerebral Palsy
The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study.
Cerebral Palsy
The Influence of Botulinum Toxin A Injections into the Calf Muscles on Genu Recurvatum in Children With Cerebral Palsy.
Cerebral Palsy
The key-muscle concept: a long-term low-dose injection strategy for botulinum toxin A treatment in cerebral palsy.
Cerebral Palsy
The role of botulinum toxin A and abduction bracing in the management of hip development in children with cerebral palsy.
Cerebral Palsy
The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy.
Cerebral Palsy
The role of botulinum toxin in multimodal treatment of spasticity in ambulatory children with spastic Cerebral Palsy: extensive evaluation of a cost-effectiveness trial.
Cerebral Palsy
The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy--a pilot study.
Cerebral Palsy
The short-term effects of combined modified constraint-induced movement therapy and botulinum toxin injection for children with spastic hemiplegic cerebral palsy.
Cerebral Palsy
The treatment of posterior drooling by botulinum toxin in a child with cerebral palsy.
Cerebral Palsy
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
Cerebral Palsy
The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb.
Cerebral Palsy
The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy.
Cerebral Palsy
The utility of shear wave elastography in the evaluation of muscle stiffness in patients with cerebral palsy after botulinum toxin A injection.
Cerebral Palsy
Therapeutic use of botulinum toxin type A in cerebral palsy. Botulinum-toxin therapy shows promising future.
Cerebral Palsy
To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study.
Cerebral Palsy
Transcutaneous needle-free injection of botulinum toxin: a novel treatment of childhood constipation and anal fissure.
Cerebral Palsy
Treating spastic equinus foot from cerebral palsy with botulinum toxin type a: what factors influence the results?: an analysis of 189 consecutive cases.
Cerebral Palsy
Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports.
Cerebral Palsy
Treatment of cerebral palsy with botulinum toxin: evaluation with gross motor function measure.
Cerebral Palsy
Treatment of lateralisation and subluxation of the hip in cerebral palsy with Botulinum toxin A: preliminary results based on the analysis of migration percentage data.
Cerebral Palsy
Treatment of muscle spasticity in patients with cerebral palsy using BTX-A: a pilot study.
Cerebral Palsy
Treatment of recurrent posterior dislocation of the shoulder in cerebral palsy by injection with botulinum toxin A into the M. subscapularis.
Cerebral Palsy
Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
Cerebral Palsy
Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation.
Cerebral Palsy
Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study.
Cerebral Palsy
Treatment with botulinum toxin in children with cerebral palsy: a qualitative study of parents' experiences.
Cerebral Palsy
Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy.
Cerebral Palsy
Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy.
Cerebral Palsy
Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives.
Cerebral Palsy
Ultrasound-guided botulinum toxin type A injection to the iliopsoas muscle in the management of children with cerebral palsy.
Cerebral Palsy
Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy.
Cerebral Palsy
Upper extremity function and occupational performance in children with spastic cerebral palsy following lower extremity botulinum toxin injections.
Cerebral Palsy
Upper limb corticomotor projections and physiological changes that occur with botulinum toxin-A therapy in children with hemiplegic cerebral palsy.
Cerebral Palsy
Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases.
Cerebral Palsy
Upper limb motion analysis in children with hemiplegic cerebral palsy: proximal kinematic changes after distal botulinum toxin or surgical treatments.
Cerebral Palsy
Upper-extremity Spasticity-reducing Treatment in Adjunct to Movement Training and Orthoses in Children with Cerebral Palsy at Gross Motor Function- and Manual Ability Classification System Levels IV-V: A Descriptive Study.
Cerebral Palsy
Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial.
Cerebral Palsy
Use of a dynamic foot pressure index to monitor the effects of treatment for equinus gait in children with cerebral palsy.
Cerebral Palsy
Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study.
Cerebral Palsy
Use of botulinum toxin in the treatment of ankle plantar flexor spasticity in children with cerebral palsy.
Cerebral Palsy
Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review.
Cerebral Palsy
Use of intramuscular botulinum toxin in Malaysian children with cerebral palsy.
Cerebral Palsy
Use of Shear Wave Elastography for Quantitative Assessment of Muscle Stiffness After Botulinum Toxin Injection in Children With Cerebral Palsy.
Cerebral Palsy
Use of videographic examination for analysis of efficacy of botulinum toxin in the lower limbs in children with cerebral palsy.
Cerebral Palsy
Validity of bispectral index monitoring during deep sedation in children with spastic cerebral palsy undergoing injection of botulinum toxin.
Cerebral Palsy
Validity, reliability and responsiveness to change of the French version of the drooling impact scale.
Cerebral Palsy
Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: A cost-effectiveness study.
Cerebral Palsy
Vector-field statistics for the analysis of time varying clinical gait data.
Cerebral Palsy
Visual Analogue Scale to score the effects of Botulinum Toxin A treatment in children with cerebral palsy in daily clinical practice.
Cerebral Palsy
When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy.
Cerebral Palsy
Why do children with cerebral palsy discontinue therapy with botulinum toxin A?
Cerebral Palsy
[Botulinum toxin A in children with infantile cerebral palsy: indications and treatment concepts]
Cerebral Palsy
[Botulinum toxin A in the treatment of infantile cerebral palsy. Taking into account multilevel, integrated treatment]
Cerebral Palsy
[Botulinum Toxin A Treatment in Spastic Forms of Cerebral Palsy: A Retrospective Clinical Study.]
Cerebral Palsy
[Botulinum toxin for postoperative care after limb surgery in cerebral palsy children]
Cerebral Palsy
[Botulinum toxin in spastic infantile cerebral palsy: results in 27 cases during one year]
Cerebral Palsy
[Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children]
Cerebral Palsy
[Botulinum toxin treatment for horizontal strabismus in children with cerebral palsy]
Cerebral Palsy
[Botulinum toxin type A for the treatment of spasticity in children with cerebral palsy]
Cerebral Palsy
[Botulinum toxin type A in children: evaluation of indications with a review of the literature]
Cerebral Palsy
[Botulinum toxine treatment and the formation of antibodies to botulotoxin in patients with cerebral palsy].
Cerebral Palsy
[Cervical myelopathy associated with os odontoideum after botulinum toxin treatment in a patient with cerebral palsy].
Cerebral Palsy
[Development of motor functions and manual abilities in pediatric patients with spastic cerebral palsy after botulinum toxin treatment and complex rehabilitation].
Cerebral Palsy
[Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy: a prospective study].
Cerebral Palsy
[Effects of botulinum toxin guided by electric stimulation on spasticity in ankle plantar flexor of children with cerebral palsy: a randomized trial]
Cerebral Palsy
[Efficacy of botulinum toxin in the treatment of dynamic equinus and equinovarus foot deformities in children with hemiplegic cerebral palsy].
Cerebral Palsy
[Evaluation of a program of application of the botulinum toxin type A in children with cerebral palsy in Vale do Jequitinhonha].
Cerebral Palsy
[Evaluation of analgesic protocol with nitrous oxide and EMLA cream during botulinum toxin injections in children]
Cerebral Palsy
[Experiences with botulinum toxin injections against spasticity in children]
Cerebral Palsy
[Foot deformity in children with spastic forms of cerebral palsy: the treatment with botulinum toxin type A (disport)]
Cerebral Palsy
[High doses of botulinum toxin type A in children: efficacy and safety in clinical practice]
Cerebral Palsy
[Iatrogenic botulism: a complication to be taken into account in the treatment of child spasticity]
Cerebral Palsy
[Influence of toxin botulin on walk stereotype of children with juvenile cerebral palsy. The functional examination performed by BTS, comprehensive movement analysis system. A preliminary report].
Cerebral Palsy
[Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV-V)].
Cerebral Palsy
[New therapeutic methods for spasticity and dystonia in children with cerebral palsy require multidisciplinary team work. Comprehensive approach yields good results]
Cerebral Palsy
[Preliminary trial of botulinum toxin A therapy for lower extremity spasticity in children with cerebral palsy]
Cerebral Palsy
[Prevalence of hand dysfunction in cerebral palsy following Botulinum toxin therapy.]
Cerebral Palsy
[Sedation-analgesia protocol for the injection of botulinum toxin A in cerebral palsy].
Cerebral Palsy
[Spasticity in children cerebral palsy: diagnosis and treatment strategies].
Cerebral Palsy
[Submandibular gland resection for the management of sialorrhea in paediatric patients with cerebral palsy and unresponsive to type A botullinum toxin. Pilot study].
Cerebral Palsy
[The efficacy of botulinum toxin-A in the treatment of hypersalivation in children with cerebral palsy]
Cerebral Palsy
[The use of botulinum toxin in the treatment of spastic hip joint instability in children with cerebral palsy]
Cerebral Palsy
[Therapeutic effects of different doses of botulinum toxin A injection on tiptoe deformation in children with cerebral palsy].
Cerebral Palsy
[Treatment of spasticity in children with cerebral palsy with botulinum toxin A.]
Cerebral Palsy
[Treatment of the motor cerebral palsy child with botulinum toxin A: mode of action, injection places in management]
Cerebral Palsy
[Upper extremity botulinum toxin treatment in cerebral palsy. Treatment guidelines the first step towards national cooperation]
Cerebral Palsy
[Use of botulinum toxin in the preventive and palliative treatment of the hips in children with infantile cerebral palsy]
Cerebrovascular Disorders
Erratum to 'Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy' [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 1 (January), 2020: 104481].
Chagas Disease
Echoendoscopic evaluation of botulinum toxin intrasphincteric injections in Chagas' disease achalasia.
Charcot-Marie-Tooth Disease
Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A.
CHARGE Syndrome
Botulinum toxin injections into salivary glands to decrease oral secretions in CHARGE syndrome: Prospective case study.
Chickenpox
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Cholera
Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.
Cholera
Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.
Cholera
Liposome polymerase chain reaction assay for the sub-attomolar detection of cholera toxin and botulinum neurotoxin type A.
Cholera
Low molecular mass GTP-binding proteins are secreted from mammary epithelial cells in association with lipid globules.
Cholera
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Cholera
Modeling of SEB-induced host gene expression to correlate in vitro to in vivo responses.
Cholera
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
Cholera
Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin.
Chorea
Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery.
Chronic Exertional Compartment Syndrome
Botulinum Toxin A for Chronic Exertional Compartment Syndrome Evaluated With Shear Wave Elastography: A Case Report.
Chronic Exertional Compartment Syndrome
Botulinum Toxin A for Chronic Exertional Compartment Syndrome: A Retrospective Study of 16 Upper- and Lower-Limb Cases.
Chronic Exertional Compartment Syndrome
Botulinum Toxin as a Novel Treatment for Chronic Exertional Compartment Syndrome in the U.S. Military.
Chronic Exertional Compartment Syndrome
Botulinum Toxin for Chronic Exertional Compartment Syndrome: A Case Report With 14 Month Follow-Up.
Chronic Exertional Compartment Syndrome
Intramuscular Pressure Before and After Botulinum Toxin in Chronic Exertional Compartment Syndrome of the Leg: A Preliminary Study.
Cleft Lip
Botulinum Toxin for a Better Scar in Cleft Lip Surgery: A Prospective Randomized Control Trial.
Cleft Lip
Botulinum toxin injections for modulation of nasal and facial grimaces in a cleft lip and palate patient.
Cleft Lip
Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial.
Cleft Lip
Botulinum toxin type A as a novel method of preventing cleft lip scar hypertrophy-A literature review.
Cleft Lip
Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair.
Cleft Lip
Donor Site Aesthetic Enhancement With Preoperative Botulinum Toxin in Forehead Flap Nasal Reconstruction.
Cleft Lip
The use of botulinum toxin type A to minimize scarring in cleft lip repair: A literature review.
Clubfoot
A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
Clubfoot
A preliminary report of the use of botulinum toxin type A in infants with clubfoot: four case studies.
Clubfoot
A randomized controlled trial of selective neurotomy versus botulinum toxin for spastic equinovarus foot after stroke.
Clubfoot
Botulin toxin A in the treatment of dynamic equinovarus foot in cerebral palsied children.
Clubfoot
Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.
Clubfoot
Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.
Clubfoot
Botulinum Toxin Type A Versus Placebo for Idiopathic Clubfoot: A Two-Center, Double-Blind, Randomized Controlled Trial.
Clubfoot
Botulinum toxin type-A in the management of spastic equinovarus deformity after stroke. Comparison of 2 injection techniques.
Clubfoot
Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke.
Clubfoot
Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use.
Clubfoot
Current issues and considerations about the central role of rehabilitation therapies in the functional recovery of neurological impairments after stroke in adults.
Clubfoot
Diagnostic nerve block in prediction of outcome of botulinum toxin treatment for spastic equinovarus foot after stroke: A retrospective observational study.
Clubfoot
Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis.
Clubfoot
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Clubfoot
Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot.
Clubfoot
Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus.
Clubfoot
Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients.
Clubfoot
Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke.
Clubfoot
Outcomes of Botulinum Toxin Type A for equinovarus deformity in patients with CVA: A case series.
Clubfoot
Short-term effect of botulinum toxin a injection on spastic equinovarus foot in cerebral palsy patients: a study using the foot pressure measurement system.
Clubfoot
The efficacy of serial casting after botulinum toxin type A injection in improving equinovarus deformity in patients with chronic stroke.
Clubfoot
The use of botulinum type A toxin in the treatment of idiopathic clubfoot: 5-year follow-up.
Clubfoot
Ultrasonographic Evaluation of Botulinum Toxin Injection Site for the Medial Approach to Tibialis Posterior Muscle in Chronic Stroke Patients with Spastic Equinovarus Foot: An Observational Study.
Clubfoot
[Efficacy of botulinum toxin in the treatment of dynamic equinus and equinovarus foot deformities in children with hemiplegic cerebral palsy].
Cluster Headache
A review of nonvalidated and complementary therapies for cluster headache.
Cluster Headache
Botulinum toxin type-A therapy in cluster headache: a novel molecular mechanism.
Cluster Headache
Cluster Headache Associated with Secondary Unilateral Blepharospasm: A Case Report and Review of the Literature.
Cluster Headache
Long-Term Outcome of Patients With Intractable Chronic Cluster Headache Treated With Injection of Onabotulinum Toxin A Toward the Sphenopalatine Ganglion - An Observational Study.
Cluster Headache
O048. Chronic migraine, cluster headache or both? The suggestion of botulinum toxin.
Cluster Headache
OnabotulinumtoxinA in the treatment of refractory chronic cluster headache.
Cluster Headache
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache.
Cluster Headache
Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache.
Cluster Headache
Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
Cluster Headache
The role of nerve blocks and botulinum toxin injections in the management of cluster headaches.
Cluster Headache
[Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes]
Cockayne Syndrome
Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report.
Coloboma
Treacher Collins syndrome: an undescribed characteristic of the condition and its management with botulinum toxin and surgery.
Colonic Neoplasms
Diallyl disulfide inhibits colon cancer metastasis by suppressing Rac1-mediated epithelial-mesenchymal transition.
Communicable Diseases
Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan.
Communicable Diseases
Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome.
Communicable Diseases
[Poisoning with Clostridium botulinum toxin (data of the Infectious Disease Clinic and District Hospital for Infectious Diseases in GdaÅsk)]
Compartment Syndromes
Botulinum Toxin A for Chronic Exertional Compartment Syndrome Evaluated With Shear Wave Elastography: A Case Report.
Compartment Syndromes
Botulinum Toxin A for Chronic Exertional Compartment Syndrome: A Retrospective Study of 16 Upper- and Lower-Limb Cases.
Compartment Syndromes
Botulinum Toxin as a Novel Treatment for Chronic Exertional Compartment Syndrome in the U.S. Military.
Compartment Syndromes
Botulinum Toxin for Chronic Exertional Compartment Syndrome: A Case Report With 14 Month Follow-Up.
Compartment Syndromes
Intramuscular Pressure Before and After Botulinum Toxin in Chronic Exertional Compartment Syndrome of the Leg: A Preliminary Study.
Compartment Syndromes
Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk.
Complex Regional Pain Syndromes
Botulinum Toxin A (Botox) for Treatment of Proximal Myofascial Pain in Complex Regional Pain Syndrome: Two Cases.
Complex Regional Pain Syndromes
Botulinum Toxin A for Treatment of Allodynia of Complex Regional Pain Syndrome: A Pilot Study.
Complex Regional Pain Syndromes
Botulinum toxin for neuropathic pain and spasticity: an overview.
Complex Regional Pain Syndromes
Intra-articular botulinum toxin injection in complex regional pain syndrome: Case report and review of the literature.
Complex Regional Pain Syndromes
Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome.
Complex Regional Pain Syndromes
Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review.
Complex Regional Pain Syndromes
Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome.
Complex Regional Pain Syndromes
Lumbar Sympathetic Block with Botulinum Toxin Type B for Complex Regional Pain Syndrome: A Case Study.
Complex Regional Pain Syndromes
Subcutaneous botulinum toxin A for the treatment of refractory complex regional pain syndrome.
Complex Regional Pain Syndromes
Sympathetic block with botulinum toxin to treat complex regional pain syndrome.
Complex Regional Pain Syndromes
[Functional rehabilitation and analgesia with botulinum toxin A in upper limb complex regional pain syndrome type I: case reports.]
Confusion
Botulinum toxin injection, dilution confusion: The impact of toxin diffusion on clinical practice.
Confusion
Erratum: Botulinum neurotoxin formulations: overcoming the confusion [Corrigendum].
Confusion
Hyaluronic acid fillers and botulinum toxin type a: rationale for their individual and combined use for injectable facial rejuvenation.
Congenital Abnormalities
A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
Congenital Abnormalities
A preliminary report of the use of botulinum toxin type A in infants with clubfoot: four case studies.
Congenital Abnormalities
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
Congenital Abnormalities
Botulinum toxin as an alternative for the treatment of aesthetic deformities.
Congenital Abnormalities
Botulinum toxin injection site localization for the tibialis posterior muscle.
Congenital Abnormalities
Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy.
Congenital Abnormalities
Botulinum toxin type A as an adjunct to the surgical treatment of the medial rotation deformity of the shoulder in birth injuries of the brachial plexus.
Congenital Abnormalities
Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.
Congenital Abnormalities
Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy.
Congenital Abnormalities
Botulinum Toxin Type-A as an alternative treatment for gummy smile: a case report.
Congenital Abnormalities
Botulinum toxin type-A in the management of spastic equinovarus deformity after stroke. Comparison of 2 injection techniques.
Congenital Abnormalities
Cerebral palsy hip deformities: is there a consensus? II. Botulinum toxin A: a clinical experiment.
Congenital Abnormalities
Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle Paralysis from Botulinum Toxin Injection.
Congenital Abnormalities
Does botulinum toxin prevent or promote deformity in children with cerebral palsy?
Congenital Abnormalities
Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis.
Congenital Abnormalities
Effectiveness and safety of early intramuscular botulinum toxin injections to prevent shoulder deformity in babies with brachial plexus birth injury (POPB-TOX), a randomised controlled trial: study protocol.
Congenital Abnormalities
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Congenital Abnormalities
Effectiveness of primary conservative management for infants with obstetric brachial plexus palsy.
Congenital Abnormalities
Efficacy of Botulinum Toxin A Treatment for Pes Varus during Gait.
Congenital Abnormalities
Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients.
Congenital Abnormalities
Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial.
Congenital Abnormalities
Lack of effectiveness of primary conservative management for infants with brachial plexus birth palsy.
Congenital Abnormalities
Management of Children With Ambulatory Cerebral Palsy: An Evidence-based Review.
Congenital Abnormalities
Nonsurgical treatment for hallux abducto valgus with botulinum toxin A.
Congenital Abnormalities
Optimal injection points for the neuromuscular blockade of forearm flexor muscles: a cadaveric study.
Congenital Abnormalities
Outcomes of Botulinum Toxin Type A for equinovarus deformity in patients with CVA: A case series.
Congenital Abnormalities
Overview of foot deformity management in children with cerebral palsy.
Congenital Abnormalities
Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies.
Congenital Abnormalities
Postural & striatal deformities in Parkinson`s disease: Are these rare?
Congenital Abnormalities
Quantitative assessment for flexed-elbow deformity during gait following botulinum toxin A treatment.
Congenital Abnormalities
Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results.
Congenital Abnormalities
Safety and Efficacy of Botulinum Toxin A in Children Undergoing Lower Limb Lengthening and Deformity Correction: Results of a Double-blind, Multicenter, Randomized Controlled Trial.
Congenital Abnormalities
Selective botulinum toxin injection in the treatment of recurrent deformity following surgical correction of club foot: a preliminary report of 3 children.
Congenital Abnormalities
Spinal lordosis with marked opisthotonus secondary to dystonia musculorum deformans: case report with surgical management.
Congenital Abnormalities
The Clinical Efficacy of Botulinum Toxin Injections to the Upper Lumbrical Muscles for Clenched Fist Deformity in Chronic Stroke Patients.
Congenital Abnormalities
The efficacy of serial casting after botulinum toxin type A injection in improving equinovarus deformity in patients with chronic stroke.
Congenital Abnormalities
The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy--a pilot study.
Congenital Abnormalities
Treatment of muscular contraction deformities with botulinum toxin type A after latissimus dorsi flap and sub-pectoral implant breast reconstruction.
Congenital Abnormalities
Treatment of post-traumatic chin deformities using bilateral botulinum toxin injections.
Congenital Microtia
A Case of Parotid Gland Fistula After Microtia Reconstruction Successfully Treated With Botulinum Toxin Type A.
Conjunctivitis, Allergic
IgG specific antibodies to rye grass and ragweed pollen antigens in the tear secretions of patients with vernal conjunctivitis.
Contracture
A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury.
Contracture
Add-on Home-Centered Activity-Based Therapy vs Conventional Physiotherapy in Improving Walking Ability at 6-Months in Children With Diplegic Cerebral Palsy: A Randomized Controlled Trial.
Contracture
Botulin toxin A in the treatment of dynamic equinovarus foot in cerebral palsied children.
Contracture
Botulinum Neurotoxin A injections influence stretching of the gastrocnemius muscle-tendon unit in an animal model.
Contracture
Botulinum Toxin A Plays an Important Role in the Placement of Implants Deep Within the Pectoralis Major Muscle for Mammaplasty: A Systematic Review and Meta-analysis.
Contracture
Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.
Contracture
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
Contracture
Botulinum toxin for amelioration of knee contracture in Duchenne muscular dystrophy.
Contracture
Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: A novel approach.
Contracture
Botulinum toxin injection causes hyperreflexia and increased muscle stiffness of the triceps surae muscle in the rat.
Contracture
Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report.
Contracture
Botulinum Toxin Injection for Internal Rotation Contractures in Brachial Plexus Birth Palsy. A Minimum 5-Year Prospective Observational Study.
Contracture
Botulinum Toxin Type A as a Tool for Correcting Capsular Contracture after Reconstructive Breast Surgery.
Contracture
Botulinum Toxin Type A for the Treatment of Equinus Deformity in to Patients With Mucopolysaccharidosis Type II.
Contracture
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.
Contracture
Botulinum toxin type A in the treatment of painful adductor muscle contracture after total hip arthroplasty.
Contracture
Botulinum Toxin Type A Inhibits ?-Smooth Muscle Actin and Myosin II Expression in Fibroblasts Derived From Scar Contracture.
Contracture
Botulinum toxin type A injection increases range of motion in hip, knee and ankle joint contractures of children with cerebral palsy.
Contracture
Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.
Contracture
Botulinum toxin type A injections for the management of muscle tightness following total hip arthroplasty: a case series.
Contracture
Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion.
Contracture
Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy.
Contracture
Can the early use of botulinum toxin in post stroke spasticity reduce contracture development? A randomised controlled trial.
Contracture
Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment.
Contracture
Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study.
Contracture
Contractures elicited by tetraethylammonium in avian muscle treated with methohexitone.
Contracture
Decreased flexion contracture after total knee arthroplasty using Botulinum toxin A: a randomized controlled trial.
Contracture
Dynamic splinting after treatment with botulinum toxin type-A: A randomized controlled pilot study.
Contracture
Effectiveness of a programme comprising serial casting, botulinum toxin, splinting and motor training for contracture management: a randomized controlled trial.
Contracture
Effects of botulinum toxin A on functional outcome during distraction osteogenesis.
Contracture
Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A.
Contracture
Four unrelated patients with Lubs X-linked mental retardation syndrome and different Xq28 duplications.
Contracture
How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Contracture
Intramuscular injection of collagenase clostridium histolyticum may decrease spastic muscle contracture for children with cerebral palsy.
Contracture
Knee flexion contracture treated with botulinum toxin type A in patients with haemophilia (PWH).
Contracture
Long-term effects of combined botulinum toxin treatment and rehabilitation on upper limb muscle spasms: a case report.
Contracture
Long-Term Resolution of Severe Ankle Contractures Using Botulinum Toxin, Serial Casting, Splinting, and Motor Retraining.
Contracture
Management of Children With Ambulatory Cerebral Palsy: An Evidence-based Review.
Contracture
Muscle disuse caused by botulinum toxin injection leads to increased central gain of the stretch reflex in the rat.
Contracture
Myositis ossificans traumatica of the temporalis muscle: a case report and diagnostic considerations.
Contracture
Nishida procedure associated with botulinum toxin in a long-standing complete bilateral sixth cranial nerve palsy.
Contracture
Onabotulinum toxinA injection as an adjunct in the treatment of posterior shoulder subluxation in neonatal brachial plexus palsy.
Contracture
Outcomes of Botulinum Toxin Injection for Shoulder Internal Rotation Contractures in Infants with Brachial Plexus Birth Injury.
Contracture
Palliative care in 9 children with neurodegeneration with brain iron accumulation.
Contracture
Persisting hypotropias following protective ptosis induced by botulinum neurotoxin.
Contracture
Side effects and potential risk factors of botulinum toxin type A intramuscular injections in knee flexion contractures of hemophiliacs.
Contracture
Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy.
Contracture
Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm.
Contracture
The Effect of Botox on the Implant Stabilization and Capsular Formation: An Experimental Study.
Contracture
The effect of botulinum neurotoxin type A on capsule formation around silicone implants: the in vivo and in vitro study.
Contracture
The use of botulinum toxin in the treatment of the consequences of bruxism on cervical spine musculature.
Contracture
Treatment with posterior capsular release, botulinum toxin injection, hamstring tenotomy, and peroneal nerve decompression improves flexion contracture after total knee arthroplasty: minimum 2-year follow-up.
Contracture
Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature.
Contracture
Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy.
Contracture
[Advances in the research of prevention and treatment of postburn contractures of hand].
Contracture
[Botulinum toxin in the treatment of psoas muscle contracture in mucopolysaccharidosis]
Contracture
[Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?]
Contracture
[Clinical presentations, differential diagnosis and management of obstetric brachial palsy]
Contracture
[Functional results of type A botulinum toxin versus oral anti-inflammatory agents in the rehabilitation of painful shoulder syndrome caused by rotator cuff lesion].
Contracture
[How botulinum toxin enriches orthopedics. Toxin against contractures and pain]
Contracture
[Infiltration of the psoas muscles with botulinum toxin guided by computerised axial tomography: a series of cases].
Corneal Injuries
Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model.
Corneal Ulcer
Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Corticobasal Degeneration
Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome.
Cough
Bilateral Thyroarytenoid Botulinum Toxin Type A Injection for the Treatment of Refractory Chronic Cough.
Cough
Botulinum toxin A: a novel adjunct treatment for debilitating habit cough in children.
Cough
Hemi-laryngopharyngeal spasm as a novel cause of inducible laryngeal obstruction with a surgical cure: report of 3 cases.
COVID-19
"Masking" our emotions: Botulinum toxin, facial expression, and well-being in the age of COVID-19.
COVID-19
A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic.
COVID-19
A risk-stratified approach toward safely resuming OnabotulinumtoxinA injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19).
COVID-19
A video of best practice recommendations for making botulinum toxin therapy safe during the COVID-19 pandemic.
COVID-19
Botulinum Toxin Services for Neurorehabiliation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic.
COVID-19
Botulinum toxin therapy during the Covid 19 outbreak: Experience of an Italian multidisciplinary team.
COVID-19
Commentary on: A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic.
COVID-19
Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak
COVID-19
Could treatment with botulinum toxin protect against subsequent infection with COVID-19?
COVID-19
Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.
COVID-19
Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity.
COVID-19
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown.
COVID-19
Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment.
COVID-19
OnabotulinumtoxinA infiltration and nerve blocks in patients with headache and neuralgia: safety recommendations to prevent SARS-CoV-2 infection.
COVID-19
Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19.
COVID-19
Severe hyperalgesia and pain during botulinum toxin injection avoiding application in a patient 1 week after COVID-19 infection.
COVID-19
The effects of COVID-19 pandemic countermeasures on patients receiving botulinum toxin therapy and on their caregivers: a study from an Italian cohort.
COVID-19
[French Association of Urology. COVID-19: Recommendations for functional urology].
Coxsackievirus Infections
Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulinum toxin and denervation.
Cranial Nerve Diseases
Neurological aspects of biological and chemical terrorism: a review for neurologists.
Cranial Nerve Diseases
Temporary management of diplopia with botulinum toxin in multiple ocular motor cranial neuropathies.
Craniocerebral Trauma
A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury.
Craniocerebral Trauma
A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury.
Crohn Disease
Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease.
Cumulative Trauma Disorders
The Utility of Musculoskeletal Ultrasound in Rehabilitation Settings.
Cystic Fibrosis
Botulinum Neurotoxin A for Parotid Enlargement in Cystic Fibrosis: The First Case Report.
Cystic Fibrosis
Expression of miR?542?3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.
Cystitis
Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis.
Cystitis
Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
Cystitis
Botulinum toxin type A may improve bladder function in a rat chemical cystitis model.
Cystitis
Comparison of intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A injection or cystoscopic hydrodistention for ketamine-associated cystitis.
Cystitis
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA).
Cystitis
Editorial comment from Dr. Yoshimura to potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
Cystitis
Editorial comment from professor Dinis to Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
Cystitis
Editorial Comment on: Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats.
Cystitis
Effective treatment of ketamine-associated cystitis with botulinum toxin type a injection combined with bladder hydrodistention.
Cystitis
Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
Cystitis
Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis.
Cystitis
Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
Cystitis
Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats.
Cystitis
Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies.
Cystitis
Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review.
Cystitis
Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections.
Cystitis
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Cystitis
Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.
Cystitis
Potential therapeutic effect of intravesical botulinum toxin type?A on bladder pain syndrome/interstitial cystitis.
Cystitis
Re: Intrathecal Administration of Botulinum Toxin Type A Improves Urinary Bladder Function and Reduces Pain in Rats with Cystitis.
Cystitis
Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?
Cystitis
Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis.
Cystitis
von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder.
Cystitis, Interstitial
A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome.
Cystitis, Interstitial
An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders.
Cystitis, Interstitial
Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup.
Cystitis, Interstitial
Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis.
Cystitis, Interstitial
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Cystitis, Interstitial
Botulinum toxin a has antinociceptive effects in treating interstitial cystitis.
Cystitis, Interstitial
Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
Cystitis, Interstitial
Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
Cystitis, Interstitial
Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response.
Cystitis, Interstitial
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Cystitis, Interstitial
Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial.
Cystitis, Interstitial
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA).
Cystitis, Interstitial
Editorial Comment from Dr Manning to Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response.
Cystitis, Interstitial
Editorial Comment from Dr Tomoe to Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response.
Cystitis, Interstitial
Efficacy of Botulinum toxin A for the treatment of Bladder pain syndrome: A systematic review.
Cystitis, Interstitial
Experience with injections of botulinum toxin type A into the detrusor muscle.
Cystitis, Interstitial
Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis.
Cystitis, Interstitial
Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review.
Cystitis, Interstitial
Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis.
Cystitis, Interstitial
Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: a molecular mechanism.
Cystitis, Interstitial
Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study.
Cystitis, Interstitial
Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome.
Cystitis, Interstitial
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Cystitis, Interstitial
Re: The Efficacy of Botulinum Toxin A and Sacral Neuromodulation in the Management of Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS), What do we Know? ICI-RS 2017 Think Tank, Bristol.
Cystitis, Interstitial
The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.
Cystitis, Interstitial
Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study.
Cystitis, Interstitial
What is the Best Treatment Option for Coexisting Pelvic Floor Dysfunctions?
Cytomegalovirus Infections
Human leukocyte antigen E in human cytomegalovirus infection: friend or foe?
Darier Disease
Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.
Darier Disease
Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier's disease and inguinal hyperhidrosis.
Darier Disease
Letter: Botulinum Toxin Type A: An Alternative Symptomatic Management of Darier's Disease.
Deglutition Disorders
A case of dysphagia following botulinum toxin injection for neck rejuvenation.
Deglutition Disorders
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Deglutition Disorders
A methodological approach for botulinum neurotoxin injections to the longus colli muscle in dystonic anterocollis: A case series of 4 patients and a literature review.
Deglutition Disorders
ALS dysphagia pathophysiology: differential botulinum toxin response.
Deglutition Disorders
An electrophysiological approach to the diagnosis of neurogenic dysphagia; implications for botulinum toxin treatment.
Deglutition Disorders
Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle.
Deglutition Disorders
Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread.
Deglutition Disorders
Botulinum toxin A injection of UES in schizencephaly with dysphagia: Case report.
Deglutition Disorders
Botulinum Toxin A Injection Using Esophageal Balloon Radiography Combined with CT Guidance for the Treatment of Cricopharyngeal Dysphagia.
Deglutition Disorders
Botulinum toxin a treatment of cricopharyngeal dysphagia after subarachnoid hemorrhage.
Deglutition Disorders
Botulinum toxin alleviates dysphagia of patients with inclusion body myositis.
Deglutition Disorders
Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Deglutition Disorders
Botulinum toxin as a biological weapon: medical and public health management.
Deglutition Disorders
Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.
Deglutition Disorders
Botulinum toxin for cricopharyngeal dysphagia: case reports of CT-guided injection.
Deglutition Disorders
Botulinum toxin for oropharyngeal dysphagia: case report of flexible endoscope-guided injection.
Deglutition Disorders
Botulinum toxin for the treatment of hypercontractile esophagus: Results of a double-blind randomized sham-controlled study.
Deglutition Disorders
Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders.
Deglutition Disorders
Botulinum toxin improves dysphagia associated with multiple sclerosis.
Deglutition Disorders
Botulinum Toxin Injection for Dysphagia: A Blinded Retrospective Videofluoroscopic Swallowing Study Analysis.
Deglutition Disorders
Botulinum toxin injection in dysphagia syndromes with preserved esophageal peristalsis and incomplete lower esophageal sphincter relaxation.
Deglutition Disorders
Botulinum Toxin Injection in the Treatment of Postextubation Dysphagia: A Case Report.
Deglutition Disorders
Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia.
Deglutition Disorders
Botulinum toxin injection versus laparoscopic myotomy for the treatment of esophageal achalasia: economic analysis of a randomized trial.
Deglutition Disorders
Botulinum toxin injections for achalasia symptoms can approximate the short term efficacy of a single pneumatic dilation: a survival analysis approach.
Deglutition Disorders
Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders.
Deglutition Disorders
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders.
Deglutition Disorders
Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy.
Deglutition Disorders
Botulinum toxin treatment for oropharyngeal dysphagia due to tetanus.
Deglutition Disorders
Botulinum toxin treatment for oropharyngeal dysphagia in patients with stroke.
Deglutition Disorders
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.
Deglutition Disorders
Case report: botulinum toxin in hypertensive lower esophageal sphincter: a manometric case study.
Deglutition Disorders
Cervical spondylodiscitis following cricopharyngeal botulinium toxin injection.
Deglutition Disorders
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Deglutition Disorders
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Deglutition Disorders
Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia.
Deglutition Disorders
Cricopharyngeal dysfunction: A systematic review comparing outcomes of dilatation, botulinum toxin injection, and myotomy.
Deglutition Disorders
Current Australian clinical practice in use of botulinum toxin-A to manage paediatric hypertonicity.
Deglutition Disorders
Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings.
Deglutition Disorders
Dysphagia as a complication of botulinum toxin injection to treat drooling.
Deglutition Disorders
Dysphagia from esophageal diverticulosis responding to botulinum toxin injection.
Deglutition Disorders
Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study.
Deglutition Disorders
Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations.
Deglutition Disorders
Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia.
Deglutition Disorders
Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Deglutition Disorders
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Deglutition Disorders
Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction.
Deglutition Disorders
Efficacy of botulinum toxin type-A and swallowing treatment for oropharyngeal dysphagia recovery in a patient with lateral medullary syndrome.
Deglutition Disorders
Efficacy of Early Endoscopic Intervention for Restoring Normal Swallowing Function in Patients with Lateral Medullary Infarction.
Deglutition Disorders
Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia.
Deglutition Disorders
Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia.
Deglutition Disorders
Endoscopic botulinum toxin injection for treatment of pharyngeal dysphagia in patients with cricopharyngeal dysfunction.
Deglutition Disorders
Endoscopic Management of Postradiation Dysphagia in Head and Neck Cancer Patients: A Systematic Review.
Deglutition Disorders
Endoscopic-guided injection of botulinum toxin into the cricopharyngeus muscle: our experience.
Deglutition Disorders
Erratum to: Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Deglutition Disorders
Esophageal cancer in esophageal diverticula associated with achalasia.
Deglutition Disorders
Factors associated with postoperative symptoms after laparoscopic Heller myotomy.
Deglutition Disorders
Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis.
Deglutition Disorders
Hypercontractile esophageal motility disorder or functional esophageal symptoms and unrelated hypercontractility?
Deglutition Disorders
Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.
Deglutition Disorders
Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter.
Deglutition Disorders
Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.
Deglutition Disorders
Intranasal neostigmine therapy of botulinum toxin (BTX) treatment dysphagia.
Deglutition Disorders
Laparoscopic extended cardiomyotomy in children: an effective procedure for the treatment of esophageal achalasia.
Deglutition Disorders
Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy.
Deglutition Disorders
Long-lasting effect of a single botulinum toxin injection in the treatment of oropharyngeal dysphagia secondary to upper esophageal sphincter dysfunction: A pilot study.
Deglutition Disorders
Long-term Botulinum Toxin Treatment for Dysphagia Due to Large Epiphrenic Diverticulum in Elderly Patients: A Report of Two Cases.
Deglutition Disorders
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.
Deglutition Disorders
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
Deglutition Disorders
Management of oromandibular dystonia on a chorea acanthocytosis: a brief review of the literature and a clinical case.
Deglutition Disorders
Management of sialorrhoea in motor neuron disease: A survey of current UK practice.
Deglutition Disorders
Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study.
Deglutition Disorders
Outcomes of peroral endoscopic myotomy in patients with achalasia and prior bariatric surgery: A multicenter experience.
Deglutition Disorders
Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects.
Deglutition Disorders
Percutaneous chemical myotomy using botulium neurtoxin A under local anaesthesia in the treatment of cricopharyngeal dysphagia following laryngectomy.
Deglutition Disorders
Persistent post-stroke dysphagia treated with cricopharyngeal myotomy.
Deglutition Disorders
Pharyngeal Motility Before and After Thyroarytenoid Muscle Botulinum Toxin Injection.
Deglutition Disorders
Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
Deglutition Disorders
Posture-Dependent Dysphagia After Botulinum Toxin Type A Injection at Sternocleidomastoid in a Patient With Athetoid Cerebral Palsy.
Deglutition Disorders
Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review.
Deglutition Disorders
Pyridostigmine for Reversal of Severe Sequelae From Botulinum Toxin Injection.
Deglutition Disorders
Recovery of swallowing disorders in patients undergoing supracricoid laryngectomy with botulinum toxin therapy.
Deglutition Disorders
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Deglutition Disorders
Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.
Deglutition Disorders
Saliva management options for difficult-to-wean people with tracheostomy following severe acquired brain injury (ABI): A review of the literature.
Deglutition Disorders
Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease.
Deglutition Disorders
Severe Dysphagia after botulinum toxin B injection to the lower limbs and lumbar paraspinal muscles.
Deglutition Disorders
Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy.
Deglutition Disorders
Severe dysphagia due to a huge epiphrenic diverticulum: long-term treatment with balloon dilation and botulinum toxin injection: a case report.
Deglutition Disorders
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Deglutition Disorders
Solving dysphagia due to cricopharyngeal muscle dysfunction with botulinum toxin.
Deglutition Disorders
Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia.
Deglutition Disorders
Successful botulinum toxin treatment of dysphagia in a spinal muscular atrophy type 2 patient.
Deglutition Disorders
Successful botulinum toxin treatment of dysphagia in a young child with nemaline myopathy.
Deglutition Disorders
Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy.
Deglutition Disorders
Successful treatment of long-standing post-stroke dysphagia with botulinum toxin and rehabilitation.
Deglutition Disorders
Surgical and conservative methods for restoring impaired motor function - facial nerve, spinal accessory nerve, hypoglossal nerve (not including vagal nerve or swallowing).
Deglutition Disorders
Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
Deglutition Disorders
The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis.
Deglutition Disorders
The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia.
Deglutition Disorders
The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
Deglutition Disorders
Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review.
Deglutition Disorders
Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction.
Deglutition Disorders
Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method.
Deglutition Disorders
Ultrasound, electromyography, and balloon guidance for injecting botulinum toxin for cricopharyngeal achalasia: A case report.
Deglutition Disorders
Ultrasound-Guided Injection of Botulinum Toxin for Cricopharyngeal Dysphagia.
Deglutition Disorders
Use of high-resolution endoscopic ultrasonography to assess esophageal wall damage after pneumatic dilation and botulinum toxin injection to treat achalasia.
Deglutition Disorders
[Botulinum toxin injection into the cricopharyngeal muscle for dysphagia: report of 2 successful cases]
Dementia
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine.
Dementia
Applied botulinum neurotoxin injection in a patient with dementia to reduce hypersalivation.
Dementia
Botulinum toxin type A combined with cervical spine manual therapy for masseteric hypertrophy in a patient with Alzheimer-type dementia: a case report.
Dementia
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Dementia
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Dementia
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Dementia
Severe cervical dystonia in pathologically proven Parkinson's disease and dementia.
Dementia
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Dentofacial Deformities
Botulinum Toxin Type-A as an alternative treatment for gummy smile: a case report.
Dermatitis
Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system.
Dermatitis
The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond.
Dermatitis
Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin.
Dermatitis, Atopic
Evaluation of Botulinum Toxin A as an Optional Treatment for Atopic Dermatitis.
Dermatitis, Irritant
Botulinum neurotoxin A is an effective treatment for irritant dermatitis caused by ostomy leaks in patients with retractile stomas.
Dermatitis, Seborrheic
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Dermatitis, Seborrheic
Efficacy and possible mechanisms of botulinum toxin treatment of oily skin.
Dermatitis, Seborrheic
The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post-acne.
Dermatitis, Seborrheic
The efficacy of intradermal injections of botulinum toxin in the management of enlarged facial pores and seborrhea: a split face-controlled study.
Dermatomyositis
Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis.
Diabetes Complications
The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.
Diabetes Mellitus
Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.
Diabetes Mellitus, Type 1
Treatment of diabetic gastroparesis with botulinum toxin injection guided by endoscopic ultrasound in a patient with type 1 diabetes: the first report.
Diabetes Mellitus, Type 2
Botulinum toxin A in the early treatment of sixth nerve palsy in type 2 diabetes.
Diabetes Mellitus, Type 2
Botulinum toxin A in the early treatment of sixth nerve palsy-induced diplopia in type 2 diabetes.
Diabetic Nephropathies
Engulfment and cell motility protein 1 potentiates diabetic cardiomyopathy via Rac-dependent and Rac-independent ROS production.
Diabetic Neuropathies
Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy.
Diabetic Neuropathies
Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection.
Diabetic Neuropathies
OnabotulinumtoxinA Improves Tactile and Mechanical Pain Perception in Painful Diabetic Polyneuropathy.
Diabetic Neuropathies
Subcutaneous and Perineural Botulinum Toxin Type A For Neuropathic Pain: A Descriptive Review.
Diabetic Neuropathies
The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy.
Diabetic Neuropathies
The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial.
Diabetic Neuropathies
The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy.
Diabetic Retinopathy
Adaptor Protein p66Shc: A Link Between Cytosolic and Mitochondrial Dysfunction in the Development of Diabetic Retinopathy.
Diphtheria
A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol.
Diphtheria
Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes.
Diphtheria
Clostridium difficile toxins A and B: Receptors, pores, and translocation into cells.
Diphtheria
Escherichia coli hemolysin permeabilizes small unilamellar vesicles loaded with calcein by a single-hit mechanism.
Diplopia
Abobotulinum toxin A for periorbital facial rejuvenation: impact on ocular refractive parameters.
Diplopia
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
Diplopia
Botox® after Botox® - a new approach to treat diplopia secondary to cosmetic botulinic toxin use: case reports.
Diplopia
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Diplopia
Botulinum toxin A in the early treatment of sixth nerve palsy-induced diplopia in type 2 diabetes.
Diplopia
Botulinum toxin A therapy for medial rectus injury during endoscopic sinus surgery.
Diplopia
Botulinum toxin as a postoperative diplopia test - it can also reduce the angle of deviation prior to surgery.
Diplopia
Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.
Diplopia
Botulinum toxin injection for the treatment of epiphora in lacrimal outflow obstruction.
Diplopia
Botulinum toxin to the lateral rectus for the treatment of esotropia with paradoxical diplopia.
Diplopia
Diplopia associated with the cosmetic use of botulinum toxin a for facial rejuvenation.
Diplopia
Elimination of paradoxical diplopia following treatment with botulinum toxin and prism.
Diplopia
Hemifield-slide diplopia successfully managed with botulinum toxin injection in a patient with traumatic chiasmal disruption.
Diplopia
Inferior Oblique Botulinum Toxin Injection: A Postoperative Diplopia Test for Secondary Inferior Oblique Muscle Overaction.
Diplopia
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Diplopia
Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin.
Diplopia
Loss of binocular vision (diplopia) and acute comitant esotropia following surgical patch removal after unilateral penetrating keratoplasty for keratoconus; management.
Diplopia
Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies.
Diplopia
Ophthalmic adverse events following facial injections of botulinum toxin A: A systemic literature review.
Diplopia
Retinal tear and raised intraocular pressure following unintentional intraocular botulinum toxin type A injection.
Diplopia
Strabismus in adults with uveal melanoma following episcleral plaque brachytherapy.
Diplopia
Temporary management of diplopia with botulinum toxin in multiple ocular motor cranial neuropathies.
Diplopia
The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine.
Diplopia
The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment.
Diplopia
The Role of Botulinum Toxin in the Management of Ophthalmoplegia Secondary to Miller Fisher Syndrome.
Diplopia
Treatment of abnormal eye movements that impair vision: strategies based on current concepts of physiology and pharmacology.
Diplopia
[Botulinum toxin injection to the lateral rectus for the treatment of intractable diplopia]
Diplopia
[Diplopia following subcutaneous injections of botulinum toxin for cosmetic or medical use].
Diplopia
[Injection of botulinum toxin into the oculomotor muscles in disorders of ocular motility]
Diverticulosis, Esophageal
Dysphagia from esophageal diverticulosis responding to botulinum toxin injection.
Diverticulum
Long-term Botulinum Toxin Treatment for Dysphagia Due to Large Epiphrenic Diverticulum in Elderly Patients: A Report of Two Cases.
Diverticulum
Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum.
Diverticulum
Severe dysphagia due to a huge epiphrenic diverticulum: long-term treatment with balloon dilation and botulinum toxin injection: a case report.
Drug Eruptions
Fixed drug eruption caused by lactose in an injected botulinum toxin preparation.
Drug Eruptions
Generalized drug eruption with vasculopathic reaction pattern to botulinum toxin injection.
Drug-Related Side Effects and Adverse Reactions
Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase.
Drug-Related Side Effects and Adverse Reactions
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Dry Eye Syndromes
An Aesthetic Orbicularis Oculi Myectomy Technique for Blepharospasm: Use of Topical 5-Fluorouracil and Fibrin Sealant.
Dry Eye Syndromes
Application of botulinum toxin in Horner's muscle for the treatment of dry eye.
Dry Eye Syndromes
Botulinum neurotoxin type A versus punctal plug insertion in the management of dry eye disease.
Dry Eye Syndromes
Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease.
Dry Eye Syndromes
Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Dry Eye Syndromes
Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report.
Dry Eye Syndromes
Botulinum toxin type a injection for lateral canthal rhytids : effect on tear film stability and tear production.
Dry Eye Syndromes
Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Dry Eye Syndromes
Comparison Between Botulinum Toxin A Injection and Lacrimal Punctal Plugs for the Control of Post-LASIK Dry Eye Manifestations: A Prospective Study.
Dry Eye Syndromes
Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
Dry Eye Syndromes
Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Dry Eye Syndromes
Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A.
Dry Eye Syndromes
Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention.
Dry Eye Syndromes
Effect of 0.025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye.
Dry Eye Syndromes
Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.
Dry Eye Syndromes
Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
Dry Eye Syndromes
Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Dry Eye Syndromes
Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
Dry Eye Syndromes
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Dry Eye Syndromes
Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
Dry Eye Syndromes
Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model.
Dry Eye Syndromes
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model.
Dry Eye Syndromes
Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye.
Dry Eye Syndromes
Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections.
Dry Eye Syndromes
Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model.
Dry Eye Syndromes
Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening.
Dry Eye Syndromes
[Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment]
Duane Retraction Syndrome
Botulinum toxin injection in the patients with Duane syndrome type 1.
Duane Retraction Syndrome
Botulinum toxin treatment in patients up to 3 years of age who have esotropic duane retraction syndrome.
Duane Retraction Syndrome
Diagnostic use of botulinum toxin in patients with Duane syndrome.
Duane Retraction Syndrome
[Injection of botulinum toxin into the oculomotor muscles in disorders of ocular motility]
Dysarthria
Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections.
Dysarthria
The effect of botulinum toxin A (Botox) injections used to treat limb spasticity on speech patterns in children with dysarthria and cerebral palsy: A report of two cases.
Dysarthria
The effect of botulinum toxin A on the vocal symptoms of spastic dysarthria: a case study.
Dyskinesias
Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.
Dyskinesias
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Dyskinesias
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Dyskinesias
Botulinum Toxin Injection for Spastic Scapular Dyskinesia After Stroke: Case Series.
Dyskinesias
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio.
Dyskinesias
Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state.
Dyskinesias
Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.
Dyskinesias
Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study.
Dyskinesias
Effects of botulinum toxin type B on stump pain and involuntary movements of the stump.
Dyskinesias
Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application.
Dyskinesias
Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias.
Dyskinesias
Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Dyskinesias
Multidisciplinary management of a partially edentulous patient with oromandibular dystonia: A clinical report.
Dyskinesias
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
Dyskinesias
Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin.
Dyskinesias
Spinal myoclonus in the periscapular muscles after mastectomy assessed by FDG-PET.
Dyskinesias
Surgical Strategies for Cervical Deformities Associated With Neuromuscular Disorders.
Dyskinesias
Sustained benefit of painful legs moving toes syndrome with botulinum toxin type A.
Dyskinesias
The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
Dyskinesias
Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer's dyskinesia.
Dyskinesias
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
Dyskinesias
[Treatments by local injections of botulinum toxin in neurology. Indications and results]
Dyspareunia
Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial.
Dyspareunia
Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial.
Dyspareunia
Botulinum toxin type A for treatment of dyspareunia caused by localized scleroderma.
Dyspareunia
Botulinum toxin-treatment of localized provoked vulvodynia refractory to conventional treatment.
Dyspareunia
Improvement in pelvic pain with botulinum toxin type A - Single vs. repeat injections.
Dyspareunia
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Dyspareunia
Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia.
Dyspareunia
Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients' Characteristics.
Dysphonia
A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.
Dysphonia
A comparison of methods of botulinum toxin injection for abductory spasmodic dysphonia.
Dysphonia
A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
Dysphonia
A Comparison of the VHI, VHI-10, and V-RQOL for Measuring the Effect of Botox Therapy in Adductor Spasmodic Dysphonia.
Dysphonia
A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
Dysphonia
A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia.
Dysphonia
A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
Dysphonia
Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection.
Dysphonia
Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being.
Dysphonia
Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Dysphonia
Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture.
Dysphonia
Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study.
Dysphonia
Altered sensory system activity and connectivity patterns in adductor spasmodic dysphonia.
Dysphonia
Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia.
Dysphonia
Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
Dysphonia
Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia.
Dysphonia
Assessing the Effectiveness of Botulinum Toxin Injections for Adductor Spasmodic Dysphonia: Clinician and Patient Perception.
Dysphonia
Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia.
Dysphonia
Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment.
Dysphonia
Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
Dysphonia
Bilateral Posterior Cricoarytenoid Myoneurectomy for Abductor Spasmodic Dysphonia.
Dysphonia
Bipolar radiofrequency-induced thermotherapy (rfitt) for the treatment of spasmodic dysphonia. A report of three cases.
Dysphonia
Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
Dysphonia
Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.
Dysphonia
Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections.
Dysphonia
Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
Dysphonia
Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report.
Dysphonia
Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.
Dysphonia
Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report.
Dysphonia
Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Dysphonia
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Dysphonia
Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach.
Dysphonia
Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
Dysphonia
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
Dysphonia
Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Dysphonia
Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
Dysphonia
Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Dysphonia
Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
Dysphonia
Considerations for Initial Dosing of Botulinum Toxin in Treatment of Adductor Spasmodic Dysphonia.
Dysphonia
Correlation between clinical response and injection quality in treatment of spasmodic dysphonia.
Dysphonia
Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage.
Dysphonia
Differences in Botulinum Toxin Dosing Between Patients With Adductor Spasmodic Dysphonia and Essential Voice Tremor.
Dysphonia
Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
Dysphonia
Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin.
Dysphonia
Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia.
Dysphonia
Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
Dysphonia
Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
Dysphonia
Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection.
Dysphonia
Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia.
Dysphonia
Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Dysphonia
Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.
Dysphonia
Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
Dysphonia
Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Dysphonia
Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Dysphonia
False vocal cord botulinum toxin injection for refractory muscle tension dysphonia: Our experience with seven patients.
Dysphonia
Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography.
Dysphonia
Functional reinnervation of vocal folds after selective laryngeal adductor denervation-reinnervation surgery for spasmodic dysphonia.
Dysphonia
Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Dysphonia
Hemodynamic Changes Associated With Transcervical Laryngeal Injection of Botulinum Toxin.
Dysphonia
Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
Dysphonia
Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin.
Dysphonia
Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Dysphonia
Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.
Dysphonia
Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia.
Dysphonia
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset.
Dysphonia
Laryngeal Botulinum Toxin Injection: Can It Be a Cause of Obstructive Sleep Apnea as an Adverse Effect?
Dysphonia
Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia.
Dysphonia
Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
Dysphonia
Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Dysphonia
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Dysphonia
Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
Dysphonia
Long-term Dose Stability of OnabotulinumtoxinA Injection for Adductor Spasmodic Dysphonia: A 19-Year Single Institution Experience.
Dysphonia
Long-term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor.
Dysphonia
Long-Term Follow-Up of Patients with Spasmodic Dysphonia and Improved Voice despite Discontinuation of Treatment.
Dysphonia
Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Dysphonia
Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Dysphonia
Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
Dysphonia
Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
Dysphonia
Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies.
Dysphonia
Muscle fiber-type changes induced by botulinum toxin injection in the rat larynx.
Dysphonia
Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
Dysphonia
Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
Dysphonia
OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
Dysphonia
Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
Dysphonia
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Dysphonia
Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection.
Dysphonia
Perceptual structure of adductor spasmodic dysphonia and its acoustic correlates.
Dysphonia
Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia.
Dysphonia
Practice parameter: laryngeal electromyography (an evidence-based review).
Dysphonia
Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
Dysphonia
Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
Dysphonia
Proteomic changes in rat thyroarytenoid muscle induced by botulinum neurotoxin injection.
Dysphonia
Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
Dysphonia
Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dysphonia
Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle.
Dysphonia
Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
Dysphonia
Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Dysphonia
Retropharyngeal hematoma following botulinum toxin injection for abductor spasmodic dysphonia.
Dysphonia
Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
Dysphonia
Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
Dysphonia
Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Dysphonia
Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia.
Dysphonia
Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study.
Dysphonia
Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series.
Dysphonia
Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
Dysphonia
Spasmodic dysphonia in a patient with the A to G transition at nucleotide 8344 in mitochondrial DNA.
Dysphonia
Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis.
Dysphonia
Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Dysphonia
Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience.
Dysphonia
Sporadic failure of botulinum toxin treatment in usually responsive patients with adductor spasmodic dysphonia.
Dysphonia
Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection.
Dysphonia
Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.
Dysphonia
Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Dysphonia
The effect of botulinum toxin A on the vocal symptoms of spastic dysarthria: a case study.
Dysphonia
The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
Dysphonia
The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
Dysphonia
The Impact of Socioeconomic Status on Voice Outcomes in Patients With Spasmodic Dysphonia Treated With Botulinum Toxin Injections.
Dysphonia
The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
Dysphonia
The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
Dysphonia
Three-dimensional computer reconstruction of the distribution of neuromuscular junctions in the thyroarytenoid muscle.
Dysphonia
Three-dimensional reconstruction of immunolabeled neuromuscular junctions in the human thyroarytenoid muscle.
Dysphonia
Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
Dysphonia
Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report.
Dysphonia
Treatment of spasmodic dysphonia with homeopathic medicine: a clinical case report.
Dysphonia
Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia.
Dysphonia
Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
Dysphonia
Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dysphonia
Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia.
Dysphonia
Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Dysphonia
Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia.
Dysphonia
Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.
Dysphonia
Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.
Dysphonia
Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial.
Dysphonia
Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
Dysphonia
Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Dysphonia
Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
Dysphonia
Voice disorders in the workplace: Productivity in spasmodic dysphonia and the impact of botulinum toxin.
Dysphonia
Voice related quality of life after botulinum toxin injection for spasmodic dysphonia.
Dysphonia
["Off-label use" of botulinum toxin preparations in treatment of spasmodic dysphonia. Position of the German Society of Phoniatrics and Pediatric Audiology]
Dysphonia
[Abnormal movements of the larynx. Diagnostic approach and therapeutic perspectives]
Dysphonia
[Application status and prospect of botulinum toxin A in otorhinolaryngological treatment].
Dysphonia
[Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study]
Dysphonia
[Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)]
Dysphonia
[Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].
Dysphonia
[Treatment of laryngeal movement disorders with botulinum toxins: part 1: History and mode of action]
Dyspnea
Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.
Dyspnea
Cricothyroid Muscle Botulinum Toxin Injection to Improve Airway for Bilateral Recurrent Laryngeal Nerve Paralysis, A Case Series.
Dyspnea
Vocal fold botulinum toxin injection for refractory paradoxical vocal fold motion disorder.
Dyspnea
[Effect of cricothyroid and thyroarytenoid muscle botulinum toxin injection on patients with dyspnea caused by bilateral recurrent laryngeal nerve paresis].
Dystonia
'Author's Response to Letter to the Editor On 'Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia Needs Prompt Muscle Selection, Appropriate Dosage and Precise Guidance'.
Dystonia
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
Dystonia
A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis.
Dystonia
A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A.
Dystonia
A case of thrombosis of subcutaneous anterior chest veins (Mondor's disease) as an unusual complication of botulinum type A injection.
Dystonia
A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Dystonia
A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial.
Dystonia
A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin(®): A new botulinum neurotoxin A.
Dystonia
A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Dystonia
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.
Dystonia
A Nurse-Led Clinic Model for the Treatment of Cervical Dystonia Using Botulinum Toxin.
Dystonia
A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Dystonia
A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.
Dystonia
A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia.
Dystonia
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
Dystonia
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
Dystonia
A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
Dystonia
A rare case of laryngeal dystonia associated with neurosyphilis: Response to botulinum toxin injection.
Dystonia
A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
Dystonia
A simplified ultrasonography-guided approach for neurotoxin injection into the obliquus capitis inferior muscle in spasmodic torticollis.
Dystonia
A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force.
Dystonia
Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathophysiological considerations.
Dystonia
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Dystonia
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.
Dystonia
Accuracy of Ultrasound-Guided and Non-guided Botulinum Toxin Injection Into Neck Muscles Involved in Cervical Dystonia: A Cadaveric Study.
Dystonia
Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report.
Dystonia
Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
Dystonia
Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox).
Dystonia
Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
Dystonia
Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery.
Dystonia
An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport).
Dystonia
Anatomical guide for botulinum neurotoxin injection: Application to cosmetic shoulder contouring, pain syndromes, and cervical dystonia.
Dystonia
Anatomo-sonographic identification of the longissimus capitis and splenius cervicis muscles: principles for possible application to ultrasound-guided botulinum toxin injections in cervical dystonia.
Dystonia
Anatomy-guided injections of botulinum neurotoxin in neck muscles: how accurate is needle placement?
Dystonia
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.
Dystonia
Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
Dystonia
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
Dystonia
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Dystonia
Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment.
Dystonia
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans.
Dystonia
Atypical posttraumatic dystonia treated successfully by botulinum toxin injection.
Dystonia
Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A.
Dystonia
Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.
Dystonia
Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
Dystonia
Behavioral Therapy for Tremor or Dystonia Affecting Voice in Speakers with Hyperkinetic Dysarthria: A Systematic Review.
Dystonia
Benefits, Safety, and Adjunct Modality Prevalences of Long-Term Botulinum Toxin Injections for Cervical Dystonia and Myofascial Neck Pain: A Retrospective Cohort Study.
Dystonia
Bilateral Lower Sternocleidomastoid Botulinum Toxin Injections to Address Refractory Anterocollis.
Dystonia
Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years.
Dystonia
BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Dystonia
Both Deep Brain Stimulation and Thalamotomy in a 13-Year-Old Patient with Primary Dystonia.
Dystonia
Botox Injections in Paraspinal Muscles Result in Low Maximal Specific Force and Shortening Velocity in Fast but not Slow Skinned Muscle Fibres.
Dystonia
Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
Dystonia
Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission.
Dystonia
Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Payment policy perspectives.
Dystonia
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Dystonia
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Dystonia
Botulinum neurotoxin in cervical dystonia revisited - recent advances and unanswered questions.
Dystonia
Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
Dystonia
Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features.
Dystonia
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
Dystonia
Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey.
Dystonia
Botulinum Toxin A and Task-Specific Training for Hand Dystonia due to 5 Year Old Stroke.
Dystonia
Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study.
Dystonia
Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review.
Dystonia
Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study.
Dystonia
Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia.
Dystonia
Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System.
Dystonia
Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement.
Dystonia
Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Dystonia
Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex.
Dystonia
Botulinum toxin enhancement of postoperative immobilization in patients with cervical dystonia. Technical note.
Dystonia
Botulinum toxin for cervical dystonia: addressing treatment failure and improving outcomes.
Dystonia
Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: A case series and a pilot study.
Dystonia
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Dystonia
Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service.
Dystonia
Botulinum toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome.
Dystonia
Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
Dystonia
Botulinum toxin in the elderly to the care of limbs spastic hypertonia and toes or fingers dystonias.
Dystonia
Botulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia.
Dystonia
Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report.
Dystonia
Botulinum toxin injection to improve functional independence and to alleviate parenting stress in a child with advanced pantothenate kinase-associated neurodegeneration: A case report and literature review.
Dystonia
Botulinum toxin injections reduce associative plasticity in patients with primary dystonia.
Dystonia
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Dystonia
Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia.
Dystonia
Botulinum Toxin Services for Neurorehabiliation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic.
Dystonia
Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
Dystonia
Botulinum toxin therapy, immunologic resistance, and problems with available materials.
Dystonia
Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
Dystonia
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.
Dystonia
Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia.
Dystonia
Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
Dystonia
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
Dystonia
Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Dystonia
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Dystonia
Botulinum toxin type A enhances the inhibitory spontaneous postsynaptic currents on the substantia gelatinosa neurons of the subnucleus caudalis in immature mice.
Dystonia
Botulinum toxin type A in the treatment of focal hand dystonia after surgical treatment for thumb duplication.
Dystonia
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.
Dystonia
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Dystonia
Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
Dystonia
Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosis.
Dystonia
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Dystonia
Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia.
Dystonia
Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
Dystonia
Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose-escalation pilot study.
Dystonia
Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Dystonia
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
Dystonia
Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia.
Dystonia
Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.
Dystonia
Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.
Dystonia
Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications.
Dystonia
Botulinum toxin-A for treatment of Pisa syndrome: Towards a decision-making algorithm?
Dystonia
Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Dystonia
Brachial Neuritis After Botulinum Toxin Injections for Cervical Dystonia: A Need for a Reappraisal?
Dystonia
Brain connectivity abnormalities and treatment-induced restorations in patients with cervical dystonia.
Dystonia
Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy.
Dystonia
British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
Dystonia
Can the Jankovic-assessment be used as an alternative to electromyography? A cross-sectional study on facial dystonia patients treated with Botulinum toxin.
Dystonia
Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.
Dystonia
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Dystonia
Cause or effect: Altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment.
Dystonia
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Dystonia
Cervical Dystonia Refractory to Botulinum Toxin Responding to Radiofrequency Ablation: A Case Report.
Dystonia
Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.
Dystonia
Cervical dystonia: Improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography.
Dystonia
Cervical dystonia: Injecting botulinum neurotoxin into semispinalis capitis improves goose-neck posture.
Dystonia
Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle Paralysis from Botulinum Toxin Injection.
Dystonia
Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A.
Dystonia
Change in the pattern of cervical dystonia might be the cause of benefit loss during botulinum toxin treatment.
Dystonia
Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: a functional MRI study.
Dystonia
Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait.
Dystonia
Chronic Cervical Dystonia Complicating Cervical Myelopathy-A Therapeutic Challenge Managed by Botulinum Toxin and Surgical Intervention.
Dystonia
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Dystonia
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Dystonia
Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients.
Dystonia
Clinical Characteristics and Response to Long-Term Botulinum Toxin Type A Therapy in Patients with Cervical Dystonia at a Neurology Clinic.
Dystonia
Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Dystonia
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
Dystonia
Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins.
Dystonia
Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series.
Dystonia
Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.
Dystonia
Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Dystonia
Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia.
Dystonia
Clinical Response to IncobotulinumtoxinA, after Demonstrated Loss of Clinical Response to OnabotulinumtoxinA and RimabotulininumtoxinB in a Patient with Musician's Dystonia.
Dystonia
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
Dystonia
Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.
Dystonia
Cognitive performance after facial botulinum toxin treatment in a cohort of neurological patients - an exploratory study.
Dystonia
Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift.
Dystonia
Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports.
Dystonia
Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2017, 10, 18-Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections-Muscle Innervation Zone Targeting Revisited.
Dystonia
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Dystonia
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Dystonia
Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Dystonia
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
Dystonia
Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.
Dystonia
Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
Dystonia
Computer-Aided Design/Computer-Assisted Manufacture-Derived Needle Guide for Injection of Botulinum Toxin into the Lateral Pterygoid Muscle in Patients with Oromandibular Dystonia.
Dystonia
Concurrent OnabotulinumtoxinA Treatment of Cervical Dystonia and Concomitant Migraine.
Dystonia
Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity.
Dystonia
Consensus statement on physician training for the treatment of dystonia with botulinum toxin. The Canadian Movement Disorders Group.
Dystonia
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Dystonia
Content of botulinum neurotoxin in botox(r)/vistabel(r), dysport(r)/azzalure(r), and xeomin(r)/bocouture(r).
Dystonia
Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy--is it worth it?
Dystonia
Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.
Dystonia
Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.
Dystonia
Correction to: How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.
Dystonia
Correction to: Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia.
Dystonia
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
Dystonia
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
Dystonia
Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Dystonia
Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin.
Dystonia
Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument.
Dystonia
Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
Dystonia
Current Australian clinical practice in use of botulinum toxin-A to manage paediatric hypertonicity.
Dystonia
Debunking the pathophysiological puzzle of dystonia--with special reference to botulinum toxin therapy.
Dystonia
Decreased neck muscle strength is highly associated with pain in cervical dystonia patients treated with botulinum toxin injections.
Dystonia
Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.
Dystonia
Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia.
Dystonia
Diffusion of aniline blue injected into the thyroarytenoid muscle as a proxy for botulinum toxin injection: an experimental study in cadaver larynges.
Dystonia
Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm.
Dystonia
Direct current stimulation of primary motor cortex and cerebellum and botulinum toxin a injections in a person with cervical dystonia.
Dystonia
Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy.
Dystonia
Do Botulinum Toxins Have a Role in the Management of Neuropathic Pain?: A Focused Review.
Dystonia
Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia.
Dystonia
Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres.
Dystonia
Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia.
Dystonia
Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.
Dystonia
Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.
Dystonia
Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia.
Dystonia
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies.
Dystonia
Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy.
Dystonia
Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia.
Dystonia
Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study.
Dystonia
Dystonia - new advances in classification, genetics, pathophysiology and treatment.
Dystonia
Dystonia and headaches: clinical features and response to botulinum toxin therapy.
Dystonia
Dystonia in Machado-Joseph disease: Clinical profile, therapy and anatomical basis.
Dystonia
Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.
Dystonia
Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue.
Dystonia
Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status.
Dystonia
Effect of dystonia and botulinum toxin treatment on health-related quality of life.
Dystonia
Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction.
Dystonia
Effect of Neck Botulinum Neurotoxin Injection on Proprioception and Somatosensory-Motor Cortical Processing in Cervical Dystonia.
Dystonia
Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review.
Dystonia
Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study.
Dystonia
Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.
Dystonia
Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia.
Dystonia
Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia.
Dystonia
Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
Dystonia
Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
Dystonia
Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Dystonia
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Dystonia
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Dystonia
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
Dystonia
Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review.
Dystonia
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Dystonia
Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation.
Dystonia
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options.
Dystonia
Efficacy of single-photon emission computed tomography aided botulinum toxin injection in cervical dystonia: A double-blind, randomized study.
Dystonia
Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia.
Dystonia
Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy.
Dystonia
Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia.
Dystonia
Electromyography analysis and botulinum toxin plan in a pianist with musician's dystonia: A case report.
Dystonia
Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl.
Dystonia
Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia.
Dystonia
EMG coherence and spectral analysis in cervical dystonia: discriminative tools to identify dystonic muscles?
Dystonia
Episodic paroxysmal laryngospasm: voice and pulmonary function assessment and management.
Dystonia
Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives.
Dystonia
Evidence for the use of botulinum toxin in the chronic pain setting--a review of the literature.
Dystonia
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Dystonia
Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study.
Dystonia
Exploratory structural assessment in craniocervical dystonia: Global and differential analyses.
Dystonia
Exploring the Psychosocial Impact of Botulinum Toxin Type A Injections for Individuals With Oromandibular Dystonia: A Qualitative Study of Patients' Experiences.
Dystonia
Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection.
Dystonia
Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.
Dystonia
Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Dystonia
Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study.
Dystonia
Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.
Dystonia
Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation.
Dystonia
Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
Dystonia
FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.
Dystonia
Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography.
Dystonia
Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Dystonia
Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis.
Dystonia
Focal Task-Specific Lower Limb Dystonia Only When Walking Stairs: Is It a New Disease Entity?
Dystonia
Functional recovery from chronic writer's cramp by brain-computer interface rehabilitation: a case report.
Dystonia
Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Dystonia
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases.
Dystonia
Haptic Feedback Manipulation During Botulinum Toxin Injection Therapy for Focal Hand Dystonia Patients: A Possible New Assistive Strategy.
Dystonia
Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity.
Dystonia
Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.
Dystonia
Hemodynamic Changes Associated With Transcervical Laryngeal Injection of Botulinum Toxin.
Dystonia
High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment.
Dystonia
High prevalence of self-reported non-motor symptoms and lack of correlation with motor severity in adult patients with idiopathic isolated dystonia.
Dystonia
How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.
Dystonia
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
Dystonia
Iatrogenic Botulism Due to Therapeutic Botulinum Toxin A Injection in a Pediatric Patient.
Dystonia
Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Dystonia
Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients.
Dystonia
Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
Dystonia
Immunogenicity to Botulinum Toxin Type A: A Systematic Review With Meta-Analysis Across Therapeutic Indications.
Dystonia
Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin.
Dystonia
Immunoresistance in Cervical Dystonia Patients after Treatment with AbobotulinumtoxinA (Dysport).
Dystonia
Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.
Dystonia
Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry.
Dystonia
Impact of Injection-Guiding Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Focal Spasticity and Dystonia: A Systematic Review.
Dystonia
Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.
Dystonia
Improved identification of dystonic cervical muscles via abnormal muscle activity during isometric contractions.
Dystonia
Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.
Dystonia
In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
Dystonia
IncobotulinumtoxinA (Xeomin(®)) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(®)).
Dystonia
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Dystonia
Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia.
Dystonia
Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies.
Dystonia
Initial experience with imaging-guided intramuscular botulinum toxin injection in patients with idiopathic cervical dystonia.
Dystonia
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study.
Dystonia
Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.
Dystonia
INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Dystonia
Isolated speech-induced lingual dystonia successfully treated with botulinum neurotoxin.
Dystonia
Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.
Dystonia
Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.
Dystonia
Lack of effect of botulinum toxin on cortical excitability in patients with cranial dystonia.
Dystonia
Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
Dystonia
Late-onset primary dystonia in Zhejiang province of China: a service-based epidemiological study.
Dystonia
Lateral pterygoid muscle dystonia. A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy.
Dystonia
Localization of dystonic muscles with 18F-FDG PET/CT in idiopathic cervical dystonia.
Dystonia
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Dystonia
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia).
Dystonia
Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin.
Dystonia
Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.
Dystonia
Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome.
Dystonia
Long-term botulinum toxin treatment of cervical dystonia--EMG changes in injected and noninjected muscles.
Dystonia
Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia.
Dystonia
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.
Dystonia
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Dystonia
Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
Dystonia
Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.
Dystonia
Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.
Dystonia
Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin.
Dystonia
Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
Dystonia
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
Dystonia
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
Dystonia
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.
Dystonia
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia.
Dystonia
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?
Dystonia
Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
Dystonia
Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Dystonia
Management of Anterocapitis and Anterocollis: A Novel Ultrasound Guided Approach Combined with Electromyography for Botulinum Toxin Injection of Longus Colli and Longus Capitis.
Dystonia
Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance.
Dystonia
Management of Secondary Poor Response to Botulinum Toxin in Cervical Dystonia: A Multicenter Audit.
Dystonia
Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.
Dystonia
Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A.
Dystonia
Mandibular Bone Loss after Masticatory Muscles Intervention with Botulinum Toxin: An Approach from Basic Research to Clinical Findings.
Dystonia
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Dystonia
Measurement of laryngeal resistance in the evaluation of botulinum toxin injection for treatment of focal laryngeal dystonia.
Dystonia
Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis.
Dystonia
Meige syndrome: a rare form of cranial dystonia that was treated successfully with botulinum toxin.
Dystonia
Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies.
Dystonia
Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
Dystonia
Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.
Dystonia
Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia.
Dystonia
Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.
Dystonia
Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions.
Dystonia
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Dystonia
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
Dystonia
Morphological characteristics of the posterior neck muscles and anatomical landmarks for botulinum toxin injections.
Dystonia
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Dystonia
Multichannel Electromyographic Mapping to Optimize OnabotulinumtoxinA Efficacy in Cervical Dystonia.
Dystonia
Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
Dystonia
Muscle selection for treatment of cervical dystonia with botulinum toxin--a systematic review.
Dystonia
Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia.
Dystonia
Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Dystonia
Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.
Dystonia
Neuropsychological and Neuropsychiatric Features of Idiopathic and DYT1 Dystonia and the Impact of Medical and Surgical treatment.
Dystonia
Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
Dystonia
Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A.
Dystonia
No effects on heart-rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia.
Dystonia
Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.
Dystonia
Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm.
Dystonia
Obstructive sleep apnea due to oromandibular dystonia and treated with botulinum toxin.
Dystonia
Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study.
Dystonia
OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial.
Dystonia
Oral health and oral health-related quality of life in patients with oral dystonia indicates their need for dental special care.
Dystonia
Oromandibular Dystonia Causing Recurrent Mandibular Open Lock in Two Adolescents Managed with Botulinum Toxin.
Dystonia
Oromandibular dystonia in yemeni patients with khat chewing: a response to botulinum toxin treatment.
Dystonia
Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity.
Dystonia
Oromandibular dystonia, mental distress and oro-facial dysfunction-A follow-up 8-10 years after start of treatment with botulinum toxin.
Dystonia
Oromandibular Dystonia: A Case Report of the Lateral Pterygoid Muscle Involvement and Treatment with Botulinum Toxin A.
Dystonia
Outcomes of Intrathecal Baclofen Therapy Compared With Deep Brain Stimulation in a Patient With Dystonic Cerebral Palsy: A Case Report.
Dystonia
Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known?
Dystonia
Painful cervical dystonia: clinical features and response to treatment with botulinum toxin.
Dystonia
Palliative care in 9 children with neurodegeneration with brain iron accumulation.
Dystonia
Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy.
Dystonia
Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial.
Dystonia
Pallidal neurostimulation versus botulinum toxin injections in the treatment of cervical dystonia: protocol of a randomized, sham-controlled trial (StimTox-CD).
Dystonia
Pallidal stimulation for segmental dystonia: long term follow up of 11 consecutive patients.
Dystonia
Paroxysmal autonomic instability with dystonia managed using chemodenervation including alcohol neurolysis and botulinum toxin type a injection: a case report.
Dystonia
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Dystonia
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A.
Dystonia
Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia.
Dystonia
Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.
Dystonia
Perceptions regarding communicative participation in individuals receiving botulinum toxin injections for laryngeal dystonia.
Dystonia
Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Dystonia
Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review.
Dystonia
Pharyngeal Dystonia Misdiagnosed as Cricopharyngeal Dysphagia Successfully Treated by Pharmacotherapy.
Dystonia
Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles.
Dystonia
Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Dystonia
Polymyography combined with time-locked video recording (video EMG) for presurgical assessment of patients with cervical dystonia.
Dystonia
Poster 290 Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared with Placebo in Adult Patients with Cervical Dystonia.
Dystonia
Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study.
Dystonia
Posturographic findings in patients with idiopathic cervical dystonia before and after local injections with botulinum toxin.
Dystonia
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Dystonia
Precise Muscle Selection Using Dynamic Polyelectromyography for Treatment of Post-stroke Dystonia: A Case Report.
Dystonia
Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.
Dystonia
Preoperative treatment with botulinum toxin to facilitate cervical fusion in dystonic cerebral palsy. Report of two cases.
Dystonia
Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity.
Dystonia
Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
Dystonia
Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature.
Dystonia
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.
Dystonia
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.
Dystonia
Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia.
Dystonia
Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation.
Dystonia
Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport® ).
Dystonia
Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study.
Dystonia
Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital.
Dystonia
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
Dystonia
Quality of life in patients with craniocervical dystonia: Italian validation of the "Cervical Dystonia Impact Profile (CDIP-58)" and the "Craniocervical Dystonia Questionnaire (CDQ-24)"
Dystonia
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.
Dystonia
Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia.
Dystonia
Quantitative electromyographical changes in cervical dystonia after treatment with botulinum toxin.
Dystonia
Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia.
Dystonia
Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study.
Dystonia
Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor.
Dystonia
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy.
Dystonia
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
Dystonia
Re: Botulinum toxin type B vs. Type a in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Dystonia
Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
Dystonia
Reduced Neck Muscle Strength and Altered Muscle Mechanical Properties in Cervical Dystonia Following Botulinum Neurotoxin Injections: A Prospective Study.
Dystonia
Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.
Dystonia
Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates.
Dystonia
Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A.
Dystonia
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
Dystonia
Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement.
Dystonia
Reliability of DNMSQuest as a Screening Tool for Mood Disorders in Cervical Dystonia.
Dystonia
Remote effects of chronic botulinum toxin treatment: electrophysiologic results Do not indicate subclinical remodelling of noninjected muscles.
Dystonia
Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Dystonia
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Dystonia
Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia.
Dystonia
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
Dystonia
Role for botulinum toxin in back pain treatment in adults with cerebral palsy: report of a case.
Dystonia
Safe Administration of Botulinum Toxin Type A Injections During Pregnancy: A Report of Two Cases.
Dystonia
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Dystonia
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Dystonia
Safety of transcranial direct current stimulation in a patient with deep brain stimulation electrodes.
Dystonia
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Dystonia
Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia.
Dystonia
Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®).
Dystonia
Secondary dystonia in a Botulinum Toxin Clinic: Clinical characteristics, neuroanatomical substrate and comparison with idiopathic dystonia.
Dystonia
Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test.
Dystonia
Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.
Dystonia
Secondary treatment failure in cervical dystonia after treatment with inco- and abobotulinumtoxinA.
Dystonia
Selective peripheral denervation for spasmodic torticollis: is the outcome predictable?
Dystonia
Selective peripheral denervation: comparison with pallidal stimulation and literature review.
Dystonia
Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections.
Dystonia
Sensorimotor network in cervical dystonia and the effect of botulinum toxin treatment: a functional MRI study.
Dystonia
Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease.
Dystonia
Severe cervical dystonia in pathologically proven Parkinson's disease and dementia.
Dystonia
Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy.
Dystonia
Severe Jaw-Opening Dystonia as an Unusual Manifestation of Levodopa-Related Wearing-Off in Parkinson's Disease, and Successful Treatment With Botulinum Toxin Injection.
Dystonia
Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia.
Dystonia
Skin reactions after intramuscular injection of Botulinum toxin A: a rare side effect.
Dystonia
Sleep-related adductor laryngeal dystonia causing sleep apnea: a sleep-related breathing disorder diagnosed with sleep endoscopy and treated with botulinum toxin.
Dystonia
Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an FMRI study.
Dystonia
Somatosensory temporal discrimination tested in patients receiving botulinum toxin injection for cervical dystonia.
Dystonia
Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia.
Dystonia
Spatiotemporal Gait Analysis and Lower Limb Functioning in Foot Dystonia Treated with Botulinum Toxin.
Dystonia
Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia.
Dystonia
Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment.
Dystonia
Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies.
Dystonia
Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology.
Dystonia
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia.
Dystonia
Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A.
Dystonia
Subcutaneous Botulinum Toxin Injection for Post-Thoracotomy Pain Syndrome in Palliative Care: A Case Report.
Dystonia
Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
Dystonia
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.
Dystonia
Successful Treatment of Auricular Dystonia by Unilateral Pallidothalamic Tractotomy.
Dystonia
Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach.
Dystonia
Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature.
Dystonia
Surgical Management for Dystonia: Efficacy of Deep Brain Stimulation in the Long Term.
Dystonia
Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.
Dystonia
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
Dystonia
Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
Dystonia
Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.
Dystonia
Tablet-based patient educational interventions in care and management of complex movement disorders.
Dystonia
Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A.
Dystonia
Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin.
Dystonia
The broadening application of chemodenervation in X-linked dystonia-Parkinsonism (part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
Dystonia
The broadening application of chemodenervation in X-linked dystonia-Parkinsonism (part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
Dystonia
The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.
Dystonia
The clinical syndrome of primary tic disorder associated with dystonia: A large clinical series and a review of the literature.
Dystonia
The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
Dystonia
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Dystonia
The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment.
Dystonia
The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dystonia
The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.
Dystonia
The effect of a single botulinum toxin treatment on somatosensory processing in idiopathic isolated cervical dystonia: an observational study.
Dystonia
The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study.
Dystonia
The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography.
Dystonia
The Effect of Computed Tomography-Guided Botulinum Toxin Injection on Cervical Dystonia, Confirmed by a 9-Month Follow-Up Using Positron Emission Tomography/Computed Tomography.
Dystonia
The effect of CT-guided botulinum toxin injection on cervical dystonia, confirmed by nine-month follow-up using 18F-FDG PET/CT : A case report.
Dystonia
The Effect of Globus Pallidus Interna Deep Brain Stimulation on a Dystonia Patient with the GNAL Mutation Compared to Patients with DYT1 and DYT6.
Dystonia
The effect of repetitive transcranial magnetic stimulation on dystonia: a clinical and pathophysiological approach.
Dystonia
The effective zone of botulinum toxin A injections in the sternocleidomastoid muscle.
Dystonia
The effectiveness of physiotherapy for cervical dystonia: a systematic literature review.
Dystonia
The efficacy of single-photon emission computed tomography in identifying dystonic muscles in cervical dystonia.
Dystonia
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia.
Dystonia
The HC domain of Botulinum Neurotoxin A is Not the Only Site That Binds Neurons: HN also Plays a very Active Role in Toxin-Cell binding and Interactions.
Dystonia
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
Dystonia
The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany.
Dystonia
The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Dystonia
The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
Dystonia
The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin.
Dystonia
The physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystonia.
Dystonia
The position of the head in space: a kinematic analysis in patients with cervical dystonia treated with botulinum toxin.
Dystonia
The Prevalence of Dystonic Tremor and Tremor Associated with Dystonia in Patients with Cervical Dystonia.
Dystonia
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
Dystonia
The Role of Ultrasound for the Personalized Botulinum Toxin Treatment of Cervical Dystonia.
Dystonia
The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
Dystonia
The safety and tolerability of botulinum toxins for the treatment of cervical dystonia.
Dystonia
The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review.
Dystonia
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.
Dystonia
Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Dystonia
Treating and preventing levodopa-induced dyskinesias: current and future strategies.
Dystonia
Treatment effectiveness of brain-computer interface training for patients with focal hand dystonia: A double-case study.
Dystonia
Treatment of cervical dystonia and focal hand dystonia by high cervical continuously infused intrathecal baclofen: a report of 2 cases.
Dystonia
Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.
Dystonia
Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Dystonia
Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis.
Dystonia
Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses.
Dystonia
Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: a case report.
Dystonia
Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige's syndrome.
Dystonia
Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia.
Dystonia
Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia.
Dystonia
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.
Dystonia
Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.
Dystonia
Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia.
Dystonia
Tremor in Idiopathic Cervical Dystonia - Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification.
Dystonia
Tremulous cervical dystonia is likely to be familial: Clinical characteristics of a large cohort.
Dystonia
Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia.
Dystonia
Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity.
Dystonia
Ultrasound and Electromyography Guidance for Injection of the Longus Colli With Botulinum Toxin for the Treatment of Cervical Dystonia.
Dystonia
Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia Needs Prompt Muscle Selection, Appropriate Dosage and Precise Guidance.
Dystonia
Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives.
Dystonia
Ultrasound-guided Injection of the Sternocleidomastoid Muscle: A Cadaveric Study with Implications for Chemodenervation.
Dystonia
Unilateral pallidotomy in the treatment of cervical dystonia: a retrospective observational study.
Dystonia
Unilateral whisker pad injection of botulinum toxin type a enhances spatial learning in mice.
Dystonia
Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review.
Dystonia
Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children.
Dystonia
Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction.
Dystonia
Usefulness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of cervical dystonia.
Dystonia
Utilization and perceived effectiveness of complementary and alternative medicine in patients with dystonia.
Dystonia
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
Dystonia
Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
Dystonia
Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.
Dystonia
Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.
Dystonia
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
Dystonia
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment.
Dystonia
[99mTc]MIBI SPECT/CT for Identifying Dystonic Muscles in Patients with Primary Cervical Dystonia.
Dystonia
[A case of laryngeal adductor dystonia treated with transcutaneous injections of botulinum toxin]
Dystonia
[A case report of acute polyradiculoneuritis developing after multiple injections of botulinum toxin for cervical dystonia]
Dystonia
[Botulinum A toxin treatment in patients with oromandibular dystonia with concomitant malnutrition]
Dystonia
[Botulinum toxin in blepharospasm, in hemifacial spasm, and in cervical dystonia: results in 33 patients]
Dystonia
[Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients' satisfaction along the treatment]
Dystonia
[Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study]
Dystonia
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]
Dystonia
[Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A]
Dystonia
[Clinical and therapeutical features in 135 patients with dystonia: experience of movement disorders unity of the Hospital de ClÃnicas of the Universidade Federal do Paraná]
Dystonia
[Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
Dystonia
[Dose-response relationship in the treatment of cervical dystonia with botulinum toxin type A (AGN 191622)--a phase II study]
Dystonia
[Efficacy of botulinum toxin type A against cervical dystonia and muscular hypertonia in persons with severe motor and intellectual disabilities with respiratory problems and/or dysphagia].
Dystonia
[First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A]
Dystonia
[Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia]
Dystonia
[Initial efficacy of intramuscular injection of botulinum toxin type A against cervical dystonia and general muscular hypertonia in persons with severe motor and intellectual disabilities]
Dystonia
[Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment]
Dystonia
[Laryngeal dystonia. Comparison of transcutaneous and transoral injection of botulinum toxin]
Dystonia
[Laryngeal dystonia: novel forms of therapeutic administration of botulinum toxin by direct routes].
Dystonia
[Myths and evidence on the use of botulinum toxin: neuropharmacology and dystonia].
Dystonia
[New therapeutic methods for spasticity and dystonia in children with cerebral palsy require multidisciplinary team work. Comprehensive approach yields good results]
Dystonia
[Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Dystonia
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]
Dystonia
[Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin]
Dystonia
[Progression of Botulinum toxin dosage in focal spasticity and cervical dystonia.]
Dystonia
[The treatment of laryngeal movement disorders with botulinum toxin: part 2: experience and considerations]
Dystonia
[Treatment of laryngeal movement disorders with botulinum toxins: part 1: History and mode of action]
Dystonia
[Use of botulinum toxin in the treatment of laryngeal dystonia (spasmodic dysphonia): preliminary study of twelve patients]
Dystonia Musculorum Deformans
Potency of frozen/thawed botulinum toxin type A in the treatment of torsion dystonia.
Dystonic Disorders
A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
Dystonic Disorders
A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.
Dystonic Disorders
A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
Dystonic Disorders
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
Dystonic Disorders
A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity.
Dystonic Disorders
A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes.
Dystonic Disorders
Abnormal perception of vibration-induced illusion of movement in dystonia.
Dystonic Disorders
Accuracy of muscle localization without EMG: implications for treatment of limb dystonia.
Dystonic Disorders
Anesthetic Management of a Child With Rapid-Onset Dystonia-Parkinsonism (DYT12-ATP1A3): A Case Report.
Dystonic Disorders
Application of botulinum toxin to clinical therapy: advances and cautions.
Dystonic Disorders
Associative stimulation of the supraorbital nerve fails to induce timing-specific plasticity in the human blink reflex.
Dystonic Disorders
Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance.
Dystonic Disorders
Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
Dystonic Disorders
Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses.
Dystonic Disorders
Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.
Dystonic Disorders
Botulinum neurotoxin treatment improves force regulation in writer's cramp.
Dystonic Disorders
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
Dystonic Disorders
Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm.
Dystonic Disorders
Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.
Dystonic Disorders
Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex.
Dystonic Disorders
Botulinum toxin clinic-based epidemiologic survey of adults with primary dystonia in East china.
Dystonic Disorders
Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study.
Dystonic Disorders
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Dystonic Disorders
Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.
Dystonic Disorders
Botulinum toxin in the treatment of writer's cramp: a double-blind study.
Dystonic Disorders
Botulinum toxin in writer's cramp: objective response evaluation in 31 patients.
Dystonic Disorders
Botulinum toxin injections reduce associative plasticity in patients with primary dystonia.
Dystonic Disorders
Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia.
Dystonic Disorders
Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.
Dystonic Disorders
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
Dystonic Disorders
Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
Dystonic Disorders
Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.
Dystonic Disorders
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
Dystonic Disorders
Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.
Dystonic Disorders
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
Dystonic Disorders
Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.
Dystonic Disorders
Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia.
Dystonic Disorders
Comparison of neuromuscular blockade and recovery with botulinum toxins A and F.
Dystonic Disorders
Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin.
Dystonic Disorders
Double-blind trial of botulinum toxin for treatment of focal hand dystonia.
Dystonic Disorders
Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia.
Dystonic Disorders
Effect of botulinum toxin A & task-specific training on upper limb function in post-stroke focal dystonia.
Dystonic Disorders
Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.
Dystonic Disorders
Effects of botulinum toxin on motor system excitability in patients with writer's cramp.
Dystonic Disorders
Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review.
Dystonic Disorders
Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
Dystonic Disorders
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options.
Dystonic Disorders
Epidemiology of primary focal dystonias in the western area of tottori prefecture in Japan: Comparison with prevalence evaluated in 1993.
Dystonic Disorders
Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin.
Dystonic Disorders
Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Dystonic Disorders
Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients.
Dystonic Disorders
Headache Attributed to Craniocervical Dystonia - A Little Known Headache.
Dystonic Disorders
Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.
Dystonic Disorders
Homocysteine and serum markers of immune activation in primary dystonia.
Dystonic Disorders
Human response to botulinum toxin injection: type B compared with type A.
Dystonic Disorders
Impact of Injection-Guiding Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Focal Spasticity and Dystonia: A Systematic Review.
Dystonic Disorders
Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology.
Dystonic Disorders
Intrafusal effects of botulinum toxin in post-stroke upper limb spasticity.
Dystonic Disorders
Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.
Dystonic Disorders
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset.
Dystonic Disorders
Lasting Effects of Low-Frequency Repetitive Transcranial Magnetic Stimulation in Writer's Cramp: A Case Report.
Dystonic Disorders
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Dystonic Disorders
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia).
Dystonic Disorders
Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin.
Dystonic Disorders
Management of focal dystonia of the extensor hallucis longus muscle with botulinum toxin injection: a case report.
Dystonic Disorders
Management of movement disorders in glutaryl-CoA dehydrogenase deficiency: anticholinergic drugs and botulinum toxin as additional therapeutic options.
Dystonic Disorders
Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle.
Dystonic Disorders
Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
Dystonic Disorders
Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp.
Dystonic Disorders
Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy.
Dystonic Disorders
Prevalence and diagnostic challenge of dystonia in Thailand: a service-based study in a tertiary university referral centre.
Dystonic Disorders
Prevalence, predictors, and perceived effectiveness of complementary, alternative and integrative medicine in adult-onset primary dystonia.
Dystonic Disorders
Repurposing of FDA-Approved Drugs for Treating Iatrogenic Botulism: A Paired 3D-QSAR/Docking Approach.
Dystonic Disorders
Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
Dystonic Disorders
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
Dystonic Disorders
Secondary dystonia in a Botulinum Toxin Clinic: Clinical characteristics, neuroanatomical substrate and comparison with idiopathic dystonia.
Dystonic Disorders
Sensory integration in writer's cramp: comparison with controls and evaluation of botulinum toxin effect.
Dystonic Disorders
Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment.
Dystonic Disorders
Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms.
Dystonic Disorders
Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: A review of 257 cases.
Dystonic Disorders
The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection.
Dystonic Disorders
The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site.
Dystonic Disorders
The mechanisms of action of Botulinum Toxin type A in nociceptive and neuropathic pathways in Cancer Pain.
Dystonic Disorders
The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
Dystonic Disorders
The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans.
Dystonic Disorders
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.
Dystonic Disorders
Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.
Dystonic Disorders
Treatment of focal dystonia involving multiple muscles with a single injection of botulinum toxin A to 1 muscle: A case report.
Dystonic Disorders
Treatment of focal dystonias of the hand with botulinum toxin injections.
Dystonic Disorders
Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles.
Dystonic Disorders
Ultrastructural changes in the masseter muscle of Macaca fascicularis resulting from intramuscular injections of botulinum toxin type A.
Dystonic Disorders
Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Dystonic Disorders
Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.
Dystonic Disorders
What is new in the era of focal dystonia treatment? Botulinum injections and more.
Dystonic Disorders
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment.
Dystonic Disorders
Writer's cramp: the experience with botulinum toxin injections in 25 patients.
Dystonic Disorders
[A survey about the accessibility to botulinum toxin therapy for dystonia]
Dystonic Disorders
[Botulinum toxin as a powerful new tool in the treatment of focal dystonia]
Dystonic Disorders
[Botulinum toxin in the treatment of focal dystonias: own experience with botulinum toxin]
Dystonic Disorders
[Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study]
Dystonic Disorders
[Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A]
Dystonic Disorders
[Cervical echomyography in cervical dystonia and its application to the monitoring for muscle afferent block (MAB)]
Dystonic Disorders
[Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
Dystonic Disorders
[Deep brain stimulation for dystonia : Consensus recommendations of the German Deep Brain Stimulation Association.]
Dystonic Disorders
[Efficacy and side-effects of the botulinum toxin A treatment in patients with focal dystonia.]
Dystonic Disorders
[Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: a pilot study]
Dystonic Disorders
[Long-term evolution of the doses of Botulinum toxin used in laryngeal and cervical dystonias.]
Dystonic Disorders
[Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A]
Dystonic Disorders
[Problems of treating writer's cramp with botulinum toxin injections: results from 10 years of experience]
Dystonic Disorders
[Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study]
Dystonic Disorders
[Psychosomatic aspects of idiopathic spasmodic torticollis. Results of a multicenter study]
Dystonic Disorders
[The dystonias--botulinum toxin, deep brain stimulation, pharmacotherapy, motor training]
Dystonic Disorders
[Treatment of writer's cramp and other forms of limb dystonias with botulinum toxin]
Dystonic Disorders
[Treatments by local injections of botulinum toxin in neurology. Indications and results]
Ear Diseases
The role of tensor veli platini muscle (TVP) and levetor veli platini muscle (LVP) in the opening and closing of pharyngeal orifice of Eustachian tube.
Earache
Application of Botulinum Toxin in Patients with Secondary Otalgia Caused by Bruxism.
Ecchymosis
Abobotulinum toxin A for periorbital facial rejuvenation: impact on ocular refractive parameters.
Ecchymosis
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Eczema
Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison.
Eczema
Botulinum toxin type A in chronic non-dyshidrotic palmar eczema: A side-by-side comparative study.
Encephalitis
Botulinum Toxin A for Spastic Trismus Due to Brain Stem Encephalitis in a Pediatric Intensive Care Setting: A Unique Case Report.
Encephalitis
Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis.
Encephalitis
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis.
Encephalitis, Viral
The threat of biological terrorism: a public health and infection control reality.
Encephalomyelitis, Venezuelan Equine
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
Encephalomyelitis, Venezuelan Equine
Modeling of SEB-induced host gene expression to correlate in vitro to in vivo responses.
Encephalomyelitis, Venezuelan Equine
Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Endometriosis
Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment.
Endometriosis
[Retracted] Effects of botulinum toxin A on endometriosis?associated pain and its related mechanism
Enterocolitis
Botulinum toxin injections after surgery for Hirschsprung disease: Systematic review and meta-analysis.
Enterocolitis
Impact of Botulinum Toxin on Hirschsprung-associated Enterocolitis After Primary Pull-Through.
Enterocolitis
The impact of botulinum injection for hospitalized children with Hirschsprung-associated enterocolitis.
Entropion
Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
Entropion
Botulinum toxin for the temporary treatment of involutional lower lid entropion: a clinical and morphological study.
Entropion
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Entropion
Reactivation of herpes simplex viral keratitis following the botulinum toxin injection.
Entropion
[Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]
Enuresis
Endoscopic Botulinum Toxin Injection for Refractory Enuresis Based on Urodynamic Assessment.
Eosinophilia
Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia.
Epidermal Cyst
Botulinum Neurotoxin Type A as an Adjuvant to Reduce Scarring After Dermatological Surgery.
Epidermolysis Bullosa Dystrophica
Botulinum toxin A injection for chronic anal fissures and anal sphincter spasm improves quality of life in recessive dystrophic epidermolysis bullosa.
Epidermolysis Bullosa Simplex
Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita.
Epidermolysis Bullosa Simplex
Treatment of epidermolysis bullosa simplex, Weber-Cockayne type, with botulinum toxin type A.
Epidermolysis Bullosa Simplex
Treatment of symptomatic epidermolysis bullosa simplex with botulinum toxin in a pediatric patient.
Epididymitis
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Epidural Abscess
Cervical spondylodiscitis following cricopharyngeal botulinium toxin injection.
Epilepsia Partialis Continua
Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua.
Epilepsies, Partial
Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat.
Epilepsy
Action of botulinum neurotoxins in the central nervous system: antiepileptic effects.
Epilepsy
Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.
Epilepsy
Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy.
Epilepsy
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Epilepsy
Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
Epilepsy
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Epilepsy
Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy.
Epilepsy
Safety of botulinum toxin a in children and adolescents with cerebral palsy in a pragmatic setting.
Epilepsy
The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
Epilepsy
Use of botulinum neurotoxin injections to treat recurrent shoulder dislocations in a patient with severe epilepsy: a case report.
Epilepsy, Temporal Lobe
Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy.
Equinus Deformity
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
Equinus Deformity
Botulinum Toxin Type A for the Treatment of Equinus Deformity in to Patients With Mucopolysaccharidosis Type II.
Equinus Deformity
Effects of botulinum toxin A on functional outcome during distraction osteogenesis.
Equinus Deformity
Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy.
Equinus Deformity
Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy.
Equinus Deformity
The Influence of Botulinum Toxin A Injections into the Calf Muscles on Genu Recurvatum in Children With Cerebral Palsy.
Erectile Dysfunction
Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction.
Erectile Dysfunction
Transient erectile dysfunction associated with intramuscular injection of botulinum toxin type A.
Erythema
A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea.
Erythema
A Pilot, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of IncobotulinumtoxinA Injections in the Treatment of Rosacea.
Erythema
A Split-Face Study using Botulinum Toxin Type B to Decrease Facial Erythema Index.
Erythema
Abobotulinum toxin A for periorbital facial rejuvenation: impact on ocular refractive parameters.
Erythema
Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema.
Erythema
Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study.
Erythema
Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.
Erythema
Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing.
Erythema
Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey.
Erythromelalgia
Botulinum Toxin as Successful Treatment of Refractory Erythromelalgia Pain.
Erythromelalgia
Effectiveness of botulinum toxin A in treatment of refractory erythromelalgia.
Esophageal Achalasia
A case of mediastinitis following botulinum toxin type A treatment for achalasia.
Esophageal Achalasia
A Case of Sub-Diaphragmatic Abscess after Injection of Botulinum Toxin to Treat Achalasia.
Esophageal Achalasia
A cost-minimization analysis of alternative treatment strategies for achalasia.
Esophageal Achalasia
A decade of botulinum toxin injections for achalasia: where do we stand?
Esophageal Achalasia
A decision analysis of the optimal initial approach to achalasia: laparoscopic Heller myotomy with partial fundoplication, thoracoscopic Heller myotomy, pneumatic dilatation, or botulinum toxin injection.
Esophageal Achalasia
A modified method of botulinum toxin injection in patients with achalasia: a pilot trial.
Esophageal Achalasia
A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group.
Esophageal Achalasia
Achalasia cardia with esophageal varix managed with endoscopic ultrasound-guided botulinum toxin injection.
Esophageal Achalasia
Achalasia in Pregnancy: Botulinum Toxin A Injection of Lower Esophageal Sphincter.
Esophageal Achalasia
Achalasia treatment in the elderly: is botulinum toxin injection the best option?
Esophageal Achalasia
Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin.
Esophageal Achalasia
Acute reversible gastroparesis and megaduodenum after botulinum toxin injection for achalasia.
Esophageal Achalasia
Botox, dilation, or myotomy? Clinical outcome of interventional and surgical therapies for achalasia.
Esophageal Achalasia
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Esophageal Achalasia
Botulinum toxin for achalasia: are we witnessing the birth of a new era?
Esophageal Achalasia
Botulinum toxin for achalasia: long-term outcome and predictors of response.
Esophageal Achalasia
Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.
Esophageal Achalasia
Botulinum toxin for the treatment of hypercontractile esophagus: Results of a double-blind randomized sham-controlled study.
Esophageal Achalasia
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases?
Esophageal Achalasia
Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease.
Esophageal Achalasia
Botulinum toxin injection for secondary achalasia with esophageal varices.
Esophageal Achalasia
Botulinum toxin injection versus laparoscopic myotomy for the treatment of esophageal achalasia: economic analysis of a randomized trial.
Esophageal Achalasia
Botulinum toxin injections for achalasia symptoms can approximate the short term efficacy of a single pneumatic dilation: a survival analysis approach.
Esophageal Achalasia
Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease.
Esophageal Achalasia
Botulinum toxin treatment of oesophageal achalasia in the old old and oldest old: a 1-year follow-up study.
Esophageal Achalasia
Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Esophageal Achalasia
Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial.
Esophageal Achalasia
Bridging therapy for achalasia in a second trimester pregnant patient.
Esophageal Achalasia
Cap-fitted endoscopy facilitates injection of botulinum toxin in patients with achalasia.
Esophageal Achalasia
Clinical Study on Combined Therapy of Botulinum Toxin Injection and Small Balloon Dilation in Patients with Esophageal Achalasia.
Esophageal Achalasia
Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results.
Esophageal Achalasia
Comparative neuromuscular histopathology of cricopharyngeal achalasia patients with and without previous botulinum toxin treatment.
Esophageal Achalasia
Comparison and cost analysis of different treatment strategies in achalasia.
Esophageal Achalasia
Comparison Between Botulinum Injection and Removable Covered Self-Expanding Metal Stents for the Treatment of Achalasia.
Esophageal Achalasia
Comparison of botulinium toxin injection and posterior anorectal myectomy in treatment of internal anal sphincter achalasia.
Esophageal Achalasia
Comparison of pneumatic dilation with pneumatic dilation plus botulinum toxin for treatment of achalasia.
Esophageal Achalasia
Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis.
Esophageal Achalasia
Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group.
Esophageal Achalasia
Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection.
Esophageal Achalasia
Complications of botulinum toxin injections for treatment of esophageal motility disorders.
Esophageal Achalasia
Congenital cricopharyngeal achalasia: management with botulinum toxin before myotomy.
Esophageal Achalasia
Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia.
Esophageal Achalasia
Cricopharyngeal achalasia in children: Botulinum toxin injection as a tool for diagnosis and treatment.
Esophageal Achalasia
Cricopharyngeal Achalasia: Management and Associated Outcomes-A Scoping Review.
Esophageal Achalasia
Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm.
Esophageal Achalasia
Data analyses and perspectives on laparoscopic surgery for esophageal achalasia.
Esophageal Achalasia
Development of quality indicators for the diagnosis and management of achalasia.
Esophageal Achalasia
Does botulinum toxin injection make esophagomyotomy a more difficult operation?
Esophageal Achalasia
Does Heller's myotomy provide superior clinical outcome in comparison to botulinum toxin injection for treatment of achalasia?: Best evidence topic (BET).
Esophageal Achalasia
Early experience with intrasphincteric botulinum toxin in the treatment of achalasia.
Esophageal Achalasia
Echo-guided injection of botulinum toxin in patients with achalasia: initial experience.
Esophageal Achalasia
Echo-guided injection of botulinum toxin p blind endoscopic injection in patients with achalasia: final report.
Esophageal Achalasia
Echoendoscopic evaluation of botulinum toxin intrasphincteric injections in Chagas' disease achalasia.
Esophageal Achalasia
Effects of botulinum toxin injection on anal achalasia after pull-through operations for Hirschsprung's disease: a 1-year follow-up study.
Esophageal Achalasia
Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia.
Esophageal Achalasia
Efficacy of botulinum toxin injection before pneumatic dilatation in patients with idiopathic achalasia.
Esophageal Achalasia
Endoscopic Botulinum Toxin Injection for Tacrolimus-Induced Achalasia in a Renal Transplant Recipient.
Esophageal Achalasia
Endoscopic intrasphincteric injection of botulinum toxin for the treatment of achalasia.
Esophageal Achalasia
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Esophageal Achalasia
Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia.
Esophageal Achalasia
Endoscopic therapeutic esophageal interventions: what is new? What needs further study? What can we forget?
Esophageal Achalasia
Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation.
Esophageal Achalasia
Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia.
Esophageal Achalasia
Ethanolamine oleate versus botulinum toxin in the treatment of idiopathic achalasia.
Esophageal Achalasia
Fatal heart block following treatment with botulinum toxin for achalasia.
Esophageal Achalasia
Functional outcomes in Hirschsprung disease: A single institution's 12-year experience.
Esophageal Achalasia
Gastric adenocarcinoma mimicking achalasia in a 15-year-old patient: a case report and review of the literature.
Esophageal Achalasia
Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.
Esophageal Achalasia
Gastrointestinal: Hepatic abscess after botulinum toxin type-A therapy for achalasia.
Esophageal Achalasia
Heller myotomy is the optimal index procedure for esophageal achalasia in adolescents and young adults.
Esophageal Achalasia
Impact of minimally invasive surgery on the treatment of benign esophageal disorders.
Esophageal Achalasia
In-office transnasal esophagoscope-guided botulinum toxin injection of the lower esophageal sphincter.
Esophageal Achalasia
Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial.
Esophageal Achalasia
Internal anal sphincter achalasia in children: clinical characteristics and treatment with Clostridium botulinum toxin.
Esophageal Achalasia
Intrasphincteric BoTox injections in Hirschsprung's disease: indications and outcome in 64 procedures over a ten-year period.
Esophageal Achalasia
Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia.
Esophageal Achalasia
Intrasphincteric Botulinum Toxin Injections to Treat Achalasia Diagnosed in 615 Pregnancy: A Case Report.
Esophageal Achalasia
Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia.
Esophageal Achalasia
Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis.
Esophageal Achalasia
Intrasphincteric injection of Botulinum toxin for treating achalasia in children.
Esophageal Achalasia
Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia.
Esophageal Achalasia
Laparoscopic Heller Myotomy Can Be Used As Primary Therapy for Esophageal Achalasia Regardless of Age.
Esophageal Achalasia
Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes.
Esophageal Achalasia
Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study.
Esophageal Achalasia
Long-term follow-up of achalasia patients treated with botulinum toxin.
Esophageal Achalasia
Long-term follow-up of achalasic patients treated with botulinum toxin.
Esophageal Achalasia
Long-term outcomes of balloon dilation versus botulinum toxin injection in patients with primary achalasia.
Esophageal Achalasia
Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin.
Esophageal Achalasia
Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum.
Esophageal Achalasia
Long-term results of laparoscopic Heller myotomy with partial fundoplication for the treatment of achalasia.
Esophageal Achalasia
Management of idiopathic achalasia: short-term and long-term outcomes.
Esophageal Achalasia
Manometrically-guided endoscopic injection of botulinum toxin for esophageal achalasia: a pilot trial.
Esophageal Achalasia
Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes.
Esophageal Achalasia
Meta-Analysis of Randomized and Controlled Treatment Trials for Achalasia.
Esophageal Achalasia
Multiple Preoperative Endoscopic Interventions Are Associated with Worse Outcomes After Laparoscopic Heller Myotomy for Achalasia.
Esophageal Achalasia
Mycotic aneurysm of the distal thoracic aorta after botulinum toxin injection for esophageal dysmotility.
Esophageal Achalasia
Pathophysiology and endoscopic/balloon treatment of esophageal motility disorders.
Esophageal Achalasia
Perendoscopic injection of botulinum toxin is effective in achalasia after failure of myotomy or pneumatic dilation.
Esophageal Achalasia
Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy.
Esophageal Achalasia
Persistent obstructive symptoms after surgery for Hirschsprung's disease: development of a diagnostic and therapeutic algorithm.
Esophageal Achalasia
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.
Esophageal Achalasia
Pneumatic dilation versus intrasphincteric botulinum toxin injection in the treatment of achalasia cardia in India: an economic analysis.
Esophageal Achalasia
Pneumothorax complicating botulinum toxin injection in the body of a dilated oesophagus in achalasia.
Esophageal Achalasia
Population-based cohort study of surgical myotomy and pneumatic dilatation as primary interventions for oesophageal achalasia.
Esophageal Achalasia
Prospective study of esophageal botulinum toxin injection in high-risk achalasia patients.
Esophageal Achalasia
Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia.
Esophageal Achalasia
Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia.
Esophageal Achalasia
Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia.
Esophageal Achalasia
Re-epithelialization of demucosalized stomach patch with tissue-engineered urothelial mucosa combined with Botox A in bladder augmentation.
Esophageal Achalasia
Recent advances in the surgical treatment of achalasia and gastroesophageal reflux disease.
Esophageal Achalasia
Review article: botulinum toxin in the therapy of gastrointestinal motility disorders.
Esophageal Achalasia
Review article: the management of achalasia - a comparison of different treatment modalities.
Esophageal Achalasia
Safety and efficacy of botulinum toxin injection therapy for esophageal achalasia in Japan.
Esophageal Achalasia
SEVERE RESPIRATORY FAILURE SECONDARY TO MEGAOESOPHAGUS DUE TO TERMINAL ACHALASIA.
Esophageal Achalasia
Short- and medium-term clinical efficacy of three endoscopic therapies for achalasia: a single-blinded prospective study.
Esophageal Achalasia
Surgical decision-making in the management of children with intractable functional constipation: What are we doing and are we doing it right?
Esophageal Achalasia
Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter.
Esophageal Achalasia
The enteric nervous system III: a target for pharmacological treatment.
Esophageal Achalasia
The long-term outcome of balloon dilation versus botulinum toxin injection in patients with primary achalasia.
Esophageal Achalasia
The treatment of internal anal sphincter achalasia with botulinum toxin.
Esophageal Achalasia
The use of botulinum toxin for pediatric cricopharyngeal achalasia.
Esophageal Achalasia
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Esophageal Achalasia
The use of high frequency endoscopic ultrasonography probes in the evaluation of achalasia.
Esophageal Achalasia
Treatment choices and outcomes of patients with manometrically diagnosed achalasia.
Esophageal Achalasia
Treatment of achalasia by injection of botulinum toxin or sclerosants?
Esophageal Achalasia
Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance.
Esophageal Achalasia
Treatment of achalasia with botulinum toxin injection guided by endoscopic ultrasonography in a patient with esophageal varices.
Esophageal Achalasia
Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial.
Esophageal Achalasia
Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-Up.
Esophageal Achalasia
Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment.
Esophageal Achalasia
Treatment of anal achalasia after transanal endorectal pull-through for Hirschsprung's disease with topical botulinum toxin.
Esophageal Achalasia
Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study.
Esophageal Achalasia
Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report.
Esophageal Achalasia
Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms.
Esophageal Achalasia
Treatment with botulinum toxin of octo-nonagerians with oesophageal achalasia: a two-year follow-up study.
Esophageal Achalasia
Ultrasound, electromyography, and balloon guidance for injecting botulinum toxin for cricopharyngeal achalasia: A case report.
Esophageal Achalasia
Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung's disease and internal anal sphincter achalasia.
Esophageal Achalasia
Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia.
Esophageal Achalasia
Update on medications used to treat gastrointestinal disease in children.
Esophageal Achalasia
Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia.
Esophageal Achalasia
Use of botulinum toxin as a diagnostic/therapeutic trial to help clarify an indication for definitive therapy in patients with achalasia.
Esophageal Achalasia
Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia.
Esophageal Achalasia
Use of high-resolution endoscopic ultrasonography to assess esophageal wall damage after pneumatic dilation and botulinum toxin injection to treat achalasia.
Esophageal Achalasia
Videoscopic heller myotomy as first-line therapy for severe achalasia.
Esophageal Achalasia
[Achalasia or pseudoachalasia? Problems of diagnostic and treatment decisions in two cases]
Esophageal Achalasia
[Botulinum toxin is effective in the short-term treatment of esophageal achalasia. Preliminary results of a randomized trial]
Esophageal Achalasia
[Botulinum toxin: use in a case of achalasia of the lower sphincter of esophagus]
Esophageal Achalasia
[Intrasphincteric injection of botulinum toxin in patients with esophageal achalasia]
Esophageal Achalasia
[Is complex therapy of achalasia using botulinum toxin combined with balloon dilatation an effective approach?]
Esophageal Achalasia
[Two cases of esophageal achalasia, in which localized botulinum toxin injections were effective to improve symptoms]
Esophageal Achalasia
[Utility of botulinum toxin in stasis esophagitis secondary to achalasia. Report of a case]
Esophageal and Gastric Varices
Achalasia cardia with esophageal varix managed with endoscopic ultrasound-guided botulinum toxin injection.
Esophageal and Gastric Varices
Botulinum toxin injection for secondary achalasia with esophageal varices.
Esophageal and Gastric Varices
Treatment of achalasia with botulinum toxin injection guided by endoscopic ultrasonography in a patient with esophageal varices.
Esophageal Atresia
Control of salivary secretions in esophageal atresia with laryngeal cleft using Botulinum toxin Type A.
Esophageal Atresia
The Effect of Botulinum Toxin Type A Injections on Stricture Formation, Leakage Rates, Esophageal Elongation, and Anastomotic Healing Following Primary Anastomosis in a Long- and Short-Gap Esophageal Atresia Model - A Protocol for a Randomized, Controlled, Blinded Trial in Pigs.
Esophageal Motility Disorders
A Case of Sub-Diaphragmatic Abscess after Injection of Botulinum Toxin to Treat Achalasia.
Esophageal Motility Disorders
Botulinum toxin for the treatment of hypercontractile esophagus: Results of a double-blind randomized sham-controlled study.
Esophageal Motility Disorders
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases?
Esophageal Motility Disorders
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders.
Esophageal Motility Disorders
Complications of botulinum toxin injections for treatment of esophageal motility disorders.
Esophageal Motility Disorders
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Esophageal Motility Disorders
Esophageal pharmacology and treatment of primary motility disorders.
Esophageal Motility Disorders
Hypercontractile esophageal motility disorder or functional esophageal symptoms and unrelated hypercontractility?
Esophageal Motility Disorders
Mycotic aneurysm of the distal thoracic aorta after botulinum toxin injection for esophageal dysmotility.
Esophageal Motility Disorders
Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy.
Esophageal Motility Disorders
The Role of Botulinum Toxin Injections for Esophageal Motility Disorders.
Esophageal Motility Disorders
Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction.
Esophageal Motility Disorders
Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter.
Esophageal Neoplasms
Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer.
Esophageal Perforation
Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia.
Esophageal Spasm, Diffuse
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Esophageal Spasm, Diffuse
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders.
Esophageal Spasm, Diffuse
Fatal mediastinitis following botulinum toxin injection for esophageal spasm.
Esophageal Spasm, Diffuse
In-office transnasal esophagoscope-guided botulinum toxin injection of the lower esophageal sphincter.
Esophageal Spasm, Diffuse
Symptomatic improvement of diffuse esophageal spasm after botulinum toxin injection.
Esophageal Spasm, Diffuse
Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up.
Esophageal Spasm, Diffuse
Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up.
Esophageal Spasm, Diffuse
Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter.
Esophageal Squamous Cell Carcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Esophageal Stenosis
Comparison of endoscopic injection of botulinum toxin and steroids immediately after endoscopic submucosal dissection to prevent esophageal stricture: a prospective cohort study.
Esophageal Stenosis
Response to multiple rapid swallows shows impaired inhibitory pathways in distal esophageal spasm patients with and without concomitant esophagogastric junction outflow obstruction.
Esophagitis
[Utility of botulinum toxin in stasis esophagitis secondary to achalasia. Report of a case]
Esotropia
Action of Botulinum Toxin on Isometric Contraction of Medial and Lateral Rectus Muscles in Esotropic or Exotropic Patients.
Esotropia
Alteration of cyclic frequency by botulinum toxin injection in adult onset cyclic esotropia.
Esotropia
Botulinum neurotoxin injections in essential infantile esotropia-a comparative study with surgery in large-angle deviations.
Esotropia
Botulinum toxin augmentation as a sequential procedure for residual esotropia in traumatic sixth nerve palsy.
Esotropia
Botulinum toxin for the treatment of acute-onset concomitant esotropia in Chiari I malformation.
Esotropia
Botulinum toxin for the treatment of cyclic esotropia in a child with Chiari type I malformation.
Esotropia
Botulinum toxin for the treatment of early-onset esotropia in children with cerebral palsy.
Esotropia
Botulinum toxin in the treatment of partially accommodative esotropia with high AC/A ratio.
Esotropia
Botulinum toxin injection as primary treatment for esotropia in patients with cerebral palsy.
Esotropia
Botulinum toxin injection with and without electromyographic assistance for treatment of abducens nerve palsy: a pilot study.
Esotropia
Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness.
Esotropia
Botulinum toxin injection without electromyographic guidance in consecutive esotropia.
Esotropia
Botulinum toxin injections combined with or without sodium hyaluronate in the absence of electromyography for the treatment of infantile esotropia: a pilot study.
Esotropia
Botulinum toxin to the lateral rectus for the treatment of esotropia with paradoxical diplopia.
Esotropia
Botulinum toxin treatment in patients up to 3 years of age who have esotropic duane retraction syndrome.
Esotropia
Clinical outcomes of botulinum toxin injection in patients with cerebral palsy and esotropia.
Esotropia
Comments on: Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia - A prospective interventional study.
Esotropia
Comparing Botulinum Toxin Injections with Extraocular Muscle Surgery in Toddlers with Esotropia: A Retrospective Analysis.
Esotropia
Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia.
Esotropia
Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics.
Esotropia
Comparison of Botulinum Toxin With Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children.
Esotropia
Comparison of the Efficiency of the Botulinum Toxin for the Treatment of Esotropia in Children with and without Neurological Disease and/or Prematurity.
Esotropia
Cost comparison between botulinum neurotoxin and surgery in the treatment of infantile esotropia in a tertiary public hospital.
Esotropia
Differences of a Single Injection of Botulinum Toxin A between Infantile and Nonaccommodative Esotropia.
Esotropia
Dissociated effects of botulinum toxin chemodenervation on ocular deviation and saccade dynamics in chronic lateral rectus palsy.
Esotropia
Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin.
Esotropia
Essential infantile esotropia in neurologically impaired pediatric patients: is botulinum toxin better primary treatment than surgery?
Esotropia
Functional acute acquired comitant esotropia: clinical characteristics and efficacy of single Botulinum toxin type A injection.
Esotropia
Inadvertent Globe Penetration and Subretinal injection of Botulinum Toxin in an Oculocutaneous Albinism Patient.
Esotropia
Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A.
Esotropia
Injection of type A botulinum toxin into extraocular muscles for correction of strabismus.
Esotropia
Long-term follow-up of bilateral botulinum toxin injections versus bilateral recessions of the medial rectus muscles for treatment of infantile esotropia.
Esotropia
Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin.
Esotropia
Long-term results of botulinum toxin-augmented medial rectus recessions for large-angle infantile esotropia.
Esotropia
Management of essential infantile esotropia with botulinum toxin A: review and recommendations.
Esotropia
Management of nonresolving consecutive exotropia following botulinum toxin treatment of childhood esotropia.
Esotropia
Observations on bilateral simultaneous botulinum toxin injection in infantile esotropia.
Esotropia
Outcomes of pediatric accommodative esotropia with botulinum toxin A treatment in Thailand.
Esotropia
Response to comments on: Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia - A prospective interventional study.
Esotropia
Retreatment of children after surgery for acquired esotropia: reoperation versus botulinum injection.
Esotropia
Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.
Esotropia
The Effect of Botulinum Toxin Augmentation on Strabismus Surgery for Large-Angle Infantile Esotropia.
Esotropia
The efficacy of botulinum toxin treatment for children with a persistent esotropia following bilateral medial rectus recessions and lateral rectus resections.
Esotropia
The Efficacy of Dose Increments of Botulinum Toxin A in the Treatment of Childhood Esotropia.
Esotropia
The role of botulinum toxin A in augmentation of the effect of recession and/or resection surgery.
Esotropia
The Use of Botulinum Toxin to Treat Infantile Esotropia: A Systematic Review With Meta-Analysis.
Esotropia
To what extent may Botulinum toxin type A injections be an alternative choice to surgery in infantile esotropia?
Esotropia
Tonic pupil after botulinum toxin-A injection for treatment of esotropia in children.
Esotropia
Traumatic transection of the lateral rectus muscle with chorioretinitis sclopetaria.
Esotropia
Two horizontal rectus eye muscle surgery combined with botulinum toxin for the treatment of very large angle esotropia. A pilot study.
Esotropia
Use of botulinum toxin in small-angle heterotropia and decompensating heterophoria: a review of the literature.
Esotropia
Why do the eyes cross? A review and discussion of the nature and origin of essential infantile esotropia, microstrabismus, accommodative esotropia, and acute comitant esotropia.
Esotropia
[Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?]
Esotropia
[Botulinum toxin treatment for horizontal strabismus in children with cerebral palsy]
Esotropia
[Results with botulinum toxin in patients with esotropia and psychomotor deficit.]
Esotropia
[Spectral analysis of electromyograms in the strabismus cases--before and after botulinum toxin injection]
Esotropia
[Value of delayed botulinum toxin injection in esotropia in the child as first line treatment]
Essential Tremor
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
Essential Tremor
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Essential Tremor
Beta-blockers and anticonvulsants have not helped my essential tremor. I've heard botulinum toxin might work. Is it worth trying?
Essential Tremor
Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
Essential Tremor
Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach.
Essential Tremor
Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
Essential Tremor
Botulinum Toxin Monotherapy for the Treatment of Essential Tremor: Life Quality Effect.
Essential Tremor
Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor.
Essential Tremor
Botulinum toxin treatment for functional disability induced by essential tremor.
Essential Tremor
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials.
Essential Tremor
Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics.
Essential Tremor
Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.
Essential Tremor
Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.
Essential Tremor
Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future.
Essential Tremor
Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.
Essential Tremor
Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment.
Essential Tremor
Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics.
Essential Tremor
Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study.
Essential Tremor
Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case Series.
Exanthema
Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection.
Exotropia
Action of Botulinum Toxin on Isometric Contraction of Medial and Lateral Rectus Muscles in Esotropic or Exotropic Patients.
Exotropia
Botulinum toxin injection without electromyographic guidance in consecutive esotropia.
Exotropia
Elimination of paradoxical diplopia following treatment with botulinum toxin and prism.
Exotropia
Improvement in reading symptoms following botulinum toxin A injection for convergence insufficiency type intermittent exotropia.
Exotropia
Injection of type A botulinum toxin into extraocular muscles for correction of strabismus.
Exotropia
Large-angle exotropia corrected by intraoperative botulinum toxin A and monocular recession resection surgery.
Exotropia
Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin.
Exotropia
Management of nonresolving consecutive exotropia following botulinum toxin treatment of childhood esotropia.
Exotropia
Recession-resection combined with intraoperative botulinum toxin A chemodenervation for exotropia following subtotal ruptured of medial rectus muscle.
Exotropia
The role of botulinum toxin A in augmentation of the effect of recession and/or resection surgery.
Exotropia
Using Botulinum Toxin A as an Adjunct in the Surgery of Large-Angle Sensory Exotropia and Abducens Nerve Palsy.
Exotropia
[Observation of botulinum toxin A management in childhood with intermittent exotropia]
Eye Diseases
Re: "thyroid eye disease presenting after cosmetic botulinum toxin injections".
Eye Manifestations
Comparison Between Botulinum Toxin A Injection and Lacrimal Punctal Plugs for the Control of Post-LASIK Dry Eye Manifestations: A Prospective Study.
Facial Hemiatrophy
Botulinum toxin A for pain reduction in pediatric patients with Parry-Romberg syndrome.
Facial Hemiatrophy
Parry-Romberg Syndrome Vasculopathy and Its Treatment With Botulinum Toxin.
Facial Injuries
[Simultaneous injection of lidocaine improves predictability of effect of botulinum toxin]
Facial Nerve Diseases
Botulinum toxin and quality of life in patients with facial paralysis.
Facial Nerve Diseases
Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin.
Facial Nerve Diseases
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Facial Nerve Injuries
Botulinum toxin type A: fine-tuning treatment of facial nerve injury.
Facial Nerve Injuries
IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery.
Facial Nerve Injuries
[Facial nerve injury in neurosurgery: a rehabilitation potential of botulinum therapy].
Facial Nerve Injuries
[The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery].
Facial Neuralgia
Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application.
Facial Paralysis
An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire.
Facial Paralysis
Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis.
Facial Paralysis
Botulinum Toxin Injection in Long-Standing Facial Paralysis Patients: Improvement of Facial Symmetry Observed up to 6 Months.
Facial Paralysis
Botulinum toxin injections to cranial sutures for chronic migraine Rewinding the technique using ultrasound imaging.
Facial Paralysis
Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy.
Facial Paralysis
Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience.
Facial Paralysis
Botulinum toxin-A-induced protective ptosis in the treatment of lagophthalmos associated with facial paralysis.
Facial Paralysis
Buccinator synkinesis treated by botulinum toxin in facial palsy and hemifacial spasms.
Facial Paralysis
Comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA at the 1: 3 conversion ratio for the treatment of asymmetry after long-term facial paralysis.
Facial Paralysis
Contralateral botulinum injections in patients with residual facial asymmetry and contralateral hyperkinesis after primary facial palsy surgery.
Facial Paralysis
Contralateral Botulinum Toxin Improved Functional Recovery after Tibial Nerve Repair in Rats.
Facial Paralysis
Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis.
Facial Paralysis
Contralateral Facial Botulinum Toxin Injection in Cases with Acute Facial Paralysis May Improve the Functional Recovery: Where We Stand and the Future Direction.
Facial Paralysis
Cutaneous cooling to manage botulinum toxin injection-associated pain in patients with facial palsy: A randomised controlled trial.
Facial Paralysis
Does Botulinum Toxin Therapy Improve Quality of Life in Patients with Facial Palsy?
Facial Paralysis
Effect of botulinum toxin typeA in functionality, synkinesis and quality of life in peripheral facial palsy sequelae.
Facial Paralysis
Epidemiologic Overview of Synkinesis in 353 Patients with Longstanding Facial Paralysis under Treatment with Botulinum Toxin for 11 Years.
Facial Paralysis
Epidemiological overview of synkinesis in 353 patients with longstanding facial paralysis under treatment with botulinum toxin for 11 years.
Facial Paralysis
Evaluation of the body image of patients with facial palsy before and after the application of botulinum toxin.
Facial Paralysis
Eyebrow asymmetry: Definition and symmetrical correction using botulinum toxin A.
Facial Paralysis
Facial motor cortex plasticity in patients with unilateral peripheral facial paralysis.
Facial Paralysis
Full Face and Neck Treatment With OnabotulinumtoxinA in Patients With Facial Palsy.
Facial Paralysis
Half-mirror biofeedback exercise in combination with three botulinum toxin A injections for long-lasting treatment of facial sequelae after facial paralysis.
Facial Paralysis
Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: a case-series study.
Facial Paralysis
Long-term sequelae treatment of peripheral facial paralysis with botulinum toxin type A: Repartition and kinetics of doses used.
Facial Paralysis
Modulation of GABA receptor subunits in rat facial motoneurons after axotomy.
Facial Paralysis
Neuromuscular Retraining versus BTX-A Injection in Subjects with Chronic Facial Nerve Palsy, A Clinical Trial.
Facial Paralysis
Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.
Facial Paralysis
Orbicular synkinesis after facial paralysis: treatment with botulinum toxin.
Facial Paralysis
Partial Facial Paralysis as a Model for Prophylactic Botulinum Toxin Use for the Prevention of Facial Rhytides.
Facial Paralysis
Poster 310 EMG Guided Botulinum Toxin Type A Injections for Functional Problems Associated to Congenital Facial Palsy: A Case Report.
Facial Paralysis
Progressive Surgical Management of Hemifacial Myohyperplasia for Improved Functional and Aesthetic Results.
Facial Paralysis
Refinement in the rehabilitation of the paralyzed face using botulinum toxin.
Facial Paralysis
Reply: Epidemiologic Overview of Synkinesis in 353 Patients with Longstanding Facial Paralysis under Treatment with Botulinum Toxin for 11 Years.
Facial Paralysis
Reply: Epidemiological overview of synkinesis in 353 patients with longstanding facial paralysis under treatment with botulinum toxin for 11 years.
Facial Paralysis
The Role of Botulinum Toxin A in the Establishment of Symmetry in Pediatric Paralysis of the Lower Lip.
Facial Paralysis
Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders.
Facial Paralysis
Thread lifting: a minimally invasive surgical technique for long-standing facial paralysis.
Facial Paralysis
Treatment of hemifacial spasm with botulinum toxin. Value of preinjection electromyography abnormalities for predicting postinjection lower facial paresis.
Facial Paralysis
UNILATERAL FRONTALIS MUSCLE PARALYSIS: MANAGEMENT WITH BOTULINUM TOXIN A (CASE REPORTS).
Facial Paralysis
Variability in the development of synkinesis in a rabbit facial nerve axotomy model.
Facial Paralysis
[Involuntary lid closure caused by defective healing of facial paralysis and its treatment with botulinum toxin]
Facial Paralysis
[Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A].
Fasciculation
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
Fasciculation
Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study.
Fasciitis, Plantar
A comparison of botulinum toxin a and intralesional steroids for the treatment of plantar fasciitis: a randomized, double-blinded study.
Fasciitis, Plantar
Autologous blood injection and botulinum toxin for resistant plantar fasciitis accompanied by spasticity.
Fasciitis, Plantar
Botulinum toxin type A in chronic plantar fasciitis: clinical effects one year after injection.
Fasciitis, Plantar
Comparison of Botulinum Toxin A, Corticosteroid, and Anesthetic Injection for Plantar Fasciitis.
Fasciitis, Plantar
Comparison of efficacy of eight treatments for plantar fasciitis: A network meta-analysis.
Fasciitis, Plantar
Comparison of extracorporeal shock wave therapy with botulinum toxin type A in the treatment of plantar fasciitis.
Fasciitis, Plantar
Outcomes of Ultrasound-Guided Gastrocnemius Injection With Botulinum Toxin for Chronic Plantar Fasciitis.
Fasciitis, Plantar
Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months.
Fasciitis, Plantar
Serial ultrasonographic findings of plantar fasciitis after treatment with botulinum toxin a: a case study.
Fasciitis, Plantar
Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up.
Fasciitis, Plantar
Treatment of chronic plantar fasciitis with Botulinum toxin A: preliminary clinical results.
Fasciitis, Plantar
Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study.
Fasciitis, Plantar
Treatment of Plantar Fasciitis With Botulinum Toxin: A Randomized, Controlled Study.
Fasciitis, Plantar
Ultrasonographic guided botulinum toxin type A treatment for plantar fasciitis: an outcome-based investigation for treating pain and gait changes.
Fasciitis, Plantar
[Treatment of chronic plantar fasciitis with botulinum toxin A--an open pilot study on 25 patients with a 14-week-follow-up.]
Fecal Incontinence
Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial.
Fecal Incontinence
Botulinum toxin: an endoscopic approach for treating fecal incontinence.
Fecal Incontinence
Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence.
Fecal Incontinence
Editorial Comment: Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Fecal Incontinence
Long-term outcomes of Botulinum toxin in the treatment of chronic anal fissure: 5 years of follow-up.
Fecal Incontinence
Sacral Neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Fecal Incontinence
[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review].
Fibromyalgia
OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia.
Fissure in Ano
A comparison of botulinum toxin and nitroglycerin ointment for chronic anal fissure.
Fissure in Ano
A comparison of botulinum toxin and saline for the treatment of chronic anal fissure.
Fissure in Ano
A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.
Fissure in Ano
A contraction response of the internal anal sphincter to Botulinum toxin: Does low-pressure chronic anal fissure have a different pathophysiology?
Fissure in Ano
A pilot comparative study of fissurectomy/diltiazem and fissurectomy/botulinum toxin in the treatment of chronic anal fissure.
Fissure in Ano
A randomized trial of botulinum toxin vs lidocain pomade for chronic anal fissure.
Fissure in Ano
Anal advancement flap and botulinum toxin A (BT) for chronic anal fissure (CAF).
Fissure in Ano
Anal sphincter fibrillation - is this a new finding that identifies resistant chronic anal fissures that respond to botulinum toxin?
Fissure in Ano
Anal tone may predict recurrence after botulinum toxin for chronic anal fissure.
Fissure in Ano
Analgesic injection of botulinum toxin in anal fissures is efficient and can be performed safely in patients actively receiving chemotherapy.
Fissure in Ano
Bilateral versus posterior injection of botulinum toxin in the internal anal sphincter for the treatment of acute anal fissure.
Fissure in Ano
Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial.
Fissure in Ano
Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure.
Fissure in Ano
Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders.
Fissure in Ano
Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial.
Fissure in Ano
Botulinum toxin A with fissurectomy is a viable alternative to lateral internal sphincterotomy for chronic anal fissure.
Fissure in Ano
Botulinum toxin as second-line therapy for chronic anal fissure failing 0.2 percent glyceryl trinitrate.
Fissure in Ano
Botulinum toxin for chronic anal fissure after biliopancreatic diversion for morbid obesity.
Fissure in Ano
Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy (Br J Surg 2008; 95: 774-778).
Fissure in Ano
Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy.
Fissure in Ano
Botulinum toxin in the management of anal fissure: innovative use of a familiar agent.
Fissure in Ano
Botulinum Toxin Injection for Treatment of Chronic Anal Fissure: Is There Any Dose-Dependent Efficiency? A Meta-Analysis.
Fissure in Ano
Botulinum toxin injection inhibits myogenic tone and sympathetic nerve function in the porcine internal anal sphincter.
Fissure in Ano
Botulinum toxin injection into only one point in the external anal sphincter: a modification of the treatment for chronic anal fissure.
Fissure in Ano
Botulinum toxin injection is an effective alternative for the treatment of chronic anal fissure.
Fissure in Ano
Botulinum toxin injection versus internal anal sphincterotomy for the treatment of chronic anal fissure.
Fissure in Ano
Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta-analysis of randomized control trials.
Fissure in Ano
Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial.
Fissure in Ano
Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a non-randomized controlled trial.
Fissure in Ano
Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a randomized controlled trial.
Fissure in Ano
Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials.
Fissure in Ano
Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens.
Fissure in Ano
Botulinum toxin promoted healing and relieved symptoms of chronic anal fissure.
Fissure in Ano
Botulinum toxin therapy for chronic anal fissures: where are we at currently?
Fissure in Ano
Botulinum toxin versus botulinum toxin with low-dose glyceryltrinitrate for healing of chronic anal fissure: a prospective, randomised trial.
Fissure in Ano
Botulinum toxin versus surgical sphincterotomy in females with chronic anal fissure.
Fissure in Ano
Botulinum toxin vs glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis.
Fissure in Ano
Combined treatment approach to chronic anal fissure with associated anal fistula.
Fissure in Ano
Comment on: Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials.
Fissure in Ano
Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure.
Fissure in Ano
Comparison of surgical vs chemical sphincterotomy using botulinum toxin for the treatment of chronic anal fissure: a meta-analysis.
Fissure in Ano
Comparison of the effectiveness of two treatment modalities for chronic anal fissure: Botox versus sphincterotomy.
Fissure in Ano
Concepts in pathogenesis and treatment of chronic anal fissure--a review of the literature.
Fissure in Ano
Correction: A Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure.
Fissure in Ano
Efficacy and safety of botulinum toxin a injection compared with topical nitroglycerin ointment for the treatment of chronic anal fissure: a prospective randomized study.
Fissure in Ano
Efficacy and Safety of Endoanal Ultrasound-Guided Botulinum Toxin in Chronic Anal Fissure.
Fissure in Ano
Erratum to: Botulinum Toxin Injection for Treatment of Chronic Anal Fissure: Is There Any Dose-Dependent Efficiency? A Meta-Analysis.
Fissure in Ano
Fissurectomy combined with anoplasty and injection of botulinum toxin in treatment of anterior chronic anal fissure with hypertonia of internal anal sphincter: a pilot study.
Fissure in Ano
Fissurectomy Combined with High-Dose Botulinum Toxin Is a Safe and Effective Treatment for Chronic Anal Fissure and a Promising Alternative to Surgical Sphincterotomy.
Fissure in Ano
Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.
Fissure in Ano
Increased anal basal pressure in chronic anal fissures may be caused by overreaction of the anal-external sphincter continence reflex.
Fissure in Ano
Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure.
Fissure in Ano
Intrasphincteric botulinum toxin injection in treatment of chronic idiopathic constipation in children.
Fissure in Ano
Isosorbide dinitrate ointment versus botulinum toxin A (Dysport(®) ) as primary treatment for chronic anal fissure: a randomized multicentre study.
Fissure in Ano
Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin.
Fissure in Ano
Long-term outcomes of Botulinum toxin in the treatment of chronic anal fissure: 5 years of follow-up.
Fissure in Ano
Long-term results of botulinum toxin for the treatment of chronic anal fissure: prospective clinical and manometric study.
Fissure in Ano
Meta-analysis of botulinum toxin injection for chronic anal fissure: healing rates controversies.
Fissure in Ano
Nonsurgical treatment modalities for chronic anal fissure using botulinum toxin.
Fissure in Ano
Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin.
Fissure in Ano
Optimal Dosing of Botulinum Toxin for Treatment of Chronic Anal Fissure: A Systematic Review and Meta-Analysis.
Fissure in Ano
Partial lateral internal sphincterotomy versus combined botulinum toxin A injection and topical diltiazem in the treatment of chronic anal fissure: a randomized clinical trial.
Fissure in Ano
Prospective manometric assessment of botulinum toxin and its correlation with healing of chronic anal fissure.
Fissure in Ano
Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure (Br J Surg 2007; 94: 162-167).
Fissure in Ano
Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure.
Fissure in Ano
Randomized clinical trial of botulinum toxin plus glyceryl trinitrate vs. botulinum toxin alone for medically resistant chronic anal fissure: overall poor healing rates.
Fissure in Ano
Randomized prospective controlled trial of lateral internal sphincterotomy versus injection of botulinum toxin for the treatment of idiopathic fissure in ano.
Fissure in Ano
Relation between botulinum toxin and nitric oxide donors in the treatment of chronic anal fissure.
Fissure in Ano
Review article: botulinum toxin in the therapy of gastrointestinal motility disorders.
Fissure in Ano
Safety of botulinum neurotoxin treatment in patients with chronic anal fissure.
Fissure in Ano
Safety of botulinum toxin for the treatment of children with chronic anal fissure.
Fissure in Ano
Surgical (close lateral internal sphincterotomy) versus chemical (botulinum toxin) sphincterotomy as treatment of chronic anal fissure.
Fissure in Ano
Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study.
Fissure in Ano
Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure.
Fissure in Ano
The antinociceptive effects of botulinum toxin therapy for anal fissure are unproven.
Fissure in Ano
The Efficacy of Botulinum Toxin Injection Site in Chronic Anal Fissure Healing.
Fissure in Ano
The higher doses of botulinum toxin and the potentiate effect of its action after nitric oxide donors application for the treatment of chronic anal fissure.
Fissure in Ano
The long-term efficacy of fissurectomy and botulinum toxin injection for chronic anal fissure in females.
Fissure in Ano
The treatment algorithm instead of the unknown optimal dose of botulinum toxin for chronic anal fissure.
Fissure in Ano
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Fissure in Ano
Therapeutic effects of different doses of botulinum toxin in chronic anal fissure.
Fissure in Ano
Therapeutic properties of botulinum toxin on chronic anal fissure treatment and the patient factors role.
Fissure in Ano
Topical Diltiazem Cream versus Botulinum Toxin A for the Treatment of Chronic Anal Fissure: A Double-Blind Randomized Clinical Trial.
Fissure in Ano
Topical nitrates and the higher doses of botulinum toxin for chronic anal fissure.
Fissure in Ano
Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure.
Fissure in Ano
Transcutaneous needle-free injection of botulinum toxin: a novel treatment of childhood constipation and anal fissure.
Fissure in Ano
Treatment of anal fissure: a survey of surgical practice in Australia and New Zealand.
Fissure in Ano
Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms.
Fissure in Ano
Use of Botulinum Toxin Injections for the Treatment of Chronic Anal Fissure: Results From an American Society of Colon and Rectal Surgeons Survey.
Fissure in Ano
[Manometric factors associated with recurrence in botulinum toxin treatment for chronic anal fissure.]
Fissure in Ano
[Nitric oxide donors and their potentiating effects after botulinum toxin application for treatment of chronic anal fissure]
Fissure in Ano
[Non-surgical treatment of chronic anal fissure by intrasphincter injection of botulinum toxin type].
Fissure in Ano
[Surgical or biologic sphincterotomy in the treatment of chronic anal fissure]
Fissure in Ano
[The experience of treatment with medicines of botulinum toxin of type A Lantox of chronic anal fissure with sphincter spasm].
Fissure in Ano
[Therapy of anal fissure using botulinum toxin: perianal thrombosis as a complication]
Flatfoot
Botulinum Toxin Type A Injection Combined with Cast Immobilization for Treating Recurrent Peroneal Spastic Flatfoot without Bone Coalitions: A Case Report and Review of the Literature.
Flatfoot
Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response.
Foodborne Diseases
A food-poisoning incident caused by Clostridium botulinum toxin A in Japan.
Foodborne Diseases
A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum.
Foodborne Diseases
Anti-apoptotic activity of hemagglutinin-33 and botulinum neurotoxin and its implications to therapeutic and countermeasure issues.
Foodborne Diseases
Botulinum toxin historical aspects: from food poisoning to pharmaceutical.
Foodborne Diseases
Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
Foodborne Diseases
Molecular properties of a hemagglutinin purified from type A Clostridium botulinum.
Foodborne Diseases
Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin.
Foodborne Diseases
Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum.
Foodborne Diseases
[Food poisoning with botulinum toxin, type E, based on personal observations]
Foodborne Diseases
[The route of botulinum toxin from cause of food poisoning to medical remedy].
Foot Deformities
AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial.
Foot Deformities
Botulin toxin A in the treatment of dynamic equinovarus foot in cerebral palsied children.
Foot Deformities
Botulinum toxin type A improved ankle function in children with cerebral palsy and dynamic equinus foot deformity.
Foot Deformities
Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
Foot Deformities
Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Foot Deformities
Claw Toe: Anatomic Guide for Injection of Botulinum Toxin into Foot Muscles.
Foot Deformities
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Foot Deformities
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Foot Deformities
Effect of botulinum toxin on equinus foot deformity in cerebral palsy patients: A systematic review and network meta-analysis.
Foot Deformities
Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot.
Foot Deformities
Outcome on Balance and Gait Following Botulinum Toxin Treatment for Striatal Foot in Parkinson's Disease.
Foot Deformities
Planovalgus foot deformity in cerebral palsy corrected by botulinum toxin injection in the peroneus longus: Clinical and radiological evaluations in young children.
Foot Deformities
Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A.
Foot Deformities
Repeated botulinum toxin A injections in the treatment of spastic equinus foot.
Foot Deformities
Surgery for equinovarus deformity in Friedreich's ataxia improves mobility and independence.
Foot Deformities
[Efficacy of botulinum toxin in the treatment of dynamic equinus and equinovarus foot deformities in children with hemiplegic cerebral palsy].
Foot Deformities
[Foot deformity in children with spastic forms of cerebral palsy: the treatment with botulinum toxin type A (disport)]
Fox-Fordyce Disease
Successful treatment of refractory pruritic Fox-Fordyce disease with botulinum toxin type A.
Fox-Fordyce Disease
Treatment of pruritus with botulinum toxin in a pediatric patient with Fox-Fordyce disease.
Gait Disorders, Neurologic
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
Gait Disorders, Neurologic
More than at the Neuromuscular Synapse: Actions of Botulinum Neurotoxin A in the Central Nervous System.
Ganglioglioma
Facial spasms, but not hemifacial spasm: a case report and review of literature.
Ganglion Cysts
C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial.
Gastroesophageal Reflux
Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report.
Gastrointestinal Diseases
Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.
Gastrointestinal Diseases
Botulinum toxin for the treatment of upper gastrointestinal diseases: the future or already the past?
Gastrointestinal Diseases
Review article: botulinum toxin in the therapy of gastrointestinal motility disorders.
Gastroparesis
A case of acute pancreatitis after intrapyloric botulinum toxin injection to treat gastroparesis.
Gastroparesis
A systematic review on intrapyloric botulinum toxin injection for gastroparesis.
Gastroparesis
Acute reversible gastroparesis and megaduodenum after botulinum toxin injection for achalasia.
Gastroparesis
Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report.
Gastroparesis
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Gastroparesis
Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review.
Gastroparesis
Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients.
Gastroparesis
Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group.
Gastroparesis
Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis.
Gastroparesis
Comparison of Symptom Control in Pediatric Gastroparesis Using Endoscopic Pyloric Botulinum Toxin Injection and Dilatation.
Gastroparesis
Consideration for prophylactic antibiotics in an immunocompromised patient receiving botulinum toxin for gastroparesis.
Gastroparesis
Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study.
Gastroparesis
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Gastroparesis
Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis.
Gastroparesis
Endoscopic ultrasonography-guided intrapyloric injection of botulinum toxin to treat diabetic gastroparesis.
Gastroparesis
EUS-guided botulinum toxin injection into the pyloric sphincter for the treatment of gastroparesis.
Gastroparesis
Factors Associated with Symptom Response to Pyloric Injection of Botulinum Toxin in a Large Series of Gastroparesis Patients.
Gastroparesis
Gastric peroral endoscopic myotomy for gastroparesis, after botulinum toxin injection.
Gastroparesis
Gastrointestinal: Botulinum toxin effective in refractory gastroparesis in paediatric practice.
Gastroparesis
Idiopathic Gastroparesis: Case Report and Literature Review of Diagnostic and Treatment Modalities.
Gastroparesis
Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients.
Gastroparesis
Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients.
Gastroparesis
Intrapyloric injection of botulinum toxin a for the treatment of persistent gastroparesis following successful pancreas transplantation.
Gastroparesis
Obstructive Gastroparesis: Patient Selection and Effect of Laparoscopic Pyloroplasty.
Gastroparesis
Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
Gastroparesis
Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report.
Gastroparesis
Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis.
Gastroparesis
Pyloroplasty Offers Relief of Postfundoplication Gastroparesis in Patients Who Improved After Botulinum Toxin Injection.
Gastroparesis
Successful management of refractory diabetic gastroparesis with long-term Aprepitant treatment.
Gastroparesis
Successful treatment of gastroparesis following total esophagectomy using botulinum toxin.
Gastroparesis
The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.
Gastroparesis
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Gastroparesis
Treatment of diabetic gastroparesis with botulinum toxin injection guided by endoscopic ultrasound in a patient with type 1 diabetes: the first report.
Gastroparesis
Treatment of gastroparesis with botulinum toxin in patient after allogenic bone marrow transplantation.
Gastroparesis
Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle.
Glaucoma
Cholinergic inhibition by botulinum toxin in a rat model of congenital glaucoma raises intraocular pressure.
Glaucoma
Relief of Periorbital Pain After Acute Angle Closure Glaucoma Attack by Botulinum Toxin Type A.
Glaucoma, Angle-Closure
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm.
Glaucoma, Angle-Closure
Angle-closure glaucoma following periorbital botulinum toxin injection.
Glaucoma, Angle-Closure
Relief of Periorbital Pain After Acute Angle Closure Glaucoma Attack by Botulinum Toxin Type A.
Glioblastoma
Clostridium botulinum neurotoxin A induces apoptosis and mitochondrial oxidative stress via activation of TRPM2 channel signaling pathway in neuroblastoma and glioblastoma tumor cells.
Glioma
Alteration of the cytoskeleton of mammalian cells cultured in vitro by Clostridium botulinum C2 toxin and C3 ADP-ribosyltransferase.
Glioma
Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells.
glutaryl-coa dehydrogenase (etf) deficiency
Management of movement disorders in glutaryl-CoA dehydrogenase deficiency: anticholinergic drugs and botulinum toxin as additional therapeutic options.
Goldenhar Syndrome
Efficacy And Non Invasive Treatment Of Sialorrhea In The Goldenhar Syndrome.
Goldenhar Syndrome
One-Year Relapse of Mandibular Distraction for Hemifacial Microsomia Using Masseteric Botulinum Toxin Type A Injections.
Graft vs Host Disease
Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Granuloma
Botulinum Toxin Injections Into the Lateral Cricoarytenoid Muscles for Vocal Process Granuloma.
Granuloma
Comparison of the effects of esomeprazole plus mosapride citrate and botulinum toxin A on vocal process granuloma.
Granuloma
Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma.
Granuloma
Interarytenoid botulinum toxin injection for recalcitrant vocal process granuloma.
Granuloma
Low-Dose LEMG-Guided Botulinum Toxin Type A Injection for Intractable Vocal Process Granulomas.
Granuloma
Recurrent contact granuloma: experience with excision and botulinum toxin injection.
Granuloma
[A comparative study of therapy effects between esomeprazole plus mosapride citrate and botulinum toxin injection on vocal process granuloma].
Granuloma Annulare
Granuloma annulare after Botulonium toxin A injection: A rare association.
Granuloma, Laryngeal
Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma.
Granuloma, Laryngeal
Botulinum Toxin Injections Into the Lateral Cricoarytenoid Muscles for Vocal Process Granuloma.
Granuloma, Laryngeal
Botulinum toxin: helpful adjunct to early resolution of laryngeal granulomas.
Graves Disease
Botulinum toxin as adjunct for refractory compressive optic neuropathy in Graves' disease.
Graves Disease
Treatment of ocular motility disturbances in Graves' disease with botulinum toxin A.
Graves Ophthalmopathy
A single transcutaneous injection with Botox for dysthyroid lid retraction.
Graves Ophthalmopathy
An algorithm for Botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease: long-term results.
Graves Ophthalmopathy
An algorithm for Botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease: Long-term results.
Graves Ophthalmopathy
Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease.
Graves Ophthalmopathy
Botulinum toxin in the treatment of strabismus. A review of its use and effects.
Graves Ophthalmopathy
Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.
Graves Ophthalmopathy
Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy.
Graves Ophthalmopathy
The resurgence of botulinum toxin injection for strabismus in children.
Graves Ophthalmopathy
Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction--a pilot study.
Graves Ophthalmopathy
Thyroid Eye Disease Presenting After Cosmetic Botulinum Toxin Injections.
Graves Ophthalmopathy
Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease.
Graves Ophthalmopathy
Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection.
Graves Ophthalmopathy
[Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease]
Graves Ophthalmopathy
[The application of botulinun toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy]
Guillain-Barre Syndrome
Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease.
Guillain-Barre Syndrome
Intestinal toxicoinfection by Clostridium botulinum type F in an adult. Case associated with Guillain-Barré syndrome.
Hallucinations
Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series.
Hallux Valgus
Botulinum Toxin type A injections for patients with painful hallux valgus: a double-blind, randomized controlled study.
Hamartoma Syndrome, Multiple
The use of botulinum toxin-a in the treatment of severe bruxism in a patient with autism: a case report.
Hammer Toe Syndrome
Claw Toe: Anatomic Guide for Injection of Botulinum Toxin into Foot Muscles.
Hammer Toe Syndrome
Effective zone of botulinum toxin a injections in hallux claw toe syndrome: an anatomical study.
Head and Neck Neoplasms
Botulinum toxin for salivary disorders in the treatment of head and neck cancer.
Head and Neck Neoplasms
Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer.
Head and Neck Neoplasms
Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: A novel approach.
Head and Neck Neoplasms
Endoscopic Management of Postradiation Dysphagia in Head and Neck Cancer Patients: A Systematic Review.
Head and Neck Neoplasms
Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial.
Head and Neck Neoplasms
The role of botulinum toxin in the management of head and neck cancer patients.
Headache Disorders
Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.
Headache Disorders
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Headache Disorders
Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses.
Headache Disorders
Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study.
Headache Disorders
Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes.
Headache Disorders
Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache.
Headache Disorders
Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm.
Headache Disorders
Botulinum toxin for treatment of primary chronic headache disorders.
Headache Disorders
Botulinum toxin type a (botox) for prophylactic treatment of chronic daily headache: a response.
Headache Disorders
Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Headache Disorders
Botulinum toxin type a as a prophylactic treatment for chronic daily headache: time to conduct a large clinical trial in Taiwan?
Headache Disorders
Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Headache Disorders
Botulinum toxin type A for the prophylactic treatment of chronic daily headache.
Headache Disorders
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Headache Disorders
Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Headache Disorders
Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study.
Headache Disorders
Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Headache Disorders
Correction to: The Use of Botulinum Toxin in the Management of Headache Disorders.
Headache Disorders
Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
Headache Disorders
Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population.
Headache Disorders
Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study.
Headache Disorders
Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
Headache Disorders
Evidence based medicine on the use of botulinum toxin for headache disorders.
Headache Disorders
Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache.
Headache Disorders
Investigating prophylactic botulinum toxin type A for chronic headache disorders.
Headache Disorders
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
Headache Disorders
Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.
Headache Disorders
OnabotulinumtoxinA injections: treatment of reversible cerebral vasoconstriction syndrome chronic daily headaches.
Headache Disorders
P005. Efficacy Type-A Botulinum toxin treatment in a multidisciplinary setting for chronic headache.
Headache Disorders
Peri-incisional botulinum toxin for chronic post craniotomy headache following traumatic brain injury: A case series.
Headache Disorders
Peri-Incisional Botulinum Toxin Therapy for Treatment of Intractable Head Pain After Lateral Skull Base Surgery: A Case Series.
Headache Disorders
Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Headache Disorders
Prospective Analysis of the Greater Occipital Nerve Location in Patients Undergoing Occipital Nerve Decompression.
Headache Disorders
Regarding botulinum toxin for the prophylaxis of chronic daily headache.
Headache Disorders
Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache.
Headache Disorders
Review: Prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults.
Headache Disorders
Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain.
Headache Disorders
The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
Headache Disorders
The Use of Botulinum Toxin in the Management of Headache Disorders.
Headache Disorders
Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study.
Headache Disorders
Treatment of chronic refractory intractable headache with botulinum toxin type a: a retrospective study.
Headache Disorders
Ultrasound-guided greater occipital nerve block with botulinum toxin for patients with chronic headache in the occipital area: a randomized controlled trial.
Headache Disorders
[Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes]
Headache Disorders
[Botulinum toxin type A in headache treatment : Established and experimental indications].
Headache Disorders
[Prophylaxis of chronic daily headache with a simplified regimen of subcutaneous administration of botulinum toxin type A.]
Headache Disorders
[The effectiveness and safety of botulinum toxin in the treatment of chronic primary headaches]
Headache Disorders, Primary
Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.
Headache Disorders, Primary
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Headache Disorders, Primary
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Headache Disorders, Primary
Botulinum neurotoxin type-A for primary stabbing headache: an open study.
Headache Disorders, Primary
Botulinum toxin for the treatment of headaches: a review of current practices and evidence based-data.
Headache Disorders, Primary
Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Headache Disorders, Primary
Hemicrania Continua Responsive to Botulinum Toxin Type A: A Case Report.
Headache Disorders, Primary
Hypnic headache successfully treated with botulinum toxin type A.
Headache Disorders, Primary
Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
Headache Disorders, Secondary
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Headache Disorders, Secondary
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic.
Headache Disorders, Secondary
Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
Headache Disorders, Secondary
Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3?Years of Therapy.
Headache Disorders, Secondary
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.
Hemangioma, Cavernous
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.
Hemangiosarcoma
Human herpesvirus type 8-positive facial angiosarcoma developing at the site of botulinum toxin injection for blepharospasm.
Hematuria
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Hematuria
Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity.
Hematuria
Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Hematuria
Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.
Hematuria
Real World Performance of SNM and OnabotulinumtoxinA for OAB: Focus on Safety and Cost.
Hemianopsia
[Surgical and botulinum toxin treatment in two cases of abnormal retinal correspondence-exotropia with congenital homonymous hemianopsia]
Hemifacial Spasm
A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Hemifacial Spasm
A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin.
Hemifacial Spasm
A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
Hemifacial Spasm
Abnormal perception of vibration-induced illusion of movement in dystonia.
Hemifacial Spasm
An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm.
Hemifacial Spasm
Analysis of blink activity and anomalous eyelid movements in patients with hemifacial spasm.
Hemifacial Spasm
Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
Hemifacial Spasm
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Hemifacial Spasm
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
Hemifacial Spasm
Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
Hemifacial Spasm
Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.
Hemifacial Spasm
Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.
Hemifacial Spasm
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Hemifacial Spasm
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Hemifacial Spasm
Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis.
Hemifacial Spasm
Botulinum toxin A improves psychological distress in patients with hemifacial spasm.
Hemifacial Spasm
Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm.
Hemifacial Spasm
Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
Hemifacial Spasm
Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm.
Hemifacial Spasm
Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
Hemifacial Spasm
Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
Hemifacial Spasm
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Hemifacial Spasm
Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30).
Hemifacial Spasm
Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.
Hemifacial Spasm
Botulinum toxin injections for the treatment of hemifacial spasm over 16 years.
Hemifacial Spasm
Botulinum toxin injections for treatment of blepharospasm and hemifacial spasm.
Hemifacial Spasm
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
Hemifacial Spasm
Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
Hemifacial Spasm
Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiologic studies.
Hemifacial Spasm
Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry.
Hemifacial Spasm
Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations.
Hemifacial Spasm
Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
Hemifacial Spasm
Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.
Hemifacial Spasm
Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
Hemifacial Spasm
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
Hemifacial Spasm
Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
Hemifacial Spasm
Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience.
Hemifacial Spasm
Botulinum toxin type B (Myobloc(R)) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study.
Hemifacial Spasm
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Hemifacial Spasm
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
Hemifacial Spasm
Buccinator synkinesis treated by botulinum toxin in facial palsy and hemifacial spasms.
Hemifacial Spasm
Causes for treatment delays in dystonia and hemifacial spasm: a canadian survey.
Hemifacial Spasm
Childhood-onset hemifacial spasm: successful treatment with botulinum toxin.
Hemifacial Spasm
Clinical and electrophysiological studies of botulinum toxin type A to treat hemifacial spasm complicated with auricular symptoms.
Hemifacial Spasm
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Hemifacial Spasm
Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
Hemifacial Spasm
Cognitive performance after facial botulinum toxin treatment in a cohort of neurological patients - an exploratory study.
Hemifacial Spasm
Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Hemifacial Spasm
Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Hemifacial Spasm
Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Hemifacial Spasm
Complications of botulinum toxin application: differences between hemifacial spasm and post-facial palsy synkinesis.
Hemifacial Spasm
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Hemifacial Spasm
Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin.
Hemifacial Spasm
Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry.
Hemifacial Spasm
Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin.
Hemifacial Spasm
Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Hemifacial Spasm
Differences in improvement between patients with idiopathic versus neurovascular hemifacial spasm after botulinum toxin treatment.
Hemifacial Spasm
Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A.
Hemifacial Spasm
Effect of botulinum neurotoxin treatment in the lateral spread monitoring of microvascular decompression for hemifacial spasm.
Hemifacial Spasm
Effect of combined facial exercise with botulinum toxin A on health-related quality of life in Thai adults with hemifacial spasm: a randomised controlled pilot cross-over trial.
Hemifacial Spasm
Effect of previous botulinum neurotoxin treatment on microvascular decompression for hemifacial spasm.
Hemifacial Spasm
Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.
Hemifacial Spasm
Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin.
Hemifacial Spasm
Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Hemifacial Spasm
Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units.
Hemifacial Spasm
Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm.
Hemifacial Spasm
Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Hemifacial Spasm
Erratum to: 'Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial'.
Hemifacial Spasm
Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
Hemifacial Spasm
Evaluation of botulinum toxin effects in hemifacial spasm patients: correlation between clinical rating scales and high-speed video system measurements.
Hemifacial Spasm
Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial.
Hemifacial Spasm
Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment.
Hemifacial Spasm
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hemifacial Spasm
Experiences on The Administration of Botulinum Toxin in Movement Disorders.
Hemifacial Spasm
Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
Hemifacial Spasm
Facial motor cortex plasticity in patients with unilateral peripheral facial paralysis.
Hemifacial Spasm
Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin.
Hemifacial Spasm
Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Hemifacial Spasm
Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study.
Hemifacial Spasm
Health-related quality of life outcomes from botulinum toxin treatment in hemifacial spasm.
Hemifacial Spasm
Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox((R)) or Dysport ((R)).
Hemifacial Spasm
Hemifacial Spasm due to Compression of the Posterior Inferior Cerebellar Artery Aneurysm Treated with Botulinum Toxin Type-A: A Case Report.
Hemifacial Spasm
Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators.
Hemifacial Spasm
Hemifacial spasm in correlation with electrophysiological and radiological findings.
Hemifacial Spasm
Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.
Hemifacial Spasm
Hemifacial spasm resulting from vertebral artery dolichoectasia.
Hemifacial Spasm
Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment.
Hemifacial Spasm
Hemifacial spasm: results of treatment with low dose botulinum toxin injection.
Hemifacial Spasm
Incidental finding of dysgeusia relieved by injections of botulinum toxin A.
Hemifacial Spasm
Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
Hemifacial Spasm
Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm.
Hemifacial Spasm
Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology.
Hemifacial Spasm
Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm?: a randomized, single-blind, crossover trial.
Hemifacial Spasm
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Hemifacial Spasm
Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.
Hemifacial Spasm
Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome.
Hemifacial Spasm
Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
Hemifacial Spasm
Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm.
Hemifacial Spasm
Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
Hemifacial Spasm
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Hemifacial Spasm
Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
Hemifacial Spasm
Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Hemifacial Spasm
Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.
Hemifacial Spasm
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
Hemifacial Spasm
Microvascular decompression in patient with atypical features of hemifacial spasm secondary to compression by a tortuous vertebrobasilar system: case report.
Hemifacial Spasm
Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle.
Hemifacial Spasm
Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox.
Hemifacial Spasm
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
Hemifacial Spasm
New stereoscopic virtual reality system application to cranial nerve microvascular decompression.
Hemifacial Spasm
No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
Hemifacial Spasm
Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
Hemifacial Spasm
Periorbital pain associated with hemifacial spasms that responded to botulinum toxin treatment and microvascular decompression surgery: a case report.
Hemifacial Spasm
Plasticity of cortical hand muscle representation in patients with hemifacial spasm.
Hemifacial Spasm
Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm.
Hemifacial Spasm
Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Hemifacial Spasm
Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Hemifacial Spasm
Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
Hemifacial Spasm
Real-world experience with botulinum toxin A for the treatment of hemifacial spasm: A study of 1138 injections.
Hemifacial Spasm
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Hemifacial Spasm
Serial SFEMG studies of orbicularis oculi muscle after the first administration of botulinum toxin.
Hemifacial Spasm
Sexual Well-Being in Patients with Blepharospasm, Spasmodic Torticollis, and Hemifacial Spasm: A Pilot Study.
Hemifacial Spasm
Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm.
Hemifacial Spasm
Subjective and Objective Measures in the Treatment of Hemifacial Spasm With OnabotulinumtoxinA.
Hemifacial Spasm
Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
Hemifacial Spasm
Surgical effect and electrophysiological study of patients with hemifacial spasm treated with botulinum toxin or acupuncture before microvascular decompression.
Hemifacial Spasm
Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
Hemifacial Spasm
Synkinesis in primary and postparalytic hemifacial spasm: Clinical features and therapeutic outcomes of botulinum toxin A treatment.
Hemifacial Spasm
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm.
Hemifacial Spasm
The Difference of Treatment Results between Botulinum Toxin A Split Injection Sites and Botulinum Toxin A Non-Split Injection Sites for Hemifacial Spasm.
Hemifacial Spasm
The effects of botulinum toxin A on ephaptic transmission in idiopathic hemifacial spasm.
Hemifacial Spasm
The effects of botulinum toxin on hemifacial spasm: an electrophysiologic investigation.
Hemifacial Spasm
The influence of botulinum toxin on auditory disturbances in hemifacial spasm.
Hemifacial Spasm
The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
Hemifacial Spasm
The mechanisms of action of Botulinum Toxin type A in nociceptive and neuropathic pathways in Cancer Pain.
Hemifacial Spasm
The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
Hemifacial Spasm
The validation of the disease-specific questionnaire for health-related quality of life in Thai patients with hemifacial spasm.
Hemifacial Spasm
Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study.
Hemifacial Spasm
Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated.
Hemifacial Spasm
Treatment of hemifacial spasm with botulinum toxin. Value of preinjection electromyography abnormalities for predicting postinjection lower facial paresis.
Hemifacial Spasm
Treatment of hemifacial spasm: Botulinum toxin versus microvascular decompression.
Hemifacial Spasm
Treatment of idiopathic hemifacial spasm with radiosurgery or hypofractionated stereotactic radiotherapy: preliminary results.
Hemifacial Spasm
Treatment outcome correlates with knowledge of disease in hemifacial spasm.
Hemifacial Spasm
Treatment with botulinum toxin improves the hyperexcitability of the facial motoneuron in patients with hemifacial spasm.
Hemifacial Spasm
Two hundred and fifty patients with hemifacial spasm treated with botulinum toxin injection.
Hemifacial Spasm
Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis.
Hemifacial Spasm
Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives.
Hemifacial Spasm
Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Hemifacial Spasm
Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
Hemifacial Spasm
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
Hemifacial Spasm
Use of fillers as adjunct therapy for the treatment of lower face hemifacial spasm.
Hemifacial Spasm
Vascular Decompression of Trigeminal and Facial Nerves in the Posterior Fossa under Endoscope-Assisted Keyhole Conditions.
Hemifacial Spasm
What is new in the era of focal dystonia treatment? Botulinum injections and more.
Hemifacial Spasm
[Application status and prospect of botulinum toxin A in otorhinolaryngological treatment].
Hemifacial Spasm
[Botulinum toxin A in therapy of craniocervical dystonias and hemifacial spasm]
Hemifacial Spasm
[Botulinum toxin in blepharospasm, in hemifacial spasm, and in cervical dystonia: results in 33 patients]
Hemifacial Spasm
[Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study]
Hemifacial Spasm
[Clinical and psychological factors influencing the efficacy of botulinum toxin in the treatment of hemifacial spasm and blepharospasm]
Hemifacial Spasm
[Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm]
Hemifacial Spasm
[Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: a pilot study]
Hemifacial Spasm
[Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review.]
Hemifacial Spasm
[Experience with botulinum toxin treatment of facial-cervical dystonias and hemifacial spasm]
Hemifacial Spasm
[Hemifacial spasm and basilar impression associated with Arnold-Chiari deformity. Report of a case]
Hemifacial Spasm
[Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment]
Hemifacial Spasm
[Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients]
Hemifacial Spasm
[Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A]
Hemifacial Spasm
[Long-term treatment with botulinum toxin: dosage, treatment schedules and costs]
Hemifacial Spasm
[New applications in maxillofacial surgery: Local injections with botulinum toxin type A].
Hemifacial Spasm
[New techniques in maxillofacial surgery: local injection treatment with botulinum toxin A]
Hemifacial Spasm
[Ocular dryness in the side that has been infiltrated and not infiltrated with botulinum toxin to treat hemifacial spasm]
Hemifacial Spasm
[The long-term evolution of botulinum toxin dosage in the treatment of hemifacial spasms]
Hemifacial Spasm
[Tiapride with the horn of saiga tatarica in the treatment of hemifacial spasm]
Hemifacial Spasm
[Torticollis spasmodicus, blepharospasm and hemifacial spasm. Subjective evaluation of therapy by patients]
Hemifacial Spasm
[Treatment of blepharospasm and facial hemispasm with botulinum toxin.Apropos of 58 injections in 22 patients]
Hemifacial Spasm
[Treatment of dystonic blepharospasm and hemifacial spasm with botulinum toxin: preliminary studies]
Hemifacial Spasm
[Treatment of hemifacial spasm with type A botulinum toxin (AGN 191622): a dose finding study and the evaluation of clinical effect with electromyography]
Hemifacial Spasm
[What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?]
Hemiplegia
A randomized trial of upper limb botulimun toxin versus placebo injection, combined with physiotherapy, in children with hemiplegia.
Hemiplegia
Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia.
Hemiplegia
Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome.
Hemiplegia
Combined therapy using botulinum toxin A and single-joint hybrid assistive limb for upper-limb disability due to spastic hemiplegia.
Hemiplegia
Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study.
Hemiplegia
Comparison of two injection techniques using botulinum toxin in spastic hemiplegia.
Hemiplegia
Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy.
Hemiplegia
Effect of addition of botulinum toxin-A to standardized therapy for dynamic manual skills measured with kinematic aiming tasks in children with spastic hemiplegia.
Hemiplegia
Efficacy of two injection-site localisation techniques for botulinum toxin injections: a single-blind, crossover, randomised trial protocol among adults with hemiplegia due to stroke.
Hemiplegia
Factors Influencing Gait Velocity Improvement Following Botulinum Toxin Injection for Spasticity of the Plantar Flexors in Patients with Stroke.
Hemiplegia
Feasibility of a day-camp model of modified constraint-induced movement therapy with and without botulinum toxin A injection for children with hemiplegia.
Hemiplegia
Functional outcomes of botulinum neurotoxin-A injection followed by reciprocal electrical stimulation in children with cerebral palsy: A randomized controlled trial.
Hemiplegia
How effective is physical therapy for gait muscle activity in hemiparetic patients who receive botulinum toxin injections?
Hemiplegia
Influence of botulinum toxin therapy on postural control and lower limb intersegmental coordination in children with spastic cerebral palsy.
Hemiplegia
Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia.
Hemiplegia
Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study.
Hemiplegia
Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle.
Hemiplegia
The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response.
Hemiplegia
The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial.
Hemiplegia
The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia.
Hemiplegia
Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.
Hemiplegia
Use of three-dimensional kinematic analysis following upper limb botulinum toxin A for children with hemiplegia.
Hemiplegia
Wrist-hand extension function recovery in spastic hemiplegia patient by botulinum toxin injection plus surface electromyography biofeedback therapy: A case report.
Hemiplegia
[Comparative analysis of occupational therapy benefits in spastic patients with hands involvement before and after botulinum toxin infiltration]
Hemiplegia
[Post stroke hemiplegia: interest of botulinum toxin injection at the upper limb]
Hemophilia A
Knee flexion contracture treated with botulinum toxin type A in patients with haemophilia (PWH).
Hemophilia A
Side effects and potential risk factors of botulinum toxin type A intramuscular injections in knee flexion contractures of hemophiliacs.
Hemorrhagic Fevers, Viral
Pathobiology and management of laboratory rodents administered CDC category A agents.
Hemorrhagic Stroke
Orthotic functional electrical stimulation following botulinum toxin for a young adult with severe hand impairment due to childhood stroke.
Hepatitis
[Antigen e and anti-e in primary liver cancer, cirrhosis, and viral hepatitis in Senegal]
Hepatitis
[Antigen e and its antibodies in acute serum hepatitis and in persons with a prolonged HBs-antigenemia]
Hepatitis A
Contributions of the European OMCL Network and Biological Standardisation Programme to Animal Welfare.
Hepatitis B
Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B.
Hepatitis B
Contributions of the European OMCL Network and Biological Standardisation Programme to Animal Welfare.
Hepatitis B
Hepatitis B surface antigen, e antigen and HBV DNA in healthy antenatal patients attending Goroka Hospital and their relationship to tattooing practices.
Hepatitis B
KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
Hepatitis B
Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007-2016.
Hepatitis B
Stimulation of TRAF6/TAK1 degradation and inhibition of JNK/AP-1 signalling by ginsenoside Rg3 attenuates hepatitis B virus replication.
Hepatitis C
Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007-2016.
Hepatitis E
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Hepatitis, Chronic
[B virus chronic hepatitis in the haemodialysed uraemic patient. Correlation between hepatic lesions and the presence of antigen e in 12 patients (author's transl)]
Hepatolenticular Degeneration
Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review.
Hepatolenticular Degeneration
Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.
Hernia, Umbilical
Ventral hernia secondary to giant omphalocele in a child: combined approach of botulinum toxin and preoperative progressive pneumoperitoneum.
Hernia, Umbilical
[Patient with a giant umbilical hernia treated preoperatively with botulinum toxin type A].
Herpes Labialis
Decreased Labial Herpes Simplex Virus Outbreaks Following Botulinum Neurotoxin Type A Injection: A Case Report.
Herpes Labialis
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Herpes Simplex
A Case of Reactivation of Herpes Simplex Virus Corneal Endotheliitis Following Periocular Botulinum Toxin A Injection.
Herpes Simplex
Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons.
Herpes Simplex
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Herpes Simplex
Reactivation of herpes simplex viral keratitis following the botulinum toxin injection.
Herpes Zoster
Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: a case report and literature review.
Herpes Zoster
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Herpes Zoster
Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report.
Herpes Zoster
Treatment of Hemichoreoathetosis with Arrhythmic Proximal Tremor after Stroke: The Role of Zona Incerta as a Target for Deep Brain Stimulation.
Herpes Zoster
Two cases of herpes zoster appearing after botulinum toxin type a injections.
Herpes Zoster Ophthalmicus
Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: a case report and literature review.
Hidradenitis Suppurativa
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
Hidradenitis Suppurativa
Hidradenitis suppurativa treated with Clostridium botulinum toxin A.
Hidradenitis Suppurativa
Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A.
Hidradenitis Suppurativa
Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A.
Hidradenitis Suppurativa
Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage.
Hidrocystoma
Multiple Eccrine Hidrocystomas - from Diagnosis to Treatment: The Role of Dermatoscopy and Botulinum Toxin.
Hidrocystoma
Multiple eccrine hidrocystomas: a new therapeutic option with botulinum toxin.
Hip Dislocation
Botulinum toxin as a solution in voluntary hip dislocation after modular unipolar hemiarthroplasty.
Hip Dislocation
Childhood cerebral palsy and the use of positioning systems to control body posture: Current practices.
Hip Dislocation
Comparison of botulinum toxin type A injection and soft-tissue surgery to treat hip subluxation in children with cerebral palsy.
Hip Dislocation
Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.
Hip Dislocation
Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up.
Hip Dislocation
Intra-articular botulinum toxin A (BoNT/A) for pain management in dogs with osteoarthritis secondary to hip dysplasia: a randomized controlled clinical trial.
Hip Dislocation
Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan.
Hip Dislocation
The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial.
Hip Dislocation
[The use of botulinum toxin in the treatment of spastic hip joint instability in children with cerebral palsy]
Hirschsprung Disease
A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease.
Hirschsprung Disease
Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease.
Hirschsprung Disease
Botulinum toxin injections after surgery for Hirschsprung disease: Systematic review and meta-analysis.
Hirschsprung Disease
Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease.
Hirschsprung Disease
Effects of botulinum toxin injection on anal achalasia after pull-through operations for Hirschsprung's disease: a 1-year follow-up study.
Hirschsprung Disease
Histology and function of the internal anal sphincter after injection of botulinum toxin.
Hirschsprung Disease
Intrasphincteric BoTox injections in Hirschsprung's disease: indications and outcome in 64 procedures over a ten-year period.
Hirschsprung Disease
Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease.
Hirschsprung Disease
Intrasphincteric botulinum toxin injections for post-operative obstructive defecation problems in hirschsprung disease: A retrospective observational study.
Hirschsprung Disease
Neurostimulation-Guided Anal Intrasphincteric Botulinum Toxin Injection in Children with Hirschsprung's Disease.
Hirschsprung Disease
Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung's disease.
Hirschsprung Disease
Role of rectal biopsy in predicting response to intrasphincteric botulinum toxin injection for obstructive symptoms after a pullthrough operation.
Hirschsprung Disease
Treatment of Adult Hirschsprung's Disease by Botulinum Toxin A through Anorectal Injection.
Hirschsprung Disease
Treatment of anal achalasia after transanal endorectal pull-through for Hirschsprung's disease with topical botulinum toxin.
Hirschsprung Disease
Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung's disease and internal anal sphincter achalasia.
Hirschsprung Disease
Update on medications used to treat gastrointestinal disease in children.
Hirschsprung Disease
[Treatment of Hirschsprung disease by botulinum toxin A through anorectal injection]
Hoarseness
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Hydrocephalus
Surgeon Annual and Cumulative Volumes Predict Early Postoperative Outcomes After Brain Tumor Resection.
Hydronephrosis
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?
Hyperalgesia
Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain.
Hyperalgesia
Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat.
Hyperalgesia
Antinociceptive Effects of Botulinum Toxin Type A on Trigeminal Neuropathic Pain.
Hyperalgesia
Botulinum neurotoxin type A alleviates mechanical hypersensitivity associated with infraorbital nerve constriction injury in rats.
Hyperalgesia
Botulinum toxin - neuropathic pain: Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Hyperalgesia
Botulinum Toxin A (Botox) for Treatment of Proximal Myofascial Pain in Complex Regional Pain Syndrome: Two Cases.
Hyperalgesia
Botulinum Toxin A for Treatment of Allodynia of Complex Regional Pain Syndrome: A Pilot Study.
Hyperalgesia
Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology.
Hyperalgesia
Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and ? opioid receptor expression in neuropathic mice.
Hyperalgesia
Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.
Hyperalgesia
Botulinum toxin C3 inhibits hyperalgesia in mice with partial sciatic nerve injury.
Hyperalgesia
Botulinum Toxin Decreases Hyperalgesia and Inhibits P2X(3) Receptor Over-Expression in Sensory Neurons Induced by Ventral Root Transection in Rats.
Hyperalgesia
Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction.
Hyperalgesia
Botulinum toxin type A activity in cranial dura: implications for treatment of migraine and other headaches.
Hyperalgesia
Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial.
Hyperalgesia
Botulinum toxin type A for the treatment of nummular headache: four case studies.
Hyperalgesia
Botulinum Toxin Type A Reduces Hyperalgesia and TRPV1 Expression in Rats with Neuropathic Pain.
Hyperalgesia
Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
Hyperalgesia
Differential effect of Incobotulinumtoxin A on pain, neurogenic flare and hyperalgesia in human surrogate models of neurogenic pain.
Hyperalgesia
Dynamic optimization of chronic migraine treatment: current and future options.
Hyperalgesia
Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
Hyperalgesia
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
Hyperalgesia
In vivo pathway of thermal hyperalgesia by intrathecal administration of alpha,beta-methylene ATP in mouse spinal cord: involvement of the glutamate-NMDA receptor system.
Hyperalgesia
Intradermal injection of Botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay.
Hyperalgesia
Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat.
Hyperalgesia
Phosphorylation of extracellular signal-regulated kinase 1/2 in subepidermal nerve fibers mediates hyperalgesia following diabetic peripheral neuropathy.
Hyperalgesia
Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Hyperalgesia
Severe hyperalgesia and pain during botulinum toxin injection avoiding application in a patient 1 week after COVID-19 infection.
Hyperalgesia
SNAP-25 Contributes to Neuropathic Pain by Regulation of VGLuT2 Expression in Rats.
Hyperalgesia
Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
Hyperalgesia
Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.
Hyperalgesia
The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats.
Hyperalgesia
The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain.
Hyperalgesia
The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization.
Hyperalgesia
The effects of intraplantar and intrathecal botulinum toxin type B on tactile allodynia in mono and polyneuropathy in the mouse.
Hyperhidrosis
A case of thrombosis of subcutaneous anterior chest veins (Mondor's disease) as an unusual complication of botulinum type A injection.
Hyperhidrosis
A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis.
Hyperhidrosis
A comparative trial of ice application versus EMLA cream in alleviation of pain during botulinum toxin injections for palmar hyperhidrosis.
Hyperhidrosis
A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Hyperhidrosis
A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
Hyperhidrosis
A new multiple site marking grid for botulinum toxin application in the treatment of axillary hyperhidrosis.
Hyperhidrosis
A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis.
Hyperhidrosis
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Hyperhidrosis
A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis.
Hyperhidrosis
A review of peripheral nerve blockade as local anaesthesia in the treatment of palmar hyperhidrosis.
Hyperhidrosis
A simple technique to standardize the administration of botulinum toxin type-A for idiopathic axillary hyperhidrosis: A preliminary report.
Hyperhidrosis
Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis.
Hyperhidrosis
Amelioration of body odor after intracutaneous axillary injection of botulinum toxin A.
Hyperhidrosis
An easy and effective local anaesthesia for treating palmar hyperhidrosis with botulinum toxin injections: the Cry-ac system.
Hyperhidrosis
Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis.
Hyperhidrosis
Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations.
Hyperhidrosis
Another injection-free method to effect analgesia when injecting botulinum toxin for palmar hyperhidrosis: cryoanalgesia.
Hyperhidrosis
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Hyperhidrosis
Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
Hyperhidrosis
Axillary injection of botulinum A toxin in a patient with muscle cramps associated with severe axillary hyperhidrosis.
Hyperhidrosis
Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis.
Hyperhidrosis
Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.
Hyperhidrosis
Botulinum neurotoxin A injection for the treatment of epiphora with patent lacrymal ducts.
Hyperhidrosis
Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.
Hyperhidrosis
Botulinum toxin A for palmar hyperhidrosis: assessment with sympathetic skin responses evoked by train of stimuli.
Hyperhidrosis
Botulinum toxin a for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy.
Hyperhidrosis
Botulinum toxin A treatment for hyperhidrosis in patients with prosthetic limbs.
Hyperhidrosis
Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse.
Hyperhidrosis
Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application.
Hyperhidrosis
Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles.
Hyperhidrosis
Botulinum toxin for hyperhidrosis: an important tool but not the ultimate cure.
Hyperhidrosis
Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita.
Hyperhidrosis
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Hyperhidrosis
Botulinum toxin injection is an effective treatment for axillary hyperhidrosis.
Hyperhidrosis
Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures.
Hyperhidrosis
Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population.
Hyperhidrosis
Botulinum toxin treatment for a compensatory hyperhidrosis subsequent to an upper thoracic sympathectomy.
Hyperhidrosis
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Hyperhidrosis
Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.
Hyperhidrosis
Botulinum Toxin Type A and B Improve Quality of Life in Patients with Axillary and Palmar Hyperhidrosis.
Hyperhidrosis
Botulinum toxin type A enhances the inhibitory spontaneous postsynaptic currents on the substantia gelatinosa neurons of the subnucleus caudalis in immature mice.
Hyperhidrosis
Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier's disease and inguinal hyperhidrosis.
Hyperhidrosis
Botulinum Toxin Type A for the Treatment of Primary Hyperhidrosis: A Prospective Study of 52 Patients.
Hyperhidrosis
Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study.
Hyperhidrosis
Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments.
Hyperhidrosis
Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
Hyperhidrosis
Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.
Hyperhidrosis
Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Hyperhidrosis
Botulinum toxin type A should be PBS listed for treatment of palmar hyperhidrosis.
Hyperhidrosis
Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis.
Hyperhidrosis
Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
Hyperhidrosis
Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study.
Hyperhidrosis
Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis.
Hyperhidrosis
Botulinum Toxin Versus Placebo: A Meta-Analysis of Treatment and Quality-of-life Outcomes for Hyperhidrosis.
Hyperhidrosis
Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
Hyperhidrosis
Botulinum toxin: An effective treatment for prosthesis-related hyperhidrosis in patients with traumatic amputations.
Hyperhidrosis
Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis.
Hyperhidrosis
Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis.
Hyperhidrosis
C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial.
Hyperhidrosis
Cholinergic Urticaria Responding to Botulinum Toxin injection for Axillary Hyperhidrosis.
Hyperhidrosis
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Hyperhidrosis
Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study.
Hyperhidrosis
Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminium chloride hexahydrate in treatment of palmar hyperhidrosis.
Hyperhidrosis
Comparative Study of Efficacy and Safety of Botulinum Toxin a Injections and Subcutaneous Curettage in the Treatment of Axillary Hyperhidrosis.
Hyperhidrosis
Comparison of efficacy and diffusion of three formulations of botulinum toxin type A in two patients with forehead hyperhidrosis.
Hyperhidrosis
Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: A randomized, controlled trial.
Hyperhidrosis
Comparison of microwave ablation, botulinum toxin injection, and liposuction-curettage in the treatment of axillary hyperhidrosis: A systematic review.
Hyperhidrosis
Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis.
Hyperhidrosis
Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation.
Hyperhidrosis
Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis.
Hyperhidrosis
Content of botulinum neurotoxin in botox(r)/vistabel(r), dysport(r)/azzalure(r), and xeomin(r)/bocouture(r).
Hyperhidrosis
Cooling by frozen gel pack as pain relief during treatment of axillary hyperhidrosis with botulinum toxin a injections.
Hyperhidrosis
Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A.
Hyperhidrosis
Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis.
Hyperhidrosis
CT-Guided Chemical Thoracic Sympathectomy versus Botulinum Toxin Type A Injection for Palmar Hyperhidrosis.
Hyperhidrosis
Development of Botulinum Toxin A-Coated Microneedles for Treating Palmar Hyperhidrosis.
Hyperhidrosis
Diagnosis, impact, and management of focal hyperhidrosis: treatment review including botulinum toxin therapy.
Hyperhidrosis
Differences between objective efficacy and perceived efficacy in patients with palmar hyperhidrosis treated with either botulinum toxin or endoscopic thoracic sympathectomy.
Hyperhidrosis
Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis.
Hyperhidrosis
Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study.
Hyperhidrosis
Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis.
Hyperhidrosis
Does wrist nerve block influence the result of botulinum toxin A treatment in palmar hyperhidrosis?
Hyperhidrosis
Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry.
Hyperhidrosis
Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.
Hyperhidrosis
Duration of Efficacy Increases with the Repetition of Botulinum Toxin A Injections in Primary Axillary Hyperhidrosis: A 15-year Study in 117 Patients.
Hyperhidrosis
Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: A study in 83 patients.
Hyperhidrosis
Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: A study of 28 patients.
Hyperhidrosis
Economic evaluation of botulinum toxin versus thoracic sympathectomy for palmar hyperhidrosis: data from a real-world scenario.
Hyperhidrosis
Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis.
Hyperhidrosis
Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report.
Hyperhidrosis
Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
Hyperhidrosis
Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis.
Hyperhidrosis
Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation.
Hyperhidrosis
Effects of a Long-Pulsed 800-nm Diode Laser on Axillary Hyperhidrosis: A Randomized Controlled Half-Side Comparison Study.
Hyperhidrosis
Effects of botulinum toxin-a therapy for palmar hyperhidrosis in plantar sweat production.
Hyperhidrosis
Efficacy and Safety of Botulinum Toxin A in Axillary Bromhidrosis and Associated Histological Changes in Sweat Glands: A Prospective Randomized Double-Blind Side-by-Side Comparison Clinical Study.
Hyperhidrosis
Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study.
Hyperhidrosis
Efficacy of botulinum toxin type A in the treatment of focal axillary hyperhidrosis.
Hyperhidrosis
Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study.
Hyperhidrosis
Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
Hyperhidrosis
Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet.
Hyperhidrosis
Evaluation of objective methods to diagnose palmar hyperhidrosis and monitor effects of botulinum toxin treatment.
Hyperhidrosis
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Hyperhidrosis
Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy - A quality of life and cost effectiveness analysis.
Hyperhidrosis
Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis.
Hyperhidrosis
Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis.
Hyperhidrosis
Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A.
Hyperhidrosis
Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A.
Hyperhidrosis
Focal hyperhidrosis secondary to eccrine naevus successfully treated with botulinum toxin type A.
Hyperhidrosis
Follow-up of patients with axillary hyperhidrosis after botulinum toxin injection.
Hyperhidrosis
Fractional CO2 Laser for Transcutaneous Drug Delivery of Onabotulinum Toxin in Palmar Hyperhidrosis.
Hyperhidrosis
Fractional CO2 laser-assisted Botulinum toxin type A delivery for the treatment of primary palmar hyperhidrosis.
Hyperhidrosis
Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A.
Hyperhidrosis
Gravimetrically controlled efficacy of subcorial curettage: a prospective study for treatment of axillary hyperhidrosis.
Hyperhidrosis
High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval.
Hyperhidrosis
High-dose injection of botulinum toxin to treat focal hyperhidrosis: what's wrong with the concept?
Hyperhidrosis
How to save botulinum toxin A in the treatment of focal axillary hyperhidrosis.
Hyperhidrosis
Hyperhidrosis of face and scalp: Repeated successful treatment with botulinum toxin type A.
Hyperhidrosis
Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin.
Hyperhidrosis
Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
Hyperhidrosis
Iatrogenic botulism after the therapeutic use of botulinum toxin-a: a case report and review of the literature.
Hyperhidrosis
Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Hyperhidrosis
Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis.
Hyperhidrosis
Idiopathic localized unilateral hyperhidrosis: case report of successful treatment with botulinum toxin type A and review of the literature.
Hyperhidrosis
Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment.
Hyperhidrosis
Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations.
Hyperhidrosis
Inguinal hyperhidrosis misdiagnosed as urinary incontinence: treatment with botulinum toxin A.
Hyperhidrosis
Injectable botulinum toxin as a treatment for plantar hyperhidrosis: a case study.
Hyperhidrosis
Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis.
Hyperhidrosis
Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series.
Hyperhidrosis
Intravenous regional anaesthesia for treatment of palmar hyperhidrosis with botulinum toxin type A.
Hyperhidrosis
Intravenous regional anesthesia (Bier's block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective.
Hyperhidrosis
Intravenous regional anesthesia (Bier's block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin.
Hyperhidrosis
Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A.
Hyperhidrosis
Letter: stump hyperhidrosis in a leg amputee: treatment with botulinum toxin a.
Hyperhidrosis
Local injection of botulinum toxin A for palmar hyperhidrosis: usefulness and efficacy in relation to severity.
Hyperhidrosis
Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements.
Hyperhidrosis
Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A.
Hyperhidrosis
Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis.
Hyperhidrosis
Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
Hyperhidrosis
Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase.
Hyperhidrosis
Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative.
Hyperhidrosis
Management of primary hyperhidrosis: a summary of the different treatment modalities.
Hyperhidrosis
Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures.
Hyperhidrosis
Modified protocol for the application of botulinum toxin type A for hyperhidrosis of the nose.
Hyperhidrosis
Molecular biology of botulinum neurotoxin serotype A: a cosmetic perspective.
Hyperhidrosis
Multi-injection plate for botulinum toxin application in the treatment of axillary hyperhidrosis.
Hyperhidrosis
Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented?
Hyperhidrosis
Myaesthenia gravis exacerbation caused by axillary injection of botulinum toxin A for treatment of hyperhidrosis.
Hyperhidrosis
Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis.
Hyperhidrosis
Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.
Hyperhidrosis
No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis.
Hyperhidrosis
Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
Hyperhidrosis
Onabotulinum toxin A for treatment of chronic migraine with medication overuse.
Hyperhidrosis
Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial.
Hyperhidrosis
Open Clinical Trial for Evaluation of Efficacy and Safety of a Portable "Dry-Type" Iontophoretic Device in Treatment of Palmar Hyperhidrosis.
Hyperhidrosis
Our trick to control the depth of injection of the botulinum toxin in the treatment of hyperhidrosis.
Hyperhidrosis
Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up.
Hyperhidrosis
Palmar and plantar hyperhidrosis: best practice recommendations and special considerations.
Hyperhidrosis
Palmar hyperhidrosis. Needle-free anesthesia as an alternative to Bier's block and peripheral nerve blockade for botulinum toxin therapy.
Hyperhidrosis
Palmar hyperhidrosis. Safety efficacy of two anaesthetic techniques for botulinum toxin therapy.
Hyperhidrosis
Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A.
Hyperhidrosis
Patients with hyperhidrosis have changed grip force, coefficient of friction and safety margin.
Hyperhidrosis
Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis.
Hyperhidrosis
Plantar hyperhidrosis and pitted keratolysis treated with botulinum toxin injection.
Hyperhidrosis
Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin.
Hyperhidrosis
Poster 430 Hyperhidrosis of the Amputee Patient's Stump and Botulinum Toxin: Multicenter Observational Study.
Hyperhidrosis
Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B.
Hyperhidrosis
Prediction of compensatory hyperhidrosis with botulinum toxin A and local anesthetic.
Hyperhidrosis
Pressure-and dose-controlled, needle-free, transcutaneous pneumatic injection of botulinum neurotoxin-A for the treatment of primary axillary and palmoplantar hyperhidrosis.
Hyperhidrosis
Primary frontal hyperhidrosis successfully treated with low doses of botulinum toxin A as a useful alternative to surgical treatment.
Hyperhidrosis
Primary hyperhidrosis: Implications on symptoms, daily life, health and alcohol consumption when treated with botulinum toxin.
Hyperhidrosis
Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature.
Hyperhidrosis
Progress and lack of progress in hyperhidrosis research 2015-2020. A concise systematic review.
Hyperhidrosis
Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life.
Hyperhidrosis
Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury.
Hyperhidrosis
Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A.
Hyperhidrosis
Quality of Life and Social Isolation in Greek Adolescents with Primary Focal Hyperhidrosis Treated with Botulinum Toxin Type A: A Case Series.
Hyperhidrosis
Quality of Life in Patients with Focal Hyperhidrosis before and after Treatment with Botulinum Toxin A.
Hyperhidrosis
Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study.
Hyperhidrosis
Randomized Controlled Trial Comparing the Efficacy and Safety of Two Injection Techniques of IncobotulinumtoxinA for Axillary Hyperhidrosis.
Hyperhidrosis
Reduction of Injection Site Pain in the Treatment of Axillary Hyperhidrosis With Botulinum Toxin: A Randomized, Side-by-Side, Comparative Study of Two Injection Patterns.
Hyperhidrosis
Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
Hyperhidrosis
Repetitive injections of botulinum toxin A continuously increase the duration of efficacy in primary axillary hyperhidrosis: a retrospective analysis in 101 patients.
Hyperhidrosis
Residual Limb Hyperhidrosis and RimabotulinumtoxinB: A Randomized Placebo-Controlled Study.
Hyperhidrosis
Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report.
Hyperhidrosis
Results of a 10-year follow-up study of botulinum toxin A therapy for primary axillary hyperhidrosis in Australia.
Hyperhidrosis
Retrospective analysis of the efficacy and duration of botulinum toxin A injections in 30 patients with palmar hyperhidrosis.
Hyperhidrosis
Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes.
Hyperhidrosis
Same-patient prospective comparison of botox versus dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Hyperhidrosis
Selection of safe parameters for jet injection of botulinum toxin in palmar hyperhidrosis.
Hyperhidrosis
Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin.
Hyperhidrosis
Severe compensatory hyperhidrosis following thoracic sympathectomy successfully treated with low doses of botulinum toxin A.
Hyperhidrosis
Should local anesthetics be banned during treatment of palmar hyperhidrosis with botulinum toxin A?
Hyperhidrosis
Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis.
Hyperhidrosis
Side-effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study.
Hyperhidrosis
Skin cooling for botulinum toxin A injection in patients with focal axillary hyperhidrosis: a prospective, randomized, controlled study.
Hyperhidrosis
Subcutaneous curettage vs. injection of botulinum toxin A for treatment of axillary hyperhidrosis.
Hyperhidrosis
Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study.
Hyperhidrosis
Surgical approaches and techniques in the management of severe hyperhidrosis.
Hyperhidrosis
Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis.
Hyperhidrosis
Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin.
Hyperhidrosis
Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
Hyperhidrosis
The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections.
Hyperhidrosis
The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial.
Hyperhidrosis
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Hyperhidrosis
The Influence of Needle Size on Pain Perception in Patients Treated with Botulinum Toxin A Injections for Axillary Hyperhidrosis.
Hyperhidrosis
The place of botulinum toxin type A in the treatment of focal hyperhidrosis.
Hyperhidrosis
The successful use of botulinum toxin for the treatment of nasal hyperhidrosis.
Hyperhidrosis
Therapeutic effectiveness of botulinum toxin type A based on severity of palmar hyperhidrosis.
Hyperhidrosis
Thirty-five units of botulinum toxin type A for treatment of axillary hyperhidrosis in female patients.
Hyperhidrosis
Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study.
Hyperhidrosis
Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis.
Hyperhidrosis
Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study.
Hyperhidrosis
Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox(®) doses.
Hyperhidrosis
Treating hyperhidrosis. Surgery and botulinum toxin are treatments of choice in severe cases.
Hyperhidrosis
Treatment approaches and outcomes associated with the use of abobotulinumtoxinA for the treatment of hyperhidrosis: a systematic review.
Hyperhidrosis
Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A.
Hyperhidrosis
Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
Hyperhidrosis
Treatment of Axillary Hyperhidrosis With Botulinum Toxin: A Single Surgeon's Experience With 53 Consecutive Patients.
Hyperhidrosis
Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics.
Hyperhidrosis
Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients.
Hyperhidrosis
Treatment of Focal Hyperhidrosis With Needleless Injections of Botulinum Toxin Into Sites Other than the Axilla, Palm, and Sole.
Hyperhidrosis
Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.
Hyperhidrosis
Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature.
Hyperhidrosis
Treatment of Palmar Hyperhidrosis by Peripheral Nerve Block at the Wrist With Botulinum Toxin.
Hyperhidrosis
Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience.
Hyperhidrosis
Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach.
Hyperhidrosis
Treatment of Palmar Hyperhidrosis With Needle Injection Versus Low-Pressure Needle-Free Jet Injection of OnabotulinumtoxinA: An Open-Label Prospective Study.
Hyperhidrosis
Treatment of palmar hyperhidrosis with needle-free injection of botulinum toxin A.
Hyperhidrosis
Treatment of plantar hyperhidrosis with dermojet injections of botulinum toxin.
Hyperhidrosis
Treatment of primary axillary hyperhidrosis with botulinum toxin type a: our experience in 50 patients from 2007 to 2010.
Hyperhidrosis
Treatment of recalcitrant plantar hyperhidrosis with type-A botulinum toxin injections and aluminum chloride in salicylic acid gel.
Hyperhidrosis
Treatment of Secondary Hyperhidrosis of the Intergluteal Cleft with Botulinum Toxin.
Hyperhidrosis
Treatment of unilateral compensatory sweating after endoscopical thoracic sympathectomy for general hyperhidrosis with botulinum toxin A.
Hyperhidrosis
Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis.
Hyperhidrosis
Use of a grid to simplify botulinum toxin injection for axillary hyperhidrosis.
Hyperhidrosis
Use of a transparent dressing in the treatment of axillary hyperhidrosis with botulinum toxin type A.
Hyperhidrosis
Use of iontophoresis or phonophoresis for delivering onabotulinumtoxinA in the treatment of palmar hyperidrosis: a report on four cases.
Hyperhidrosis
UV-B irradiation attenuates dermal effects of botulinum toxin A: a randomized, double-blind, placebo-controlled study.
Hyperhidrosis
Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures.
Hyperhidrosis
Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.
Hyperhidrosis
What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A.
Hyperhidrosis
Who are the Pioneers? A Critical Analysis of Innovation and Expertise in Cutaneous Noninvasive and Minimally Invasive Cosmetic and Surgical Procedures.
Hyperhidrosis
Writer's block: "texting" impairment as a complication of botulinum toxin type A therapy for palmar hyperhidrosis.
Hyperhidrosis
[Botulinum toxin for treatment of gustatory sweating. A prospective randomized study]
Hyperhidrosis
[Botulinum toxin type A for the treatment of primary hyperhidrosis: a prospective study of 52 patients]
Hyperhidrosis
[Efficacy of botulinum toxin A in the treatment of axillary and palmar hyperhidrosis: 10 cases]
Hyperhidrosis
[Efficacy of hypnosis in the treatment of palmar hyperhidrosis with botulinum toxin type A.]
Hyperhidrosis
[Efficacy, side effects and patient satisfaction with wrist conduction block anaesthesia prior to the treatment of palmar hyperhidrosis with botulinum toxin type A]
Hyperhidrosis
[New therapeutic principle in severe hyperhidrosis. Botulinum toxin injections can replace cutting of nerves]
Hyperhidrosis
[Toxin treatment of sweat pearls. A review of the treatment of hyperhidrosis with a special view of a new therapy option using botulinum toxin A]
Hyperhidrosis
[Type A botulinum toxin: a new methods in treating focal hyperhidrosis. A summary of various possibilities in hyperhidrosis therapy with special emphasis type A botulinum toxin injections]
Hyperhidrosis
[Ultrasound-guided peripheral nerve block at wrist level for the treatment of idiopathic palmar hyperhidrosis with botulinum toxin].
Hyperhidrosis
[Usefulness of Bilateral Sympathectomy Using Video-assisted Thorascopic Surgery in the Treatment of Essential Hyperhidrosis.]
Hyperkinesis
An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire.
Hyperkinesis
Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis.
Hyperkinesis
Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study.
Hyperkinesis
Contralateral botulinum injections in patients with residual facial asymmetry and contralateral hyperkinesis after primary facial palsy surgery.
Hyperkinesis
Contralateral Facial Botulinum Toxin Injection in Cases with Acute Facial Paralysis May Improve the Functional Recovery: Where We Stand and the Future Direction.
Hyperkinesis
Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.
Hyperpigmentation
A Study of Botulinum Toxin A for Ultraviolet-Induced Hyperpigmentation: A Randomized Controlled Trial.
Hypersensitivity
A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy.
Hypersensitivity
Allergy to ragweed antigen E: effect of specific immunotherapy on the reactivity of human T lymphocytes in vitro.
Hypersensitivity
Botulinum neurotoxin type A alleviates mechanical hypersensitivity associated with infraorbital nerve constriction injury in rats.
Hypersensitivity
Botulinum toxin type A and gabapentin attenuate postoperative pain and NK1 receptor internalization in rats.
Hypersensitivity
Comment on Tamura et al's Allergic Reaction to Botulinum Toxin: Positive Intradermal Test.
Hypersensitivity
Comparison of polymerized and unpolymerized antigen E for immunotherapy of ragweed allergy.
Hypersensitivity
Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
Hypersensitivity
Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Hypersensitivity
The First Case Report of a Systemic Allergy to OnabotulinumtoxinA (Botox) in a Healthy Patient.
Hypersensitivity
The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.
Hypersensitivity
Unexpected serious adverse reactions to the therapy with botulinum toxin might be due to hypersensitivity.
Hypersensitivity
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice.
Hypertension
Arterial hypertension related to the injection of onabotulinumtoxinA in the detrusor.
Hypertension
Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus.
Hypertension
Long-Term Blood Pressure Control Effect of Celiac Plexus Block with Botulinum Toxin.
Hypertension
Renal mechanisms of salt-sensitive hypertension: contribution of two steroid receptor-associated pathways.
Hypertension
Treatment of hypertension from renal artery entrapment by percutaneous CT-guided botulinum toxin injection into diaphragmatic crus as alternative to surgery and stenting.
Hypohidrosis
Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations.
Hypohidrosis
Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Hypohidrosis
Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up.
Hypohidrosis
Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study.
Hypohidrosis
Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis.
Hypohidrosis
High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval.
Hypohidrosis
Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase.
Hypokinesia
Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series.
Hypotrichosis
A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study.
Hypoxia, Brain
Multiple Beneficial Effects of High-dose BoNT-A Injection to Improve Wound Healing and Spasticity in a Patient With Hypoxic Encephalopathy Due to High-voltage Electrical Injury.
Hypoxia, Brain
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]
Infarction, Posterior Cerebral Artery
Simultaneous loss of bilateral voluntary eyelid opening and sustained winking response following bilateral posterior cerebral artery infarction.
Infections
A Case of Cutaneous Non-Mycobacterium Infection after Illegal Botulinum Toxin Injection Diagnosed by Polymerase Chain Reaction.
Infections
A video of best practice recommendations for making botulinum toxin therapy safe during the COVID-19 pandemic.
Infections
Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.
Infections
Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
Infections
Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Infections
Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection.
Infections
Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons.
Infections
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Infections
Botulinum toxin injection to the salivary glands for the treatment of sialorrhea with chronic aspiration.
Infections
Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.
Infections
Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.
Infections
Botulinum toxin type A (Botox) and idiopathic overactive bladder. For some severely affected patients.
Infections
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Infections
Carbohydrate recognition mechanism of HA70 from Clostridium botulinum deduced from X-ray structures in complexes with sialylated oligosaccharides.
Infections
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Infections
Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial.
Infections
Could treatment with botulinum toxin protect against subsequent infection with COVID-19?
Infections
Crystal structure of the receptor binding domain of the botulinum C-D mosaic neurotoxin reveals potential roles of lysines 1118 and 1136 in membrane interactions.
Infections
Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury.
Infections
Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity.
Infections
Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Infections
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
Infections
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial.
Infections
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?
Infections
Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Infections
Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Infections
Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
Infections
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Infections
Metatranscriptomics reveals that the death of a Mongolian wild ass was caused by Clostridium botulinum in Inner Mongolia, China.
Infections
Mycobacterium abscessus cutaneous infection secondary to botulinum toxin injection: A report of 2 cases.
Infections
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Infections
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Infections
OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Infections
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review.
Infections
OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.
Infections
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Infections
Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study.
Infections
Real World Performance of SNM and OnabotulinumtoxinA for OAB: Focus on Safety and Cost.
Infections
Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Infections
Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Infections
Risk of urinary tract infection after detrusor botulinum toxin a injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Infections
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Infections
SERS detection of Clostridium botulinum neurotoxin serotypes A and B in buffer and serum: Towards the development of a biodefense test platform.
Infections
Severe hyperalgesia and pain during botulinum toxin injection avoiding application in a patient 1 week after COVID-19 infection.
Infections
Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report.
Infections
Surgical technique for patients with the apractic type of essential blepharospasm: case report.
Infections
Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms.
Infections
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Infections
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.
Infections
The role of suprapubic catheter insertion in preventing urinary tract infections following intravesical Botulinum toxin A.
Infections
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials.
Infections
Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
Infections
[Cytokines and antibodies in experimental infection of wild and laboratory rodents (rodentia) with tick-borne encephalitis virus].
Infections
[Evaluation of the immunofluorescence test in the diagnosis of botulinum toxin poisoning in humans and animals. II. Identification of Clostridium botulinum in the soil from the shores, bottom silt and water of the Konopno Lake, a source of infection of fish with Cl. botulinum E]
Inflammatory Bowel Diseases
[Endosonographic and manometric assessment of the internal anal sphincter in patients with chronic anal fissure]
Influenza, Human
Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon.
Influenza, Human
Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.
Insulinoma
ATP modulates interaction of syntaxin-1A with sulfonylurea receptor 1 to regulate pancreatic beta-cell KATP channels.
Insulinoma
Ca(2+) influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis.
Insulinoma
Phosphorylation of SNAP-25 on serine-187 is induced by secretagogues in insulin-secreting cells, but is not correlated with insulin secretion.
Insulinoma
Syntaxin-1A binds the nucleotide-binding folds of sulphonylurea receptor 1 to regulate the KATP channel.
Insulinoma
The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F.
Insulinoma
Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells.
Intellectual Disability
Discordance in informed consent response on the basis of demographic factors: brief report.
Intellectual Disability
Lorazepam does not improve the quality of recovery in day-case surgery patients: A randomised, placebo-controlled clinical trial.
Intellectual Disability
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Intellectual Disability
What could predict effectiveness of Botulinum Toxin to treat drooling: A search for evidence of discriminatory factors on the level of body functions or structures.
Intellectual Disability
[Efficacy of botulinum toxin type A against cervical dystonia and muscular hypertonia in persons with severe motor and intellectual disabilities with respiratory problems and/or dysphagia].
Intellectual Disability
[Initial efficacy of intramuscular injection of botulinum toxin type A against cervical dystonia and general muscular hypertonia in persons with severe motor and intellectual disabilities]
Intertrigo
Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier's disease and inguinal hyperhidrosis.
Intervertebral Disc Degeneration
Protocol on induction of TMJ articular disc degeneration in rats by utilization of botulinum toxin.
Intestinal Pseudo-Obstruction
Botulinum toxin in the treatment of intestinal pseudo-obstruction following a stroke.
Intracranial Hemorrhages
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.
Irritable Bowel Syndrome
Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study.
Isaacs Syndrome
Neuromyotonia in a muscle flap producing a convulsing breast: successful treatment with botulinum toxin.
Isaacs Syndrome
Ocular Neuromyotonia Noted after Recent Botulinum Toxin Injection for Sixth Nerve Palsy Following Resection of a Posterior Fossa Skull Base Meningioma.
Isaacs Syndrome
Successful use of botulinum toxin for post-irradiation unilateral jaw neuromyotonia.
Isaacs Syndrome
The use of botulinum toxin in localizing neuromyotonia to the terminal branches of the peripheral nerve.
Isaacs Syndrome
Use of botulinum toxin type A for the treatment of radiation therapy-induced myokymia and neuromyotonia in a dog.
Ischemic Stroke
Activation of neuronal Ras-related C3 botulinum toxin substrate 1 (Rac1) improves post-stroke recovery and axonal plasticity in mice.
Ischemic Stroke
BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
Ischemic Stroke
Botulinum Toxin A and Task-Specific Training for Hand Dystonia due to 5 Year Old Stroke.
Ischemic Stroke
Comprehensive Use of Dynamic Electrical Neurostimulation and Botulinum Toxin Therapy in Patients with Post-Stroke Spasticity.
Ischemic Stroke
Effectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case report.
Joint Diseases
Cervical Dystonia Refractory to Botulinum Toxin Responding to Radiofrequency Ablation: A Case Report.
Joint Diseases
Efficacy of Intra-articular Botulinum Toxin in Osteo-articular Joint Pain: A Meta-analysis of Randomized Controlled Trials.
Joint Diseases
Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: protocol for a randomised trial (RHIBOT).
Joint Dislocations
Botulinum Neurotoxin Injection for the Treatment of Recurrent Temporomandibular Joint Dislocation with and without Neurogenic Muscular Hyperactivity.
Joint Dislocations
Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia.
Joint Dislocations
Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A.
Joint Dislocations
Neurogenic temporomandibular joint dislocation treated with botulinum toxin: report of 4 cases.
Joint Dislocations
Recurrent temporomandibular joint dislocation treated with botulinum toxin: report of 3 cases.
Joint Dislocations
Recurrent TMJ Dislocation Managed with Botulinum Toxin Type A Injections in a Pediatric Patient.
Joint Dislocations
Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A.
Joint Dislocations
Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection.
Joint Dislocations
Velopharyngeal dysfunction following botulinum toxin type A injection to the lateral pterygoid muscles for recurrent jaw dislocation.
Joint Dislocations
[Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin]
Joint Dislocations
[Neurogenic temporomandibular joint dislocation. Definition and therapy with botulinum toxin]
Joint Instability
Joint instability leads to long-term alterations to knee synovium and osteoarthritis in a rabbit model.
Joint Instability
[The use of botulinum toxin in the treatment of spastic hip joint instability in children with cerebral palsy]
Keloid
A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches.
Keloid
Assessment of laser-assisted delivery vs intralesional injection of botulinum toxin A in treatment of hypertrophic scars and keloids.
Keloid
Botulinum Toxin A Affects Early Capsule Formation Around Silicone Implants in a Rat Model.
Keloid
Botulinum Toxin and Platelet Rich Plasma as Innovative Therapeutic Modalities for Keloids.
Keloid
Botulinum Toxin Type A as a Tool for Correcting Capsular Contracture after Reconstructive Breast Surgery.
Keloid
Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review.
Keloid
BTXA regulates the epithelial-mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2.
Keloid
Commentary on The Cellular Response of Keloids and Hypertrophic Scars to Botulinum Toxin A: A Comprehensive Literature Review.
Keloid
Comparison of intralesional triamcinolone acetonide, botulinum toxin type A, and their combination for the treatment of keloid lesions.
Keloid
Could -79 °C Spray-Type Cryotherapy Be an Effective Monotherapy for the Treatment of Keloid?
Keloid
Discussion: Treatment of Keloid Scars with Botulinum Toxin Type A versus Triamcinolone in an Athymic Nude Mouse Model.
Keloid
Early Postoperative Application of Botulinum Toxin Type A Prevents Hypertrophic Scarring after Epicanthoplasty: A Split-Face, Double-Blind, Randomized Trial.
Keloid
Efficacy and possible mechanisms of Botulinum Toxin type A on hypertrophic scarring.
Keloid
Efficacy and Safety of Botulinum Toxin Type A in Preventing Postoperative Scars and Improving the Cosmetic Appearance of Scars: A Systematic Review and Meta-Analysis.
Keloid
Efficacy of Botulinum Toxin A in Preventing Recurrence Keloids: Double Blinded Randomized Controlled Trial Study: Intraindividual Subject.
Keloid
Eradication of keloids: Surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin.
Keloid
Evaluation of Efficacy of Corticosteroid and Corticosteroid Combined with Botulinum Toxin Type A in the Treatment of Keloid and Hypertrophic Scars: A Meta-Analysis.
Keloid
Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial.
Keloid
Intralesional botulinum toxin type A injection as a new treatment measure for keloids.
Keloid
Intralesional excision with topical intralesional cryotherapy improves the treatment of keloid scarring in a paediatric patient.
Keloid
Intralesional Injection of Botulinum Toxin Type A Compared with Intralesional Injection of Corticosteroid for the Treatment of Hypertrophic Scar and Keloid: A Systematic Review and Meta-Analysis.
Keloid
Letter to the Editor: Evaluation of Efficacy of Corticosteroid and Corticosteroid Combined with Botulinum Toxin Type A in the Treatment of Keloid and Hypertrophic Scars-A Meta-Analysis.
Keloid
RAC Activity in Keloid Disease: Comparative Analysis of Fibroblasts from Margin of Keloid to its Surrounding Normal Skin.
Keloid
The Cellular Response of Keloids and Hypertrophic Scars to Botulinum Toxin A: A Comprehensive Literature Review.
Keloid
The molecular mechanism of GADD153 in apoptosis of keloid fibroblasts exposed to botulinum toxin type A.
Keloid
Treatment of Keloid Scars with Botulinum Toxin A Versus Triamcinolone in an Athymic Nude Mice Animal Model.
Keratitis
Bilateral herpes simplex keratitis reactivation after lacrimal gland botulinum toxin injection.
Keratitis
Botulinum toxin injection for the management of refractory filamentary keratitis.
Keratitis
Reactivation of herpes simplex viral keratitis following the botulinum toxin injection.
Keratitis
Scleral contact lens management of bilateral exposure and neurotrophic keratopathy.
Keratitis
Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin.
Keratitis, Herpetic
Bilateral herpes simplex keratitis reactivation after lacrimal gland botulinum toxin injection.
Keratoconjunctivitis
Management of superior limbic keratoconjunctivitis with botulinum toxin.
Keratoconjunctivitis
Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and Botulium Toxin A.
Keratoconjunctivitis Sicca
Botulinum toxin A treatment of epiphora secondary to autologous submandibular gland transplantation.
Keratoconjunctivitis Sicca
Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Keratoconjunctivitis Sicca
Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Keratoconjunctivitis Sicca
Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Keratoconjunctivitis Sicca
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Keratoconus
Keratoconus progression is not inhibited by reducing eyelid muscular force with botulinum toxin A treatment: a randomized trial.
Keratoderma, Palmoplantar
Botulinum toxin is helpful in aquagenic palmoplantar keratoderma.
Kernicterus
[Cervical myelopathy associated with os odontoideum after botulinum toxin treatment in a patient with cerebral palsy].
Lacrimal Apparatus Diseases
A review on use of botulinum toxin for intractable lacrimal drainage disorders.
Lacrimal Apparatus Diseases
Bilateral herpes simplex keratitis reactivation after lacrimal gland botulinum toxin injection.
Lacrimal Apparatus Diseases
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
Lacrimal Apparatus Diseases
Botulinum neurotoxin A injection for the treatment of epiphora with patent lacrymal ducts.
Lacrimal Apparatus Diseases
Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.
Lacrimal Apparatus Diseases
Botulinum toxin A treatment of epiphora secondary to autologous submandibular gland transplantation.
Lacrimal Apparatus Diseases
Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
Lacrimal Apparatus Diseases
Botulinum toxin injection for the treatment of epiphora in lacrimal outflow obstruction.
Lacrimal Apparatus Diseases
Botulinum toxin injection into the lacrimal gland for treatment of proximal nasolacrimal duct obstructions in children.
Lacrimal Apparatus Diseases
Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson's disease.
Lacrimal Apparatus Diseases
Controversies in periocular reconstruction for facial nerve palsy.
Lacrimal Apparatus Diseases
Duration of botulinum toxin effect in the treatment of crocodile tears.
Lacrimal Apparatus Diseases
Factors influencing the long-term results of autologous microvascular submandibular gland transplantation for severe dry eye disease.
Lacrimal Apparatus Diseases
Lacrimal gland botulinum toxin injection for epiphora management.
Lacrimal Apparatus Diseases
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca.
Lacrimal Apparatus Diseases
Noncosmetic periocular therapeutic applications of botulinum toxin.
Lacrimal Apparatus Diseases
Outcomes of lacrimal gland injection of botulinum toxin in functional versus nonfunctional epiphora.
Lacrimal Apparatus Diseases
Results of lacrimal gland botulinum toxin injection for epiphora in lacrimal obstruction and gustatory tearing.
Lacrimal Apparatus Diseases
The use of botulinum toxin A in the treatment of functional epiphora.
Lacrimal Apparatus Diseases
Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial.
Lacrimal Apparatus Diseases
[Role and mechanism of muscarinic acetylcholine receptor in the regulation of submandibular gland secretion].
Lacrimal Duct Obstruction
Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.
Lacrimal Duct Obstruction
Botulinum toxin injection into the lacrimal gland for treatment of proximal nasolacrimal duct obstructions in children.
Lambert-Eaton Myasthenic Syndrome
Effects of botulinum neurotoxin and Lambert-Eaton myasthenic syndrome IgG at mouse nerve terminals.
Lambert-Eaton Myasthenic Syndrome
Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome.
Laryngismus
Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin.
Laryngomalacia
Laryngeal dystonia causing inspiratory stridor in children with cerebral palsy.
Laryngopharyngeal Reflux
[Vocal cord dysfunction. An important differential diagnosis to bronchial asthma]
Lateral Medullary Syndrome
Efficacy of botulinum toxin type-A and swallowing treatment for oropharyngeal dysphagia recovery in a patient with lateral medullary syndrome.
Leiomyoma
Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial.
Leiomyoma
Treatment of cutaneous leiomyomas with botulinum toxin. Case report and review of literature.
Lesch-Nyhan Syndrome
Botulinum toxin as a novel treatment for self-mutilation in Lesch-Nyhan syndrome.
Lesch-Nyhan Syndrome
Botulinum toxin: treatment of self-mutilation in patients with Lesch-Nyhan syndrome.
Lesch-Nyhan Syndrome
Reduction of self-mutilating behavior and improved oromotor function in a patient with Lesch-Nyhan syndrome following botulinum toxin injection: A case report.
Lethargy
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population.
Leukemia
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Leukemia
RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia.
Leukemia
The role of Rac2-NADPH oxidase-ROS in human leukemia HL-60 cell apoptosis induced by diallyl disulfide.
Leukemia, T-Cell
Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Leukomalacia, Periventricular
Gait training using a hybrid assistive limb after botulinum toxin treatment for cerebral palsy: a case report.
Lichen Planus
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus.
Liver Abscess
Gastrointestinal: Hepatic abscess after botulinum toxin type-A therapy for achalasia.
Liver Diseases
Liver HLA-E Expression Is Associated with Severity of Liver Disease in Chronic Hepatitis C.
Liver Neoplasms
[Antigen e and anti-e in primary liver cancer, cirrhosis, and viral hepatitis in Senegal]
Lung Injury
[Study on Rac1/MAPK/ERK pathway mediated mechanism and role in rats with ventilator induced lung injury].
Lung Neoplasms
A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
Lung Neoplasms
ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
Lung Neoplasms
Use of Botulinum Toxin A to Treat Chemotherapy-Induced Raynaud's Phenomenon.
Lymphoma
Nox4 is involved in high glucose-induced apoptosis in renal tubular epithelial cells via Notch pathway.
Lymphoma, Non-Hodgkin
Application of NMR methods to identify detection reagents for use in development of robust nanosensors.
Lymphoma, T-Cell
Regulation of breast cancer cell motility by T-cell lymphoma invasion and metastasis-inducing protein.
Machado-Joseph Disease
Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease).
Machado-Joseph Disease
Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease.
Malaria
A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus.
Malaria
Correlation between structure, retention, property, and activity of biologically relevant 1,7-bis(aminoalkyl)diazachrysene derivatives.
Malaria
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
Malaria, Falciparum
Correlation between structure, retention, property, and activity of biologically relevant 1,7-bis(aminoalkyl)diazachrysene derivatives.
Malnutrition
Achalasia in Pregnancy: Botulinum Toxin A Injection of Lower Esophageal Sphincter.
Malnutrition
Severe dysphagia due to a huge epiphrenic diverticulum: long-term treatment with balloon dilation and botulinum toxin injection: a case report.
Malnutrition
[Botulinum A toxin treatment in patients with oromandibular dystonia with concomitant malnutrition]
Malocclusion
Botulinum toxin as a therapeutic agent to prevent relapse in deep bite patients.
Malocclusion
Correction of Malocclusion by Botulinum Neurotoxin Injection into Masticatory Muscles.
Malocclusion
Ultrasound dimensional changes of the anterior belly of the digastric muscle induced by orthognathic surgery and botulinum toxin A injection in Class II malocclusion.
Mandibular Fractures
Effect of Botulinum Toxin Type A on Mandibular Fracture Healing: An Experimental Study in Rabbits.
Mandibulofacial Dysostosis
Treacher Collins syndrome: an undescribed characteristic of the condition and its management with botulinum toxin and surgery.
Maple Syrup Urine Disease
The use of botulinum toxin and epidural analgesia for the treatment of spasticity and pain in a patient with maple syrup urine disease.
Mediastinitis
A case of mediastinitis following botulinum toxin type A treatment for achalasia.
Mediastinitis
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases?
Mediastinitis
Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia.
Mediastinitis
Fatal mediastinitis following botulinum toxin injection for esophageal spasm.
Mediastinitis
Mediastinitis, pseudo-aneurysm formation, aortic bleed, and death from endoscopic botulinum toxin injection.
Meige Syndrome
A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
Meige Syndrome
Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
Meige Syndrome
Aripiprazole in Meige Syndrome: Clinical Response and Implications for Treatment Development.
Meige Syndrome
Bilateral deep brain stimulation of the subthalamic nucleus in primary Meige syndrome.
Meige Syndrome
Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.
Meige Syndrome
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Meige Syndrome
Globus pallidus interna deep brain stimulation in a patient with medically intractable meige syndrome.
Meige Syndrome
Lidocaine tape (Penles) reduces the pain of botulinum toxin injection for Meige syndrome.
Meige Syndrome
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
Meige Syndrome
Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome.
Meige Syndrome
Long-Term Efficacy of Deep Brain Stimulation of Bilateral Globus Pallidus Internus in Primary Meige Syndrome.
Meige Syndrome
Meige syndrome: a rare form of cranial dystonia that was treated successfully with botulinum toxin.
Meige Syndrome
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
Meige Syndrome
Orbicularis oculi myo-osseous fixation: a new treatment for benign essential blepharospasm and blepharospasm associated with diffuse facial dystonia (meige syndrome).
Meige Syndrome
Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
Meige Syndrome
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
Meige Syndrome
[Deep brain stimulation in the treatment of torticollis and Meige syndrome].
Meige Syndrome
[Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients]
Melanoma
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Melanoma
Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors.
Melanoma
inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
Melanoma
Overexpression of Ras-Related C3 Botulinum Toxin Substrate 2 Radiosensitizes Melanoma Cells In Vitro and In Vivo.
Melanoma
Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Memory Disorders
Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats.
Meningioma
Ocular Neuromyotonia Noted after Recent Botulinum Toxin Injection for Sixth Nerve Palsy Following Resection of a Posterior Fossa Skull Base Meningioma.
Meningitis
[Suppurative meningitis in a patient with severe botulinum toxin type B poisoning]
Meningomyelocele
Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
Meningomyelocele
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Meningomyelocele
Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up.
Meningomyelocele
Intravesical Electromotive Botulinum Toxin Type A (Dysport) Administration in Children With Myelomeningocele.
Meningomyelocele
Intravesical Electromotive Botulinum Toxin Type A Administration-Part II: Clinical Application.
Meningomyelocele
Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
Meningomyelocele
Intravesical Injections of Botulinum Toxin Type A for Management of Neuropathic Bladder: A Comparison of Two Methods.
Meningomyelocele
Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury.
Meningomyelocele
Need for botulinum toxin injection and bladder augmentation after isolated bladder outlet procedure in pediatric patients with myelomeningocele.
Meningomyelocele
Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
Meningomyelocele
Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment.
Meningomyelocele
Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele.
Meningomyelocele
Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele.
Meningomyelocele
Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele.
Metabolic Diseases
Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.
Migraine Disorders
A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites.
Migraine Disorders
A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults.
Migraine Disorders
A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Migraine Disorders
A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Migraine Disorders
A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Migraine Disorders
A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Migraine Disorders
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine.
Migraine Disorders
A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache.
Migraine Disorders
A proposal to prevent the "Mephisto sign" side effect of botulinum toxin type A injection in chronic migraine.
Migraine Disorders
A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment.
Migraine Disorders
A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K. technology appraisal.
Migraine Disorders
A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine.
Migraine Disorders
A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
Migraine Disorders
A review of current evidence in the surgical treatment of migraine headaches.
Migraine Disorders
A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
Migraine Disorders
A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience.
Migraine Disorders
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Migraine Disorders
Accessory Nerves of the Forehead: A Newly Discovered Frontotemporal Neurovascular Bundle and Its Implications in the Treatment of Frontal Headache, Migraine Surgery, and Cosmetic Temple Filler Injection.
Migraine Disorders
Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.
Migraine Disorders
Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: A randomized controlled study.
Migraine Disorders
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Migraine Disorders
Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.
Migraine Disorders
An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
Migraine Disorders
An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Migraine Disorders
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Migraine Disorders
An update on the pharmacological management of pain in patients with multiple sclerosis.
Migraine Disorders
Analgesic effects of botulinum neurotoxin type A in a model of allyl isothiocyanate- and capsaicin-induced pain in mice.
Migraine Disorders
Anatomical Look Into OnabotulinumtoxinA Injection for Chronic Migraine Headache.
Migraine Disorders
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
Migraine Disorders
Application of botulinum toxin to clinical therapy: advances and cautions.
Migraine Disorders
Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
Migraine Disorders
Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A.
Migraine Disorders
Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed.
Migraine Disorders
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
Migraine Disorders
Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.
Migraine Disorders
BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
Migraine Disorders
Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
Migraine Disorders
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Migraine Disorders
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.
Migraine Disorders
Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.
Migraine Disorders
Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.
Migraine Disorders
Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison.
Migraine Disorders
Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study.
Migraine Disorders
Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
Migraine Disorders
Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
Migraine Disorders
Botulinum toxin a relieved neuropathic pain in a case of post-herpetic neuralgia.
Migraine Disorders
Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines.
Migraine Disorders
Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse.
Migraine Disorders
Botulinum toxin as a preventive treatment for migraine and chronic tension headache.
Migraine Disorders
Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
Migraine Disorders
Botulinum toxin for chronic migraine: Clinical trials and technical aspects.
Migraine Disorders
Botulinum toxin for the treatment of chronic migraine: the placebo effect.
Migraine Disorders
Botulinum toxin for the treatment of headache: a promising path on a "dead end road"?
Migraine Disorders
Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.
Migraine Disorders
Botulinum toxin in the management of chronic migraine: clinical evidence and experience.
Migraine Disorders
Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
Migraine Disorders
Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation.
Migraine Disorders
Botulinum toxin injections to cranial sutures for chronic migraine Rewinding the technique using ultrasound imaging.
Migraine Disorders
Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.
Migraine Disorders
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
Migraine Disorders
Botulinum toxin type A (Botox) in the treatment of migraine and other headaches.
Migraine Disorders
Botulinum toxin type A activity in cranial dura: implications for treatment of migraine and other headaches.
Migraine Disorders
Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Migraine Disorders
Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Migraine Disorders
Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Migraine Disorders
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Migraine Disorders
Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Migraine Disorders
Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial.
Migraine Disorders
Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
Migraine Disorders
Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Migraine Disorders
Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study.
Migraine Disorders
Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Migraine Disorders
Botulinum toxin type a in the prophylactic treatment of transformed migraine in Taiwanese patients: a review of 30 consecutive cases.
Migraine Disorders
Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Migraine Disorders
Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Migraine Disorders
Botulinum toxin type a therapy in migraine: preclinical and clinical trials.
Migraine Disorders
Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.
Migraine Disorders
Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
Migraine Disorders
Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
Migraine Disorders
Botulinum Toxin versus Placebo: A Meta- Analysis of Prophylactic Treatment for Migraine.
Migraine Disorders
Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Migraine Disorders
Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal.
Migraine Disorders
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.
Migraine Disorders
Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review.
Migraine Disorders
Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis.
Migraine Disorders
Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison.
Migraine Disorders
Can Botulinum Toxin Help Prevent Migraine in Adults?: A Cochrane Review Summary With Commentary.
Migraine Disorders
Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle Paralysis from Botulinum Toxin Injection.
Migraine Disorders
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
Migraine Disorders
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic.
Migraine Disorders
Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy.
Migraine Disorders
Chronic Migraine With Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol.
Migraine Disorders
Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.
Migraine Disorders
Cleavage of SNAP-25 ameliorates cancer pain in a mouse model of melanoma.
Migraine Disorders
Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine.
Migraine Disorders
Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Migraine Disorders
Clinical results of botulinum toxin type a treatment of migraine headache.
Migraine Disorders
Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine.
Migraine Disorders
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
Migraine Disorders
Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
Migraine Disorders
Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
Migraine Disorders
Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines.
Migraine Disorders
Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats.
Migraine Disorders
Concurrent OnabotulinumtoxinA Treatment of Cervical Dystonia and Concomitant Migraine.
Migraine Disorders
Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.
Migraine Disorders
Correction to: OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use.
Migraine Disorders
Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
Migraine Disorders
Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
Migraine Disorders
Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
Migraine Disorders
Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
Migraine Disorders
Cost-Effectiveness of Long-Term, Targeted OnabotulinumtoxinA versus Peripheral Trigger Site Deactivation Surgery for the Treatment of Refractory Migraine Headaches.
Migraine Disorders
Craniofacial Autonomic Dysfunction in Migraine: Implications for Treatment and Prognosis.
Migraine Disorders
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.
Migraine Disorders
Current and emerging evidence-based treatment options in chronic migraine: a narrative review.
Migraine Disorders
Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA.
Migraine Disorders
Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female.
Migraine Disorders
Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.
Migraine Disorders
Discussion: Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Migraine Disorders
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.
Migraine Disorders
Does myofascial and trigger point treatment reduce pain and analgesic intake in patients undergoing OnabotulinumtoxinA injection due to chronic intractable migraine? A pilot, single-blind randomized controlled trial.
Migraine Disorders
Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine.
Migraine Disorders
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
Migraine Disorders
Duration of migraine is a predictor for response to botulinum toxin type A.
Migraine Disorders
Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA.
Migraine Disorders
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study.
Migraine Disorders
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Migraine Disorders
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
Migraine Disorders
Effect of circadian rhythm on the pain associated with preventive onabotulinumtoxinA injections for migraines.
Migraine Disorders
Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction.
Migraine Disorders
Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
Migraine Disorders
Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
Migraine Disorders
Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release.
Migraine Disorders
Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.
Migraine Disorders
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Migraine Disorders
Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population.
Migraine Disorders
Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
Migraine Disorders
Effects of Botulinum Toxin on Migraine Attack Features in Chronic Migraine: A Six-Month Open-Label Observation Study through Electronic Diary Smartphone Application.
Migraine Disorders
Effects of OnabotulintoxinA on Habituation of Laser Evoked Responses in Chronic Migraine.
Migraine Disorders
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
Migraine Disorders
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Migraine Disorders
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
Migraine Disorders
Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.
Migraine Disorders
Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
Migraine Disorders
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown.
Migraine Disorders
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
Migraine Disorders
Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature.
Migraine Disorders
Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Migraine Disorders
Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine.
Migraine Disorders
Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.
Migraine Disorders
Emerging treatment for chronic migraine and refractory chronic migraine.
Migraine Disorders
Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
Migraine Disorders
Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
Migraine Disorders
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.
Migraine Disorders
Erratum: Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.
Migraine Disorders
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
Migraine Disorders
Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.
Migraine Disorders
Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study.
Migraine Disorders
Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
Migraine Disorders
Evidence based medicine on the use of botulinum toxin for headache disorders.
Migraine Disorders
Evidence for antinociceptive activity of botulinum toxin type A in pain management.
Migraine Disorders
Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine.
Migraine Disorders
Evidence-based medicine: botulinum toxin A in migraine and tension-type headache.
Migraine Disorders
Expanding the Use of Botulinum Toxin in Primary Care for Chronic Migraine.
Migraine Disorders
Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic.
Migraine Disorders
Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks.
Migraine Disorders
Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
Migraine Disorders
Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment.
Migraine Disorders
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats.
Migraine Disorders
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Migraine Disorders
Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study.
Migraine Disorders
Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.
Migraine Disorders
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Migraine Disorders
Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients.
Migraine Disorders
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Migraine Disorders
Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: a case report and literature review.
Migraine Disorders
High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis.
Migraine Disorders
How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).
Migraine Disorders
Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Migraine Disorders
Impact of the botulinum-A toxin on prevention of adult migraine disorders.
Migraine Disorders
Implications of current clinical trials focused on medication overuse and therapeutic prophylaxis.
Migraine Disorders
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
Migraine Disorders
Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
Migraine Disorders
Incidental Treatment of a Subclinical Chronic Tension-Type Headache by Cosmetic Use of Botulinum Toxin A: A Case Report.
Migraine Disorders
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
Migraine Disorders
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Migraine Disorders
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.
Migraine Disorders
Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice.
Migraine Disorders
Investigating prophylactic botulinum toxin type A for chronic headache disorders.
Migraine Disorders
Involvement of ?-opioid receptors in antinociceptive action of botulinum toxin type A.
Migraine Disorders
Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
Migraine Disorders
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
Migraine Disorders
Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
Migraine Disorders
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
Migraine Disorders
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Migraine Disorders
Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3?Years of Therapy.
Migraine Disorders
Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
Migraine Disorders
Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study.
Migraine Disorders
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
Migraine Disorders
Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.
Migraine Disorders
Migraine prophylaxis with Botulinum Toxin A is associated with perception of headache.
Migraine Disorders
Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice.
Migraine Disorders
Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine.
Migraine Disorders
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Migraine Disorders
O048. Chronic migraine, cluster headache or both? The suggestion of botulinum toxin.
Migraine Disorders
O051. Chronic migraine and onabotulinumtoxinA: a prospective study on patients treated at the Headache Centre of the Padua University and analysis of possible predictors of responsivity.
Migraine Disorders
O059. Predictors of response to botulinum toxin for the treatment of chronic migraine: data from a Headache Center.
Migraine Disorders
O068. A 2 years prospective evaluation study on onabotulinumtoxinA 195 U in chronic migraine.
Migraine Disorders
Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
Migraine Disorders
Onabotulinum toxin A for treatment of chronic migraine with medication overuse.
Migraine Disorders
Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.
Migraine Disorders
Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.
Migraine Disorders
OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
Migraine Disorders
OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Migraine Disorders
OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine.
Migraine Disorders
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.
Migraine Disorders
OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood-brain barrier.
Migraine Disorders
OnabotulinumtoxinA decreases interictal CGRP plasma levels in chronic migraine patients.
Migraine Disorders
OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
Migraine Disorders
OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients.
Migraine Disorders
OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience.
Migraine Disorders
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Migraine Disorders
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation.
Migraine Disorders
OnabotulinumtoxinA for the treatment of chronic migraine not quite there. . .
Migraine Disorders
OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-Week PREEMPT clinical program.
Migraine Disorders
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Migraine Disorders
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Migraine Disorders
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Migraine Disorders
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Migraine Disorders
OnabotulinumtoxinA for Treatment of Chronic Migraine: The Unblinding Problem.
Migraine Disorders
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
Migraine Disorders
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Migraine Disorders
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study.
Migraine Disorders
OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.
Migraine Disorders
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
Migraine Disorders
OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy.
Migraine Disorders
OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience.
Migraine Disorders
OnabotulinumtoxinA Injections for the Treatment of Cyclic Vomiting Syndrome.
Migraine Disorders
OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.
Migraine Disorders
OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia.
Migraine Disorders
OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
Migraine Disorders
OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report.
Migraine Disorders
OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm.
Migraine Disorders
OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
Migraine Disorders
OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine.
Migraine Disorders
OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse.
Migraine Disorders
Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.
Migraine Disorders
P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment.
Migraine Disorders
P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients.
Migraine Disorders
P042. Mechanism of action and clinical evidence of botulinum toxin in chronic migraine.
Migraine Disorders
P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse.
Migraine Disorders
P053. An Italian study on the actual cost/benefit of onabotulinumtoxinA (BT-A) in chronic migraine: preliminary results.
Migraine Disorders
P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice.
Migraine Disorders
P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience.
Migraine Disorders
P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine.
Migraine Disorders
Pathophysiological targets for non-pharmacological treatment of migraine.
Migraine Disorders
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Migraine Disorders
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
Migraine Disorders
Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice Guideline.
Migraine Disorders
Peri-Incisional Botulinum Toxin Therapy for Treatment of Intractable Head Pain After Lateral Skull Base Surgery: A Case Series.
Migraine Disorders
Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients.
Migraine Disorders
Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018.
Migraine Disorders
Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine.
Migraine Disorders
Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections.
Migraine Disorders
Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.
Migraine Disorders
Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine.
Migraine Disorders
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
Migraine Disorders
Positive botulinum toxin type a response is a prognosticator for migraine surgery success.
Migraine Disorders
Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Migraine Disorders
Practical considerations for the treatment of elderly patients with migraine.
Migraine Disorders
Predicting migraine responsiveness to botulinum toxin type A injections.
Migraine Disorders
Prediction of patient's response to OnabotulinumtoxinA treatment for migraine.
Migraine Disorders
Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Migraine Disorders
Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
Migraine Disorders
Procedures for administering botulinum toxin type A for migraine and tension-type headache.
Migraine Disorders
Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans.
Migraine Disorders
Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.
Migraine Disorders
Prospective Analysis of the Greater Occipital Nerve Location in Patients Undergoing Occipital Nerve Decompression.
Migraine Disorders
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
Migraine Disorders
Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
Migraine Disorders
Real world preventative drug management of migraine among Spanish neurologists.
Migraine Disorders
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
Migraine Disorders
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Migraine Disorders
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
Migraine Disorders
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study.
Migraine Disorders
Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.
Migraine Disorders
Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
Migraine Disorders
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
Migraine Disorders
Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.
Migraine Disorders
Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial.
Migraine Disorders
Reply: Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Migraine Disorders
Reply: Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraines.
Migraine Disorders
Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine.
Migraine Disorders
Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
Migraine Disorders
Repurposing of FDA-Approved Drugs for Treating Iatrogenic Botulism: A Paired 3D-QSAR/Docking Approach.
Migraine Disorders
Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment.
Migraine Disorders
Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
Migraine Disorders
Review of botulinum toxin type A and its clinical applications in migraine headache.
Migraine Disorders
Review: Prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults.
Migraine Disorders
Role of botulinum toxin type A in the prophylactic treatment of migraine headaches.
Migraine Disorders
Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region.
Migraine Disorders
Selective denervation of the corrugator supercilii muscle for the treatment of idiopatic trigeminal neuralgia purely paroxysmal distributed in the supraorbital and suprathrochlear dermatomes.
Migraine Disorders
Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains.
Migraine Disorders
Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.
Migraine Disorders
Single-site botulinum toxin type a injection for elimination of migraine trigger points.
Migraine Disorders
Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain.
Migraine Disorders
Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
Migraine Disorders
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.
Migraine Disorders
Subcutaneous Botulinum Toxin Injection for Post-Thoracotomy Pain Syndrome in Palliative Care: A Case Report.
Migraine Disorders
Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Migraine Disorders
Surgical intervention for chronic migraine headache: A systematic review.
Migraine Disorders
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
Migraine Disorders
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.
Migraine Disorders
The "Ram's Horns Sign": A Case Report of an Unusual Side Effect of OnabotulinumtoxinA in a Chronic Migraine Patient.
Migraine Disorders
The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
Migraine Disorders
The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
Migraine Disorders
The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study.
Migraine Disorders
The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization.
Migraine Disorders
The Efficacy of Botulinum Toxin in Pediatric Chronic Migraine: A Literature Review.
Migraine Disorders
The first world report of botulinum A toxin injection for status migrainosus.
Migraine Disorders
The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
Migraine Disorders
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
Migraine Disorders
The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.
Migraine Disorders
The role of the otolaryngologist in the evaluation and management of headaches.
Migraine Disorders
The supraorbital region revisited: An anatomic exploration of the neuro-vascular bundle with regard to frontal migraine headache.
Migraine Disorders
The zygomaticotemporal branch of the trigeminal nerve: an anatomical study.
Migraine Disorders
There is value in anecdotal reports of relief from migraine with botulinum toxin.
Migraine Disorders
Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis.
Migraine Disorders
Topographic Relationship between the Supratrochlear Nerve and Corrugator Supercilii Muscle--Can This Anatomical Knowledge Improve the Response to Botulinum Toxin Injections in Chronic Migraine?
Migraine Disorders
Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study.
Migraine Disorders
Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety.
Migraine Disorders
Treatment patterns, health resource consumption, and costs of patients with migraine in an Italian real-world setting.
Migraine Disorders
Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition?
Migraine Disorders
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
Migraine Disorders
TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities.
Migraine Disorders
Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.
Migraine Disorders
Ultrasound-Guided Perisutural Botulinum Toxin Injection for Chronic Migraine Headache: Initial Report With Technical Description.
Migraine Disorders
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
Migraine Disorders
Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.
Migraine Disorders
Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
Migraine Disorders
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
Migraine Disorders
Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression.
Migraine Disorders
Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
Migraine Disorders
Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience.
Migraine Disorders
Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
Migraine Disorders
What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group.
Migraine Disorders
[Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes]
Migraine Disorders
[Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Migraine Disorders
[Botulinum toxin type A in headache treatment : Established and experimental indications].
Migraine Disorders
[Botulinum toxin type A in the prophylactic treatment of chronic migraine].
Migraine Disorders
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]
Migraine Disorders
[First results of clinical studies on botulinum toxin A in migraine and headache]
Migraine Disorders
[OnabotulinumtoxinA in chronic migraine: from the theory of clinical trials to clinical practice].
Migraine Disorders
[Positioning of headache units in the field of neurology: the importance of OnabotulinumtoxinA and other therapies in the treatment of headaches].
Migraine Disorders
[Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine].
Migraine Disorders
[Real need for headache services and their resource consumption: a retrospective observational study on a cohort in Cantabria].
Migraine Disorders
[Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society].
Migraine Disorders
[What is the optimal dose for the prophylactic treatment of chronic migraine patients?].
Migraine with Aura
The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
Migraine without Aura
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Migraine without Aura
Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
Miller Fisher Syndrome
The Role of Botulinum Toxin in the Management of Ophthalmoplegia Secondary to Miller Fisher Syndrome.
Motor Neuron Disease
Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.
Motor Neuron Disease
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Motor Neuron Disease
Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Motor Neuron Disease
Decreased spasticity in primary lateral sclerosis after botulinum toxin injection: A case report.
Motor Neuron Disease
Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progress.
Mouth Neoplasms
Botulinum toxin A for oral cavity cancer patients: in microsurgical patients BTX injections in major salivary glands temporarily reduce salivary production and the risk of local complications related to saliva stagnation.
Movement Disorders
A 9-year review of dystonia from a movement disorders clinic in Singapore.
Movement Disorders
A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A.
Movement Disorders
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
Movement Disorders
A re-evaluation of the mechanism of action of botulinum toxin on facial movement disorders in man.
Movement Disorders
A Review of Periocular Botulinum Neurotoxin on the Tear Film Homeostasis and the Ocular Surface Change.
Movement Disorders
Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery.
Movement Disorders
An open-label study of botulinum toxin A for treatment of tardive dystonia.
Movement Disorders
An update on new and unique uses of botulinum toxin in movement disorders.
Movement Disorders
APPENDIX B: AAN Summary of Evidence-Based Guidelines for Clinicians: Use of Botulinum Neurotoxin for the Treatment of Movement Disorders.
Movement Disorders
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Movement Disorders
Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment.
Movement Disorders
Beneficial effects of botulinum toxin type a for patients with painful tic convulsif.
Movement Disorders
Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.
Movement Disorders
Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up.
Movement Disorders
Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension.
Movement Disorders
Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
Movement Disorders
Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.
Movement Disorders
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Movement Disorders
Botulinum toxin in the treatment of lingual dystonia induced by speaking.
Movement Disorders
Botulinum Toxin Injection to Treat Masticatory Movement Disorder Corrected Mandibular Asymmetry in a Growing Patient.
Movement Disorders
Botulinum toxin injections reduce associative plasticity in patients with primary dystonia.
Movement Disorders
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
Movement Disorders
Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.
Movement Disorders
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis.
Movement Disorders
Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study.
Movement Disorders
Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience.
Movement Disorders
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Movement Disorders
Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?
Movement Disorders
Causes for treatment delays in dystonia and hemifacial spasm: a canadian survey.
Movement Disorders
Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia.
Movement Disorders
Clinical application of botulinum toxin in otolaryngology, head and neck practice (brief review).
Movement Disorders
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Movement Disorders
Clinical comparison of botulinum toxin in motor and autonomic disorders: Similarities and differences.
Movement Disorders
Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series.
Movement Disorders
Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.
Movement Disorders
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Movement Disorders
Consensus statement on physician training for the treatment of dystonia with botulinum toxin. The Canadian Movement Disorders Group.
Movement Disorders
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Movement Disorders
Cortical somatosensory processing after botulinum toxin therapy in post-stroke spasticity.
Movement Disorders
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy.
Movement Disorders
Development and utilization of the patient knowledge questionnaire on botulinum toxin use in movement disorders.
Movement Disorders
Dose response with onabotulinumtoxinA for post-stroke spasticity: A pooled data analysis.
Movement Disorders
Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke.
Movement Disorders
Effects of Repeated Botulinum Toxin Treatment for Sialorrhea in Patients with Parkinson's Disease.
Movement Disorders
Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Movement Disorders
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial.
Movement Disorders
Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.
Movement Disorders
European consensus table 2006 on botulinum toxin for children with cerebral palsy.
Movement Disorders
Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure.
Movement Disorders
Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries.
Movement Disorders
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Movement Disorders
Experiences on The Administration of Botulinum Toxin in Movement Disorders.
Movement Disorders
Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin.
Movement Disorders
Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Movement Disorders
Functional stereotactic surgery for treatment of cervical dystonia: review of the experience from the lesional era.
Movement Disorders
Guidelines for the therapeutic use of botulinum toxin in movement disorders.
Movement Disorders
Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.
Movement Disorders
Guidelines for the use of botulinum toxin in movement disorders and spasticity.
Movement Disorders
Human response to botulinum toxin injection: type B compared with type A.
Movement Disorders
Human T-cell responses to botulinum neurotoxin Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
Movement Disorders
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
Movement Disorders
Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients.
Movement Disorders
Jitter Evaluation in Distant and Adjacent Muscles after Botulinum Neurotoxin Type A Injection in 78 Cases.
Movement Disorders
Late-onset primary dystonia in Zhejiang province of China: a service-based epidemiological study.
Movement Disorders
Long-term efficacy and safety of botulinum toxin injections in dystonia.
Movement Disorders
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
Movement Disorders
Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
Movement Disorders
Management of movement disorders in glutaryl-CoA dehydrogenase deficiency: anticholinergic drugs and botulinum toxin as additional therapeutic options.
Movement Disorders
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
Movement Disorders
Morphological characteristics of the posterior neck muscles and anatomical landmarks for botulinum toxin injections.
Movement Disorders
Novel movement disorder of the lower lip: is it epilepsia partialis continua? Clues from a secondary case.
Movement Disorders
Ocular surface changes following botulinum toxin injection for strabismus.
Movement Disorders
Office-based endoscopic botulinum toxin injection in laryngeal movement disorders.
Movement Disorders
OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: a Systematic Literature Review.
Movement Disorders
Patient Knowledge, Attitude and Perceptions towards Botulinum Toxin Treatment for Movement Disorders in India.
Movement Disorders
Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease.
Movement Disorders
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.
Movement Disorders
Real-world experience with botulinum toxin A for the treatment of hemifacial spasm: A study of 1138 injections.
Movement Disorders
Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.
Movement Disorders
Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement.
Movement Disorders
Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.
Movement Disorders
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity.
Movement Disorders
Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
Movement Disorders
Successful Treatment of Auricular Dystonia by Unilateral Pallidothalamic Tractotomy.
Movement Disorders
Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature.
Movement Disorders
Tablet-based patient educational interventions in care and management of complex movement disorders.
Movement Disorders
The role of botulinum toxin in the management of head and neck cancer patients.
Movement Disorders
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
Movement Disorders
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.
Movement Disorders
Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Movement Disorders
Treatment of Hemichoreoathetosis with Arrhythmic Proximal Tremor after Stroke: The Role of Zona Incerta as a Target for Deep Brain Stimulation.
Movement Disorders
Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report.
Movement Disorders
Treatment of various movement disorders with botulinum A toxin injection: an experience of 900 patients.
Movement Disorders
Tremor in Idiopathic Cervical Dystonia - Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification.
Movement Disorders
Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia.
Movement Disorders
Two hundred and fifty patients with hemifacial spasm treated with botulinum toxin injection.
Movement Disorders
[Botulinum toxin--interventional neuropediatrics in spastic movement disorders in childhood]
Movement Disorders
[Cervical dystonia: ways to improve the effectiveness of botulinum therapy].
Movement Disorders
[The treatment of laryngeal movement disorders with botulinum toxin: part 2: experience and considerations]
Movement Disorders
[Therapeutic use of botulinum toxin in otorhinolaryngology. 1: Treatment of movement disorders of mimetic muscles]
Movement Disorders
[Therapeutic use of botulinum toxin in otorhinolaryngology. 2. Movement disorders of craniocervical musculature (except for mimetic musculature) and disorders of the autonomic nervous system]
Mucopolysaccharidoses
Botulinum Toxin Type A for the Treatment of Equinus Deformity in to Patients With Mucopolysaccharidosis Type II.
Mucopolysaccharidoses
[Botulinum toxin in the treatment of psoas muscle contracture in mucopolysaccharidosis]
Mucopolysaccharidosis II
Botulinum Toxin Type A for the Treatment of Equinus Deformity in to Patients With Mucopolysaccharidosis Type II.
Multiple Sclerosis
A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
Multiple Sclerosis
Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Multiple Sclerosis
Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.
Multiple Sclerosis
Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses.
Multiple Sclerosis
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.
Multiple Sclerosis
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.
Multiple Sclerosis
Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
Multiple Sclerosis
Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Multiple Sclerosis
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study.
Multiple Sclerosis
Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations.
Multiple Sclerosis
Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report.
Multiple Sclerosis
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Multiple Sclerosis
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
Multiple Sclerosis
Botulinum toxin treatment of painful tonic spasms in multiple sclerosis.
Multiple Sclerosis
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials.
Multiple Sclerosis
Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis.
Multiple Sclerosis
Botulinum toxin type A therapy for bilateral focal neuropathic pruritus in multiple sclerosis: a case report.
Multiple Sclerosis
Botulinum toxin type?A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.
Multiple Sclerosis
Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Multiple Sclerosis
Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin.
Multiple Sclerosis
Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective.
Multiple Sclerosis
Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use.
Multiple Sclerosis
Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.
Multiple Sclerosis
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
Multiple Sclerosis
Do gait parameters improve after botulinum toxin injections in post stroke patients? A prospective study.
Multiple Sclerosis
Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis.
Multiple Sclerosis
Effectiveness of interventions aimed at improving the sexuality of women with multiple sclerosis: a systematic review.
Multiple Sclerosis
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials.
Multiple Sclerosis
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Multiple Sclerosis
Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States.
Multiple Sclerosis
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Multiple Sclerosis
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Multiple Sclerosis
Higher Neural Correlates in Multiple Sclerosis Patients with Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
Multiple Sclerosis
Impact of intradetrusor botulinum toxin A injections on serum and urinary concentrations of nerve growth factor and brain-derived neurotrophic factor in patients with multiple sclerosis and neurogenic detrusor overactivity.
Multiple Sclerosis
IncobotulinumtoxinA versus OnabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
Multiple Sclerosis
Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study.
Multiple Sclerosis
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-a for detrusor overactivity in patients with multiple sclerosis.
Multiple Sclerosis
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
Multiple Sclerosis
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Multiple Sclerosis
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
Multiple Sclerosis
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA.
Multiple Sclerosis
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Multiple Sclerosis
OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results.
Multiple Sclerosis
Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
Multiple Sclerosis
Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
Multiple Sclerosis
Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments.
Multiple Sclerosis
PAW26 Are the beneficial effects of Botulinum toxin for refractory detrusor overactivity in multiple sclerosis sustained with repeat injections?
Multiple Sclerosis
Perioperative Botulinum Toxin Injections to Enhance Surgical Outcomes in Patients With Spasticity: Preoperative, Intraoperative, and Postoperative Case Reports.
Multiple Sclerosis
Quantitative analysis of the pendulum test: application to multiple sclerosis patients treated with botulinum toxin.
Multiple Sclerosis
Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
Multiple Sclerosis
Sleep bruxism possibly triggered by multiple sclerosis attacks and treated successfully with botulinum toxin: Report of three cases.
Multiple Sclerosis
Symptomatic Relief of Botulinum Neurotoxin/A Intoxication with Aminopyridines: A New Twist on an Old Molecule.
Multiple Sclerosis
Synergic use of botulinum toxin injection and radial extracorporeal shockwave therapy in Multiple Sclerosis spasticity.
Multiple Sclerosis
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Multiple Sclerosis
The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
Multiple Sclerosis
The place of the botulinum toxin in the management of multiple sclerosis.
Multiple Sclerosis
Therapeutic benefit of botulinum toxin A for the spasticity of the triceps surae in patients with multiple sclerosis: An observational study.
Multiple Sclerosis
Transcranial Direct Current Stimulation Combined with Botulinum Neurotoxin Type A Injections for Treatment of Upper Limb Intention Tremor in Multiple Sclerosis: A Case Report.
Multiple Sclerosis
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Multiple Sclerosis
Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Multiple Sclerosis
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Multiple Sclerosis
Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report.
Multiple Sclerosis
[Botulinum neurotoxin type A in neurogenic detrusor overactivity : Consensus paper of the Working Group Neuro-Urology of the DMGP].
Multiple Sclerosis
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]
Multiple Sclerosis
[Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
Multiple Sclerosis
[Long-term outcomes of intradetrusor botulinum toxin A in multiple sclerosis patients].
Multiple Sclerosis
[Neurogenic temporomandibular joint dislocation. Definition and therapy with botulinum toxin]
Multiple Sclerosis
[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]
Multiple Sclerosis
[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
Multiple Sclerosis
[The application of botulinum toxin type A in the treatment of spastic paraparesis]
Multiple Sclerosis
[Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin].
Multiple Sclerosis, Chronic Progressive
Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis.
Multiple System Atrophy
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Multiple System Atrophy
Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy.
Muscle Cramp
Axillary injection of botulinum A toxin in a patient with muscle cramps associated with severe axillary hyperhidrosis.
Muscle Cramp
Botulinum Toxin Treatment for Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial.
Muscle Cramp
Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study.
Muscle Cramp
Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.
Muscle Cramp
Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles.
Muscle Hypertonia
Botulinum toxin A prolongs functional durability of voice prostheses in laryngectomees with pharyngoesophageal spasm.
Muscle Hypertonia
Evaluation of articular disc loading in the temporomandibular joints after prosthetic and pharmacological treatment in model studies.
Muscle Hypertonia
OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process.
Muscle Hypertonia
Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature.
Muscle Hypertonia
[Efficacy and safety of botulinum toxin in external urethral sphincter by transperineal way guided transrectal ultrasound and electromyography on chronic urinary retention due to spinal cord injury.]
Muscle Hypotonia
Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
Muscle Spasticity
A clinically relevant BTX-A injection protocol leads to persistent weakness, contractile material loss, and an altered mRNA expression phenotype in rabbit quadriceps muscles.
Muscle Spasticity
A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research.
Muscle Spasticity
A dose-response relationship research on botulinum toxin type A local intramuscular injections of lower extremity spasticity in children with cerebral palsy.
Muscle Spasticity
A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
Muscle Spasticity
A Novel Use of Regional Anesthesia for Spastic Hemiplegia Evaluation and Treatment: A Case Report.
Muscle Spasticity
A pilot study of delayed versus immediate serial casting after botulinum toxin injection for partially reducible spastic equinus.
Muscle Spasticity
A Pilot Study of Two Different Constraint-Induced Movement Therapy Interventions in Children With Hemiplegic Cerebral Palsy After Botulinum Toxin Injection During Preschool Education.
Muscle Spasticity
A pilot study to investigate the combined use of botulinum neurotoxin type a and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke.
Muscle Spasticity
A pilot study to investigate the combined use of Botulinum toxin type-a and ankle foot orthosis for the treatment of spastic foot in chronic hemiplegic patients.
Muscle Spasticity
A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.
Muscle Spasticity
A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
Muscle Spasticity
A Randomized Control Trial of Botulinum Toxin A Administration under Ultrasound Guidance against Manual Palpation in Spastic Cerebral Palsy.
Muscle Spasticity
A randomized controlled trial of selective neurotomy versus botulinum toxin for spastic equinovarus foot after stroke.
Muscle Spasticity
A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.
Muscle Spasticity
A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.
Muscle Spasticity
A Retrospective Review of Unintended Effects After Single-Event Multi-Level Chemoneurolysis With Botulinum Toxin-A and Phenol in Children With Cerebral Palsy.
Muscle Spasticity
A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot.
Muscle Spasticity
A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity.
Muscle Spasticity
Accuracy of botulinum toxin type A injection into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist: manual needle placement evaluated using ultrasonography.
Muscle Spasticity
Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography.
Muscle Spasticity
Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography.
Muscle Spasticity
Add-on Home-Centered Activity-Based Therapy vs Conventional Physiotherapy in Improving Walking Ability at 6-Months in Children With Diplegic Cerebral Palsy: A Randomized Controlled Trial.
Muscle Spasticity
Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial.
Muscle Spasticity
Adjunct therapies after botulinum toxin injections in spastic adults: systematic review and SOFMER recommendations.
Muscle Spasticity
Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.
Muscle Spasticity
An unusual case of Dantrolene sodium-induced urinary retention in post-traumatic minimally responsive state.
Muscle Spasticity
Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.
Muscle Spasticity
Anatomical locations of the motor endplates of sartorius muscle for botulinum toxin injections in treatment of muscle spasticity.
Muscle Spasticity
Ankle and Foot Spasticity Patterns in Chronic Stroke Survivors with Abnormal Gait.
Muscle Spasticity
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.
Muscle Spasticity
Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion.
Muscle Spasticity
Assessing the immediate impact of botulinum toxin injection on impedance of spastic muscle.
Muscle Spasticity
Atrophy of the intrinsic musculature of the hands associated with the use of botulinum toxin-A injections for hyperhidrosis: a case report and review of the literature.
Muscle Spasticity
Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders.
Muscle Spasticity
Botulinum neurotoxin treatment in children with cerebral palsy: validation of a needle placement protocol using passive muscle stretching and relaxing.
Muscle Spasticity
Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.
Muscle Spasticity
Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey.
Muscle Spasticity
Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.
Muscle Spasticity
Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Muscle Spasticity
Botulinum Toxin (BT) injection improves voluntary motor control in selected patients with post-stroke spasticity.
Muscle Spasticity
Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes.
Muscle Spasticity
Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE).
Muscle Spasticity
Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy.
Muscle Spasticity
Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.
Muscle Spasticity
Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review.
Muscle Spasticity
Botulinum Toxin A for Spastic Trismus Due to Brain Stem Encephalitis in a Pediatric Intensive Care Setting: A Unique Case Report.
Muscle Spasticity
Botulinum toxin A in the treatment of hemiplegic spastic foot drop--clinical and functional outcomes.
Muscle Spasticity
Botulinum toxin A in the treatment of spasticity: functional implications and patient selection.
Muscle Spasticity
Botulinum toxin A injection for spasticity in diplegic-type cerebral palsy.
Muscle Spasticity
Botulinum Toxin A Injection in Treatment of Upper Limb Spasticity in Children with Cerebral Palsy: A Systematic Review of Randomized Controlled Trials.
Muscle Spasticity
Botulinum toxin a injection into calf muscles for treatment of spastic equinus in cerebral palsy: a controlled trial comparing sonography and electric stimulation-guided injection techniques: a preliminary report.
Muscle Spasticity
Botulinum toxin A injections and occupational therapy in children with unilateral spastic cerebral palsy: a randomized controlled trial.
Muscle Spasticity
Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.
Muscle Spasticity
Botulinum toxin a treatment of cricopharyngeal dysphagia after subarachnoid hemorrhage.
Muscle Spasticity
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Muscle Spasticity
Botulinum toxin B increases mouth opening in patients with spastic trismus.
Muscle Spasticity
Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.
Muscle Spasticity
Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.
Muscle Spasticity
Botulinum Toxin Effect on Voluntary and Stretch Reflex-Related Torque Produced by the Quadriceps: An Isokinetic Pilot Study.
Muscle Spasticity
Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice.
Muscle Spasticity
Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications.
Muscle Spasticity
Botulinum toxin in the elderly to the care of limbs spastic hypertonia and toes or fingers dystonias.
Muscle Spasticity
Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres.
Muscle Spasticity
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Muscle Spasticity
Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report.
Muscle Spasticity
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases?
Muscle Spasticity
Botulinum Toxin Injection for Spastic Scapular Dyskinesia After Stroke: Case Series.
Muscle Spasticity
Botulinum Toxin Injection in Children with Hemiplegic Cerebral Palsy: Correction of Growth through Comparison of Treated and Unaffected Limbs.
Muscle Spasticity
Botulinum toxin injection in patients with hereditary spastic paraparesis.
Muscle Spasticity
Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques.
Muscle Spasticity
Botulinum toxin injection of spastic finger flexors in hemiplegic patients.
Muscle Spasticity
Botulinum Toxin Injections and Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke.
Muscle Spasticity
Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.
Muscle Spasticity
Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy.
Muscle Spasticity
Botulinum toxin treatment in upper limb spasticity: Treatment consistency.
Muscle Spasticity
Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.
Muscle Spasticity
Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites.
Muscle Spasticity
Botulinum Toxin Treatment on Upper Limb Function in School Age Children With Bilateral Spastic Cerebral Palsy: One Year Follow-up.
Muscle Spasticity
Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients.
Muscle Spasticity
Botulinum toxin type A and dynamic equinus in children with cerebral palsy: new indication. Better than repeat casts.
Muscle Spasticity
Botulinum toxin type A combined with cervical spine manual therapy for masseteric hypertrophy in a patient with Alzheimer-type dementia: a case report.
Muscle Spasticity
Botulinum toxin type A for spastic cerebral palsy: Is it time to change praxis?
Muscle Spasticity
Botulinum toxin type a for the treatment of the spastic equinus foot in cerebral palsy.
Muscle Spasticity
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy.
Muscle Spasticity
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.
Muscle Spasticity
Botulinum Toxin Type A Injection Combined with Cast Immobilization for Treating Recurrent Peroneal Spastic Flatfoot without Bone Coalitions: A Case Report and Review of the Literature.
Muscle Spasticity
Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.
Muscle Spasticity
Botulinum toxin type A injection increases range of motion in hip, knee and ankle joint contractures of children with cerebral palsy.
Muscle Spasticity
Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques.
Muscle Spasticity
Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke.
Muscle Spasticity
Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response.
Muscle Spasticity
Botulinum Toxin Type A Injections Impact Hamstring Muscles and Gait Parameters in Children with Flexed Knee Gait.
Muscle Spasticity
Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome.
Muscle Spasticity
Botulinum toxin type A injections into the calf muscles for treatment of spastic equinus in cerebral palsy: a randomized trial comparing single and multiple injection sites.
Muscle Spasticity
Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy.
Muscle Spasticity
Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy.
Muscle Spasticity
Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity?
Muscle Spasticity
Botulinum Toxin Type A Possibly Affects Cav3.2 Calcium Channel Subunit in Rats with Spinal Cord Injury-Induced Muscle Spasticity.
Muscle Spasticity
Botulinum Toxin Type A Treatment Combined with Intensive Rehabilitation for Gait Poststroke: A Preliminary Study.
Muscle Spasticity
Botulinum toxin type A versus phenol. A clinical and neurophysiological study in the treatment of ankle clonus.
Muscle Spasticity
Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Muscle Spasticity
Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study.
Muscle Spasticity
Botulinum toxin type-A in the management of spastic equinovarus deformity after stroke. Comparison of 2 injection techniques.
Muscle Spasticity
Botulinum toxin, physical and occupational therapy, and neuromuscular electrical stimulation to treat spastic upper limb of children with cerebral palsy: a pilot study.
Muscle Spasticity
Botulinum toxin-induced paralysis leads to slower myosin heavy chain isoform composition and reduced titin content in juvenile rat gastrocnemius muscle.
Muscle Spasticity
Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin.
Muscle Spasticity
Can the positions of the spastic upper limb in stroke survivors help muscle choice for botulinum toxin injections?
Muscle Spasticity
Casting Protocols Following BoNT-A Injections to Treat Spastic Hypertonia of the Triceps Surae in Children with Cerebral Palsy and Equinus Gait: A Randomized Controlled Trial.
Muscle Spasticity
Casting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single-blind randomised trial on adult stroke patients.
Muscle Spasticity
Change of stretch reflex threshold in spasticity: effect of botulinum toxin injections.
Muscle Spasticity
Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection.
Muscle Spasticity
Changes in Muscle Mass after Botulinum Toxin Injection in Children with Spastic Hemiplegic Cerebral Palsy.
Muscle Spasticity
Changes in Sonoelastography After Using Botulinum Toxin Type A for the Treatment of the Patients with Post-stroke Spasticity: Report of 2 Cases.
Muscle Spasticity
Changes in spastic muscle stiffness after botulinum toxin A injections as part of rehabilitation therapy in patients with spastic cerebral palsy.
Muscle Spasticity
Changes in the Neural and Non-neural Related Properties of the Spastic Wrist Flexors After Treatment With Botulinum Toxin A in Post-stroke Subjects: An Optimization Study.
Muscle Spasticity
Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment?
Muscle Spasticity
Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review.
Muscle Spasticity
Combination therapy with repetitive facilitative exercise program and botulinum toxin type A to improve motor function for the upper-limb spastic paresis in chronic stroke: A randomized controlled trial.
Muscle Spasticity
Combined botulinum toxin type A and electrical stimulation in individuals with C5-C6 and C6-C7 tetraplegia: a pilot study.
Muscle Spasticity
Combined Effects of Isokinetic Training and Botulinum Toxin Type A on Spastic Equinus Foot in Patients with Chronic Stroke: A Pilot, Single-blind, Randomized Controlled Trial.
Muscle Spasticity
Combined effects of robot-assisted gait training and botulinum toxin type A effect on spastic equinus foot in patients with chronic stroke: a pilot, single blind, randomized controlled trial.
Muscle Spasticity
Combined therapeutic application of botulinum toxin type A, low-frequency rTMS, and intensive occupational therapy for post-stroke spastic upper limb hemiparesis.
Muscle Spasticity
Combined treatment of botulinumtoxin and robot-assisted rehabilitation therapy on poststroke, upper limb spasticity: A case report.
Muscle Spasticity
Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
Muscle Spasticity
Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy.
Muscle Spasticity
Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study.
Muscle Spasticity
Comparison between botulinum toxin type A injection and selective posterior rhizotomy in improving gait performance in children with cerebral palsy.
Muscle Spasticity
Comparison of botulinum toxin type A injection and soft-tissue surgery to treat hip subluxation in children with cerebral palsy.
Muscle Spasticity
Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Muscle Spasticity
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Muscle Spasticity
Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections.
Muscle Spasticity
Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial.
Muscle Spasticity
Comparison of treatment effects between children with spastic cerebral palsy under and over five years after botulinum toxin type a injection.
Muscle Spasticity
Comparison of two injection techniques using botulinum toxin in spastic hemiplegia.
Muscle Spasticity
Complications of botulinum toxin injections for treatment of esophageal motility disorders.
Muscle Spasticity
Comprehensive evaluation of gait, spasticity, and muscle morphology: A case report of a child with spastic paresis treated with Botulinum NeuroToxin-A, serial casting, and physiotherapy.
Muscle Spasticity
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop.
Muscle Spasticity
Cortical somatosensory processing after botulinum toxin therapy in post-stroke spasticity.
Muscle Spasticity
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Muscle Spasticity
Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use.
Muscle Spasticity
Cyclic functional electrical stimulation does not enhance gains in hand grasp function when used as an adjunct to onabotulinumtoxinA and task practice therapy: a single-blind, randomized controlled pilot study.
Muscle Spasticity
Decreased flexion contracture after total knee arthroplasty using Botulinum toxin A: a randomized controlled trial.
Muscle Spasticity
Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy.
Muscle Spasticity
Diagnostic nerve block in prediction of outcome of botulinum toxin treatment for spastic equinovarus foot after stroke: A retrospective observational study.
Muscle Spasticity
Different approaches to dental management of self-inflicted oral trauma: oral shield, botulinum toxin type A neuromuscular block, and oral surgery.
Muscle Spasticity
Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity?
Muscle Spasticity
Do gait parameters improve after botulinum toxin injections in post stroke patients? A prospective study.
Muscle Spasticity
Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.
Muscle Spasticity
Does Botulinum Toxin Treatment Affect the Ultrasonographic Characteristics of Post-Stroke Spastic Equinus? A Retrospective Pilot Study.
Muscle Spasticity
Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis.
Muscle Spasticity
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies.
Muscle Spasticity
Early botulinum toxin treatment for spastic pes equinovarus--a randomized double-blind placebo-controlled study.
Muscle Spasticity
Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy.
Muscle Spasticity
Effect of botulinum toxin on equinus foot deformity in cerebral palsy patients: A systematic review and network meta-analysis.
Muscle Spasticity
Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
Muscle Spasticity
Effect of combined rehabilitation program with botulinum toxin type A injections on gross motor function scores in children with spastic cerebral palsy.
Muscle Spasticity
Effect of Dual Therapy with Botulinum Toxin A Injection and Electromyography-controlled Functional Electrical Stimulation on Active Function in the Spastic Paretic Hand.
Muscle Spasticity
Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients.
Muscle Spasticity
Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
Muscle Spasticity
Effect of repetitive arm cycling following botulinum toxin injection for poststroke spasticity: evidence from FMRI.
Muscle Spasticity
Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait.
Muscle Spasticity
Effect of Upper Limb Botulinum Toxin Injections on Impairment, Activity, Participation, and Quality of Life Among Stroke Patients.
Muscle Spasticity
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Muscle Spasticity
Effectiveness of botulinum toxin injection with and without needle electromyographic guidance for the treatment of spasticity in hemiplegic patients: a randomized controlled trial.
Muscle Spasticity
Effectiveness of electrical stimulation after administration of botulinum toxin in children with spastic diplegic cerebral palsy: A prospective, randomized clinical study.
Muscle Spasticity
Effectiveness of multiple botulinum toxin sessions and the duration of effects in spasticity therapy in children with cerebral palsy.
Muscle Spasticity
Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): protocol study for a randomised controlled, investigator blinded study.
Muscle Spasticity
Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial.
Muscle Spasticity
Effects of botulinum toxin A injection and exercise on the growth of juvenile rat gastrocnemius muscle.
Muscle Spasticity
Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review.
Muscle Spasticity
Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy.
Muscle Spasticity
Effects of botulinum toxin A therapy and multidisciplinary rehabilitation on lower limb spasticity classified by spastic muscle echo intensity in post-stroke patients.
Muscle Spasticity
Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy.
Muscle Spasticity
Effects of botulinum toxin type A and a programme of functional activity to improve manual ability in children and adolescents with cerebral palsy.
Muscle Spasticity
Effects of botulinum toxin type A for spastic foot in post-stroke patients enrolled in a rehabilitation program.
Muscle Spasticity
Effects of different dilutions of botulinum toxin type A treatment for children with cerebral palsy with spastic ankle plantarflexor: a randomized controlled trial.
Muscle Spasticity
Effects of robot-assisted gait training in chronic stroke patients treated by botulinum toxin-a: A pivotal study.
Muscle Spasticity
Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy.
Muscle Spasticity
Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis.
Muscle Spasticity
Efficacy and safety of abobotulinumtoxinA for the treatment of hemiparesis in adults with lower limb spasticity previously treated with botulinum toxin: A secondary analysis of a randomized controlled trial.
Muscle Spasticity
Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
Muscle Spasticity
Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.
Muscle Spasticity
Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy.
Muscle Spasticity
Efficacy of a Combined Treatment of Botulinum Toxin and Intensive Physiotherapy in Hereditary Spastic Paraplegia.
Muscle Spasticity
Efficacy of botulinum toxin A, serial casting, and combined treatment for spastic equinus: a retrospective analysis.
Muscle Spasticity
Efficacy of radial extracorporeal shock wave therapy compared with botulinum toxin type A injection in treatment of lower extremity spasticity in subjects with cerebral palsy: A randomized, controlled, cross-over study.
Muscle Spasticity
Efficacy of Repeat AbobotulinumtoxinA (Dysport®) Injections in Improving Gait in Children with Spastic Cerebral Palsy.
Muscle Spasticity
Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cerebral Palsy-A Secondary Analysis of the Randomized Clinical Trial.
Muscle Spasticity
Efficacy of therapeutic ultrasound and transcutaneous electrical nerve stimulation compared with botulinum toxin type a in the treatment of spastic equinus in adults with chronic stroke: a pilot randomized controlled trial.
Muscle Spasticity
Electrical stimulation of antagonist muscles after botulinum toxin type A for post-stroke spastic equinus foot. A randomized single-blind pilot study.
Muscle Spasticity
Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art.
Muscle Spasticity
Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study.
Muscle Spasticity
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Muscle Spasticity
Ergonomic Recommendations in Ultrasound-Guided Botulinum Neurotoxin Chemodenervation for Spasticity: An International Expert Group Opinion.
Muscle Spasticity
Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy.
Muscle Spasticity
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients; an observational study.
Muscle Spasticity
Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure.
Muscle Spasticity
Evaluation of botulinum toxin therapy of spastic equinus in paediatric patients with cerebral palsy.
Muscle Spasticity
Evaluation of clinical outcomes of patients with post-stroke wrist and finger spasticity after ultrasonography-guided BTX-A injection and rehabilitation training.
Muscle Spasticity
Experience with type A botulinum toxin for treatment of outlet-type constipation.
Muscle Spasticity
Exploratory Randomized Double-Blind Placebo-Controlled Trial of Botulinum Therapy on Grasp Release After Stroke (PrOMBiS).
Muscle Spasticity
Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
Muscle Spasticity
Frequency of botulinum toxin injections for spastic equinus: how much is enough?
Muscle Spasticity
Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX).
Muscle Spasticity
Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia.
Muscle Spasticity
Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: A study in patients with hereditary spastic paraplegia.
Muscle Spasticity
Functional electrical stimulation combined with botulinum toxin type A to improve hand function in children with spastic hemiparesis - a pilot study.
Muscle Spasticity
Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury.
Muscle Spasticity
Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy.
Muscle Spasticity
Functional outcome of botulinum toxin injection of gastrocnemius and adductors in spastic hemiplegic cerebral palsied children.
Muscle Spasticity
Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients.
Muscle Spasticity
Functional Outcomes of Multilevel Botulinum Toxin and Comprehensive Rehabilitation in Cerebral Palsy.
Muscle Spasticity
Functional recovery from chronic writer's cramp by brain-computer interface rehabilitation: a case report.
Muscle Spasticity
Goal Attainment Scaling in Individuals with Upper Limb Spasticity Post Stroke.
Muscle Spasticity
Guided Self-rehabilitation Contracts Combined With AbobotulinumtoxinA in Adults With Spastic Paresis.
Muscle Spasticity
Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection.
Muscle Spasticity
Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study.
Muscle Spasticity
Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up.
Muscle Spasticity
How do we get better outcome with botulinum toxin in the treatment of children with spastic hemiplegia?
Muscle Spasticity
How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Muscle Spasticity
Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Muscle Spasticity
IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study.
Muscle Spasticity
Indications and efficacy of botulinum toxin in disorders of the gastrointestinal tract.
Muscle Spasticity
Influence of botulinum toxin therapy on postural control and lower limb intersegmental coordination in children with spastic cerebral palsy.
Muscle Spasticity
Influence of Rehabilitation Medicine Residency Training in Performing Chemodenervation in Children with Cerebral Palsy in Thailand.
Muscle Spasticity
Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial.
Muscle Spasticity
Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial.
Muscle Spasticity
Interobserver reliability of the Australian Spasticity Assessment Scale (ASAS).
Muscle Spasticity
Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A.
Muscle Spasticity
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy.
Muscle Spasticity
Intramuscular distribution of nerves in the human triceps surae muscle: anatomical bases for treatment of spastic drop foot with botulinum toxin.
Muscle Spasticity
Intramuscular injection of collagenase clostridium histolyticum may decrease spastic muscle contracture for children with cerebral palsy.
Muscle Spasticity
Intramuscular nerve distribution pattern of ankle invertor muscles in human cadaver using Sihler stain.
Muscle Spasticity
Intramuscular nerve distribution patterns of anterior forearm muscles in children: a guide for botulinum toxin injection.
Muscle Spasticity
Intrinsic properties and functional changes in spastic muscle after application of BTX-A in children with cerebral palsy: systematic review.
Muscle Spasticity
Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial.
Muscle Spasticity
Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?
Muscle Spasticity
Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
Muscle Spasticity
Isokinetic assessment of the effects of botulinum toxin injection on spasticity and voluntary strength in patients with spastic hemiparesis.
Muscle Spasticity
Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.
Muscle Spasticity
Joint and Muscle Assessments of the Separate Effects of Botulinum NeuroToxin-A and Lower-Leg Casting in Children With Cerebral Palsy.
Muscle Spasticity
Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to stroke.
Muscle Spasticity
Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia-The SPASTOX Trial.
Muscle Spasticity
Literature Review and Comparison of Two Statistical Methods to Evaluate the Effect of Botulinum Toxin Treatment on Gait in Children with Cerebral Palsy.
Muscle Spasticity
Local botulinum toxin type A injections in the treatment of spastic toes.
Muscle Spasticity
Local muscle injection of botulinum toxin type a synergistically improves the beneficial effects of repetitive transcranial magnetic stimulation and intensive occupational therapy in post-stroke patients with spastic upper limb hemiparesis.
Muscle Spasticity
Localization of center of intramuscular nerve dense regions in adult anterior brachial muscles: a guide for botulinum toxin A injection to treat muscle spasticity.
Muscle Spasticity
Localization of the center of the intramuscular nerve dense region of the medial femoral muscles and the significance for blocking spasticity.
Muscle Spasticity
Long lasting benefits following the combination of static night upper extremity splinting with botulinum toxin A injections in cerebral palsy children.
Muscle Spasticity
Long-term effects of injection of botulinum toxin type A combined with home-based functional training for post-stroke patients with spastic upper limb hemiparesis.
Muscle Spasticity
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Muscle Spasticity
Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke.
Muscle Spasticity
Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy.
Muscle Spasticity
Low- and high-dose botulinum toxin A treatment: a retrospective analysis.
Muscle Spasticity
Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke.
Muscle Spasticity
Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study.
Muscle Spasticity
Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A.
Muscle Spasticity
Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes.
Muscle Spasticity
Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.
Muscle Spasticity
Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications.
Muscle Spasticity
Meaningful improvement in walking performance after Botulinum neurotoxin A (BoNT-A) in chronic spastic patients.
Muscle Spasticity
Medial gastrocnemius muscle volume and fascicle length in children aged 2 to 5 years with cerebral palsy.
Muscle Spasticity
Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy.
Muscle Spasticity
Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure.
Muscle Spasticity
Molecular mechanisms of treadmill therapy on neuromuscular atrophy induced via botulinum toxin A.
Muscle Spasticity
Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy.
Muscle Spasticity
Muscle histopathology in children with spastic cerebral palsy receiving botulinum toxin type A.
Muscle Spasticity
Muscle structure and stiffness assessment after botulinum toxin type A injection. A systematic review.
Muscle Spasticity
Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.
Muscle Spasticity
Neuromuscular Partitioning of Subscapularis Based on Intramuscular Nerve Distribution Patterns: Implications for Botulinum Toxin Injections.
Muscle Spasticity
Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
Muscle Spasticity
Neurorehabilitation with versus without resistance training after botulinum toxin treatment in children with cerebral palsy: a randomized pilot study.
Muscle Spasticity
Neurotomy of the rectus femoris nerve: Short-term effectiveness for spastic stiff knee gait: Clinical assessment and quantitative gait analysis.
Muscle Spasticity
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Muscle Spasticity
Optimal injection points for the neuromuscular blockade of forearm flexor muscles: a cadaveric study.
Muscle Spasticity
Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity.
Muscle Spasticity
Out of the spasticity box: Off-label uses of botulinum toxin in children.
Muscle Spasticity
Passive mechanical properties and related proteins change with botulinum neurotoxin A injection of normal skeletal muscle.
Muscle Spasticity
Peri-operative Botulinum Neurotoxin injection to improve outcomes of surgeries on spastic limbs: A systematic review.
Muscle Spasticity
Physiological anatomy of botulinum toxin effect on the spastic muscle of children with cerebral palsy.
Muscle Spasticity
Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B.
Muscle Spasticity
Poster 308 Improvement of Spasticity, Active Movements and Active Function after Repeated Injections of AbobotulinumtoxinA (Dysport) in Adults with Spastic Paresis in the Upper Limb: Results of a Phase III Open-Label Extension Study.
Muscle Spasticity
Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies.
Muscle Spasticity
Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patients on Anticoagulation or Antiplatelet Therapy.
Muscle Spasticity
Quantitative assessment for flexed-elbow deformity during gait following botulinum toxin A treatment.
Muscle Spasticity
Quantitative evaluation for spasticity of calf muscle after botulinum toxin injection in patients with cerebral palsy: a pilot study.
Muscle Spasticity
Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
Muscle Spasticity
RE: Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Spastic Equinus in Adults with Stroke.
Muscle Spasticity
RE: BOTULINUM TOXIN TYPE A INJECTION INTO THE GASTROCNEMIUS MUSCLE FOR SPASTIC EQUINUS IN ADULTS WITH STROKE.
Muscle Spasticity
Reactivation of herpes simplex viral keratitis following the botulinum toxin injection.
Muscle Spasticity
Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study.
Muscle Spasticity
Rehabilitation therapies after botulinum toxin-A injection to manage limb spasticity: a systematic review.
Muscle Spasticity
Relationship between age and spasticity in children with diplegic cerebral palsy.
Muscle Spasticity
Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement.
Muscle Spasticity
Repeated botulinum toxin A injections in the treatment of spastic equinus foot.
Muscle Spasticity
Repeated botulinum toxin injections can improve mobility in patients with spinal cord lesions.
Muscle Spasticity
Repetitive peripheral magnetic stimulation for the assessment of wrist spasticity: reliability, validation and correlation with clinical measures.
Muscle Spasticity
Reply to: "Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia-The SPASTOX Trial".
Muscle Spasticity
Review article: botulinum toxin in the therapy of gastrointestinal motility disorders.
Muscle Spasticity
Review of electrical stimulation, botulinum toxin, and their combination for spastic drop foot.
Muscle Spasticity
Role of botulinum neurotoxin-A in cerebral revascularization graft vasospasm prevention: current state of knowledge.
Muscle Spasticity
Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection.
Muscle Spasticity
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Muscle Spasticity
Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies.
Muscle Spasticity
Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity.
Muscle Spasticity
Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population.
Muscle Spasticity
Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes.
Muscle Spasticity
Serial casting vs combined intervention with botulinum toxin A and serial casting in the treatment of spastic equinus in children.
Muscle Spasticity
Severe trismus as a complication of cerebrovascular accident: a case report.
Muscle Spasticity
Short-term effect of botulinum toxin a injection on spastic equinovarus foot in cerebral palsy patients: a study using the foot pressure measurement system.
Muscle Spasticity
Short-term effects of combined serial casting and botulinum toxin injection for spastic equinus in ambulatory children with cerebral palsy.
Muscle Spasticity
Should botulinum toxin A injections be repeated in children with cerebral palsy? A systematic review.
Muscle Spasticity
Sonoelastographic Evaluation of Medial Gastrocnemius Muscles Intrinsic Stiffness After Rehabilitation Therapy With Botulinum Toxin A Injection in Spastic Cerebral Palsy.
Muscle Spasticity
Sonographic and clinical effects of botulinum toxin Type A combined with extracorporeal shock wave therapy on spastic muscles of children with cerebral palsy.
Muscle Spasticity
Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy.
Muscle Spasticity
Spatial characterization of innervation zones under electrically elicited M-wave.
Muscle Spasticity
Spinal arteriovenous malformation presenting as spastic monoplegic cerebral palsy in a child.
Muscle Spasticity
Spread of Botulinum Neurotoxin Type A at Standard Doses Is Inherent to the Successful Treatment of Spastic Equinus Foot in Cerebral Palsy: Short-Term Neurophysiological and Clinical Study.
Muscle Spasticity
Study protocol: precision of a protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle in the lower extremity during BTX-A treatment in children with spastic cerebral palsy, as verified by means of electrical stimulation.
Muscle Spasticity
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
Muscle Spasticity
Surgical treatment for atlantoaxial rotatory fixation in an adult with spastic torticollis: A case report.
Muscle Spasticity
Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study.
Muscle Spasticity
Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A.
Muscle Spasticity
Tetanus and botulinum toxins block the release of acetylcholine from slices of rat striatum and from the isolated electric organ of Torpedo at different concentrations.
Muscle Spasticity
The change of intrinsic stiffness in gastrocnemius after intensive rehabilitation with botulinum toxin a injection in spastic diplegic cerebral palsy.
Muscle Spasticity
The effect and complication of botulinum toxin type a injection with serial casting for the treatment of spastic equinus foot.
Muscle Spasticity
The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response.
Muscle Spasticity
The effect of botulinum toxin injections on gait control in spastic stroke patients presenting with a stiff-knee gait.
Muscle Spasticity
The Effect of Botulinum Toxin Injections on Gross Motor Function for Lower Limb Spasticity in Children with Cerebral Palsy.
Muscle Spasticity
The effect of botulinum toxin type A injection into the gastrocnemius muscle on sit-to-stand transfer in children with spastic diplegic cerebral palsy.
Muscle Spasticity
The effect of botulinum toxin type-A injection on spasticity, range of motion and gait patterns in children with spastic diplegic cerebral palsy: an Egyptian study.
Muscle Spasticity
The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation.
Muscle Spasticity
The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury.
Muscle Spasticity
The effect of spasticity on cortical somatosensory-evoked potentials: changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection.
Muscle Spasticity
The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity.
Muscle Spasticity
The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study.
Muscle Spasticity
The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait--a pilot study.
Muscle Spasticity
The effects of botulinum toxin type A on improvement and dynamic spastic equinus correction in children with cerebral palsy - preliminary results.
Muscle Spasticity
The Effects of Distributed vs. Condensed Schedule for Robot-Assisted Training with Botulinum Toxin A Injection for Spastic Upper Limbs in Chronic Post-Stroke Subjects.
Muscle Spasticity
The impact of botulinum toxin A and abduction bracing on long-term hip development in children with cerebral palsy.
Muscle Spasticity
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey.
Muscle Spasticity
The role of botulinum toxin in multimodal treatment of spasticity in ambulatory children with spastic Cerebral Palsy: extensive evaluation of a cost-effectiveness trial.
Muscle Spasticity
The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy--a pilot study.
Muscle Spasticity
The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke.
Muscle Spasticity
The short-term effects of combined modified constraint-induced movement therapy and botulinum toxin injection for children with spastic hemiplegic cerebral palsy.
Muscle Spasticity
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Muscle Spasticity
The use of botulinum toxin for the treatment of muscle spasticity in the first 2 years of life.
Muscle Spasticity
The utility of shear wave elastography in the evaluation of muscle stiffness in patients with cerebral palsy after botulinum toxin A injection.
Muscle Spasticity
The WE-Study: does botulinum toxin A make walking easier in children with cerebral palsy?: Study protocol for a randomized controlled trial.
Muscle Spasticity
Therapeutic efficacy and safety of various botulinum toxin A doses and concentrations in spastic foot after stroke: a randomized controlled trial.
Muscle Spasticity
Three-Dimensional Innervation Zone Imaging from Multi-Channel Surface EMG Recordings.
Muscle Spasticity
To what extent may Botulinum toxin type A injections be an alternative choice to surgery in infantile esotropia?
Muscle Spasticity
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.
Muscle Spasticity
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population.
Muscle Spasticity
Treadmill running upregulates the expression of acetylcholine receptor in rat gastrocnemius following botulinum toxin A injection.
Muscle Spasticity
Treating spastic equinus foot from cerebral palsy with botulinum toxin type a: what factors influence the results?: an analysis of 189 consecutive cases.
Muscle Spasticity
Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction.
Muscle Spasticity
Treatment of muscle spasticity in patients with cerebral palsy using BTX-A: a pilot study.
Muscle Spasticity
Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.
Muscle Spasticity
Treatment of spastic equinus gait with botulinum toxin A: Does dose matter? Analysis of a clinical cohort.
Muscle Spasticity
Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter.
Muscle Spasticity
Ultrasonographic Evaluation of Botulinum Toxin Injection Site for the Medial Approach to Tibialis Posterior Muscle in Chronic Stroke Patients with Spastic Equinovarus Foot: An Observational Study.
Muscle Spasticity
Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy.
Muscle Spasticity
Ultrasound Elastography to Assess Botulinum Toxin A Treatment for Post-stroke Spasticity: A Feasibility Study.
Muscle Spasticity
Ultrasound-guided injection of botulinum toxin A in the treatment of iliopsoas spasticity.
Muscle Spasticity
Unstable gait due to spasticity of the rectus femoris: gait analysis and motor nerve block.
Muscle Spasticity
Upper extremity function and occupational performance in children with spastic cerebral palsy following lower extremity botulinum toxin injections.
Muscle Spasticity
Use of botulinum toxin injection in 17 children with spastic cerebral palsy.
Muscle Spasticity
Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait.
Muscle Spasticity
Validity of bispectral index monitoring during deep sedation in children with spastic cerebral palsy undergoing injection of botulinum toxin.
Muscle Spasticity
Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: A cost-effectiveness study.
Muscle Spasticity
Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles.
Muscle Spasticity
What are the long-term consequences of botulinum toxin injections in spastic cerebral palsy?
Muscle Spasticity
When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?
Muscle Spasticity
[An electromyographic study on the development of optimal tactics of botulinum toxin type A injections in children with spastic forms of cerebral palsy].
Muscle Spasticity
[Botulinum therapy of spastic forms of cerebral palsy in various locomotor patterns].
Muscle Spasticity
[Botulinum toxin A in the treatment of infantile cerebral palsy. Taking into account multilevel, integrated treatment]
Muscle Spasticity
[Botulinum Toxin A Treatment in Spastic Forms of Cerebral Palsy: A Retrospective Clinical Study.]
Muscle Spasticity
[Botulinum toxin for postoperative care after limb surgery in cerebral palsy children]
Muscle Spasticity
[Botulinum toxin in spastic infantile cerebral palsy: results in 27 cases during one year]
Muscle Spasticity
[Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children]
Muscle Spasticity
[Botulinum toxin in the treatment of adult spasticity : An interdisciplinary german 10-point consensus 2010.]
Muscle Spasticity
[Botulinum toxin is effective in the short-term treatment of esophageal achalasia. Preliminary results of a randomized trial]
Muscle Spasticity
[Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]
Muscle Spasticity
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]
Muscle Spasticity
[Botulinum toxin type A in children: evaluation of indications with a review of the literature]
Muscle Spasticity
[Botulinum toxin--interventional neuropediatrics in spastic movement disorders in childhood]
Muscle Spasticity
[Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)]
Muscle Spasticity
[Changes of the spasticity patterns in children with cerebral palsy GMFCS III at the age of 2 to 12 years].
Muscle Spasticity
[Clinical experience of the repeated multilevel injections of the botulinum toxin type A (abobotulinum toxin A) in the spastic forms of cerebral palsy].
Muscle Spasticity
[Clinical research of electroacupuncture combined with acupoint-injection of botulinum toxin A in treating the muscle spasticity by spinal cord injury]
Muscle Spasticity
[Comparative analysis of occupational therapy benefits in spastic patients with hands involvement before and after botulinum toxin infiltration]
Muscle Spasticity
[Development of motor functions and manual abilities in pediatric patients with spastic cerebral palsy after botulinum toxin treatment and complex rehabilitation].
Muscle Spasticity
[Effects of botulinum toxin therapy for respiratory distress in patients with cervical hypertonia].
Muscle Spasticity
[Evaluation of a program of application of the botulinum toxin type A in children with cerebral palsy in Vale do Jequitinhonha].
Muscle Spasticity
[Experiences with botulinum toxin injections against spasticity in children]
Muscle Spasticity
[Foot deformity in children with spastic forms of cerebral palsy: the treatment with botulinum toxin type A (disport)]
Muscle Spasticity
[Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV-V)].
Muscle Spasticity
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]
Muscle Spasticity
[Post stroke hemiplegia: lower limb benefit from botulinum toxin (review)]
Muscle Spasticity
[Prevalence of hand dysfunction in cerebral palsy following Botulinum toxin therapy.]
Muscle Spasticity
[Selection of a dose of the botulinum toxin A in spastic forms of cerebral palsy].
Muscle Spasticity
[The First Russian Consensus on the Multilevel Abobotulinumtoxin A Injections in Spastic Forms of Cerebral Palsy].
Muscle Spasticity
[The profile of adult patients with upper limb muscle spasticity treated with botulinum toxin type A (an international survey)].
Muscle Spasticity
[The results of single-event multilevel orthopedic surgeries and the early rehabilitation used in complex with botulinum toxin treatment in patients with spastic forms of cerebral palsy].
Muscle Spasticity
[The risk-benefit of high doses of botulinum toxin injections for muscle spasticity ]
Muscle Spasticity
[The use of botulinum toxin in the treatment of spastic hip joint instability in children with cerebral palsy]
Muscle Spasticity
[Treatment of the spastic drop foot with botulinum toxin type A in adult patients]
Muscle Spasticity
[Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].
Muscle Weakness
Adaptive changes in locomotor activity following botulinum toxin injection in ankle extensor muscles of cats.
Muscle Weakness
Altered cell metabolism in tissues of the knee joint in a rabbit model of Botulinum toxin A-induced quadriceps muscle weakness.
Muscle Weakness
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
Muscle Weakness
Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.
Muscle Weakness
Botulinum toxin injection for postoperative diplopia testing in adult strabismus.
Muscle Weakness
Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiologic studies.
Muscle Weakness
Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics.
Muscle Weakness
Comparison Between Botulinum Toxin and Corticosteroid Injection in the Treatment of Acute and Subacute Tennis Elbow: A Prospective, Randomized, Double-Blind, Active Drug-Controlled Pilot Study.
Muscle Weakness
Correction of Malocclusion by Botulinum Neurotoxin Injection into Masticatory Muscles.
Muscle Weakness
Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis.
Muscle Weakness
Effect of muscle weakness and joint inflammation on the onset and progression of osteoarthritis in the rabbit knee.
Muscle Weakness
Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns.
Muscle Weakness
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Muscle Weakness
Frequency and length-dependent effects of Botulinum toxin-induced muscle weakness.
Muscle Weakness
Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future.
Muscle Weakness
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases.
Muscle Weakness
Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.
Muscle Weakness
Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations.
Muscle Weakness
In vivo study of paraspinal muscle weakness using botulinum toxin in one primate model.
Muscle Weakness
Interaction between gastrocnemius muscle weakness and moderate exercise deteriorates joint integrity in rat knee.
Muscle Weakness
Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism.
Muscle Weakness
Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.
Muscle Weakness
Muscle Weakness After Repeated Injection of Botulinum Toxin Type A Evaluated According to Bite Force Measurement of Human Masseter Muscle.
Muscle Weakness
Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented?
Muscle Weakness
Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity.
Muscle Weakness
No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
Muscle Weakness
No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy.
Muscle Weakness
Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation.
Muscle Weakness
Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity.
Muscle Weakness
Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
Muscle Weakness
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Muscle Weakness
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.
Muscle Weakness
Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A.
Muscle Weakness
Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study.
Muscle Weakness
Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach.
Muscle Weakness
[Does intravesical application of botulinum toxin lead to systemic muscle weakness? An approach to an uro-geriatric problem].
Muscular Atrophy
Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review.
Muscular Atrophy
Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.
Muscular Atrophy
Botulinum toxin type A injections in the psoas muscle of children with cerebral palsy: muscle atrophy after motor end plate-targeted injections.
Muscular Atrophy
Botulinum Toxin-induced Muscle Paralysis Inhibits Heterotopic Bone Formation.
Muscular Atrophy
Comparison between neurectomy and botulinum toxin A injection for denervated skeletal muscle.
Muscular Atrophy
Contralateral Botulinum Toxin Improved Functional Recovery after Tibial Nerve Repair in Rats.
Muscular Atrophy
Decreased mandibular cortical bone quality after botulinum toxin injections in masticatory muscles in female adults.
Muscular Atrophy
Early molecular response and microanatomical changes in the masseter muscle and mandibular head after botulinum toxin intervention in adult mice.
Muscular Atrophy
Effects of botulinum toxin induced muscle paralysis on endocytosis and lysosomal enzyme activities in mouse skeletal muscle.
Muscular Atrophy
Effects of hypertonia on contracture development in rat spinal cord injury.
Muscular Atrophy
Effects of repeated botulinum toxin injections on orbicularis oculi muscle.
Muscular Atrophy
Effects on craniofacial growth and development of unilateral botulinum neurotoxin injection into the masseter muscle.
Muscular Atrophy
Histology and function of the internal anal sphincter after injection of botulinum toxin.
Muscular Atrophy
Inhibition of the proteasome partially attenuates atrophy in botulinum neurotoxin treated skeletal muscle.
Muscular Atrophy
Knee muscle atrophy is a risk factor for development of knee osteoarthritis in a rat model.
Muscular Atrophy
Muscle Atrophy Beyond the Clinical Effect After a Single Dose of OnabotulinumtoxinA Injected in the Procerus Muscle: A Study with Magnetic Resonance Imaging.
Muscular Atrophy
Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers.
Muscular Atrophy
Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.
Muscular Atrophy
Neuromuscular dysfunction, independent of gait dysfunction, modulates trabecular bone homeostasis in mice.
Muscular Atrophy
Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type A in rats.
Muscular Atrophy
The influence of masticatory hypofunction on developing rat craniofacial structure.
Muscular Atrophy
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
Muscular Atrophy
[A comparative study of botulinum toxin A and denervation-induced masseter muscle atrophy in rabbits.]
Muscular Atrophy, Spinal
Successful botulinum toxin treatment of dysphagia in a spinal muscular atrophy type 2 patient.
Muscular Diseases
A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin-deficient mice with muscle hypertrophy.
Muscular Diseases
A novel method for intraoral access to the superior head of the human lateral pterygoid muscle.
Muscular Diseases
Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction.
Muscular Diseases
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Muscular Diseases
Botulinum toxin injection for restrictive myopathy of thyroid-associated orbitopathy: success rate and predictive factors.
Muscular Diseases
Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects.
Muscular Diseases
Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology.
Muscular Diseases
Crystal structure of botulinum neurotoxin type A and implications for toxicity.
Muscular Diseases
Identification of novel small molecule ligands that bind to tetanus toxin.
Muscular Diseases
Prevention of diisopropylphosphorofluoridate-induced myopathy by botulinum toxin type A blockage of quantal release of acetylcholine.
Muscular Diseases
Properties and use of botulinum toxin and other microbial neurotoxins in medicine.
Muscular Diseases
Review article: botulinum toxin in the therapy of gastrointestinal motility disorders.
Muscular Diseases
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Muscular Diseases
Topical Botulinum Toxin: A Non-invasive Way for Treatment of Muscle Disorders.
Muscular Dystrophy, Duchenne
Botulinum toxin for amelioration of knee contracture in Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Poster 273 Botulinum Toxin Injections to the Salivary Glands for Treatment of Sialorrhea in a Patient with Duchenne Muscular Dystrophy: A Case Report.
Muscular Dystrophy, Oculopharyngeal
Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.
Muscular Dystrophy, Oculopharyngeal
Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy.
Musculoskeletal Diseases
Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature.
Musculoskeletal Pain
A double-blind, controlled study of botulinum toxin A in chronic myofascial pain.
Musculoskeletal Pain
An update on the pharmacological management of pain in patients with multiple sclerosis.
Musculoskeletal Pain
Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses.
Musculoskeletal Pain
Commentary Re: Botox Article by Berger & Knoll IPH 19(5):243-244 on "The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis".
Musculoskeletal Pain
Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials.
Musculoskeletal Pain
The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.
Myalgia
A Critical Appraisal of the Evidence for Botulinum Toxin Type A in the Treatment for Cervico-Thoracic Myofascial Pain Syndrome.
Myalgia
A randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA trigger point injections for myofascial pelvic pain.
Myalgia
Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension.
Myalgia
Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders.
Myalgia
Effect of botulinum toxin on pressure pain threshold and EMG power spectrum of masseter muscle during sustained fatiguing contraction.
Myalgia
Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study.
Myalgia
Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection.
Myalgia
More than a cosmetic fix. Combined with physical therapy, botulinum toxin type A can help provide relief for chronic muscle pain.
Myalgia
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Myalgia
Persistent unilateral tibialis anterior muscle hypertrophy with complex repetitive discharges and myalgia: report of two unique cases and response to botulinum toxin.
Myalgia
Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Myalgia
Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain.
Myalgia
Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain.
Myalgia
The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache.
Myalgia
Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles.
Myalgia
Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study.
Myalgia
Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter.
Myasthenia Gravis
Active management in patients with ocular manifestations of myasthenia gravis.
Myasthenia Gravis
Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis.
Myasthenia Gravis
Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis.
Myasthenia Gravis
Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation.
Myasthenia Gravis
Botulinum toxin treatment for blepharospasm associated with myasthenia gravis.
Myasthenia Gravis
Cosmetic Injection of Botulinum Toxin Unmasking Subclinical Myasthenia Gravis: A Case Report and Literature Review.
Myasthenia Gravis
Electrophysiology of Extraocular Cranial Nerves: Oculomotor, Trochlear, and Abducens Nerve.
Myasthenia Gravis
Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria.
Myasthenia Gravis
Subclinical Myasthenia Gravis causing increased sensitivity to botulinum toxin therapy.
Myasthenia Gravis
Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.
Myasthenia Gravis
The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis.
Myasthenia Gravis
Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis.
Myasthenia Gravis
Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.
Myasthenia Gravis
Variable ptosis after botulinum toxin type a injection with positive ice test mimicking ocular myasthenia gravis.
Mycobacterium Infections, Nontuberculous
Mycobacterium abscessus infections following injection of botulinum toxin.
Mydriasis
Acute angle closure following periorbital botulinum toxin injection in a patient with retinitis pigmentosa.
Mydriasis
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm.
Mydriasis
Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure.
Mydriasis
[Persistent mydriasis after botulinum toxin injection for infantile early onset esotropia].
Myelitis, Transverse
Botulinum toxin A in the treatment of spasticity - An open label study.
Myoclonus
Botulinum toxin injection for objective tinnitus from palatal myoclonus: a case report.
Myoclonus
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis.
Myoclonus
Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin.
Myoclonus
Efficacy and complication of botulinum toxin injection in palatal myoclonus: experience from a patient.
Myoclonus
In reference to Palatal myoclonus: Algorithm for management with botulinum toxin based on clinical disease characteristics.
Myoclonus
In response to Palatal myoclonus: Algorithm for management with botulinum toxin based on clinical disease characteristics.
Myoclonus
Objective tinnitus from palatal myoclonus. Use of botulinum toxin: a case report.
Myoclonus
Palatal myoclonus: Algorithm for management with botulinum toxin based on clinical disease characteristics.
Myoclonus
Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A.
Myoclonus
Successful Treatment of Auricular Dystonia by Unilateral Pallidothalamic Tractotomy.
Myoclonus
Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua.
Myoclonus
Sustained remission of segmental myoclonus due to peripheral nerve injury after treatment with onabotulinumtoxinA.
Myoclonus
The use of clostridium botulinum toxin in palatal myoclonus. A preliminary report.
Myoclonus
Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin.
Myoclonus
Two new families with hereditary essential chin myoclonus: clinical features, neurophysiological findings and treatment.
Myoclonus
[Myoclonic spasms: their clinical and neurophysiological characteristics, aetiology and treatment].
Myofascial Pain Syndromes
A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.
Myofascial Pain Syndromes
A Critical Appraisal of the Evidence for Botulinum Toxin Type A in the Treatment for Cervico-Thoracic Myofascial Pain Syndrome.
Myofascial Pain Syndromes
A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans.
Myofascial Pain Syndromes
A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review.
Myofascial Pain Syndromes
A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome.
Myofascial Pain Syndromes
Analgesic Effect of Botulinum Toxin A in Myofascial Pain Syndrome Patients Previously Treated with Local Infiltration of Anesthetic and Steroids.
Myofascial Pain Syndromes
Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study.
Myofascial Pain Syndromes
Botulinum toxin for myofascial pain syndromes in adults.
Myofascial Pain Syndromes
Botulinum toxin for the treatment of musculoskeletal pain and spasm.
Myofascial Pain Syndromes
Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective.
Myofascial Pain Syndromes
Botulinum toxin treatment of myofascial pain: a critical review of the literature.
Myofascial Pain Syndromes
Botulinum toxin type a and myofascial pain syndrome: A retrospective study of 301 patients.
Myofascial Pain Syndromes
Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Myofascial Pain Syndromes
Botulinum toxin type A for the treatment of chronic neck pain after neck dissection.
Myofascial Pain Syndromes
Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome: A systematic review and meta-analysis.
Myofascial Pain Syndromes
Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Myofascial Pain Syndromes
Botulinum Type A Toxin Complex for the Relief of Upper Back Myofascial Pain Syndrome: How Do Fixed-Location Injections Compare with Trigger Point-Focused Injections?
Myofascial Pain Syndromes
Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome.
Myofascial Pain Syndromes
Effect of Electrical Stimulation on Botulinum Toxin A Therapy in Patients With Chronic Myofascial Pain Syndrome: A 16-Week Randomized Double-Blinded Study.
Myofascial Pain Syndromes
Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
Myofascial Pain Syndromes
Evidence for antinociceptive activity of botulinum toxin type A in pain management.
Myofascial Pain Syndromes
Intra-articular botulinum toxin injection in complex regional pain syndrome: Case report and review of the literature.
Myofascial Pain Syndromes
Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice.
Myofascial Pain Syndromes
Safety and Efficacy of PrabotulinumtoxinA (Nabota®) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study.
Myofascial Pain Syndromes
The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial.
Myofascial Pain Syndromes
Ultrasound imaging for sarcopenia, spasticity and painful muscle syndromes.
Myofascial Pain Syndromes
Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter.
Myofascial Pain Syndromes
[Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes]
Myofascial Pain Syndromes
[Treatment of myofascial pain syndrome (MPS) with botulinum toxin type A (BoNT-A)].
Myokymia
Botulinum toxin A is effective in treating trismus associated with postradiation myokymia and muscle spasm.
Myokymia
Botulinum toxin type A for the treatment of postamputation residual limb myokymia: a case report.
Myokymia
Ptosis caused by orbicularis myokymia and treated with botulinum toxin: a case report.
Myokymia
Sustained atypical myokymia of the abductor pollicis brevis with a focal slowing of the median nerve motor axons at the wrist.
Myokymia
Use of botulinum toxin type A for the treatment of radiation therapy-induced myokymia and neuromyotonia in a dog.
Myopathies, Nemaline
Successful botulinum toxin treatment of dysphagia in a young child with nemaline myopathy.
Myositis
A severe case of non-infective myositis six weeks post intramuscular injections of Onabotulinum toxin A (Botox) in a young man with tetraplegia: case report.
Myositis
Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Myositis
Erratum to: Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Myositis
Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.
Myositis, Inclusion Body
Botulinum toxin alleviates dysphagia of patients with inclusion body myositis.
Myositis, Inclusion Body
Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Myositis, Inclusion Body
Erratum to: Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.
Myositis, Inclusion Body
Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.
Myotonia
Botulinum toxin type A in the treatment of facial myotonia in Schwartz-Jampel syndrome.
Myotonia Congenita
Botulinum toxin for treating unilateral apraxia of eyelid opening in a patient with congenital myotonia.
Myotonia Congenita
Botulinum toxin in myotonia congenita: it does not help against rigidity and pain.
Nasal Obstruction
Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study.
Nasopharyngeal Carcinoma
Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.
Neonatal Brachial Plexus Palsy
Botulinum toxin for the treatment of motor imbalance in obstetrical brachial plexus palsy.
Neonatal Brachial Plexus Palsy
Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy.
Neonatal Brachial Plexus Palsy
Muscle loading is necessary for the formation of a functional tendon enthesis.
Neonatal Brachial Plexus Palsy
Out of the spasticity box: Off-label uses of botulinum toxin in children.
Neonatal Brachial Plexus Palsy
Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy.
Neoplasm Metastasis
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Neoplasms
19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.
Neoplasms
A Cell-Permeable Fusion Protein Based on Clostridium botulinum C2 Toxin for Delivery of p53 Tumorsuppressor into Cancer Cells.
Neoplasms
Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors.
Neoplasms
Anti-photoaging potential of Botulinum Toxin Type A in UVB-induced premature senescence of human dermal fibroblasts in vitro through decreasing senescence-related proteins.
Neoplasms
Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo.
Neoplasms
Application of NMR methods to identify detection reagents for use in development of robust nanosensors.
Neoplasms
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
Neoplasms
Botulinum toxin A for oral cavity cancer patients: in microsurgical patients BTX injections in major salivary glands temporarily reduce salivary production and the risk of local complications related to saliva stagnation.
Neoplasms
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.
Neoplasms
Clostridium botulinum neurotoxin A induces apoptosis and mitochondrial oxidative stress via activation of TRPM2 channel signaling pathway in neuroblastoma and glioblastoma tumor cells.
Neoplasms
Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies.
Neoplasms
Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes.
Neoplasms
Fibronectin (FN) cooperated with TLR2/TLR4 receptor to promote innate immune responses of macrophages via binding to integrin ?1.
Neoplasms
Genes associated with inflammation and the cell cycle may serve as biomarkers for the diagnosis and prognosis of acute myocardial infarction in a Chinese population.
Neoplasms
Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators.
Neoplasms
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.
Neoplasms
Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.
Neoplasms
In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.
Neoplasms
Inhibition of the Rac1-WAVE2-Arp2/3 signaling pathway promotes radiosensitivity via downregulation of cofilin-1 in U251 human glioma cells.
Neoplasms
Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats.
Neoplasms
Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan.
Neoplasms
Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Neoplasms
OnabotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation.
Neoplasms
Overexpression of Ras-Related C3 Botulinum Toxin Substrate 2 Radiosensitizes Melanoma Cells In Vitro and In Vivo.
Neoplasms
P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.
Neoplasms
Phosphorylation of SNAP-25 on serine-187 is induced by secretagogues in insulin-secreting cells, but is not correlated with insulin secretion.
Neoplasms
Post-surgical role of botulinum toxin-A injection in patients with head and neck cancer: personal experience.
Neoplasms
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Neoplasms
Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer.
Neoplasms
Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
Neoplasms
Retargeted clostridial neurotoxins as novel agents for treating chronic diseases.
Neoplasms
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.
Neoplasms
The mechanisms of action of Botulinum Toxin type A in nociceptive and neuropathic pathways in Cancer Pain.
Neoplasms
Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore.
Neoplasms
[Efficacy of semiconductor laser therapy combined with botulinum toxin A type injection in treatment of temporomandibular disorders].
Neoplasms
[Treatment of sixth nerve palsy of traumatic or tumor etiology using botulinum toxin]
Nerve Compression Syndromes
Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience.
Nerve Compression Syndromes
Treatment of Frontal Secondary Headache Attributed to Supratrochlear and Supraorbital Nerve Entrapment With Oral Medication or Botulinum Toxin Type A vs Endoscopic Decompression Surgery.
Nervous System Diseases
A Case of Reactivation of Herpes Simplex Virus Corneal Endotheliitis Following Periocular Botulinum Toxin A Injection.
Nervous System Diseases
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies.
Nervous System Diseases
A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A.
Nervous System Diseases
Agrin Influences Botulinum Neurotoxin A-Induced Nerve Sprouting via miR-144-agrin-MuSK Signaling.
Nervous System Diseases
Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study.
Nervous System Diseases
Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated.
Nervous System Diseases
Botulinum Toxin A for Treatment of Sialorrhea in Children: An Effective, Minimally Invasive Approach.
Nervous System Diseases
Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.
Nervous System Diseases
Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Nervous System Diseases
Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life.
Nervous System Diseases
Botulinum toxin in the management of bowel and bladder function in spinal cord injury and other neurologic disorders.
Nervous System Diseases
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system.
Nervous System Diseases
Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.
Nervous System Diseases
Botulinum Toxin in WW2 German and Allied Armies: Failures and Myths of Weaponization.
Nervous System Diseases
Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders.
Nervous System Diseases
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.
Nervous System Diseases
Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence.
Nervous System Diseases
Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders.
Nervous System Diseases
Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.
Nervous System Diseases
Botulinum toxin type B (Myobloc, NeuroBloc): a new choice in cervical dystonia.
Nervous System Diseases
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Nervous System Diseases
Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Nervous System Diseases
Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
Nervous System Diseases
Content of botulinum neurotoxin in botox(r)/vistabel(r), dysport(r)/azzalure(r), and xeomin(r)/bocouture(r).
Nervous System Diseases
Costs of treating dystonias and hemifacial spasm with botulinum toxin A.
Nervous System Diseases
Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?
Nervous System Diseases
Effect of botulinum toxin a injection into the salivary glands for sialorrhea in children with neurologic disorders.
Nervous System Diseases
Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
Nervous System Diseases
Efficacy and duration of botulinum toxin treatment for drooling in 131 children.
Nervous System Diseases
Efficacy and safety of botulinum toxin for treating sialorrhea: A systematic review and meta-analysis.
Nervous System Diseases
Emergency response to a cluster of suspected food-borne botulism in Abuja, Nigeria: challenges with diagnosis and treatment in a resource-poor setting.
Nervous System Diseases
Endoscopic botulinum toxin injection for treatment of pharyngeal dysphagia in patients with cricopharyngeal dysfunction.
Nervous System Diseases
Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
Nervous System Diseases
Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.
Nervous System Diseases
High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.
Nervous System Diseases
Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins.
Nervous System Diseases
Historical note on the therapeutic use of botulinum toxin in neurological disorders.
Nervous System Diseases
In vitro quantification of botulinum neurotoxin type A1 using immobilized nerve cell-mimicking nanoreactors in a microfluidic platform.
Nervous System Diseases
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.
Nervous System Diseases
Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology.
Nervous System Diseases
Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
Nervous System Diseases
Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia.
Nervous System Diseases
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.
Nervous System Diseases
Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.
Nervous System Diseases
Periorbital injections of botulinum toxin a: a novel therapeutic option for convergence spasm in neuropsychiatric disorders.
Nervous System Diseases
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Nervous System Diseases
Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.
Nervous System Diseases
Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice.
Nervous System Diseases
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
Nervous System Diseases
Single intracerebroventricular injection of botulinum toxin type A produces slow onset and long-term memory impairment in rats.
Nervous System Diseases
Successful management of drooling with botulinum toxin A in neurologically disabled children.
Nervous System Diseases
Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
Nervous System Diseases
The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®).
Nervous System Diseases
The Effectiveness of Botulinum Toxin Type A Injections in the Management of Sialorrhea.
Nervous System Diseases
The use of urodynamic studies for the followup of neurogenic bladders treated with onabotulinumtoxinA.
Nervous System Diseases
Toxic potential of botulinum toxin type A on senescence in a Drosophila melanogaster model.
Nervous System Diseases
Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Nervous System Diseases
Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders.
Nervous System Diseases
Treatment of tension-type headache with botox: a review of the literature.
Nervous System Diseases
Ultrasound guided injection of botulinum toxin into the salivary glands of children with neurological disorders.
Nervous System Diseases
Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Nervous System Diseases
Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.
Nervous System Diseases
[Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders.]
Nervous System Diseases
[Myths and evidence on the use of botulinum toxin: neuropharmacology and dystonia].
Nervous System Diseases
[Treatment of neurological disorders with botulinum toxin: recent progress]
Neural Tube Defects
[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]
Neuralgia
A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury.
Neuralgia
A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury.
Neuralgia
A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury: Retraction.
Neuralgia
Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain.
Neuralgia
Antinociceptive Effects of Botulinum Toxin Type A on Trigeminal Neuropathic Pain.
Neuralgia
Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers.
Neuralgia
Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models.
Neuralgia
Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.
Neuralgia
Botulinum toxin - intraorally: Intraoral administration of botulinum toxin for trigeminal neuropathic pain.
Neuralgia
Botulinum toxin - neuropathic pain: Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Neuralgia
Botulinum toxin A for neuropathic pain after neck dissection: a dose-finding study.
Neuralgia
Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations.
Neuralgia
Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and ? opioid receptor expression in neuropathic mice.
Neuralgia
Botulinum toxin a relieved neuropathic pain in a case of post-herpetic neuralgia.
Neuralgia
Botulinum toxin A treatment for post-herpetic neuralgia: A systematic review and meta-analysis.
Neuralgia
Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines.
Neuralgia
Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System.
Neuralgia
Botulinum Toxin B Affects Neuropathic Pain but Not Functional Recovery after Peripheral Nerve Injury in a Mouse Model.
Neuralgia
Botulinum Toxin Decreases Hyperalgesia and Inhibits P2X(3) Receptor Over-Expression in Sensory Neurons Induced by Ventral Root Transection in Rats.
Neuralgia
Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.
Neuralgia
Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial: botulinum toxin for neuropathic pain?
Neuralgia
Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series.
Neuralgia
Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence.
Neuralgia
Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction.
Neuralgia
Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2/MyD88 and SNAP23.
Neuralgia
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Neuralgia
Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation.
Neuralgia
Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
Neuralgia
Botulinum Toxin Type A Injection for Neuropathic Pain in a Patient With a Brain Tumor: A Case Report.
Neuralgia
Botulinum toxin type A promotes microglial M2 polarization and suppresses chronic constriction injury-induced neuropathic pain through the P2X7 receptor.
Neuralgia
Botulinum Toxin Type A Reduces Hyperalgesia and TRPV1 Expression in Rats with Neuropathic Pain.
Neuralgia
Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection.
Neuralgia
Botulinum Toxin Type A-A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions.
Neuralgia
Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study.
Neuralgia
Botulinum Toxin Type-A (Botulax®) Treatment in Patients with Intractable Chronic Occipital Neuralgia: A Pilot Study.
Neuralgia
Can Botulinum Toxin Type A effectively treat neuropathic pain in spinal cord injury?: A protocol of systematic review and meta-analysis.
Neuralgia
Combination of Botulinum Toxin and minocycline Ameliorates Neuropathic Pain Through Antioxidant Stress and Anti-Inflammation via Promoting SIRT1 Pathway.
Neuralgia
Cross-Excitation in Peripheral Sensory Ganglia Associated with Pain Transmission.
Neuralgia
Effect of Botulinum Toxin on Disabling Neuropathic Pain: A Case Presentation Suggesting a New Therapeutic Strategy.
Neuralgia
Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain.
Neuralgia
Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience.
Neuralgia
Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?
Neuralgia
Intraoral Administration of Botulinum Toxin for Continuous Dentoalveolar Neuropathic Pain: A Case Series.
Neuralgia
Involvement of substance P in the antinociceptive effect of botulinum toxin type A: Evidence from knockout mice.
Neuralgia
OnabotulinumtoxinA Improves Tactile and Mechanical Pain Perception in Painful Diabetic Polyneuropathy.
Neuralgia
OnabotulinumtoxinA infiltration and nerve blocks in patients with headache and neuralgia: safety recommendations to prevent SARS-CoV-2 infection.
Neuralgia
Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain.
Neuralgia
Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations.
Neuralgia
Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects.
Neuralgia
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Neuralgia
Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice.
Neuralgia
Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Neuralgia
Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice.
Neuralgia
Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports.
Neuralgia
Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury-Induced Neuropathic Pain Models.
Neuralgia
Subcutaneous and Perineural Botulinum Toxin Type A For Neuropathic Pain: A Descriptive Review.
Neuralgia
Subcutaneous Injection of Botulinum Toxin in Patients with Post Herpetic Neuralgia. A Preliminary Study.
Neuralgia
The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
Neuralgia
The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord.
Neuralgia
The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain.
Neuralgia
The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial.
Neuralgia
The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy.
Neuralgia
The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.
Neuralgia
The efficacy of intradermal injection of botulinum toxin in patients with post-herpetic neuralgia.
Neuralgia
The Safety and Effect of Local Botulinumtoxin A Injections for Long-Term Management of Chronic Pain in Post-Herpetic Neuralgia: Literature Review and Cases Report Treated with Incobotulinumtoxin A.
Neuralgia
Topical Review: Potential Use of Botulinum Toxin in the Management of Painful Posttraumatic Trigeminal Neuropathy.
Neuralgia
Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.
Neuralgia
Ultrasound-Guided Nerve Block with Botulinum Toxin Type A for Intractable Neuropathic Pain.
Neuralgia
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice.
Neuralgia
Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
Neuralgia
Use of Botulinum Toxin Type A Injection for Neuropathic Pain after Trigeminal Nerve Injury.
Neuralgia
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]
Neuralgia, Postherpetic
BoTN-A: The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Neuralgia, Postherpetic
Botulinum Toxin A in Postherpetic Neuralgia: A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial.
Neuralgia, Postherpetic
Botulinum Toxin A Might Be an Alternative or Adjunct Therapy for the Treatment of Trigeminal and Postherpetic Neuralgia.
Neuralgia, Postherpetic
Combining Botulinum Toxin (A) Injection With Peripheral Nerve Stimulation in a Patient for Intractable Ophthalmic Postherpetic Neuralgia.
Neuralgia, Postherpetic
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus.
Neuralgia, Postherpetic
Interventional Treatments for Postherpetic Neuralgia: A Systematic Review.
Neuralgia, Postherpetic
Subcutaneous and Perineural Botulinum Toxin Type A For Neuropathic Pain: A Descriptive Review.
Neuralgia, Postherpetic
Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia.
Neuralgia, Postherpetic
The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Neuralgia, Postherpetic
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]
Neuroblastoma
Analysis of Motor Neurons Differentiated from Human Induced Pluripotent Stem Cells for the Use in Cell-Based Botulinum Neurotoxin Activity Assays.
Neuroblastoma
Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I.
Neuroblastoma
Botulinum neurotoxin A and an engineered derivate targeted secretion inhibitor (TSI) A enter cells via different vesicular compartments.
Neuroblastoma
Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells.
Neuroblastoma
Characterization of Clostridial botulinum neurotoxin channels in neuroblastoma cells.
Neuroblastoma
Clostridium botulinum neurotoxin A induces apoptosis and mitochondrial oxidative stress via activation of TRPM2 channel signaling pathway in neuroblastoma and glioblastoma tumor cells.
Neuroblastoma
Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Disruption of lipid rafts enhances activity of botulinum neurotoxin serotype A.
Neuroblastoma
Dramatic neurological and biological effects by botulinum neurotoxin type A on SH-SY5Y neuroblastoma cells, beyond the blockade of neurotransmitter release.
Neuroblastoma
Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.
Neuroblastoma
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Neuroblastoma
Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin.
Neuroblastoma
Natural Compounds and their Analogues as Potent Antidotes against the Most Poisonous Bacterial toxin.
Neuroblastoma
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.
Neuroblastoma
Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis.
Neuroblastoma
Stimulation-dependent regulation of the pH, volume and quantal size of bovine and rodent secretory vesicles.
Neurodegenerative Diseases
Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Neurodegenerative Diseases
Intrapallidal injection of botulinum toxin A recovers gait deficits in a parkinsonian rodent model.
Neurodegenerative Diseases
Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.
Neurodegenerative Diseases
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Neurodegenerative Diseases
Reply: Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
Neurodegenerative Diseases
Successful management of drooling with botulinum toxin A in neurologically disabled children.
Neurodegenerative Diseases
Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
Neurodegenerative Diseases
Unilateral whisker pad injection of botulinum toxin type a enhances spatial learning in mice.
Neurodegenerative Diseases
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
Neuroendocrine Tumors
Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Neuroendocrine Tumors
Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells.
Neurogenic Inflammation
Botulinum toxin A does not alter capsaicin-induced pain perception in human skin.
Neurogenic Inflammation
Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
Neurogenic Inflammation
Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
Neurogenic Inflammation
Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.
Neurogenic Inflammation
Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin.
Neurogenic Inflammation
Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment.
Neurogenic Inflammation
Inhibitory effect of botulinum toxin type A on the NANC system in rat respiratory models of neurogenic inflammation.
Neurogenic Inflammation
Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model.
Neurogenic Inflammation
Management of nail psoriasis with a single injection of abobotulinum toxin.
Neurogenic Inflammation
Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin.
Neurogenic Inflammation
Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
Neurogenic Inflammation
The effect of botulinum neurotoxin A in patients with plaque psoriasis - an exploratory trial.
Neurogenic Inflammation
Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles.
Neuroinflammatory Diseases
Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson's Disease Models.
Neuroinflammatory Diseases
Botulinum toxin type A ameliorates adjuvant-arthritis pain by inhibiting microglial activation-mediated neuroinflammation and intracellular molecular signaling.
Neuroinflammatory Diseases
Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures.
Neuroinflammatory Diseases
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice.
Neurologic Manifestations
An Outbreak of Botulinum Types A, B, and E Associated With Vacuum-Packaged Salted Fish and Ham.
Neuroma
[Clinical presentations, differential diagnosis and management of obstetric brachial palsy]
Neuroma, Acoustic
Botulinum toxin for temporary corneal protection after surgery for vestibular schwannoma.
Neuromuscular Diseases
Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study.
Neuromuscular Diseases
Chronic denervation caused by botulinum neurotoxin as a model of a neuromuscular disease.
Neuromuscular Diseases
Education Research: Neurology resident education: Trending skills, confidence, and professional preparation.
Neuromuscular Diseases
Efficacy of Botulinum Toxin for Treating Sialorrhea in Neuromuscular Conditions.
Neuromuscular Diseases
Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.
Neuromuscular Diseases
Evaluation of assessment of caregiver experience with neuromuscular disease: reliability and responsiveness of a new caregiver-reported outcome measure in patients with cerebral palsy.
Neuromuscular Diseases
Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections.
Neuromuscular Diseases
Innervation zones of the upper and lower limb muscles estimated by using multichannel surface EMG.
Neuromuscular Diseases
Ocular surface changes following botulinum toxin injection for strabismus.
Neuromuscular Diseases
Transcutaneous innervation zone imaging from high-density surface electromyography recordings.
Neuromuscular Junction Diseases
Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation.
Neurosyphilis
A rare case of laryngeal dystonia associated with neurosyphilis: Response to botulinum toxin injection.
Nystagmus, Congenital
[Botulinum toxin A in the treatment of congenital nystagmus in children]
Nystagmus, Congenital
[Injection of botulinum toxin into the oculomotor muscles in disorders of ocular motility]
Nystagmus, Pathologic
Effectiveness of botulinum toxin administered to abolish acquired nystagmus.
Nystagmus, Pathologic
Periodic alternating nystagmus treated with retrobulbar botulinum toxin and large horizontal muscle recession.
Nystagmus, Pathologic
The Use of Botulinum Toxin in a Case of Acquired Periodic Alternating Nystagmus.
Nystagmus, Pathologic
Treatment of Nystagmus in Brainstem Cavernous Malformation with Botulinum Toxin.
Nystagmus, Pathologic
Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin.
Nystagmus, Pathologic
[Use of botulinum toxin in a patient with pendular congenital nystagmus].
Obesity
Botulinum neurotoxin-A does not spread to distant muscles after intragastric injection: A double-blind single-fiber electromyography study.
Obesity
Comparative efficacy of bariatric endoscopic procedures in the treatment of morbid obesity: a systematic review and network meta-analysis.
Obesity
Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression.
Obesity
Efficacy of Intragastric Balloon Placement and Botulinum Toxin Injection in Bariatric Endoscopy.
Obesity
Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study.
Obesity
Endoscopic intragastric injection of botulinum toxin A in obese patients on bariatric surgery waiting lists: A randomised double-blind study (IntraTox study).
Obesity
Intragastric Botulinum Toxin A Injection Is an Effective Obesity Therapy for Patients with BMI?>?40 kg/m2: a Systematic Review and Meta-analysis.
Obesity
Intragastric injection of botulinum toxin for the treatment of obesity. Where are we?
Obesity
Reviewing the reviewers: critical appraisal of "Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression".
Obesity
The Effect of Intragastric Administration of Botulinum Toxin Type A on Reducing Adiposity in a Rat Model of Obesity Using Micro-CT and Histological Examinations.
Obesity
The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients.
Obesity
Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study.
Obesity
Treatment of Obesity by Endoscopic Gastric Intramural Injection of Botulinum Toxin A: A Randomized Clinical Trial.
Obesity
[Intragastric injection of botulinum toxin. A real alternative for obesity treatment? A systematic review].
Obesity, Morbid
Botulinum toxin for chronic anal fissure after biliopancreatic diversion for morbid obesity.
Obesity, Morbid
Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats.
Obesity, Morbid
Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study.
Obstetric Labor, Premature
Clostridium botulinum toxin A inhibits contractility in pregnant human myometrium in vitro.
Obstetric Labor, Premature
Clostridium botulinum toxin inhibits myometrial activity in vitro: possible application on the prevention of preterm labor after fetal surgery.
Ocular Motility Disorders
Botulinum toxin in the management of internuclear ophthalmoplegia.
Ocular Motility Disorders
Botulinum toxin treatment of supranuclear ocular motility disorders.
Ocular Motility Disorders
Improvement in reading symptoms following botulinum toxin A injection for convergence insufficiency type intermittent exotropia.
Ocular Motility Disorders
Selective lesions of rabbit extraocular muscles injected with the anti-AChR immunotoxin saporin-mAb 73.
Ocular Motility Disorders
Sustained improvement of reading symptoms following botulinum toxin A injection for convergence insufficiency.
Ocular Motility Disorders
[Injection of botulinum toxin into the oculomotor muscles in disorders of ocular motility]
Oculomotor Nerve Diseases
The role of Botulinum toxin in management of acute traumatic third-nerve palsy.
Oculomotor Nerve Injuries
The role of Botulinum toxin in management of acute traumatic third-nerve palsy.
Open Bite
Correction of post-traumatic anterior open bite by injection of botulinum toxin type A into the anterior belly of the digastric muscle: case report.
Open Bite
Screening for variations in anterior digastric musculature prior to correction of post-traumatic anterior open bite by injection of botulinum toxin type A: a technical note.
Ophthalmoplegia
The Role of Botulinum Toxin in the Management of Ophthalmoplegia Secondary to Miller Fisher Syndrome.
Ophthalmoplegic Migraine
The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine.
Optic Nerve Diseases
Botulinum toxin as adjunct for refractory compressive optic neuropathy in Graves' disease.
Optic Nerve Diseases
Cilioretinal artery occlusion and anterior ischaemic optic neuropathy due to periocular botulinum toxin a injection: A case report.
Optic Nerve Diseases
Effect of botulinum toxin type A on the cervical sympathetic trunk in chronic relapsing inflammatory optic neuropathy.
Optic Neuritis
An update on the pharmacological management of pain in patients with multiple sclerosis.
Oral Ulcer
Application of botulinum toxin in maxillofacial field: Part III. Ancillary treatment for maxillofacial surgery and summary.
Oral Ulcer
Management of oromandibular dystonia on a chorea acanthocytosis: a brief review of the literature and a clinical case.
Osteoarthritis
A Comparative Study of Botulinum Toxin: A with Triamcinolone Compared to Triamcinolone alone in the treatment of Osteoarthritis of Knee.
Osteoarthritis
Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain.
Osteoarthritis
Botulinum toxin as a novel addition to anti-arthritis armamentarium: An experimental study in rabbits.
Osteoarthritis
Effects of intra-articular botulinum toxin type A (Botox) in dogs with chronic osteoarthritis.
Osteoarthritis
Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study.
Osteoarthritis
Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial.
Osteoarthritis
Efficacy of Long-term Effect and Repeat Intraarticular Botulinum toxin in Patients with Painful Total Joint Arthroplasty: A Retrospective Study.
Osteoarthritis
Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle.
Osteoarthritis
Intra-articular botulinum toxin A (BoNT/A) for pain management in dogs with osteoarthritis secondary to hip dysplasia: a randomized controlled clinical trial.
Osteoarthritis
Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: protocol for a randomised trial (RHIBOT).
Osteoarthritis
Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: A randomized, double-blinded, placebo-controlled clinical trial.
Osteoarthritis
Intra-articular botulinum toxin type A for treatment of knee osteoarthritis: Clinical trial.
Osteoarthritis
Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature.
Osteoarthritis
Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain.
Osteoarthritis
Osteoarthritis of the hip conservative treatment with type A botulinum toxin.
Osteoarthritis
The analgesic effect of intraarticular OnabotulinumtoxinA in a female murine model of collagenase induced chronic degenerative monoarthritis.
Osteoarthritis
Usefulness of intra-articular botulinum toxin injections. A systematic review.
Osteoarthritis
[The influence of botulinum toxin on the masticatory muscles of the temporomandibular joint osteoarthritis in rabbit]
Osteoarthritis, Hip
AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study.
Osteoarthritis, Hip
Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results.
Osteoarthritis, Hip
Osteoarthritis of the hip conservative treatment with type A botulinum toxin.
Osteoarthritis, Knee
A Comparative Study of Botulinum Toxin: A with Triamcinolone Compared to Triamcinolone alone in the treatment of Osteoarthritis of Knee.
Osteoarthritis, Knee
Beyond the muscular effects - onabotulinumtoxinA injections for pain control in chronic knee osteoarthritis: a case report.
Osteoarthritis, Knee
Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a randomized controlled trial.
Osteoarthritis, Knee
Effect of therapeutic exercise on knee osteoarthritis after intra-articular injection of botulinum toxin type A, hyaluronate or saline: A randomized controlled trial.
Osteoarthritis, Knee
Effects of Botulinum Toxin Landmark-Guided Intra-articular Injection in Subjects With Knee Osteoarthritis.
Osteoarthritis, Knee
Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study.
Osteoarthritis, Knee
Efficacy of Intra-Articular Botulinum Toxin Type A in Painful Knee Osteoarthritis: A Pilot Study.
Osteoarthritis, Knee
Intra-articular botulinum toxin type A for treatment of knee osteoarthritis: Clinical trial.
Osteoarthritis, Knee
Physical therapy, intra-articular dextrose prolotherapy, botulinum neurotoxin, and hyaluronic acid for knee osteoarthritis: randomized clinical trial.
Osteoarthritis, Knee
The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis.
Osteoarthritis, Knee
Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis.
Osteoarthritis, Knee
Therapeutic Effects of Intra-articular Botulinum Neurotoxin Versus Physical Therapy in Knee Osteoarthritis.
Osteoarthropathy, Primary Hypertrophic
Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases.
Osteoarthropathy, Primary Hypertrophic
Pachydermoperiostosis: aesthetic treatment of prematurely aging face with facelift and botulinum toxin a.
Osteoarthropathy, Primary Hypertrophic
Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A.
Osteochondrodysplasias
Botulinum toxin A injections for the treatment of Schwartz-jampel syndrome: a case series.
Osteochondrodysplasias
Botulinum toxin type A in the treatment of facial myotonia in Schwartz-Jampel syndrome.
Osteochondrodysplasias
Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections.
Osteochondrodysplasias
Treatment of Blepharospasm in Schwartz-Jampel Syndrome: Botulinum Toxin A Injection or Surgery.
Osteolysis
Botulinum Toxin Injection of a Patient with Intractable Acromio-Clavicular Joint Pain due to Distal Clavicular Osteolysis.
Osteoporosis
Botulinum toxin used to treat recurrent dislocation of the temporomandibular joint in a patient with osteoporosis.
Osteoporosis
Experimental model of osteoporosis: comparison between ovariectomy and botulinum toxin a.
Otitis
Evaluation of the protective effect of Botulinum toxin type A injection on otitis media with effusion().
Otitis Media
Evaluation of the protective effect of Botulinum toxin type A injection on otitis media with effusion().
Otitis Media with Effusion
Evaluation of the protective effect of Botulinum toxin type A injection on otitis media with effusion().
Ovarian Neoplasms
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Pachyonychia Congenita
Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita.
Pachyonychia Congenita
Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases.
Pachyonychia Congenita
Treatment of pachyonychia congenita with plantar injections of botulinum toxin.
Pancreatic Fistula
Protocol of a randomised controlled phase II clinical trial investigating PREoperative endoscopic injection of BOTulinum toxin into the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy: the PREBOTPilot trial.
Pancreatic Fistula
Reproducibility of preoperative endoscopic injection of botulinum toxin into the sphincter of Oddi to prevent postoperative pancreatic fistula.
Pancreatic Fistula
Sphincter of Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy.
Pancreatic Neoplasms
CCN1 promotes tumorigenicity through Rac1/Akt/NF-?B signaling pathway in pancreatic cancer.
Pancreatitis
A case of acute pancreatitis after intrapyloric botulinum toxin injection to treat gastroparesis.
Pancreatitis
Botulinum toxin injection as a diagnostic tool for verification of sphincter of Oddi dysfunction causing recurrent pancreatitis.
Pancreatitis
Endoscopic botulinum toxin injection into the minor papilla for treatment of idiopathic recurrent pancreatitis in patients with pancreas divisum.
Pancreatitis
Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction.
Pancreatitis, Chronic
Percutaneous celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis.
Panniculitis
Vasculitis with panniculitis following botulinum toxin A injection for cosmetic use.
Pantothenate Kinase-Associated Neurodegeneration
Botulinum toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome.
Pantothenate Kinase-Associated Neurodegeneration
Botulinum toxin injection to improve functional independence and to alleviate parenting stress in a child with advanced pantothenate kinase-associated neurodegeneration: A case report and literature review.
Pantothenate Kinase-Associated Neurodegeneration
Efficacy of botulinum toxin A treatment in a case of pantothenate kinase associated neurodegeneration (PKAN).
Pantothenate Kinase-Associated Neurodegeneration
[Hallervorden-Spatz disease and botulinum toxin]
Paralysis
"Masking" our emotions: Botulinum toxin, facial expression, and well-being in the age of COVID-19.
Paralysis
A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.
Paralysis
A capillary electrophoresis method to assay catalytic activity of botulinum neurotoxin serotypes: implications for substrate specificity.
Paralysis
A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity.
Paralysis
A Novel OnabotulinumtoxinA Treatment Technique to Obtain Predictable Outcomes in Eyebrow Position and Shape.
Paralysis
A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin.
Paralysis
A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Paralysis
A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.
Paralysis
A randomized trial of botulinum toxin vs lidocain pomade for chronic anal fissure.
Paralysis
A Rapid, Sensitive, and Portable Biosensor Assay for the Detection of Botulinum Neurotoxin Serotype A in Complex Food Matrices.
Paralysis
A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre.
Paralysis
A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning.
Paralysis
A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.
Paralysis
Abducens paralysis repaired with muscle transposition and intraoperative botulinum toxin.
Paralysis
Abnormal vocal cord movement treated with botulinum toxin in patients with asthma resistant to optimised management.
Paralysis
Abstract 28: effect of glabellar paralysis by botulinum toxin on ability to communicate emotion.
Paralysis
Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination.
Paralysis
Achilles tendon compositional and structural properties are altered after unloading by botox.
Paralysis
Actions of calcium and magnesium on the rate of onset of botulinum toxin paralysis of the rat diaphragm.
Paralysis
Activity-dependent vs. neurotrophic modulation of acetylcholine receptor expression: Evidence from rat soleus and extensor digitorum longus muscles confirms the exclusive role of activity.
Paralysis
Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study.
Paralysis
Adeno-associated virus transfer of a gene encoding SNAP-25 resistant to botulinum toxin A attenuates neuromuscular paralysis associated with botulism.
Paralysis
An assessment of the spread of the signal for terminal sprouting within and between muscles.
Paralysis
An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation.
Paralysis
An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire.
Paralysis
Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.
Paralysis
Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
Paralysis
Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations.
Paralysis
Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine.
Paralysis
Antimicrobial susceptibility of 260 Clostridium botulinum types A, B, Ba and Bf strains and a neurotoxigenic Clostridium baratii type F strain isolated from California infant botulism patients.
Paralysis
Architectural and biochemical adaptations in skeletal muscle and bone following rotator cuff injury in a rat model.
Paralysis
Augmented vertical recti transposition with intraoperative botulinum toxin for complete and chronic sixth nerve palsy.
Paralysis
Barbiturate ingestion in three adult captive tigers (Panthera tigris) and concomitant fatal botulism of one.
Paralysis
Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.
Paralysis
Bilateral inferior oblique palsies following botulinum toxin injections to the frontalis muscle.
Paralysis
Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin.
Paralysis
BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
Paralysis
Botox-induced muscle paralysis alters intracortical porosity and osteocyte lacunar density in skeletally mature rats.
Paralysis
Botulinum neurotoxin devoid of receptor binding domain translocates active protease.
Paralysis
Botulinum neurotoxin dose-dependently inhibits release of neurosecretory vesicle-vargeted luciferase from neuronal cells.
Paralysis
Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study.
Paralysis
Botulinum Neurotoxin Type A as an Adjuvant to Reduce Scarring After Dermatological Surgery.
Paralysis
Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages.
Paralysis
Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.
Paralysis
Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Paralysis
Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission.
Paralysis
Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).
Paralysis
Botulinum Toxin A as an Adjunct to Abdominal Wall Reconstruction for Incisional Hernia.
Paralysis
Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans.
Paralysis
Botulinum toxin A in the early treatment of sixth nerve palsy in type 2 diabetes.
Paralysis
Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.
Paralysis
Botulinum toxin A-induced paralysis of the lateral abdominal wall after damage-control laparotomy: A multi-institutional, prospective, randomized, placebo-controlled pilot study.
Paralysis
Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders.
Paralysis
Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.
Paralysis
Botulinum toxin augmentation as a sequential procedure for residual esotropia in traumatic sixth nerve palsy.
Paralysis
Botulinum toxin chemodenervation of the inferior oblique muscle for chronic and acute IV nerve palsies: results in 15 cases.
Paralysis
Botulinum Toxin for a Better Scar in Cleft Lip Surgery: A Prospective Randomized Control Trial.
Paralysis
Botulinum toxin for relief of bilateral abductor paralysis of the larynx: histologic study in an animal model.
Paralysis
Botulinum toxin for the treatment of motor imbalance in obstetrical brachial plexus palsy.
Paralysis
Botulinum toxin in management of synkinesis in patients with unilateral and bilateral vocal fold paralysis.
Paralysis
Botulinum toxin in masticatory muscles: short- and long-term effects on muscle, bone, and craniofacial function in adult rabbits.
Paralysis
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Paralysis
Botulinum Toxin in the Surgical Treatment of Complex Abdominal Hernias: A Surgical Anatomy Approach, Current Evidence and Outcomes.
Paralysis
Botulinum Toxin Induces Muscle Paralysis and Inhibits Bone Regeneration in Zebrafish.
Paralysis
Botulinum Toxin Injection for Internal Rotation Contractures in Brachial Plexus Birth Palsy. A Minimum 5-Year Prospective Observational Study.
Paralysis
Botulinum Toxin Injection for Treatment of Acute Traumatic Superior Oblique Muscle Palsy.
Paralysis
Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report.
Paralysis
Botulinum toxin injection of the inferior oblique muscle for the treatment of superior oblique muscle palsy.
Paralysis
Botulinum toxin injection with and without electromyographic assistance for treatment of abducens nerve palsy: a pilot study.
Paralysis
Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers.
Paralysis
Botulinum toxin paralysis of the orbicularis oculi muscle. Types and time course of alterations in muscle structure, physiology and lid kinematics.
Paralysis
Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction.
Paralysis
Botulinum Toxin Therapy versus Anterior Belly of Digastric Transfer in the Management of Marginal Mandibular Branch of the Facial Nerve Palsy: A Patient Satisfaction Survey.
Paralysis
Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation.
Paralysis
Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases.
Paralysis
Botulinum toxin treatment of the sixth nerve palsy: an experience of 5-year duration in Thailand.
Paralysis
Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis.
Paralysis
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Paralysis
Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells.
Paralysis
Botulinum toxin type A: kinetics of calcium dependent paralysis of the neuromuscular junction and antagonism by drugs and animal toxins.
Paralysis
Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
Paralysis
Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy.
Paralysis
Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: A review.
Paralysis
Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design.
Paralysis
Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.
Paralysis
Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Paralysis
Capillary electrophoresis laser-induced fluorescence for screening combinatorial peptide libraries in assays of botulinum neurotoxin A.
Paralysis
Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle Paralysis from Botulinum Toxin Injection.
Paralysis
Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
Paralysis
Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.
Paralysis
Co-expression Network Approach to Studying the Effects of Botulinum Neurotoxin-A.
Paralysis
Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.
Paralysis
Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
Paralysis
Comparison between the effects of botulinum toxin-induced paralysis and denervation on molecular forms of acetylcholinesterase in muscles.
Paralysis
Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.
Paralysis
Comparison of effects of denervation and botulinum toxin paralysis on muscle properties in mice.
Paralysis
Complications of botulinum toxin application: differences between hemifacial spasm and post-facial palsy synkinesis.
Paralysis
Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis.
Paralysis
Constraint-induced movement therapy promotes motor recovery after neonatal stroke in the absence of neural precursor activation.
Paralysis
Contralateral botulinum injections improve drinking ability and facial symmetry in patients with facial paralysis.
Paralysis
Contralateral Botulinum Toxin Improved Functional Recovery after Tibial Nerve Repair in Rats.
Paralysis
Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a.
Paralysis
Correction of Malocclusion by Botulinum Neurotoxin Injection into Masticatory Muscles.
Paralysis
Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.
Paralysis
Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.
Paralysis
Cricothyroid Muscle Botulinum Toxin Injection to Improve Airway for Bilateral Recurrent Laryngeal Nerve Paralysis, A Case Series.
Paralysis
Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism.
Paralysis
Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action.
Paralysis
Detection of Clostridium botulinum toxin by local paralysis elicited with intramuscular challenge.
Paralysis
Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.
Paralysis
Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Paralysis
Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Paralysis
Development and preclinical evaluation of a new F(ab')? antitoxin against botulinum neurotoxin serotype A.
Paralysis
Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type A endopeptidase kinetics using SNAPtide.
Paralysis
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
Paralysis
Diagnosis and management with botulinum toxin in 11 cases of laryngeal synkinesis.
Paralysis
Dissociated effects of botulinum toxin chemodenervation on ocular deviation and saccade dynamics in chronic lateral rectus palsy.
Paralysis
Disuse and orchidectomy have additional effects on bone loss in the aged male rat.
Paralysis
DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice.
Paralysis
Docking Simulation and Sandwich Assay for Aptamer-Based Botulinum Neurotoxin Type C Detection.
Paralysis
Dramatic Changes in Muscle Contractile and Structural Properties After Two Botulinum Toxin Injections.
Paralysis
Early molecular response and microanatomical changes in the masseter muscle and mandibular head after botulinum toxin intervention in adult mice.
Paralysis
Edwards P, Sakzewski L, Copeland L, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics. 136(5):895-904.
Paralysis
Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
Paralysis
Effect of botulinum toxin A-induced paralysis and exercise training on mechanosensing and signalling gene expression in juvenile rat gastrocnemius muscle.
Paralysis
Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy.
Paralysis
Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis.
Paralysis
Effect of whole-body vibration and insulin-like growth factor-I on muscle paralysis-induced bone degeneration after botulinum toxin injection in mice.
Paralysis
Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: alterations of the discharge pattern.
Paralysis
Effects of botulinum toxin induced muscle paralysis on endocytosis and lysosomal enzyme activities in mouse skeletal muscle.
Paralysis
Effects of Botulinum Toxin on Reducing the Co-contraction of Antagonists in Birth Brachial Plexus Palsy.
Paralysis
Effects of botulinum toxin on synapse formation and acetylcholine sensitivity in skeletal muscle in the newt.
Paralysis
Effects of botulinum toxin-induced paralysis on postnatal development of the supraspinatus muscle.
Paralysis
Effects of denervation and botulinum toxin on muscle sensitivity to acetylcholine and acceptance of foreign innervation in the frog.
Paralysis
Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
Paralysis
Effects of selective paralysis of the supraspinatus muscle using botulinum neurotoxin a in rotator cuff healing in rats.
Paralysis
Effects of treadmill running on rat gastrocnemius function following botulinum toxin A injection.
Paralysis
Electromyography-Guided Botulinum Toxin Injection Into the Cricothyroid Muscles in Bilateral Vocal Fold Abductor Paralysis.
Paralysis
Elimination of superfluous neuromuscular junctions in rat calf muscles recovering from botulinum toxin-induced paralysis.
Paralysis
Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research.
Paralysis
Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy.
Paralysis
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus.
Paralysis
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Paralysis
Exploring strategies to prevent post-lobectomy space: transient diaphragmatic paralysis using Botulinum toxin type A (BTX-A).
Paralysis
Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin.
Paralysis
External Rotation Predicts Outcomes After Closed Glenohumeral Joint Reduction With Botulinum Toxin Type A in Brachial Plexus Birth Palsy.
Paralysis
Frequency and length-dependent effects of Botulinum toxin-induced muscle weakness.
Paralysis
Function of skeletal muscle tissue formed after myoblast transplantation into irradiated mouse muscles.
Paralysis
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
Paralysis
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.
Paralysis
Historical approaches to the treatment of Adductor-Type Spasmodic Dysphonia (ADSD): review and tutorial.
Paralysis
Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin.
Paralysis
Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.
Paralysis
Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).
Paralysis
Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions.
Paralysis
Image-guided botulinum toxin injection in the lateral abdominal wall prior to abdominal wall reconstruction surgery: review of techniques and results.
Paralysis
In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.
Paralysis
Increased electrotonic coupling in spinal motoneurons after transient botulinum neurotoxin paralysis in the neonatal rat.
Paralysis
Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
Paralysis
Interstitial fluid velocity is decreased around cortical bone vascular pores and depends on osteocyte position in a rat model of disuse osteoporosis.
Paralysis
Intramuscular Botulinum toxin A injections induce central changes to axon initial segments and cholinergic boutons on spinal motoneurones in rats.
Paralysis
Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.
Paralysis
Laparoscopic repair of complex ventral hernia facilitated by pre-operative chemical component relaxation using Botulinum Toxin A.
Paralysis
Long-term changes in myosin heavy chain composition after botulinum toxin a injection into rat medial rectus muscle.
Paralysis
Long-Term Changes in the Treatment Pattern of Botulinum Toxin A Injections for Postfacial Paralysis Synkinesis Following Modified Selective Neurectomy.
Paralysis
Long-Term Quantitative Evaluation of Muscle and Bone Wasting Induced by Botulinum Toxin in Mice Using Microcomputed Tomography.
Paralysis
Long-term results of vertical rectus muscle transposition and botulinum toxin for sixth nerve palsy.
Paralysis
Loss of Bone Strength is Dependent on Skeletal Site in Disuse Osteoporosis in Rats.
Paralysis
Low level mechanical stimulation is sufficient to improve tendon healing in rats.
Paralysis
Mandibular Bone Loss after Masticatory Muscles Intervention with Botulinum Toxin: An Approach from Basic Research to Clinical Findings.
Paralysis
Masseter muscle atrophy impairs bone quality of the mandibular condyle but not the alveolar process early after induction.
Paralysis
Mastoparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model.
Paralysis
Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin.
Paralysis
Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.
Paralysis
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
Paralysis
Multiple types of calcium channels mediate transmitter release during functional recovery of botulinum toxin type A-poisoned mouse motor nerve terminals.
Paralysis
Muscle Paralysis Induces Bone Marrow Inflammation and Predisposition to Formation of Giant Osteoclasts.
Paralysis
Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
Paralysis
Myectomy and botulinum toxin for paralysis of the marginal mandibular branch of the facial nerve: a series of 76 cases.
Paralysis
Nerve dependent regulation of neural cell adhesion molecule expression in skeletal muscle.
Paralysis
Nerve sprouting in muscle is induced and guided by processes extended by Schwann cells.
Paralysis
Neural regulation of muscle acetylcholinesterase is exerted on the level of its mRNA.
Paralysis
Neurological aspects of biological and chemical terrorism: a review for neurologists.
Paralysis
Neuromuscular dysfunction, independent of gait dysfunction, modulates trabecular bone homeostasis in mice.
Paralysis
Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Paralysis
Neuromuscular transmission and muscle contractility in SNAP-25-deficient coloboma mice.
Paralysis
Nishida procedure associated with botulinum toxin in a long-standing complete bilateral sixth cranial nerve palsy.
Paralysis
Nodal and terminal sprouting from motor nerves in fast and slow muscles of the mouse.
Paralysis
None detectable retrograde transport of Chinese botulinum toxin type A in mice by single intramuscular injection.
Paralysis
Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling.
Paralysis
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Paralysis
Objective tinnitus from palatal myoclonus. Use of botulinum toxin: a case report.
Paralysis
Ocular Neuromyotonia Noted after Recent Botulinum Toxin Injection for Sixth Nerve Palsy Following Resection of a Posterior Fossa Skull Base Meningioma.
Paralysis
Office-based Electromyography-guided Botulinum Toxin Injection to the Cricopharyngeus Muscle: Optimal Patient Selection and Technique.
Paralysis
On the possible origin of giant or slow-rising miniature end-plate potentials at the neuromuscular junction.
Paralysis
Onabotulinum toxinA injection as an adjunct in the treatment of posterior shoulder subluxation in neonatal brachial plexus palsy.
Paralysis
Osteopenic consequences of botulinum toxin injections in the masticatory muscles: a pilot study.
Paralysis
Outcomes of Chemical Component Paralysis Using Botulinum Toxin for Incisional Hernia Repairs.
Paralysis
Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye.
Paralysis
Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Paralysis
Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Paralysis
Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party.
Paralysis
Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine.
Paralysis
Preoperative abdominal muscle elongation with botulinum toxin A for complex incisional ventral hernia repair.
Paralysis
Preoperative chemical component relaxation using Botulinum toxin A: enabling laparoscopic repair of complex ventral hernia.
Paralysis
Preoperative progressive pneumoperitoneum complementing chemical component relaxation in complex ventral hernia repair.
Paralysis
Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery.
Paralysis
Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain.
Paralysis
Prolonged paralysis, caused by the local injection of botulinum toxin, fails to cause motor nerve terminal sprouting in skeletal muscle of the frog.
Paralysis
Properties and use of botulinum toxin and other microbial neurotoxins in medicine.
Paralysis
Quantifying how location and dose of botulinum toxin injections affect muscle paralysis.
Paralysis
Rapidly Progressive Muscle Paralysis and Acute Respiratory Failure Following Endoscopic Botulinum Toxin Injection.
Paralysis
Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A.
Paralysis
Regional Diffusion of Botulinum Toxin in Facial Muscles: A Rando-mised Double-blind Study and a Consideration for Clinical Studies with Split-face Design.
Paralysis
Regulation of motoneuronal calcitonin gene-related peptide (CGRP) during axonal growth and neuromuscular synaptic plasticity induced by botulinum toxin in rats.
Paralysis
Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues.
Paralysis
Restriction of Postoperative Joint Loading in a Murine Model of Anterior Cruciate Ligament Reconstruction: Botulinum Toxin Paralysis and External Fixation.
Paralysis
Results of a prospective randomized trial of botulinum toxin therapy in acute unilateral sixth nerve palsy.
Paralysis
Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning.
Paralysis
Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice.
Paralysis
Reversible blockade of rodent whisking: Botulinum toxin as a tool for developmental studies.
Paralysis
Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
Paralysis
Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers.
Paralysis
Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis.
Paralysis
Safety of Ultrasound-Guided Botulinum Toxin Injections for Sialorrhea as Performed by Pediatric Otolaryngologists.
Paralysis
Selective muscle botulinum toxin A component paralysis in complex ventral hernia repair.
Paralysis
Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.
Paralysis
Short-term safety of preoperative administration of botulinum toxin A for the treatment of large ventral hernia with loss of domain.
Paralysis
Stimulation of nodal and terminal sprouting of mouse motor nerves by gangliosides.
Paralysis
Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
Paralysis
Study of crotoxin on the induction of paralysis in extraocular muscle in animal model.
Paralysis
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
Paralysis
Subtenon injection of botulinum toxin for treatment of traumatic sixth nerve palsy.
Paralysis
Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
Paralysis
Tetanus and botulinum toxins block the release of acetylcholine from slices of rat striatum and from the isolated electric organ of Torpedo at different concentrations.
Paralysis
The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine.
Paralysis
The effects of black widow spider venom on the innervation of muscles paralysed by botulinum toxin.
Paralysis
The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars.
Paralysis
The efficacy of botulinum neurotoxin A for the treatment of complete and partially recovered chronic sixth nerve palsy.
Paralysis
The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption.
Paralysis
The influence of adaptation on visual motion detection in chronic sixth nerve palsy after treatment with botulinum toxin.
Paralysis
The interaction between divalent cations and botulinum toxin type A in the paralysis of the rat phrenic nerve-hemidiaphragm preparation.
Paralysis
The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin.
Paralysis
The plasticity of the corticospinal tract in children with obstetric brachial plexus palsy after Botulinum Toxin A treatment.
Paralysis
The Potential Role of Botulinum Toxin in Improving Superficial Cutaneous Scarring: A Review.
Paralysis
The Role of Botulinum Toxin A in the Establishment of Symmetry in Pediatric Paralysis of the Lower Lip.
Paralysis
The role of botulinum toxin in the management of airway compromise due to bilateral vocal fold paralysis.
Paralysis
The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy.
Paralysis
The role of the paravertebral muscles in adolescent idiopathic scoliosis evaluated by temporary paralysis.
Paralysis
The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.
Paralysis
The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
Paralysis
The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.
Paralysis
The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.
Paralysis
Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction.
Paralysis
Time course for the reappearance of vibrissal motor representation following botulinum toxin injection into the vibrissal pad of the adult rat.
Paralysis
Transient muscle paralysis disrupts bone homeostasis by rapid degradation of bone morphology.
Paralysis
Transposition of Both Oblique Muscles Combined With Lateral Rectus Botulinum Toxin Injection and Globe Fixation Suture in the Treatment of Congenital Cranial Nerve III Palsy.
Paralysis
Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy.
Paralysis
Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates.
Paralysis
Treatment of sixth nerve palsy in adults with combined botulinum toxin chemodenervation and surgery.
Paralysis
Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications.
Paralysis
Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E.
Paralysis
Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells.
Paralysis
Types and time course of the alterations induced in monkey blink movements by botulinum toxin.
Paralysis
Unaugmented vertical muscle transposition surgery for chronic sixth nerve paralysis.
Paralysis
UNILATERAL FRONTALIS MUSCLE PARALYSIS: MANAGEMENT WITH BOTULINUM TOXIN A (CASE REPORTS).
Paralysis
Unmasking, after cholinergic paralysis by botulinum toxin, of a reversed action of nicotine on the mammalian intestine, revealing the probable presence of local inhibitory ganglion cells in the enteric plexuses.
Paralysis
Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial.
Paralysis
Use of botulinum toxin to lateralize true vocal cords: a biochemical method to relieve bilateral abductor vocal cord paralysis.
Paralysis
Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy.
Paralysis
Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study.
Paralysis
Using Botulinum Toxin A as an Adjunct in the Surgery of Large-Angle Sensory Exotropia and Abducens Nerve Palsy.
Paralysis
Utility of ultrasound-guided injection of botulinum toxin type A for muscle imbalance in children with obstetric brachial plexus palsy: Description of the procedure and action protocol.
Paralysis
Utilizing Ayurvedic literature for the identification of novel phytochemical inhibitors of botulinum neurotoxin A.
Paralysis
Vertical rectus muscle transposition and botulinum toxin for complete sixth nerve palsy.
Paralysis
Vertical rectus muscle transposition with intraoperative botulinum injection for treatment of chronic sixth nerve palsy.
Paralysis
[Action of serotonin on neuromuscular transmission in normal guinea pigs and those treated with paralyzing doses of botulinum toxin type A]
Paralysis
[Adverse events of botulinum toxin A in facial injection: Mechanism, prevention and treatment].
Paralysis
[Botulinum toxin injection effective for post-peripheral facial nerve palsy synkinesis]
Paralysis
[Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?]
Paralysis
[Botulinum toxin type A-induced "rebalancing" in bilateral vocal cord paralysis?]
Paralysis
[Mechanism of action, clinical indication and results of treatment of botulinum toxin]
Paralysis
[Morphological and histochemical reactions of an organism to the administration of Clostridium botulinum toxin. IX. Reactions of the neurons of the abducens nerve nucleus and of the Darkshevich's nucleus to the administration of C. botulinum type B toxin]
Paralysis
[New applications in maxillofacial surgery: Local injections with botulinum toxin type A].
Paralysis
[New techniques in maxillofacial surgery: local injection treatment with botulinum toxin A]
Paralysis
[Paralysis of the anterior tibial muscle of the rat by the central action of botulinum toxin]
Paralysis
[Recent advances in the molecular mechanism of action of bacterial toxins, in particular of diphtheria, cholera, coli, botulinum and shigella toxins as well as tetanospasmin and the toxins of staphylococcus aureus]
Paralysis
[The results of single-event multilevel orthopedic surgeries and the early rehabilitation used in complex with botulinum toxin treatment in patients with spastic forms of cerebral palsy].
Paralysis
[Tratamiento conservador de la osteoartrosis de cadera con toxina botulínica tipo A].
Paralysis
[Treatment of sixth nerve palsy of traumatic or tumor etiology using botulinum toxin]
Paraparesis
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]
Paraparesis, Spastic
Botulinum toxin injection in patients with hereditary spastic paraparesis.
Paraparesis, Spastic
Botulinum Toxin Injections for Pediatric Patients With Hereditary Spastic Paraparesis.
Paraparesis, Spastic
Botulinum toxin type-A treatment in spastic paraparesis: a neurophysiological study.
Paraparesis, Spastic
Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Paraparesis, Spastic
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities.
Paraparesis, Spastic
[The application of botulinum toxin type A in the treatment of spastic paraparesis]
Paraparesis, Spastic
[Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long-term treatment]
Paraplegia
Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.
Paraplegia
OnabotulinumtoxinA injections in detrusor facilitate self-catheterisation in a patient with paraplegia and bladder outlet dyssynergia.
Paraplegia
[Botulinum neurotoxin type A in neurogenic detrusor overactivity : Consensus paper of the Working Group Neuro-Urology of the DMGP].
Paresis
Association between botulinum toxin injection into the arm and changes in gait in adults after stroke.
Paresis
BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild-type in murine running wheel assay.
Paresis
Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey.
Paresis
Botulinum toxin A modifies nociceptive withdrawal reflex in subacute stroke patients.
Paresis
Botulinum toxin a, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study.
Paresis
Botulinum toxin for temporary corneal protection after surgery for vestibular schwannoma.
Paresis
Botulinum toxin injection of the inferior oblique muscle for the treatment of superior oblique muscle palsy.
Paresis
Botulinum Toxin Injections and Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke.
Paresis
Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.
Paresis
Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis.
Paresis
Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke.
Paresis
Botulinum toxin type A versus phenol. A clinical and neurophysiological study in the treatment of ankle clonus.
Paresis
Changes in electromyographic activity after botulinum toxin injection of the rectus femoris in patients with hemiparesis walking with a stiff-knee gait.
Paresis
Chemical denervation with botulinum neurotoxin a improves the surgical manipulation of the muscle-tendon unit: an experimental study in an animal model.
Paresis
Combination therapy with repetitive facilitative exercise program and botulinum toxin type A to improve motor function for the upper-limb spastic paresis in chronic stroke: A randomized controlled trial.
Paresis
Combined Effects of Isokinetic Training and Botulinum Toxin Type A on Spastic Equinus Foot in Patients with Chronic Stroke: A Pilot, Single-blind, Randomized Controlled Trial.
Paresis
Combined therapeutic application of botulinum toxin type A, low-frequency rTMS, and intensive occupational therapy for post-stroke spastic upper limb hemiparesis.
Paresis
Comparative Effectiveness of Injection Therapies in Lateral Epicondylitis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Paresis
Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.
Paresis
Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.
Paresis
Comprehensive evaluation of gait, spasticity, and muscle morphology: A case report of a child with spastic paresis treated with Botulinum NeuroToxin-A, serial casting, and physiotherapy.
Paresis
Cyclic functional electrical stimulation does not enhance gains in hand grasp function when used as an adjunct to onabotulinumtoxinA and task practice therapy: a single-blind, randomized controlled pilot study.
Paresis
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies.
Paresis
Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy.
Paresis
Effect of botulinum toxin injection on length and force of the rectus femoris and triceps surae muscles during locomotion in patients with chronic hemiparesis (FOLOTOX).
Paresis
Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients.
Paresis
Effect of rehabilitation and botulinum toxin injection on gait in chronic stroke patients: a randomized controlled study.
Paresis
Effect of repetitive arm cycling following botulinum toxin injection for poststroke spasticity: evidence from FMRI.
Paresis
Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): protocol study for a randomised controlled, investigator blinded study.
Paresis
Effects on craniofacial growth and development of unilateral botulinum neurotoxin injection into the masseter muscle.
Paresis
Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis.
Paresis
Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
Paresis
Efficacy and safety of abobotulinumtoxinA for the treatment of hemiparesis in adults with lower limb spasticity previously treated with botulinum toxin: A secondary analysis of a randomized controlled trial.
Paresis
Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
Paresis
Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity.
Paresis
Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.
Paresis
Exploratory Randomized Double-Blind Placebo-Controlled Trial of Botulinum Therapy on Grasp Release After Stroke (PrOMBiS).
Paresis
From hemiparesis to finishing a marathon: a case of stiff-knee gait treated with injections of high-dose botulinum toxin into the four heads of the quadriceps.
Paresis
Functional electrical stimulation combined with botulinum toxin type A to improve hand function in children with spastic hemiparesis - a pilot study.
Paresis
Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.
Paresis
Guided Self-rehabilitation Contracts Combined With AbobotulinumtoxinA in Adults With Spastic Paresis.
Paresis
Hemiparetic gait and changes in functional performance due to OnabotulinumtoxinA injection to lower limb muscles.
Paresis
How effective is physical therapy for gait muscle activity in hemiparetic patients who receive botulinum toxin injections?
Paresis
How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Paresis
In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
Paresis
Isokinetic assessment of the effects of botulinum toxin injection on spasticity and voluntary strength in patients with spastic hemiparesis.
Paresis
Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.
Paresis
Local muscle injection of botulinum toxin type a synergistically improves the beneficial effects of repetitive transcranial magnetic stimulation and intensive occupational therapy in post-stroke patients with spastic upper limb hemiparesis.
Paresis
Long-term effects of injection of botulinum toxin type A combined with home-based functional training for post-stroke patients with spastic upper limb hemiparesis.
Paresis
Lower Limb Coordination in Hemiparetic Subjects: Impact of Botulinum Toxin Injections Into Rectus Femoris.
Paresis
Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.
Paresis
Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm.
Paresis
Neurotomy of the rectus femoris nerve: Short-term effectiveness for spastic stiff knee gait: Clinical assessment and quantitative gait analysis.
Paresis
Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B.
Paresis
Poster 308 Improvement of Spasticity, Active Movements and Active Function after Repeated Injections of AbobotulinumtoxinA (Dysport) in Adults with Spastic Paresis in the Upper Limb: Results of a Phase III Open-Label Extension Study.
Paresis
Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies.
Paresis
Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patients on Anticoagulation or Antiplatelet Therapy.
Paresis
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Paresis
Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study.
Paresis
Spinal arteriovenous malformation presenting as spastic monoplegic cerebral palsy in a child.
Paresis
The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury.
Paresis
The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial.
Paresis
The effects of botulinum neurotoxin A induced muscle paresis during a critical period upon muscle and spinal cord development in the rat.
Paresis
The influence of masticatory hypofunction on developing rat craniofacial structure.
Paresis
The surgical innervational effect: utilizing it to treat monocular elevation deficiency strabismus.
Paresis
Therapeutic Synergism in the Treatment of Post-stroke Arm Paresis Utilizing Botulinum Toxin, Robotic Therapy, and Constraint-induced Movement Therapy.
Paresis
Transient superior oblique paresis after injection of Botulinum Toxin A for facial rejuvenation.
Paresis
Treatment of hemifacial spasm with botulinum toxin. Value of preinjection electromyography abnormalities for predicting postinjection lower facial paresis.
Paresis
Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.
Paresis
When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?
Paresis
X-ray microanalysis of elements in the masticatory muscle after paresis of the right masseter.
Paresis
[Botulinum toxin treatment of neurogenic dislocation of the temporomandibular joint]
Paresis
[Botulinum toxin type A in the treatment of neurogenic dislocation of the temporomandibular joint].
Paresis
[Diplopia following subcutaneous injections of botulinum toxin for cosmetic or medical use].
Paresis
[Effect of cricothyroid and thyroarytenoid muscle botulinum toxin injection on patients with dyspnea caused by bilateral recurrent laryngeal nerve paresis].
Paresis
[The features of botulinum therapy for different patterns of poststroke spasticity].
Paresthesia
Botulinum toxin type A for the treatment of nummular headache: four case studies.
Paresthesia
Not only gustatory sweating and flushing: Signs and symptoms associated to the Frey syndrome and the role of botulinum toxin A therapy.
Paresthesia
[Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group]
Parkinson Disease
"Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
Parkinson Disease
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Parkinson Disease
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Parkinson Disease
Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease.
Parkinson Disease
Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Parkinson Disease
Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.
Parkinson Disease
Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson's disease model.
Parkinson Disease
Botulinum neurotoxin type a subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.
Parkinson Disease
Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson's Disease Models.
Parkinson Disease
Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Parkinson Disease
Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.
Parkinson Disease
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Parkinson Disease
Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease.
Parkinson Disease
Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Parkinson Disease
Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Parkinson Disease
Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
Parkinson Disease
Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: A case series and a pilot study.
Parkinson Disease
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study.
Parkinson Disease
Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach.
Parkinson Disease
Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
Parkinson Disease
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Parkinson Disease
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Parkinson Disease
Botulinum toxin injections do not improve freezing of gait in Parkinson disease.
Parkinson Disease
Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease.
Parkinson Disease
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Parkinson Disease
Botulinum toxin treatment of freezing of gait in Parkinson's disease patients as reflected in functional magnetic resonance imaging of leg movement.
Parkinson Disease
Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Parkinson Disease
Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.
Parkinson Disease
Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
Parkinson Disease
Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Parkinson Disease
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio.
Parkinson Disease
Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients.
Parkinson Disease
Botulinum toxin type a in patients with Parkinson's disease and refractory overactive bladder.
Parkinson Disease
Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease.
Parkinson Disease
Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study.
Parkinson Disease
Changes in Cortical Excitability and Parkinson Tremor After Botulinum Toxin Therapy.
Parkinson Disease
Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.
Parkinson Disease
Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.
Parkinson Disease
Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
Parkinson Disease
Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson's disease patients?
Parkinson Disease
Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns.
Parkinson Disease
Effectiveness of BoNT A in Parkinson's Disease Upper Limb Tremor Management.
Parkinson Disease
Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review.
Parkinson Disease
Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson's disease and depression.
Parkinson Disease
Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats.
Parkinson Disease
Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia.
Parkinson Disease
Effects of Repeated Botulinum Toxin Treatment for Sialorrhea in Patients with Parkinson's Disease.
Parkinson Disease
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Parkinson Disease
Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A.
Parkinson Disease
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Parkinson Disease
Intrastriatal administration of botulinum neurotoxin A normalizes striatal D2 R binding and reduces striatal D1 R binding in male hemiparkinsonian rats.
Parkinson Disease
Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.
Parkinson Disease
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Parkinson Disease
Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
Parkinson Disease
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Parkinson Disease
OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease.
Parkinson Disease
Outcome on Balance and Gait Following Botulinum Toxin Treatment for Striatal Foot in Parkinson's Disease.
Parkinson Disease
Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment.
Parkinson Disease
Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.
Parkinson Disease
Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
Parkinson Disease
Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease.
Parkinson Disease
Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin.
Parkinson Disease
Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Parkinson Disease
Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
Parkinson Disease
Severe Jaw-Opening Dystonia as an Unusual Manifestation of Levodopa-Related Wearing-Off in Parkinson's Disease, and Successful Treatment With Botulinum Toxin Injection.
Parkinson Disease
Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
Parkinson Disease
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Parkinson Disease
Tablet-based patient educational interventions in care and management of complex movement disorders.
Parkinson Disease
The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study.
Parkinson Disease
The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.
Parkinson Disease
The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.
Parkinson Disease
Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.
Parkinson Disease
Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case Series.
Parkinson Disease
Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.
Parkinson Disease
Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: Efficacy and possible mechanisms.
Parkinson Disease
Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence.
Parkinson Disease
Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease.
Parkinson Disease
Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal.
Parkinson Disease
Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Parkinsonian Disorders
Advances in the diagnosis, treatment, and understanding of Parkinson's disease and parkinsonism.
Parkinsonian Disorders
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Parkinsonian Disorders
Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease.
Parkinsonian Disorders
Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia.
Parkinsonian Disorders
Botulinum toxin treatment of lateral axial dystonia in parkinsonism.
Parkinsonian Disorders
Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Parkinsonian Disorders
Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea.
Parkinsonian Disorders
Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism.
Parkinsonian Disorders
Development of parkinsonism after long-standing cervical dystonia - A cohort.
Parkinsonian Disorders
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
Parkinsonian Disorders
Severe cervical dystonia in pathologically proven Parkinson's disease and dementia.
Parkinsonian Disorders
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Parkinsonian Disorders
The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study.
Parkinsonian Disorders
The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders.
Parkinsonian Disorders
Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin.
Parotitis
Botulinum toxin for chronic parotid sialadenitis: A case series and systematic review.
Parotitis
Botulinum Toxin for the Management of Sjögren Syndrome-Associated Recurrent Parotitis.
Parotitis
Botulinum Toxin Injection for Chronic Parotitis: A Multi-Center and Prospective Trial.
Parotitis
Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjögren syndrome.
Parotitis
Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders.
Parotitis
Positive Effects of Local Botulinum Toxin Injection and Colchicine for Complicated Chronic Recurrent Parotitis: A Case Report.
Patellofemoral Pain Syndrome
Anterior knee pain caused by patellofemoral pain syndrome can be relieved by Botulinum toxin type A injection.
Patellofemoral Pain Syndrome
Botulinum toxin type A for nonsurgical lateral release in patellofemoral pain syndrome: a case study.
Pelvic Floor Disorders
Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
Pelvic Floor Disorders
Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders (Br J Surg 2002; 89: 950-61).
Pelvic Floor Disorders
Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders.
Pelvic Floor Disorders
Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders.
Pelvic Floor Disorders
Botulinum toxin: new option for refractory lower urinary tract symptoms in women.
Pelvic Floor Disorders
Future Directions of Research and Care for Urinary Incontinence: Findings from the National Institute of Diabetes and Digestive and Kidney Diseases Summit on Urinary Incontinence Clinical Research in Women.
Pelvic Floor Disorders
Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.
Pemphigus, Benign Familial
An enhanced transcutaneous delivery of botulinum toxin for the treatment of Hailey-Hailey disease.
Pemphigus, Benign Familial
Botulinum Toxin A for the Treatment of Familial Benign Pemphigus.
Pemphigus, Benign Familial
Botulinum toxin a for the treatment of familial benign pemphigus.
Pemphigus, Benign Familial
Botulinum toxin in treating Hailey-Hailey disease: A systematic review.
Pemphigus, Benign Familial
Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease.
Pemphigus, Benign Familial
Botulinum toxin type A as an effective adjuvant therapy for Hailey-Hailey disease.
Pemphigus, Benign Familial
Botulinum toxin type A for the first-line treatment of Hailey-Hailey disease.
Pemphigus, Benign Familial
Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease.
Pemphigus, Benign Familial
Recalcitrant Hailey-Hailey disease responds to oral tacrolimus and botulinum toxin type A.
Pemphigus, Benign Familial
Recalcitrant vulvar Hailey-Hailey disease treated with alitretinoin and onabotulinumtoxinA: A case report.
Pemphigus, Benign Familial
Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey-Hailey disease.
Pemphigus, Benign Familial
The efficacy of botulinum toxin type A in the treatment of Hailey-Hailey disease.
Penile Induration
Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in Peyronie's Disease.
Penile Induration
Re: Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in Peyronie's Disease.
Peripheral Nerve Injuries
Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers.
Peripheral Nerve Injuries
Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models.
Peripheral Nerve Injuries
Botulinum Toxin B Affects Neuropathic Pain but Not Functional Recovery after Peripheral Nerve Injury in a Mouse Model.
Peripheral Nerve Injuries
Botulinum toxin is effective in myoclonus secondary to peripheral nerve injury.
Peripheral Nerve Injuries
Neuromuscular dysfunction, independent of gait dysfunction, modulates trabecular bone homeostasis in mice.
Peripheral Nerve Injuries
Sustained remission of segmental myoclonus due to peripheral nerve injury after treatment with onabotulinumtoxinA.
Peripheral Nervous System Diseases
Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers.
Peripheral Nervous System Diseases
Botulinum toxin effects on gasatrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulceration.
Peripheral Nervous System Diseases
Botulinum toxin effects on gastrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulcerations.
Peripheral Nervous System Diseases
Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy.
Peripheral Nervous System Diseases
Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
Peripheral Nervous System Diseases
Systematic review of treatments for diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy.
Peritonitis
Antinociceptive effect of botulinum toxin type A on experimental abdominal pain.
Peroneal Neuropathies
Botulinum toxin A in the treatment of hemiplegic spastic foot drop--clinical and functional outcomes.
Peroneal Neuropathies
Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study.
Peroneal Neuropathies
Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop.
Persistent Vegetative State
Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state.
Phantom Limb
A Prospective Randomized Double-Blinded Pilot Study to Examine the Effect of Botulinum Toxin Type A Injection Versus Lidocaine/Depomedrol Injection on Residual and Phantom Limb Pain: Initial Report.
Phantom Limb
Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series.
Phantom Limb
[Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use?].
Phantom Limb
[Long-term treatment of phantom- and stump pain with Botulinum toxin type A over 12 months. A first clinical observation]
Pheochromocytoma
Comparison of the intracellular effects of clostridial neurotoxins on exocytosis from streptolysin O-permeabilized rat pheochromocytoma (PC 12) and bovine adrenal chromaffin cells.
Photophobia
Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients.
Photophobia
Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections.
Photophobia
Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway.
Piriformis Muscle Syndrome
An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome.
Piriformis Muscle Syndrome
BOTOX and physical therapy in the treatment of piriformis syndrome.
Piriformis Muscle Syndrome
Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study.
Piriformis Muscle Syndrome
Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective.
Piriformis Muscle Syndrome
Botulinum toxin type A use in piriformis muscle syndrome: a pilot study.
Piriformis Muscle Syndrome
Guidelines for botulinum neurotoxin injections in piriformis syndrome.
Piriformis Muscle Syndrome
Long-Term Efficacy of Ultrasound-Guided Injection of IncobotulinumtoxinA in Piriformis Syndrome.
Piriformis Muscle Syndrome
Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome.
Piriformis Muscle Syndrome
Piriformis syndrome: pain response outcomes following CT-guided injection and incremental value of botulinum toxin injection.
Piriformis Muscle Syndrome
Relapsing piriformis syndrome treated with botulinum toxin injections.
Piriformis Muscle Syndrome
Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature.
Piriformis Muscle Syndrome
Usefulness of Magnetic Resonance Neurography for Diagnosis of Piriformis Muscle Syndrome and Verification of the Effect After Botulinum Toxin Type A Injection: Two Cases.
Plagiocephaly, Nonsynostotic
Treatment of recalcitrant idiopathic muscular torticollis in infants with botulinum toxin type a.
Plague
Current therapy and the development of therapeutic options for the treatment of diseases due to bacterial agents of potential biowarfare and bioterrorism.
Plague
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Pneumonia, Aspiration
A pilot study of botulinum toxin injection for the treatment of delayed gastric emptying following esophagectomy.
Pneumonia, Aspiration
Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy.
Pneumonia, Aspiration
Safety of Ultrasound-Guided Botulinum Toxin Injections for Sialorrhea as Performed by Pediatric Otolaryngologists.
Pneumonia, Aspiration
Salivary botulinum toxin injection may reduce aspiration pneumonia in neurologically impaired children.
Pneumonia, Aspiration
Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
Pneumoperitoneum
Adjunct botox to preoperative progressive pneumoperitoneum for incisional hernia with loss of domain: no additional effect but may improve outcomes.
Pneumoperitoneum
Combination of botulinum toxin A, progressive pre-operative pneumoperitoneum for the repair of loss domain inguinal hernias.
Pneumoperitoneum
Combination of Preoperative Progressive Pneumoperitoneum and Botulinum Toxin A Enables the Laparoscopic Transabdominal Preperitoneal Approach for Repairing Giant Inguinoscrotal Hernias.
Pneumoperitoneum
Complex ventral hernia repair in a child: An association of botulinum toxin, progressive pneumoperitoneum and negative pressure therapy. A case report on an arising surgical technique.
Pneumoperitoneum
Fascial closure in giant ventral hernias after preoperative botulinum toxin a and progressive pneumoperitoneum: A systematic review and meta-analysis.
Pneumoperitoneum
Implementing preoperative Botulinum toxin A and progressive pneumoperitoneum through the use of an algorithm in giant ventral hernia repair.
Pneumoperitoneum
Minimally Invasive Multidisciplinary Approach to Chronic Giant Inguinoscrotal Hernias.
Pneumoperitoneum
Modified components separation technique: experience treating large, complex ventral hernias at a University Hospital.
Pneumoperitoneum
Preoperative Botulinum Toxin and Progressive Pneumoperitoneum Are Useful in the Treatment of Large Incisional Hernias.
Pneumoperitoneum
Preoperative Botulinum Toxin and Progressive Pneumoperitoneum in Loss of Domain Hernias-Our First 100 Cases.
Pneumoperitoneum
Preoperative combination of progressive pneumoperitoneum and botulinum toxin type A in patients with loss of domain hernia.
Pneumoperitoneum
Preoperative preparation of «loss of domain» hernia. Progressive pneumoperitoneum and botulinum toxin type A.
Pneumoperitoneum
Preoperative progressive pneumoperitoneum and botulinum toxin type A in patients with large incisional hernia.
Pneumoperitoneum
Preoperative Progressive Pneumoperitoneum and Botulinum Toxin Type A in Patients With Large Parastomal Hernia.
Pneumoperitoneum
Ventral hernia secondary to giant omphalocele in a child: combined approach of botulinum toxin and preoperative progressive pneumoperitoneum.
Pneumoperitoneum
[Pre- and intra-operative methods of increasing abdominal compliance in surgery of ventral hernias].
Pneumothorax
Pneumothorax complicating botulinum toxin injection in the body of a dilated oesophagus in achalasia.
Poliomyelitis
Contributions of the European OMCL Network and Biological Standardisation Programme to Animal Welfare.
Polyneuropathies
Bilateral analgesic effects of abobotulinumtoxinA (Dysport(®) ) following unilateral administration in the rat.
Polyneuropathies
The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial.
Polyneuropathies
The effects of intraplantar and intrathecal botulinum toxin type B on tactile allodynia in mono and polyneuropathy in the mouse.
Polyradiculoneuropathy
Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.
Polyradiculoneuropathy
Re: polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.
Polyradiculoneuropathy
[A case report of acute polyradiculoneuritis developing after multiple injections of botulinum toxin for cervical dystonia]
Popliteal Artery Entrapment Syndrome
Botulinum Toxin as a Treatment for Functional Popliteal Artery Entrapment Syndrome.
Popliteal Artery Entrapment Syndrome
Functional popliteal artery entrapment syndrome: use of ultrasound guided Botox injection as a non-surgical treatment option.
Popliteal Artery Entrapment Syndrome
The effects of Botulinum Toxin injection in an elite sportsman with Functional Popliteal Artery Entrapment Syndrome: A case report.
Post-Traumatic Headache
Botulinum toxin in the treatment of post-traumatic headache - case study.
Post-Traumatic Headache
Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study.
Post-Traumatic Headache
The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials.
Post-Traumatic Headache
The efficacy of botulinum toxin in patients with cervicogenic headache: a placebo-controlled clinical trial.
Post-Traumatic Headache
Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria.
Postpoliomyelitis Syndrome
Preliminary experience with dexmedetomidine for monitored anesthesia care during ENT surgical procedures.
Pressure Ulcer
Botulinum toxin B suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model: Possible regulation of oxidative and endoplasmic reticulum stress.
Pressure Ulcer
Botulinum toxin treatment for difficult-to-treat finger pressure ulcers caused by severe hand flexion: case report.
Pressure Ulcer
Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.
Pressure Ulcer
Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress.
Pressure Ulcer
[French Association of Urology. COVID-19: Recommendations for functional urology].
Priapism
[Prophylaxis of recurring low-flow priapism : Experimental botulinum neurotoxin injection into the ischiocavernosus muscle].
Primary Dysautonomias
Does botulinum toxin alter laryngeal secretions and mucociliary transport?
Primary Dysautonomias
Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literature.
Primary Dysautonomias
Long lasting dysautonomia due to botulinum toxin B poisoning: clinical-laboratory follow up and difficulties in initial diagnosis.
Prion Diseases
The role of activity in synaptic degeneration in a protein misfolding disease, prion disease.
Prostatic Diseases
Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.
Prostatic Hyperplasia
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of OnabotulinumtoxinA 200 U to Treat Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.
Prostatic Hyperplasia
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Prostatic Hyperplasia
Botulinum toxin a in prostate disease: a venom from bench to bed-side.
Prostatic Hyperplasia
Botulinum Toxin A Injection in the Bladder Neck: A Promising Treatment for Urinary Retention.
Prostatic Hyperplasia
Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Prostatic Hyperplasia
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review).
Prostatic Hyperplasia
Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
Prostatic Hyperplasia
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Prostatic Hyperplasia
Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates.
Prostatic Hyperplasia
Botulinum Toxin Type A Inhibits the Growth of LNCaP Human Prostate Cancer Cells In Vitro and In Vivo.
Prostatic Hyperplasia
Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
Prostatic Hyperplasia
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Prostatic Hyperplasia
Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin - A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case-Control Study.
Prostatic Hyperplasia
Effects of Purified Newly Developed Botulinum Neurotoxin Type A in Rat Prostate.
Prostatic Hyperplasia
Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.
Prostatic Hyperplasia
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
Prostatic Hyperplasia
Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Prostatic Hyperplasia
Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia.
Prostatic Hyperplasia
Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Prostatic Hyperplasia
Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia:preliminary results with a newly purified neurotoxin.
Prostatic Hyperplasia
Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Prostatic Hyperplasia
Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
Prostatic Hyperplasia
Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport.
Prostatic Hyperplasia
Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat.
Prostatic Hyperplasia
Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Prostatic Hyperplasia
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.
Prostatic Hyperplasia
Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
Prostatic Hyperplasia
Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Prostatic Hyperplasia
Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Prostatic Hyperplasia
Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
Prostatic Hyperplasia
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Prostatic Hyperplasia
Therapeutic modulation of urinary bladder function: multiple targets at multiple levels.
Prostatic Hyperplasia
Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.
Prostatic Hyperplasia
Urodynamic Effects of Transrectal Intraprostatic Ona botulinum Toxin A Injections for Symptomatic Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Prostatic Hyperplasia
[Botulinum toxin in the treatment of benign prostatic hyperplasia : An overview.]
Prostatic Hyperplasia
[Botulinum toxin type-A toxin activity in prostate cancer cell lines].
Prostatic Hyperplasia
[Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia]
Prostatic Neoplasms
Botulinum Toxin Type A Inhibits the Growth of LNCaP Human Prostate Cancer Cells In Vitro and In Vivo.
Prostatic Neoplasms
Cholinergic innervation and muscarinic receptors in the human prostate.
Prostatitis
Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
Prostatitis
Chronic prostatitis/chronic pelvic pain syndrome: is there a role for local drug infiltration therapy?
Prostatitis
Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.
Prostatitis
Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A.
Prostatitis
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.
Prostatitis
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review.
Prostatitis
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.
Pruritus
Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus.
Pruritus
Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study.
Pruritus
Botulinum toxin type A therapy for bilateral focal neuropathic pruritus in multiple sclerosis: a case report.
Pruritus
Commentary on: Synergistic Effect on Botulinum Toxin Type-A and Triamcinolone Alleviates Scar Pruritus by Modulating Epidermal Hyperinnervation: A Preliminary Report.
Pruritus
Comparison of the effectiveness of two treatment modalities for chronic anal fissure: Botox versus sphincterotomy.
Pruritus
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus.
Pruritus
Evaluation of Efficacy of Corticosteroid and Corticosteroid Combined with Botulinum Toxin Type A in the Treatment of Keloid and Hypertrophic Scars: A Meta-Analysis.
Pruritus
Intralesional excision with topical intralesional cryotherapy improves the treatment of keloid scarring in a paediatric patient.
Pruritus
Relief of intractable pruritus after administration of botulinum toxin A (botox): a case report.
Pruritus
Synergic Effect of Botulinum Toxin Type-A and Triamcinolone Alleviates Scar Pruritus By Modulating Epidermal Hyperinnervation: A Preliminary Report.
Pruritus
The use of botulinum toxin in the management of burns itching: Preliminary results.
Pruritus
Treatment of pruritus with botulinum toxin in a pediatric patient with Fox-Fordyce disease.
Psoriasis
Botulinum toxin type-A versus 5-fluorouracil in the treatment of plaque psoriasis: Comparative study.
Psoriasis
Breaking paradigms in the treatment of psoriasis: Use of Botulinum toxin for the treatment of plaque psoriasis.
Psoriasis
Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis.
Psoriasis
Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus.
Psoriasis
Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A.
Psoriasis
Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA.
Psoriasis
The effect of botulinum neurotoxin A in patients with plaque psoriasis - an exploratory trial.
Psoriasis
Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation.
Psychomotor Agitation
Improvement of both tardive dystonia and akathisia after botulinum toxin injection.
Psychomotor Disorders
[Treatment of strabismus associated with psychomotor impairment using botulinum toxin.]
Purpura, Thrombocytopenic, Idiopathic
Back to the future: recombinant polyclonal antibody therapeutics.
Pyloric Stenosis
Prevention of delayed gastric emptying after esophagectomy: a single center's experience with botulinum toxin.
Pyloric Stenosis, Hypertrophic
Lack of response to botulinum toxin A in patients with hypertrophic pyloric stenosis.
Pyloric Stenosis, Hypertrophic
Review article: the use of botulinum toxin in the alimentary tract.
Quadriplegia
Combined botulinum toxin type A and electrical stimulation in individuals with C5-C6 and C6-C7 tetraplegia: a pilot study.
Quadriplegia
Correction: Combined botulinum toxin type A and electrical stimulation in individuals with C5-C6 and C6-C7 tetraplegia: a pilot study.
Quadriplegia
Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases.
Quadriplegia
The effect of botulinum toxin A on the function if a person with poststroke quadriplegia.
Rabies
Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.
Rabies
Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.
Rabies
[Guidelines for antifungal prophylaxis, diagnosis and therapy in pediatric hematology and oncology - a review of literature and expert recommendations.]
Radiation Fibrosis Syndrome
The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report.
Radiculopathy
Cervical radiculopathy following botulinum toxin therapy for cervical dystonia.
Raynaud Disease
A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
Raynaud Disease
A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon.
Raynaud Disease
Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy.
Raynaud Disease
Iatrogenic Thenar Eminence Atrophy After Botox A Injection for Secondary Raynaud Phenomenon.
Raynaud Disease
Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment.
Raynaud Disease
Interdigital injection of botulinum toxin for patients with Raynaud phenomenon.
Raynaud Disease
Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin.
Raynaud Disease
Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A.
Raynaud Disease
The Effect of Botulinum Neurotoxin-A on Blood Flow in Rats: A Potential Mechanism for Treatment of Raynaud Phenomenon.
Raynaud Disease
The Use of Ultrasound Guidance for the Treatment of Raynaud Disease of the Hand With Botulinum Toxin.
Rectal Fistula
Combined treatment approach to chronic anal fissure with associated anal fistula.
Rectal Neoplasms
The Value of Botox-A in Acute Radiation Proctitis: Results from a Phase I/II Study Using a Three-Dimensional Scoring System.
Rectal Prolapse
Excellent response rate of anismus to Botulinum toxin if rectal prolapse misdiagnosed as anismus ("pseudoanismus") is excluded.
Rectocele
Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders.
Recurrent Laryngeal Nerve Injuries
[Effect of cricothyroid and thyroarytenoid muscle botulinum toxin injection on patients with dyspnea caused by bilateral recurrent laryngeal nerve paresis].
Reflex, Abnormal
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Reflex, Abnormal
Botulinum toxin injection causes hyperreflexia and increased muscle stiffness of the triceps surae muscle in the rat.
Reflex, Abnormal
Effect of Intravesical Botulinum Neurotoxin-A Injection on Detrusor Hyperreflexia in Spinal Cord Injured Patients.
Reflex, Abnormal
Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
Reflex, Abnormal
Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report.
Reflex, Abnormal
[Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia]
Refractive Errors
Abobotulinum toxin A for periorbital facial rejuvenation: impact on ocular refractive parameters.
Refractive Errors
Management of nonresolving consecutive exotropia following botulinum toxin treatment of childhood esotropia.
Renal Insufficiency, Chronic
[Kidney transplantation and lower tract obstructive uropathy treated by Botox: a case report]
Reperfusion Injury
Botulinum toxin A increases allograft tolerance in an experimental transplantation model: a preliminary study.
Reperfusion Injury
Botulinum toxin B suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model: Possible regulation of oxidative and endoplasmic reticulum stress.
Reperfusion Injury
Comparison of perivascular and intramuscular applied botulinum toxin a pretreatment on muscle flap ischemia-reperfusion injury and chemical delay.
Reperfusion Injury
Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress.
Reperfusion Injury
Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury.
Reperfusion Injury
The Effect of Botulinum Toxin A on Ischemia-Reperfusion Injury in a Rat Model.
Respiratory Insufficiency
A Rapid, Sensitive, and Portable Biosensor Assay for the Detection of Botulinum Neurotoxin Serotype A in Complex Food Matrices.
Respiratory Insufficiency
Botulinum neurotoxin vaccines: Past history and recent developments.
Respiratory Insufficiency
Rapidly Progressive Muscle Paralysis and Acute Respiratory Failure Following Endoscopic Botulinum Toxin Injection.
Respiratory Insufficiency
[Severe respiratory failure after injection of botulinum toxin: case report and review of the literature]
Respiratory Paralysis
Exploring strategies to prevent post-lobectomy space: transient diaphragmatic paralysis using Botulinum toxin type A (BTX-A).
Respiratory Tract Infections
Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Respiratory Tract Infections
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Restless Legs Syndrome
A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome.
Restless Legs Syndrome
Botulinum Toxin in Restless Legs Syndrome-A Randomized Double-Blind Placebo-Controlled Crossover Study.
Restless Legs Syndrome
Double-blind, placebo-controlled, pilot trial of botulinum toxin A in restless legs syndrome.
Restless Legs Syndrome
Pilot Trial of OnabotulinumtoxinA (Botox) in Moderate to Severe Restless Legs Syndrome.
Restless Legs Syndrome
Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A.
Retinal Detachment
Inadvertent Globe Penetration and Subretinal injection of Botulinum Toxin in an Oculocutaneous Albinism Patient.
Retinal Detachment
Retinal detachment from inadvertent intraocular injection of botulinum toxin A.
Retinal Detachment
The use of botulinum toxin to treat strabismus following retinal detachment surgery.
Retinal Detachment
Treatment of strabismus after retinal detachment surgery with botulinum neurotoxin A.
Retinal Detachment
Vitreous hemorrhage and Rhegmatogenous retinal detachment that developed after botulinum toxin injection to the extraocular muscle: case report.
Retinal Neovascularization
Silencing of Rac1 expression via RNA interference inhibits retinal neovascularization in rats.
Retinal Perforations
Retinal detachment from inadvertent intraocular injection of botulinum toxin A.
Retinal Perforations
Retinal tear and raised intraocular pressure following unintentional intraocular botulinum toxin type A injection.
Retinitis Pigmentosa
Acute angle closure following periorbital botulinum toxin injection in a patient with retinitis pigmentosa.
Retinitis Pigmentosa
Repeated bilateral retrobulbar injection of botulinum toxin in a blind patient with retinitis pigmentosa and incapacitating nystagmus.
Rett Syndrome
The Treatment of Hypersalivation in Rett Syndrome with Botulinum Toxin: Efficacy and Clinical Implications.
Rhinitis
Botolinum toxin in rhinitis: Literature review and posterior nasal injection in allergic rhinitis.
Rhinitis
Effect of Botulinum Neurotoxin A Injection into the Submucoperichondrium of the Nasal Septum in Reducing Idiopathic Non-Allergic Rhinitis and Persistent Allergic Rhinitis.
Rhinitis
Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia.
Rhinitis
Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia.
Rhinitis
Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis.
Rhinitis
Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study.
Rhinitis
[Application status and prospect of botulinum toxin A in otorhinolaryngological treatment].
Rhinitis, Allergic
A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy.
Rhinitis, Allergic
A novel botulinum neurotoxin topical gel: Treatment of allergic rhinitis in rats and comparative safety profile.
Rhinitis, Allergic
Effect of Botulinum Neurotoxin A Injection into the Submucoperichondrium of the Nasal Septum in Reducing Idiopathic Non-Allergic Rhinitis and Persistent Allergic Rhinitis.
Rhinitis, Allergic
Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial.
Rhinitis, Allergic
Investigate the effect of botulinum toxin type A (BTX-A) on nasal symptoms inpatients with allergic rhinitis.
Rhinitis, Allergic
Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis.
Rhinitis, Allergic
The Effect of Gelfoam Impregnated With Botulinum Toxin on Allergic Rhinitis.
Rhinitis, Allergic
The nasal response to histamine challenge: effect of the pollen season and immunotherapy.
Rhinitis, Allergic
Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice.
Rhinitis, Allergic
[Experimental studies for botulinum toxin type A on allergic rhinitis in the rat]
Rhinitis, Allergic
[Experimental studies for botulinum toxin type A to antagonist the VIP/PACAP expression on nasal mucosa in allergic rhinitis rat].
Rhinitis, Allergic, Seasonal
Cooperation between human thymus-derived and bone marrow-derived lymphocytes in the antibody response to ragweed antigen E in vitro.
Rhinitis, Allergic, Seasonal
Generation of antigen-specific suppressor cells during allergy desensitization.
Rhinitis, Allergic, Seasonal
Immunologic responses to conjugates of antigen E in patients with ragweed hay fever.
Rhinitis, Allergic, Seasonal
Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos.
Rhinitis, Allergic, Seasonal
Polymerized ragweed antigen E. IV. The analysis of the stability of molecular size and antigenic reactivity of the polymer.
Rhinitis, Allergic, Seasonal
The effect of immunotherapy on humoral and cellular responses in ragweed hayfever.
Rhinitis, Vasomotor
The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis.
Rhinitis, Vasomotor
[The influence of botulinum toxin type A on vasomotor rhinitis and morphological study]
Rosacea
A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea.
Rosacea
A Pilot, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of IncobotulinumtoxinA Injections in the Treatment of Rosacea.
Rosacea
An unusual tell sign of botulinum toxin injection in patients with facial flushing: incorporating a new questionnaire in the evaluation of botulinum toxin patients.
Rosacea
Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema.
Rosacea
Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.
Rosacea
Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea.
Rosacea
Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing.
Rosacea
Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey.
Salivary Gland Calculi
Acute sialadenitis secondary to submandibular calculi after botulinum neurotoxin injection for sialorrhea in a child with cerebral palsy.
Salivary Gland Diseases
Botulinum Neurotoxin A for Parotid Enlargement in Cystic Fibrosis: The First Case Report.
Salivary Gland Fistula
[Botulinum toxin A as a treatment of traumatic salivary gland fistulas]
Sarcoma
A barley SKP1-like protein controls abundance of the susceptibility factor RACB and influences the interaction of barley with the barley powdery mildew fungus.
Sarcopenia
Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice.
Schizencephaly
Botulinum toxin A injection of UES in schizencephaly with dysphagia: Case report.
Sciatic Neuropathy
Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and ? opioid receptor expression in neuropathic mice.
Scleroderma, Localized
Botulinum toxin type A for treatment of dyspareunia caused by localized scleroderma.
Scleroderma, Localized
Improvement of "En Coup de Sabre" Morphea and Associated Headaches With Botulinum Toxin Injections.
Scleroderma, Localized
Thoracic outlet syndrome secondary to localized scleroderma treated with botulinum toxin injection.
Scleroderma, Systemic
Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Scleroderma, Systemic
Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Scleroderma, Systemic
Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis.
Scleroderma, Systemic
Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress.
Scleroderma, Systemic
Is Botulinum Toxin Useful in Systemic Sclerosis Related Peripheral Vasculopathy? A Literature Review.
Scleroderma, Systemic
Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin.
Scleroderma, Systemic
Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
Scleroderma, Systemic
[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis.]
Scleroderma, Systemic
[Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis.]
Scoliosis
Counterparalysis for treatment of paralytic scoliosis with botulinum toxin type A.
Scoliosis
Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan.
Scoliosis
State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.
Scoliosis
The effect of botulinum toxin A injections in the spine muscles for cerebral palsy scoliosis, examined in a prospective, randomized triple-blinded study.
Seizures
Action of botulinum neurotoxins in the central nervous system: antiepileptic effects.
Seizures
BoNT/E prevents seizure-induced activation of caspase 3 in the rat hippocampus.
Seizures
Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.
Seizures
Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy.
Seizures
Botulinum toxin for painful spasms from focal seizures: theoretical considerations and case report.
Seizures
Botulinum toxin injections for simple partial motor seizures associated with pain.
Seizures
Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.
Seizures
Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy.
Seizures
Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.
Seizures
Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.
Seizures
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Sensation Disorders
Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.
Sensation Disorders
Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Sensation Disorders
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
Sensation Disorders
Systematic test of neurotoxin dose and volume on muscle function in a rat model.
Sensation Disorders
Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.
Sepsis
Mycotic aneurysm of the distal thoracic aorta after botulinum toxin injection for esophageal dysmotility.
Shoulder Dislocation
Use of botulinum neurotoxin injections to treat recurrent shoulder dislocations in a patient with severe epilepsy: a case report.
Shoulder Impingement Syndrome
Clinical Effectiveness of Botulinum Toxin Type B in the Treatment of Subacromial Bursitis or Shoulder Impingement Syndrome.
Shoulder Impingement Syndrome
Subacromial impingement syndrome as a consequence of botulinum therapy to the upper trapezii: a case report.
Shoulder Pain
A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity.
Shoulder Pain
A survey of the current practice of intramuscular Botulinum toxin injections for hemiplegic shoulder pain in the UK.
Shoulder Pain
Botulinum Toxin A Injection into the Subscapularis Muscle to Treat Intractable Hemiplegic Shoulder Pain.
Shoulder Pain
Clinical effectiveness of ultrasound guided subacromial-subdeltoid bursa injection of botulinum toxin type A in hemiplegic shoulder pain: A retrospective cohort study.
Shoulder Pain
Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials.
Shoulder Pain
Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial.
Shoulder Pain
Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial.
Shoulder Pain
Effectiveness of Botulinum Toxin A in Treatment of Hemiplegic Shoulder Pain: A Systematic Review and Meta-analysis.
Shoulder Pain
Effectiveness of Botulinum Toxin for Shoulder Pain Treatment: A Systematic Review and Meta-Analysis.
Shoulder Pain
Efficacy of intra-articular injection of botulinum toxin type A in refractory hemiplegic shoulder pain.
Shoulder Pain
Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.
Shoulder Pain
Hemiplegic shoulder pain: Comparison of two sites of intramuscular injections of botulinum toxin type A, "epautox" study.
Shoulder Pain
Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
Shoulder Pain
Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature.
Shoulder Pain
Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide.
Shoulder Pain
Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial.
Shoulder Pain
Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle.
Shoulder Pain
Treatment of pain and limited movement of the shoulder in hemiplegic patients with botulinum toxin a in the subscapular muscle.
Shoulder Pain
Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.
Shoulder Pain
Ultrasound-Guided BoNT-A (Botulinum Toxin A) Injection Into the Subscapularis for Hemiplegic Shoulder Pain: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sialadenitis
Acute sialadenitis secondary to submandibular calculi after botulinum neurotoxin injection for sialorrhea in a child with cerebral palsy.
Sialadenitis
Botulinum toxin for chronic parotid sialadenitis: A case series and systematic review.
Sialadenitis
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Sialorrhea
A 10-year Retrospective Review of Botulinum Toxin Injections and Surgical Management of Sialorrhea.
Sialorrhea
A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
Sialorrhea
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Sialorrhea
A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases.
Sialorrhea
Acute sialadenitis secondary to submandibular calculi after botulinum neurotoxin injection for sialorrhea in a child with cerebral palsy.
Sialorrhea
Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.
Sialorrhea
Applied botulinum neurotoxin injection in a patient with dementia to reduce hypersalivation.
Sialorrhea
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Sialorrhea
Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.
Sialorrhea
Botulinum Toxin A for Treatment of Sialorrhea in Children: An Effective, Minimally Invasive Approach.
Sialorrhea
Botulinum toxin a injection of salivary glands in children with drooling and chronic aspiration.
Sialorrhea
Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Sialorrhea
Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.
Sialorrhea
Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.
Sialorrhea
Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.
Sialorrhea
Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
Sialorrhea
Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer.
Sialorrhea
Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis.
Sialorrhea
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Sialorrhea
Botulinum toxin in the treatment of drooling in tetraplegic patients with brain injury.
Sialorrhea
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Sialorrhea
Botulinum toxin injection to the salivary glands for the treatment of sialorrhea with chronic aspiration.
Sialorrhea
Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience.
Sialorrhea
Botulinum Toxin Services for Neurorehabiliation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic.
Sialorrhea
Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders.
Sialorrhea
Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.
Sialorrhea
Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis.
Sialorrhea
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Sialorrhea
Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Sialorrhea
Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence.
Sialorrhea
Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy.
Sialorrhea
Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Sialorrhea
Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease.
Sialorrhea
Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy.
Sialorrhea
Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study.
Sialorrhea
Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea.
Sialorrhea
Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.
Sialorrhea
Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: A review.
Sialorrhea
Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities.
Sialorrhea
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
Sialorrhea
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Sialorrhea
Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion.
Sialorrhea
Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial.
Sialorrhea
Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions.
Sialorrhea
Cumulative Efficacy of Longitudinal Repeat Salivary Gland OnabotulinumtoxinA Injection: A Retrospective Study.
Sialorrhea
Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease.
Sialorrhea
Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
Sialorrhea
Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson's disease patients?
Sialorrhea
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
Sialorrhea
Drooling in Parkinson's disease: a novel speech and language therapy intervention.
Sialorrhea
Drooling: Are Botulinum Toxin Injections Into the Major Salivary Glands a Good Treatment Option?
Sialorrhea
Effect of botulinum toxin a injection into the salivary glands for sialorrhea in children with neurologic disorders.
Sialorrhea
Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
Sialorrhea
Effect of botulinum toxin type a on morphology of salivary glands in patients with cerebral palsy.
Sialorrhea
Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review.
Sialorrhea
Effects of chronic treatment with botulinum toxin type A in salivary glands of rats: Histological and immunohistochemical analyses.
Sialorrhea
Effects of Repeated Botulinum Toxin Treatment for Sialorrhea in Patients with Parkinson's Disease.
Sialorrhea
Effects of salivary gland botulinum Toxin-A on drooling and respiratory morbidity in children with neurological dysfunction.
Sialorrhea
Efficacy and duration of botulinum toxin treatment for drooling in 131 children.
Sialorrhea
Efficacy and safety of botulinum toxin for treating sialorrhea: A systematic review and meta-analysis.
Sialorrhea
Efficacy of Botulinum Toxin for Treating Sialorrhea in Neuromuscular Conditions.
Sialorrhea
Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
Sialorrhea
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.
Sialorrhea
IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.
Sialorrhea
International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction.
Sialorrhea
Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
Sialorrhea
Is injection of botulinum toxin type A effective in the treatment of drooling in children with cerebral palsy?
Sialorrhea
Localization of Salivary Glands for Botulinum Toxin Treatment: Ultrasound Versus Landmark Guidance.
Sialorrhea
Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
Sialorrhea
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.
Sialorrhea
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Sialorrhea
Long-term Safety and Efficacy Data on Botulinum Toxin Type A: An Injection for Sialorrhea.
Sialorrhea
Managing autonomic dysfunction in Parkinson's disease: a review of emerging drugs.
Sialorrhea
Manually guided botulinum toxin type A submandibular injections for the treatment of sialorrhea in tube-fed patients with advanced amyotrophic lateral sclerosis.
Sialorrhea
MicroRNA-mRNA expression profiles and functional network after injection of botulinum toxin type A into submandibular glands.
Sialorrhea
Negative effects of submandibular botulinum neurotoxin A injections on oral motor function in children with drooling due to central nervous system disorders.
Sialorrhea
Oral health effects of botulinum toxin treatment for drooling: a systematic review.
Sialorrhea
Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy.
Sialorrhea
Parotid gland injections of botulinum toxin a are effective in treating sialorrhea in amyotrophic lateral sclerosis.
Sialorrhea
Pediatric Sialorrhea: Submandibular Duct Rerouting and Intraparotid Botulinum Toxin A Injection With Literature Review.
Sialorrhea
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Sialorrhea
Poster 273 Botulinum Toxin Injections to the Salivary Glands for Treatment of Sialorrhea in a Patient with Duchenne Muscular Dystrophy: A Case Report.
Sialorrhea
Posterior drooling in children with cerebral palsy and other neurodevelopmental disorders.
Sialorrhea
Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Sialorrhea
Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Sialorrhea
Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature.
Sialorrhea
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.
Sialorrhea
Qualitative and quantitative scintigraphy in sialorrhea before and after botulinum toxin injection.
Sialorrhea
Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin.
Sialorrhea
Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands.
Sialorrhea
Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities.
Sialorrhea
Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.
Sialorrhea
Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.
Sialorrhea
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Sialorrhea
Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: A review.
Sialorrhea
Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability.
Sialorrhea
Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Sialorrhea
Safety of combined salivary gland and multilevel intramuscular onabotulinumtoxinA injections with and without ethanol in pediatric patients with cerebral palsy: A retrospective study.
Sialorrhea
Safety of Ultrasound-Guided Botulinum Toxin Injections for Sialorrhea as Performed by Pediatric Otolaryngologists.
Sialorrhea
Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
Sialorrhea
Salivary botulinum toxin injection may reduce aspiration pneumonia in neurologically impaired children.
Sialorrhea
Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review.
Sialorrhea
Secondary effects of botulinum toxin injections into salivary glands for the management of pediatric drooling.
Sialorrhea
Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands.
Sialorrhea
Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.
Sialorrhea
Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
Sialorrhea
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Sialorrhea
Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling.
Sialorrhea
Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy.
Sialorrhea
Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study.
Sialorrhea
Submandibular gland botulinum toxin injections for drooling: the safe and risky zones.
Sialorrhea
Successful management of drooling with botulinum toxin A in neurologically disabled children.
Sialorrhea
Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
Sialorrhea
Surgery versus botulinum neurotoxin A to reduce drooling and improve daily life for children with neurodevelopmental disabilities: a randomized controlled trial.
Sialorrhea
Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis.
Sialorrhea
The Challenges Faced and Lessons Learnt in the Multidisciplinary Management of Medication Refractory Post-Stroke Sialorrhea: A Case Report.
Sialorrhea
The effect of local injection of botulinum toxin A on the parotid gland of the rat: an immunohistochemical and morphometric study.
Sialorrhea
The Effect of Nebulized Glycopyrrolate on Posterior Drooling in Patients with Brain Injury: Two Cases of Different Brain Lesions.
Sialorrhea
The Effectiveness of Botulinum Toxin Type A Injections in the Management of Sialorrhea.
Sialorrhea
The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study.
Sialorrhea
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Sialorrhea
The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.
Sialorrhea
The Role of Radiation Therapy and Botulinum Toxin Injections in the Management of Sialorrhea in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review.
Sialorrhea
The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands.
Sialorrhea
The Treatment of Hypersalivation in Rett Syndrome with Botulinum Toxin: Efficacy and Clinical Implications.
Sialorrhea
The treatment of posterior drooling by botulinum toxin in a child with cerebral palsy.
Sialorrhea
The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders.
Sialorrhea
The use of botulinum toxin injections to manage drooling in amyotrophic lateral sclerosis/motor neurone disease: a systematic review.
Sialorrhea
Tolerance of salivary gland botulinum toxin A injection under local anesthesia for the treatment of sialorrhea in children: An observational study.
Sialorrhea
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population.
Sialorrhea
Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: Efficacy and possible mechanisms.
Sialorrhea
Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
Sialorrhea
Ultrasound and electromyography & electrical stimulation-guided botulinum toxin injection of salivary glands for drooling: A case report with a description of the technique.
Sialorrhea
Ultrasound-Guided Botulinum Toxin Injections into the Salivary Glands for the Treatment of Drooling.
Sialorrhea
Ultrasound-Guided Botulinum Toxin Type A Salivary Gland Injection in Children for Refractory Sialorrhea: 10-Year Experience at a Large Tertiary Children's Hospital.
Sialorrhea
Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy.
Sialorrhea
Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis.
Sialorrhea
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
Sialorrhea
Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study.
Sialorrhea
Validity, reliability and responsiveness to change of the French version of the drooling impact scale.
Sialorrhea
Videoendoscopic rehabilitation of iatrogenous Stensen-duct-acquired atresia in a patient with ring chromosome 21 syndrome and drooling.
Sialorrhea
What could predict effectiveness of Botulinum Toxin to treat drooling: A search for evidence of discriminatory factors on the level of body functions or structures.
Sialorrhea
[Botulinum toxin for the treatment of secretory disorders of the head and neck area].
Sialorrhea
[Drooling following radiation. Botulinum toxin as a successful treatment modality].
Sialorrhea
[Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders.]
Sialorrhea
[Interests of the ultrasound-guidance in the treatment of drooling through botulinum toxin injections, our experience over 10 years].
Sialorrhea
[Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature]
Sialorrhea
[The efficacy of botulinum toxin-A in the treatment of hypersalivation in children with cerebral palsy]
Skin Diseases
Botulinum Toxin A: An Effective Treatment for Linear Immunoglobulin A Bullous Dermatosis Located in the Axillae.
Skin Diseases
Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis.
Skin Diseases
Rehabilitation Interventions in the Multidisciplinary Management of Patients With Sclerotic Graft-Versus-Host Disease of the Skin and Fascia.
Skin Neoplasms
Perceptions of Expertise in Cutaneous Surgery and Cosmetic Procedures: What Primary Care Physicians Think.
Skin Ulcer
Botulinum Toxin A Injection for Treatment of Chronic Skin Ulcer: A Case Series and Literature Review.
Sleep Apnea Syndromes
Sleep-related adductor laryngeal dystonia causing sleep apnea: a sleep-related breathing disorder diagnosed with sleep endoscopy and treated with botulinum toxin.
Sleep Apnea, Obstructive
Laryngeal Botulinum Toxin Injection: Can It Be a Cause of Obstructive Sleep Apnea as an Adverse Effect?
Sleep Apnea, Obstructive
Obstructive sleep apnea due to oromandibular dystonia and treated with botulinum toxin.
Sleep Bruxism
Botulinum toxin injection for bruxism associated with brain injury: case report.
Sleep Bruxism
Botulinum Toxin Therapy for Managing Sleep Bruxism: A Randomized and Placebo-Controlled Trial.
Sleep Bruxism
Does botulinum toxin have any role in the management of chronic pain associated with bruxism?
Sleep Bruxism
Effect of Botulinum Toxin Injection on Nocturnal Bruxism: A Randomized Controlled Trial.
Sleep Bruxism
Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report.
Sleep Bruxism
Effects of Botulinum Toxin on Jaw Motor Events during Sleep in Sleep Bruxism Patients: A Polysomnographic Evaluation.
Sleep Bruxism
Efficacy of botulinum toxin in the management of temporomandibular myofascial pain and sleep bruxism.
Sleep Bruxism
Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?
Sleep Bruxism
Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review.
Sleep Bruxism
Mandibular Bone Loss after Masticatory Muscles Intervention with Botulinum Toxin: An Approach from Basic Research to Clinical Findings.
Sleep Bruxism
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study.
Sleep Bruxism
Sleep bruxism possibly triggered by multiple sclerosis attacks and treated successfully with botulinum toxin: Report of three cases.
Sleep Bruxism
The Current Trend in Management of Bruxism and Chronic Pain: An Overview of Systematic Reviews.
Sleep Bruxism
The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism.
Sleep Bruxism
Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study.
Sleep Initiation and Maintenance Disorders
Association of Long-Term Treatment by Botulinum Neurotoxins and Occupational Therapy with Subjective Physical Status in Patients with Post-Stroke Hemiplegia.
Sleep Initiation and Maintenance Disorders
Obstructive sleep apnea due to oromandibular dystonia and treated with botulinum toxin.
Sleep Initiation and Maintenance Disorders
Ultrasound guided injections of botulinum toxin type A into stellate ganglion to treat insomnia.
Sleep Wake Disorders
Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison.
small monomeric gtpase deficiency
Rab3a-mediated vesicle recruitment regulates short-term plasticity at the mouse diaphragm synapse.
Smallpox
Bioterrorism: class A agents and their potential presentations in immunocompromised patients.
Smallpox
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Smallpox
Pathobiology and management of laboratory rodents administered CDC category A agents.
Smallpox
The threat of biological terrorism: a public health and infection control reality.
Spasm
A case of painful hemimasticatory spasm with masseter muscle hypertrophy responsive to botulinum toxin.
Spasm
A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.
Spasm
A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
Spasm
A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Spasm
Alteration of central motor excitability in a patient with hemimasticatory spasm after treatment with botulinum toxin injections.
Spasm
An update on the pharmacological management of pain in patients with multiple sclerosis.
Spasm
Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.
Spasm
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
Spasm
Atypical Pharyngeal Pouch Arising Bilaterally between the Hyoid Bone and Thyroid Cartilage.
Spasm
Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases.
Spasm
Botoulinum Toxin A Injection to Facial and Cervical Paraspinal Muscles in a Patient With Stiff Person Syndrome: A Case Report.
Spasm
Botulinum A toxin injection. Failures in clinical practice and a biomechanical system for the study of toxin-induced paralysis.
Spasm
Botulinum neurotoxin for pharyngeal constrictor muscle spasm in tracheoesophageal voice restoration.
Spasm
Botulinum neurotoxin type A injection of the pelvic floor muscle in pain due to spasticity: a review of the current literature.
Spasm
Botulinum toxin A (Botox) injection into muscles of pelvic floor as a treatment for persistent pelvic pain secondary to pelvic floor muscular spasm: A pilot study.
Spasm
Botulinum toxin A injection for chronic anal fissures and anal sphincter spasm improves quality of life in recessive dystrophic epidermolysis bullosa.
Spasm
Botulinum toxin A is effective in treating trismus associated with postradiation myokymia and muscle spasm.
Spasm
Botulinum toxin A prolongs functional durability of voice prostheses in laryngectomees with pharyngoesophageal spasm.
Spasm
Botulinum toxin a treatment of cricopharyngeal dysphagia after subarachnoid hemorrhage.
Spasm
Botulinum toxin application to the internal and external oblique muscles for abdominal spasms in spinal cord injury.
Spasm
Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment.
Spasm
Botulinum toxin for painful spasms from focal seizures: theoretical considerations and case report.
Spasm
Botulinum toxin in a case of hemimasticatory spasm with severe worsening during pregnancy.
Spasm
Botulinum toxin in masticatory muscles: short- and long-term effects on muscle, bone, and craniofacial function in adult rabbits.
Spasm
Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction.
Spasm
Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain: Multicentre, randomized, double-blind study.
Spasm
Botulinum toxin injection for failed tracheo-oesophageal voice in laryngectomees: the Sunderland experience.
Spasm
Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia.
Spasm
Botulinum toxin injection to facilitate rehabilitation of muscle imbalance syndromes in sports medicine.
Spasm
Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a randomized controlled trial.
Spasm
Botulinum toxin reduces anal spasm but has no effect on pain after haemorrhoidectomy.
Spasm
Botulinum toxin to improve vessel graft patency in cerebral revascularization surgery: report of 3 cases.
Spasm
Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
Spasm
Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial.
Spasm
Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.
Spasm
Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy.
Spasm
Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.
Spasm
Botulinum toxin type A: an effective treatment to restore phonation in laryngectomized patients unable to voice.
Spasm
Botulinum toxin use as an adjunctive modality in a patient with multiple flexor tendon ruptures.
Spasm
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
Spasm
Cellular responses to acute injury: the role of the plasma membrane in cell response to two clostridial toxins.
Spasm
Chemomyectomy of the orbicularis oculi muscles for the treatment of localized hemifacial spasm.
Spasm
Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China.
Spasm
Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
Spasm
Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
Spasm
Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study.
Spasm
Computerized manometry use to evaluate spasm in pharyngoesophageal segment in patients with poor tracheoesophageal speech before and after treatment with botulinum toxin.
Spasm
Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm.
Spasm
Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction.
Spasm
Effect of intravesical botulinum toxin injection on symptoms of autonomic dysreflexia in a patient with chronic spinal cord injury: a case report.
Spasm
Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
Spasm
Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
Spasm
Efficacy of botulinum toxin A for treatment of unilateral spasms of the eyelid and its prognosis.
Spasm
Efficiency of ultrasound and water capsule-guided local injection of botulinum toxin type A treatment on patients with facial spasm.
Spasm
Episodic hemilaryngopharyngeal spasm (HELPS) syndrome: case report of a surgically treatable novel neuropathy.
Spasm
Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure.
Spasm
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
Spasm
Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
Spasm
Fissurectomy-botulinum toxin: a novel sphincter-sparing procedure for medically resistant chronic anal fissure.
Spasm
Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.
Spasm
Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?
Spasm
Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection.
Spasm
Intramuscular injection of Botox causes tendon atrophy by induction of senescence of tendon-derived stem cells.
Spasm
Intravesical Botulinum Toxin for Persistent Autonomic Dysreflexia in a Pediatric Patient.
Spasm
Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing.
Spasm
Long-term effects of combined botulinum toxin treatment and rehabilitation on upper limb muscle spasms: a case report.
Spasm
Masticatory muscle spasm in a non-Japanese patient with Satoyoshi syndrome successfully treated with botulinum toxin.
Spasm
Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies.
Spasm
Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.
Spasm
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
Spasm
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
Spasm
No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
Spasm
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Spasm
Obturator nerve block with botulinum toxin type B for patient with adductor thigh muscle spasm -a case report-.
Spasm
Palmaris brevis spasm: Identified by high resolution ultrasound and treated by botulinum toxin.
Spasm
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Spasm
Pectoral muscle spasms after mastectomy successfully treated with botulinum toxin injections.
Spasm
Periorbital injections of botulinum toxin a: a novel therapeutic option for convergence spasm in neuropsychiatric disorders.
Spasm
Phenomenology of Muscle Spasms in Satoyoshi Syndrome and Treatment With Botulinum Toxin Injections.
Spasm
Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles.
Spasm
Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review.
Spasm
Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction.
Spasm
Randomized prospective controlled trial of lateral internal sphincterotomy versus injection of botulinum toxin for the treatment of idiopathic fissure in ano.
Spasm
Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome.
Spasm
Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm.
Spasm
Simplified technique for injection of Botulinum Toxin to Obturator Internus muscle using ultrasound-guided nerve stimulation for persistent pelvic pain.
Spasm
Subcutaneous and Perineural Botulinum Toxin Type A For Neuropathic Pain: A Descriptive Review.
Spasm
Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm.
Spasm
Synkinesis in primary and postparalytic hemifacial spasm: Clinical features and therapeutic outcomes of botulinum toxin A treatment.
Spasm
Teaching NeuroImages: Concurrent hemifacial spasm and trigeminal neuralgia due to vertebrobasilar dolichoectasia.
Spasm
Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms.
Spasm
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Spasm
The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.
Spasm
The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
Spasm
The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles.
Spasm
Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports.
Spasm
Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.
Spasm
Treatment of lateralisation and subluxation of the hip in cerebral palsy with Botulinum toxin A: preliminary results based on the analysis of migration percentage data.
Spasm
Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms.
Spasm
Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia.
Spasm
Types and time course of the alterations induced in monkey blink movements by botulinum toxin.
Spasm
Ultrasound-guided botulinum toxin injection: A simple in-office technique to improve tracheoesophageal speech in postlaryngectomy patients.
Spasm
Ultrasound-guided botulinum toxin injections and EMG biofeedback therapy the lower limb muscle spasm after cerebral infarction.
Spasm
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
Spasm
Use of botulinum toxin-A for musculoskeletal pain in patients with whiplash associated disorders [ISRCTN68653575].
Spasm
Use of computerized manometry for the detection of pharyngoesophageal spasm in tracheoesophageal speech.
Spasm
Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters.
Spasm
Videofluoroscopic-guided botulinum toxin injections for pharyngoesophageal spasm after total laryngectomy.
Spasm
Videostroboscopy of the pharyngoesophageal segment in laryngectomy patients treated with botulinum toxin.
Spasm
[Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients' satisfaction along the treatment]
Spasm
[Changes in the blink reflex in patients with essential blepharospasm and hemifacial spasm]
Spasm
[The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm]
Spasm
[Treatment of facial hemispasms and median facial spasms by injection of botulinum toxin. Initial results]
Spastic Paraplegia, Hereditary
Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations.
Spastic Paraplegia, Hereditary
Botulinum Toxin Injections for Pediatric Patients With Hereditary Spastic Paraparesis.
Spastic Paraplegia, Hereditary
Efficacy of a Combined Treatment of Botulinum Toxin and Intensive Physiotherapy in Hereditary Spastic Paraplegia.
Spastic Paraplegia, Hereditary
Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia.
Spastic Paraplegia, Hereditary
Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: A study in patients with hereditary spastic paraplegia.
Spastic Paraplegia, Hereditary
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.
Sphincter of Oddi Dysfunction
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Sphincter of Oddi Dysfunction
Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.
Sphincter of Oddi Dysfunction
Botulinum toxin injection as a diagnostic tool for verification of sphincter of Oddi dysfunction causing recurrent pancreatitis.
Sphincter of Oddi Dysfunction
Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study.
Sphincter of Oddi Dysfunction
Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction.
Sphincter of Oddi Dysfunction
Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction.
Sphincter of Oddi Dysfunction
Intrasphincteric botulinum toxin type A for the diagnosis of sphincter of Oddi dysfunction: a case report.
Sphincter of Oddi Dysfunction
Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction.
Sphincter of Oddi Dysfunction
The role of intrasphincteric botulinum toxin injection in the management of functional biliary pain: a systematic review and meta-analysis.
Sphincter of Oddi Dysfunction
The use of botulinum toxin for the treatment of gastrointestinal motility disorders.
Spinal Cord Compression
Severe motor tics causing cervical myelopathy in Tourette's syndrome.
Spinal Cord Compression
[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
Spinal Cord Diseases
Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Spinal Cord Diseases
Preoperative treatment with botulinum toxin to facilitate cervical fusion in dystonic cerebral palsy. Report of two cases.
Spinal Cord Diseases
[Cervical myelopathy associated with os odontoideum after botulinum toxin treatment in a patient with cerebral palsy].
Spinal Cord Diseases
[Usefulness of botulinum toxin injections in the treatment of postoperative pain after cervical spine surgery: Preliminary results.]
Spinal Cord Injuries
A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury.
Spinal Cord Injuries
A Meta-Analysis of Botulinum Toxin Sphincteric Injections in the Treatment of Incomplete Voiding After Spinal Cord Injury.
Spinal Cord Injuries
A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury.
Spinal Cord Injuries
A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury: Retraction.
Spinal Cord Injuries
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.
Spinal Cord Injuries
Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion.
Spinal Cord Injuries
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Spinal Cord Injuries
Blocking neuromuscular junctions with botulinum toxin A injection enhances neurological heterotopic ossification development after spinal cord injury in mice.
Spinal Cord Injuries
Botulinum toxin A improves neurogenic bladder fibrosis by suppressing transforming growth factor ?1 expression in rats.
Spinal Cord Injuries
Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
Spinal Cord Injuries
Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.
Spinal Cord Injuries
Botulinum toxin application to the internal and external oblique muscles for abdominal spasms in spinal cord injury.
Spinal Cord Injuries
Botulinum Toxin Effect on Voluntary and Stretch Reflex-Related Torque Produced by the Quadriceps: An Isokinetic Pilot Study.
Spinal Cord Injuries
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity.
Spinal Cord Injuries
Botulinum toxin in the management of bowel and bladder function in spinal cord injury and other neurologic disorders.
Spinal Cord Injuries
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Spinal Cord Injuries
Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI.
Spinal Cord Injuries
Botulinum Toxin Type A for Neuropathic Pain in Patients with Spinal Cord Injury.
Spinal Cord Injuries
Botulinum toxin type A for rehabilitation after a spinal cord injury: a case report.
Spinal Cord Injuries
Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.
Spinal Cord Injuries
Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Spinal Cord Injuries
Botulinum toxin type-A infiltration of the external anal sphincter to treat outlet constipation in motor incomplete spinal cord injury: pilot cohort study.
Spinal Cord Injuries
Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.
Spinal Cord Injuries
Botulinum toxin?A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: Multi-institutional experience in Japan.
Spinal Cord Injuries
Can Botulinum Toxin Type A effectively treat neuropathic pain in spinal cord injury?: A protocol of systematic review and meta-analysis.
Spinal Cord Injuries
Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury.
Spinal Cord Injuries
Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Spinal Cord Injuries
Chemodenervation for treatment of limb spasticity following spinal cord injury: a systematic review.
Spinal Cord Injuries
Comparing a transrectal ultrasound-guided with a cystoscopy-guided botulinum toxin a injection in treating detrusor external sphincter dyssynergia in spinal cord injury.
Spinal Cord Injuries
Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A.
Spinal Cord Injuries
Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective.
Spinal Cord Injuries
Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury.
Spinal Cord Injuries
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
Spinal Cord Injuries
Editorial Comment to Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: Multi-institutional experience in Japan.
Spinal Cord Injuries
Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment.
Spinal Cord Injuries
Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report.
Spinal Cord Injuries
Effect of Intravesical Botulinum Neurotoxin-A Injection on Detrusor Hyperreflexia in Spinal Cord Injured Patients.
Spinal Cord Injuries
Effect of intravesical botulinum toxin injection on symptoms of autonomic dysreflexia in a patient with chronic spinal cord injury: a case report.
Spinal Cord Injuries
Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
Spinal Cord Injuries
Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury.
Spinal Cord Injuries
Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia.
Spinal Cord Injuries
Effects of hypertonia on contracture development in rat spinal cord injury.
Spinal Cord Injuries
Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor.
Spinal Cord Injuries
Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.
Spinal Cord Injuries
Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis.
Spinal Cord Injuries
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials.
Spinal Cord Injuries
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Spinal Cord Injuries
Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States.
Spinal Cord Injuries
Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
Spinal Cord Injuries
Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases.
Spinal Cord Injuries
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Spinal Cord Injuries
Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?
Spinal Cord Injuries
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Spinal Cord Injuries
IncobotulinumtoxinA versus OnabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
Spinal Cord Injuries
Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Spinal Cord Injuries
Intradetrusor OnabotulinumtoxinA Injections Ameliorate Autonomic Dysreflexia while Improving Lower Urinary Tract Function and Urinary Incontinence-Related Quality of Life in Individuals with Cervical and Upper Thoracic Spinal Cord Injury.
Spinal Cord Injuries
Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Spinal Cord Injuries
Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
Spinal Cord Injuries
Intravesical Botulinum Toxin for Persistent Autonomic Dysreflexia in a Pediatric Patient.
Spinal Cord Injuries
Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury.
Spinal Cord Injuries
Long-term effects of combined botulinum toxin treatment and rehabilitation on upper limb muscle spasms: a case report.
Spinal Cord Injuries
Long-term neurogenic lower urinary tract dysfunction: A case of cardiovascular nightmares.
Spinal Cord Injuries
Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Spinal Cord Injuries
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA.
Spinal Cord Injuries
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction.
Spinal Cord Injuries
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Spinal Cord Injuries
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology.
Spinal Cord Injuries
Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
Spinal Cord Injuries
Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
Spinal Cord Injuries
Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.
Spinal Cord Injuries
Perioperative Botulinum Toxin Injections to Enhance Surgical Outcomes in Patients With Spasticity: Preoperative, Intraoperative, and Postoperative Case Reports.
Spinal Cord Injuries
Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury.
Spinal Cord Injuries
Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
Spinal Cord Injuries
Re: side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings.
Spinal Cord Injuries
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
Spinal Cord Injuries
Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice.
Spinal Cord Injuries
Safety and efficacy of trigonal BTX-A injections for children with neurological detrusor overactivity secondary to spinal cord injury.
Spinal Cord Injuries
Side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings.
Spinal Cord Injuries
Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury.
Spinal Cord Injuries
The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats.
Spinal Cord Injuries
The effect of botulinum toxin on hand function after incomplete spinal cord injury at the level of C5/6: a case report.
Spinal Cord Injuries
The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization.
Spinal Cord Injuries
Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Spinal Cord Injuries
Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance.
Spinal Cord Injuries
Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury.
Spinal Cord Injuries
Treatment of Detrusor External Sphincter Dyssynergia Using Ultrasound-Guided Trocar Catheter Transurethral Botulinum Toxin A Injection in Men With Spinal Cord Injury.
Spinal Cord Injuries
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Spinal Cord Injuries
[Botulinum toxin for the treatment of overactive bladder - an overview.]
Spinal Cord Injuries
[Clinical research of electroacupuncture combined with acupoint-injection of botulinum toxin A in treating the muscle spasticity by spinal cord injury]
Spinal Cord Injuries
[Efficacy and safety of botulinum toxin in external urethral sphincter by transperineal way guided transrectal ultrasound and electromyography on chronic urinary retention due to spinal cord injury.]
Spinal Cord Injuries
[Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
Spinal Cord Injuries
[Medico-economic evaluation of urological cares of spinal cord injured patients: A review].
Spinal Cord Injuries
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]
Spinal Cord Injuries
[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]
Spinal Cord Injuries
[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
Spinal Curvatures
Conservative Treatment of Neuromuscular Scoliosis in Adult Tetraplegia: A Case Report.
Spinal Dysraphism
Intra-Detrusor Injections of Botulinum Toxin Type a in Children with Spina Bifida: a Multicenter Study.
Spinal Dysraphism
Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism.
Spinal Dysraphism
Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
Spinal Dysraphism
Outcomes of Intradetrusor OnabotulinumtoxinA Injection in Adults with Congenital Spinal Dysraphism in Tertiary Transitional Urology Clinic.
Spinal Dysraphism
Re: Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism.
Spinal Dysraphism
Study of botulinum toxin A in neurogenic bladder due to spina bifida in children.
Spinal Muscular Atrophies of Childhood
Successful botulinum toxin treatment of dysphagia in a spinal muscular atrophy type 2 patient.
Spinal Stenosis
Botulinum Toxin Treatment for Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial.
Spinocerebellar Ataxias
Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease).
Spinocerebellar Ataxias
Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy.
Spondylolysis
Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm.
Squamous Cell Carcinoma of Head and Neck
Resveratrol suppresses malignant progression of oral squamous cell carcinoma cells by inducing the ZNF750/RAC1 signaling pathway.
Status Epilepticus
Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy.
Status Epilepticus
Intranasal Delivery of Botulinum Neurotoxin A Protects against Hippocampal Neuron Death in the Lithium-Pilocarpine Rat Model.
Stiff-Person Syndrome
Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome.
Stiff-Person Syndrome
Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A.
Stomatitis, Aphthous
The value of local botulinum toxin A injection in the treatment of the pain of aphthous ulcer.
Strabismus
A case of thrombosis of subcutaneous anterior chest veins (Mondor's disease) as an unusual complication of botulinum type A injection.
Strabismus
A five-year analysis of botulinum toxin type A injections: some unusual features.
Strabismus
Acquired Esotropia in Cerebellar Disease: A Case Series Illustrating Misdiagnosis as Isolated Lateral Rectus Paresis and Progression Over Time.
Strabismus
Action of Botulinum Toxin on Isometric Contraction of Medial and Lateral Rectus Muscles in Esotropic or Exotropic Patients.
Strabismus
Adjustable graded augmentation of superior rectus transposition for treatment of abducens nerve palsy and Duane syndrome.
Strabismus
Adjustable versus non-adjustable suture techniques for concomitant horizontal strabismus: a comparative study.
Strabismus
Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.
Strabismus
An investigation of the clinical use of botulinum toxin A as a postoperative adjustment procedure in the therapy of strabismus.
Strabismus
Augmented superior rectus transposition with medial rectus recession in patients with abducens nerve palsy.
Strabismus
Botulinum isn't just a poison anymore. Botulinum toxin in treatment of strabismus and essential blepharospasm.
Strabismus
Botulinum toxin a as an intraoperative adjunct to horizontal strabismus surgery.
Strabismus
Botulinum toxin A therapy for medial rectus injury during endoscopic sinus surgery.
Strabismus
Botulinum toxin as a postoperative diplopia test - it can also reduce the angle of deviation prior to surgery.
Strabismus
Botulinum Toxin as an Adjunct to Monocular Recession-Resect?on Surgery for Large-angle Sensory Strabismus.
Strabismus
Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas.
Strabismus
Botulinum toxin chemodenervation for childhood strabismus in England: National and local patterns of practice.
Strabismus
Botulinum toxin chemodenervation in infants and children: an alternative to incisional strabismus surgery.
Strabismus
Botulinum Toxin for the Treatment of Cyclic Strabismus in Children: Three Case Reports.
Strabismus
Botulinum toxin in the treatment of paralytic strabismus and essential blepharospasm.
Strabismus
Botulinum toxin in the treatment of strabismus. A review of its use and effects.
Strabismus
Botulinum toxin injection for postoperative diplopia testing in adult strabismus.
Strabismus
Botulinum Toxin Injection for the Treatment of Strabismus: A Report by the American Academy of Ophthalmology.
Strabismus
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
Strabismus
Botulinum toxin injection into the superior rectus muscle of the non-dominant eye for dissociated vertical deviation.
Strabismus
Botulinum toxin injection of the inferior oblique muscles for V-pattern strabismus and primary position hypertropia
Strabismus
Botulinum toxin therapy for strabismus and blepharospasm: Bascom Palmer Eye Institute experience.
Strabismus
Botulinum toxin treatment of extraocular muscles in rabbits results in increased myofiber remodeling.
Strabismus
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Strabismus
Botulinum toxin uses in strabismus: A review of the injections performed during one year in a general hospital.
Strabismus
Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.
Strabismus
Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics.
Strabismus
Comparison of Botulinum Toxin With Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children.
Strabismus
Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study.
Strabismus
Electrophysiology of Extraocular Cranial Nerves: Oculomotor, Trochlear, and Abducens Nerve.
Strabismus
Evolving trends in strabismus following retinal surgery: is there still a role for botulinum toxin?
Strabismus
Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment.
Strabismus
Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.
Strabismus
Horner's syndrome and sixth nerve paresis secondary to a petrous internal carotid artery aneurysm.
Strabismus
Injection of type A botulinum toxin into extraocular muscles for correction of strabismus.
Strabismus
Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology.
Strabismus
Ketamine and botulinum: a safe combinationfor the management of childhood strabismus.
Strabismus
Long-term management of strabismus with multiple repeated injections of botulinum toxin.
Strabismus
Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.
Strabismus
Observations on bilateral simultaneous botulinum toxin injection in infantile esotropia.
Strabismus
Ophthalmology: Botulinum Toxin Therapy in the Management of Strabismus and Lid Disorders.
Strabismus
Predictors of Good Motor and Sensory Outcomes Following Strabismus Surgery for Patients with Third Nerve Palsies.
Strabismus
Presence of fusion in albinism after strabismus surgery augmented with botulinum toxin (type a) injection.
Strabismus
Prospective evaluation of anesthetic protocols during pediatric ophthalmic surgery.
Strabismus
Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm.
Strabismus
Rates of Reoperation and Abnormal Binocularity Following Strabismus Surgery in Children.
Strabismus
Recession-resection surgery augmented with botulinum toxin a chemodenervation for paralytic horizontal strabismus.
Strabismus
Registered eye position: short- and long-term effects of botulinum toxin injected into eye muscle.
Strabismus
Role of inferior rectus botulinum toxin injection in iatrogenic vertical strabismus.
Strabismus
Role of inferior rectus botulinum toxin injection in vertical strabismus resulting from orbital pathology.
Strabismus
Strabismus in adults with uveal melanoma following episcleral plaque brachytherapy.
Strabismus
Strabismus surgery for adults: a report by the American Academy of Ophthalmology.
Strabismus
The aetiology and management of long-lasting sixth nerve palsy in ophthalmoplegic migraine.
Strabismus
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Strabismus
The Effect of Botulinum Toxin Augmentation on Strabismus Surgery for Large-Angle Infantile Esotropia.
Strabismus
The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismus.
Strabismus
The Efficacy of Dose Increments of Botulinum Toxin A in the Treatment of Childhood Esotropia.
Strabismus
The management of strabismus in patients with chronic progressive external ophthalmoplegia.
Strabismus
The mechanisms of action of Botulinum Toxin type A in nociceptive and neuropathic pathways in Cancer Pain.
Strabismus
The pupillary effects of retrobulbar injection of botulinum toxin A (oculinum) in albino rats.
Strabismus
The Role of Botulinum Toxin in the Management of Ophthalmoplegia Secondary to Miller Fisher Syndrome.
Strabismus
The role of botulinus toxin type A in treatment--with special reference to children.
Strabismus
The Use of Botulinum Toxin in a Case of Acquired Periodic Alternating Nystagmus.
Strabismus
The Use of Botulinum Toxin to Treat Infantile Esotropia: A Systematic Review With Meta-Analysis.
Strabismus
The use of botulinum toxin to treat strabismus following retinal detachment surgery.
Strabismus
Three-dimensional computer reconstruction of the distribution of neuromuscular junctions in the thyroarytenoid muscle.
Strabismus
To what extent may Botulinum toxin type A injections be an alternative choice to surgery in infantile esotropia?
Strabismus
Treating strabismus by injecting the agonist muscle with bupivacaine and the antagonist with botulinum toxin.
Strabismus
Treatment of strabismus after retinal detachment surgery with botulinum neurotoxin A.
Strabismus
Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications.
Strabismus
Ultrastructural changes in myotendinous nerve endings induced by injection of botulinum toxin into the extraocular muscle.
Strabismus
Ultrastructural changes in the masseter muscle of Macaca fascicularis resulting from intramuscular injections of botulinum toxin type A.
Strabismus
Use of botulinum toxin in small-angle heterotropia and decompensating heterophoria: a review of the literature.
Strabismus
Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children.
Strabismus
Using Botulinum Toxin A as an Adjunct in the Surgery of Large-Angle Sensory Exotropia and Abducens Nerve Palsy.
Strabismus
Vitreous hemorrhage and Rhegmatogenous retinal detachment that developed after botulinum toxin injection to the extraocular muscle: case report.
Strabismus
[Ameliorating strabismus, preventing blepharospasm: botulinum toxin can do more than smooth wrinkles]
Strabismus
[Botulinum injection in infantile strabismus. Results and incidence on secondary surgery in a long-term survey of 74 cases treated before 36 months of age]
Strabismus
[Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?]
Strabismus
[Botulinum toxin treatment for horizontal strabismus in children with cerebral palsy]
Strabismus
[Metabolic changes in brain cortex related with the strabismus treatment. Preliminary results with SPECT]
Strabismus
[Results with botulinum toxin in patients with esotropia and psychomotor deficit.]
Strabismus
[Spectral analysis of electromyograms in the strabismus cases--before and after botulinum toxin injection]
Strabismus
[The application of botulinun toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy]
Strabismus
[Treatment of strabismus associated with psychomotor impairment using botulinum toxin.]
Strabismus
[Treatment of strabismus by injecting botulinum toxin A into the oculomotor muscles]
Stroke
A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury.
Stroke
A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
Stroke
A pilot study to investigate the combined use of botulinum neurotoxin type a and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke.
Stroke
A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke.
Stroke
A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Stroke
A randomized controlled trial of selective neurotomy versus botulinum toxin for spastic equinovarus foot after stroke.
Stroke
A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.
Stroke
A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.
Stroke
Accuracy of botulinum toxin type A injection into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist: manual needle placement evaluated using ultrasonography.
Stroke
Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial.
Stroke
An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial.
Stroke
Analysis of a 15-years' experience in including shoulder muscles, when treating upper-limb spasticity post-stroke with botulinum toxin type A.
Stroke
Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients.
Stroke
Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke.
Stroke
Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population.
Stroke
Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A.
Stroke
Association between botulinum toxin injection into the arm and changes in gait in adults after stroke.
Stroke
Association of Long-Term Treatment by Botulinum Neurotoxins and Occupational Therapy with Subjective Physical Status in Patients with Post-Stroke Hemiplegia.
Stroke
Beyond speed: Gait changes after botulinum toxin injections in chronic stroke survivors (a systematic review).
Stroke
BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
Stroke
Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Stroke
Botulinum Toxin (BT) injection improves voluntary motor control in selected patients with post-stroke spasticity.
Stroke
Botulinum Toxin A and Task-Specific Training for Hand Dystonia due to 5 Year Old Stroke.
Stroke
Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes.
Stroke
Botulinum toxin A modifies nociceptive withdrawal reflex in subacute stroke patients.
Stroke
Botulinum toxin a, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study.
Stroke
Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: A meta-analysis.
Stroke
Botulinum toxin for the management of muscle overactivity and spasticity after stroke.
Stroke
Botulinum Toxin for the Upper Limb After Stroke (BoTULS) Trial: Effect on Impairment, Activity Limitation, and Pain.
Stroke
Botulinum toxin in the treatment of intestinal pseudo-obstruction following a stroke.
Stroke
Botulinum Toxin Injection for Hypertonicity of the Upper Extremity Within 12 Weeks After Stroke: A Randomized Controlled Trial.
Stroke
Botulinum Toxin Injection for Spastic Scapular Dyskinesia After Stroke: Case Series.
Stroke
Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques.
Stroke
Botulinum Toxin Injections and Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke.
Stroke
Botulinum Toxin Therapy Combined with Rehabilitation for Stroke: A Systematic Review of Effect on Motor Function.
Stroke
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
Stroke
Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity.
Stroke
Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial.
Stroke
Botulinum toxin type A combined with neurodynamic mobilization for upper limb spasticity after stroke: a case report.
Stroke
Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients.
Stroke
Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis.
Stroke
Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
Stroke
Botulinum Toxin Type A for Upper Limb Spasticity in Poststroke Patients: A Meta-analysis of Randomized Controlled Trials.
Stroke
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.
Stroke
Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques.
Stroke
Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke.
Stroke
Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
Stroke
Botulinum Toxin Type A Treatment Combined with Intensive Rehabilitation for Gait Poststroke: A Preliminary Study.
Stroke
Botulinum toxin type-A in the management of spastic equinovarus deformity after stroke. Comparison of 2 injection techniques.
Stroke
Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.
Stroke
BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Stroke
Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques.
Stroke
Can the early use of botulinum toxin in post stroke spasticity reduce contracture development? A randomised controlled trial.
Stroke
Can the positions of the spastic upper limb in stroke survivors help muscle choice for botulinum toxin injections?
Stroke
Casting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single-blind randomised trial on adult stroke patients.
Stroke
Changes in cerebral activity after decreased upper-limb hypertonus: an EMG-fMRI study.
Stroke
Changes in the Neural and Non-neural Related Properties of the Spastic Wrist Flexors After Treatment With Botulinum Toxin A in Post-stroke Subjects: An Optimization Study.
Stroke
Characterization of Differences in the Time Course of Reflex and Voluntary Responses Following Botulinum Toxin Injections in Chronic Stroke Survivors.
Stroke
Clinical study of botulinum toxin A injection combined with spasmodic muscle therapeutic instrument on lower limb spasticity in patients with stroke.
Stroke
Color Doppler ultrasound-guided botulinum toxin type A injection combined with an ankle foot brace for treating lower limb spasticity after a stroke.
Stroke
Combination therapy with repetitive facilitative exercise program and botulinum toxin type A to improve motor function for the upper-limb spastic paresis in chronic stroke: A randomized controlled trial.
Stroke
Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity: A Randomized Controlled Study.
Stroke
Combined effect of botulinum toxin and splinting on motor components and function of people suffering a stroke.
Stroke
Combined effects of backward treadmill training and botulinum toxin type A therapy on gait and balance in patients with chronic stroke: A pilot, single-blind, randomized controlled trial.
Stroke
Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke.
Stroke
Combined effects of botulinum toxin type A and repetitive transcranial magnetic stimulation with intensive motor training immediately after injection in a patient with chronic stroke: A case report.
Stroke
Combined Effects of Isokinetic Training and Botulinum Toxin Type A on Spastic Equinus Foot in Patients with Chronic Stroke: A Pilot, Single-blind, Randomized Controlled Trial.
Stroke
Combined effects of robot-assisted gait training and botulinum toxin type A effect on spastic equinus foot in patients with chronic stroke: a pilot, single blind, randomized controlled trial.
Stroke
Combined therapeutic application of botulinum toxin type A, low-frequency rTMS, and intensive occupational therapy for post-stroke spastic upper limb hemiparesis.
Stroke
Combined treatment of botulinumtoxin and robot-assisted rehabilitation therapy on poststroke, upper limb spasticity: A case report.
Stroke
Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity.
Stroke
Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study.
Stroke
Constraint-induced movement therapy after injection of Botulinum toxin improves spasticity and motor function in chronic stroke patients.
Stroke
Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report.
Stroke
Cortical Activation Changes in Patients Suffering from Post-Stroke Arm Spasticity and Treated with Botulinum Toxin A.
Stroke
Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: real and imagined hand movement.
Stroke
Cortical somatosensory processing after botulinum toxin therapy in post-stroke spasticity.
Stroke
Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective.
Stroke
Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial.
Stroke
Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use.
Stroke
Current issues and considerations about the central role of rehabilitation therapies in the functional recovery of neurological impairments after stroke in adults.
Stroke
Design and implementation of botulinum toxin on cricopharyngeal dysfunction guided by a combination of catheter balloon, ultrasound, and electromyography (BECURE) in patients with stroke: study protocol for a randomized, double-blinded, placebo-controlled trial.
Stroke
Diagnostic nerve block in prediction of outcome of botulinum toxin treatment for spastic equinovarus foot after stroke: A retrospective observational study.
Stroke
Disabling overactivity of the extensor hallucis longus after stroke: clinical expression and efficacy of botulinum toxin type A.
Stroke
Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity.
Stroke
Do gait parameters improve after botulinum toxin injections in post stroke patients? A prospective study.
Stroke
Does botulinum toxin injection site determine outcome in post-stroke plantarflexion spasticity? Comparison study of two injection sites in the gastrocnemius muscle: a randomized double-blind controlled trial.
Stroke
Does Botulinum Toxin Treatment Affect the Ultrasonographic Characteristics of Post-Stroke Spastic Equinus? A Retrospective Pilot Study.
Stroke
Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial.
Stroke
Does low-dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot study to estimate effect size.
Stroke
Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.
Stroke
Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis.
Stroke
Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.
Stroke
Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.
Stroke
Early Botulinum Toxin Type A Injection for Post-Stroke Spasticity: A Longitudinal Cohort Study.
Stroke
Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study.
Stroke
Effect of Botulinum Toxin on the Spatial Distribution of Biceps Brachii EMG Activity Using a Grid of Surface Electrodes: A Case Study.
Stroke
Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke.
Stroke
Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot).
Stroke
Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients.
Stroke
Effect of rehabilitation and botulinum toxin injection on gait in chronic stroke patients: a randomized controlled study.
Stroke
Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait.
Stroke
Effect of the combination of botulinum toxin A injection in elbow flexor muscles and rehabilitation on cortical oscillatory activity in individuals with stroke.
Stroke
Effect of Upper Limb Botulinum Toxin Injections on Impairment, Activity, Participation, and Quality of Life Among Stroke Patients.
Stroke
Effective use of chemodenervation and chemical neurolysis in the management of poststroke spasticity.
Stroke
Effectiveness of Botulinum Toxin for Lower Limbs Spasticity after Stroke: A Systematic Review and Meta-Analysis.
Stroke
Effectiveness of botulinum toxin treatment for upper limb spasticity after stroke over different ICF domains: a systematic review and meta-analysis.
Stroke
Effectiveness of Robot-Assisted Upper Limb Training on Spasticity, Function and Muscle Activity in Chronic Stroke Patients Treated With Botulinum Toxin: A Randomized Single-Blinded Controlled Trial.
Stroke
Effectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case report.
Stroke
Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): protocol study for a randomised controlled, investigator blinded study.
Stroke
Effects of botulinum neurotoxin on spatio-temporal gait parameters of patients with chronic stroke: a prospective open-label study.
Stroke
Effects of botulinum toxin type A for spastic foot in post-stroke patients enrolled in a rehabilitation program.
Stroke
Effects of l-Carnitine Supplementation, Botulinum Neurotoxin Injection, and Rehabilitation for a Chronic Stroke Patient.
Stroke
Effects of robot-assisted gait training in chronic stroke patients treated by botulinum toxin-a: A pivotal study.
Stroke
Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis.
Stroke
Efficacy and Optimal Dose of Botulinum Toxin A in Post-Stroke Lower Extremity Spasticity: A Systematic Review and Meta-Analysis.
Stroke
Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials.
Stroke
Efficacy and safety of Botulinum Toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.
Stroke
Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.
Stroke
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Stroke
Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity.
Stroke
Efficacy of physical therapy associated with botulinum toxin type A on functional performance in post-stroke spasticity: A randomized, double-blinded, placebo-controlled trial.
Stroke
Efficacy of therapeutic ultrasound and transcutaneous electrical nerve stimulation compared with botulinum toxin type a in the treatment of spastic equinus in adults with chronic stroke: a pilot randomized controlled trial.
Stroke
Efficacy of two injection-site localisation techniques for botulinum toxin injections: a single-blind, crossover, randomised trial protocol among adults with hemiplegia due to stroke.
Stroke
Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke.
Stroke
Erratum to 'Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy' [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 1 (January), 2020: 104481].
Stroke
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients; an observational study.
Stroke
Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity.
Stroke
Experienced consequences of spasticity and effects of botulinum toxin injections: a qualitative study amongst patients with disabling spasticity after stroke.
Stroke
Exploratory Randomized Double-Blind Placebo-Controlled Trial of Botulinum Therapy on Grasp Release After Stroke (PrOMBiS).
Stroke
Factors Influencing Gait Velocity Improvement Following Botulinum Toxin Injection for Spasticity of the Plantar Flexors in Patients with Stroke.
Stroke
Feasibility of single and combined with other treatments using transcranial direct current stimulation for chronic stroke: A pilot study.
Stroke
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
Stroke
Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.
Stroke
Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX).
Stroke
Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.
Stroke
Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients.
Stroke
Further Assessment to Determine the Additive Effect of Botulinum Toxin Type A on an Upper Extremity Exercise Program to Enhance Function Among Individuals With Chronic Stroke but Extensor Capability.
Stroke
Gait improvement by low-dose botulinum toxin A injection treatment of the lower limbs in subacute stroke patients.
Stroke
Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection.
Stroke
Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study.
Stroke
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Stroke
How effective is physical therapy for gait muscle activity in hemiparetic patients who receive botulinum toxin injections?
Stroke
Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial.
Stroke
Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study.
Stroke
Impact of instrumental analysis of stiff knee gait on treatment appropriateness and associated costs in stroke patients.
Stroke
IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study.
Stroke
Influence of physician empathy on the outcome of botulinum toxin treatment for upper limb spasticity in patients with chronic stroke: A cohort study.
Stroke
Intensive therapy after botulinum toxin in adults with spasticity after stroke versus botulinum toxin alone or therapy alone: a pilot, feasibility randomized trial.
Stroke
Intracortical Circuits in the Contralesional Primary Motor Cortex in Patients With Chronic Stroke After Botulinum Toxin Type A Injection: Case Studies.
Stroke
Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide.
Stroke
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
Stroke
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke.
Stroke
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Stroke
Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial.
Stroke
Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
Stroke
Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients?
Stroke
Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to stroke.
Stroke
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
Stroke
Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke.
Stroke
Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke.
Stroke
Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors.
Stroke
Modification of altered ankle motor control after stroke using focal application of botulinum toxin type A.
Stroke
Modulation of Cortical Activity in Patients Suffering from Upper Arm Spasticity following Stroke and Treated with Botulinum Toxin A: An fMRI Study.
Stroke
More than a black box of rehabilitation: Characterizing therapy programmes following botulinum toxin injections for spasticity in adults with stroke.
Stroke
Multidimensional evaluation of changes in limb function following botulinum toxin injection in persons with stroke.
Stroke
Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.
Stroke
Orthotic functional electrical stimulation following botulinum toxin for a young adult with severe hand impairment due to childhood stroke.
Stroke
Outcomes of ambulatory rehabilitation programmes following botulinum toxin for spasticity in adults with stroke.
Stroke
Pain and muscles properties modifications after botulinum toxin type A (BTX-A) and radial Extracorporeal Shock Wave (rESWT) combined treatment.
Stroke
Passive Properties of the Wrist and Fingers Following Chronic Hemiparetic Stroke: Interlimb Comparisons in Persons With and Without a Clinical Treatment History That Includes Botulinum Neurotoxin.
Stroke
Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.
Stroke
Patient Registry of Spasticity Care World: Data Analysis Based on Physician Experience.
Stroke
Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments.
Stroke
Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk.
Stroke
Perioperative Botulinum Toxin Injections to Enhance Surgical Outcomes in Patients With Spasticity: Preoperative, Intraoperative, and Postoperative Case Reports.
Stroke
Pharmacological interventions other than botulinum toxin for spasticity after stroke.
Stroke
Physical therapy for an adult with chronic stroke after botulinum toxin injection for spasticity: a case report.
Stroke
Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B.
Stroke
Possible Adverse Effects of Repeated Botulinum Toxin A Injections to Decrease Post-Stroke Spasticity in Adults Undergoing Rehabilitation: A Review of the Literature.
Stroke
Potential Benefits for Caregivers of Stroke Survivors Receiving BTX-A and Exercise for Upper Extremity Spasticity.
Stroke
Precise quantification of the time course of voluntary activation capacity following Botulinum toxin injections in the biceps brachii muscles of chronic stroke survivors.
Stroke
Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patients on Anticoagulation or Antiplatelet Therapy.
Stroke
Quantitative assessment for flexed-elbow deformity during gait following botulinum toxin A treatment.
Stroke
Quantitative measurement of poststroke spasticity and response to treatment with botulinum toxin: a 2-patient case report.
Stroke
RE: Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Spastic Equinus in Adults with Stroke.
Stroke
RE: BOTULINUM TOXIN TYPE A INJECTION INTO THE GASTROCNEMIUS MUSCLE FOR SPASTIC EQUINUS IN ADULTS WITH STROKE.
Stroke
Recovery of gait and other motor functions after stroke: novel physical and pharmacological treatment strategies.
Stroke
Rectus Femoris Characteristics in Post Stroke Spasticity: Clinical Implications from Ultrasonographic Evaluation.
Stroke
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Stroke
Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
Stroke
Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial.
Stroke
Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.
Stroke
Robotic rehabilitation for end-effector device and botulinum toxin in upper limb rehabilitation in chronic post-stroke patients: an integrated rehabilitative approach.
Stroke
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Stroke
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity.
Stroke
Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.
Stroke
SBOTE study: extracorporeal shock wave therapy versus electrical stimulation after botulinum toxin type a injection for post-stroke spasticity-a prospective randomized trial.
Stroke
Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study.
Stroke
Self-rehabilitation combined with botulinum toxin to improve arm function in people with chronic stroke. A randomized controlled trial.
Stroke
Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb.
Stroke
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Stroke
Somatosensory evoked potentials of hand muscles in stroke and their modification by botulinum toxin: a preliminary study.
Stroke
Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy.
Stroke
Spinal plasticity in stroke patients after botulinum neurotoxin A injection in ankle plantar flexors.
Stroke
Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Stroke
The Clinical Efficacy of Botulinum Toxin Injections to the Upper Lumbrical Muscles for Clenched Fist Deformity in Chronic Stroke Patients.
Stroke
The effect of botulinum toxin injections on gait control in spastic stroke patients presenting with a stiff-knee gait.
Stroke
The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation.
Stroke
The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury.
Stroke
The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial.
Stroke
The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia.
Stroke
The efficacy of serial casting after botulinum toxin type A injection in improving equinovarus deformity in patients with chronic stroke.
Stroke
The Efficacy of Ultrasound-guided Selective Botulinum Toxin Type A Therapy for Finger Spasticity Following Stroke: A Case Report.
Stroke
The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke.
Stroke
Therapeutic efficacy and safety of various botulinum toxin A doses and concentrations in spastic foot after stroke: a randomized controlled trial.
Stroke
Therapeutic Synergism in the Treatment of Post-stroke Arm Paresis Utilizing Botulinum Toxin, Robotic Therapy, and Constraint-induced Movement Therapy.
Stroke
Time course analysis of the effects of botulinum toxin type a on elbow spasticity based on biomechanic and electromyographic parameters.
Stroke
Transcranial magnetic stimulation predicts functional recovery after botulinum toxin treatment in stroke patients.
Stroke
Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.
Stroke
Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201.
Stroke
Treatment With Botulinum Toxin Improves Upper-Extremity Function Post Stroke: A Systematic Review and Meta-Analysis.
Stroke
Ultrasonographic Evaluation of Botulinum Toxin Injection Site for the Medial Approach to Tibialis Posterior Muscle in Chronic Stroke Patients with Spastic Equinovarus Foot: An Observational Study.
Stroke
Ultrasound-Guided BoNT-A (Botulinum Toxin A) Injection Into the Subscapularis for Hemiplegic Shoulder Pain: A Randomized, Double-Blind, Placebo-Controlled Trial.
Stroke
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
Stroke
Upper limb motor improvement in chronic stroke after combining botulinum toxin A injection and multi-joints robot-assisted therapy: a case report.
Stroke
Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait.
Stroke
Use of surface EMG for evaluation of upper limb spasticity during botulinum toxin therapy in stroke patients.
Stroke
[Comparative analysis of occupational therapy benefits in spastic patients with hands involvement before and after botulinum toxin infiltration]
Stroke
[Experience in using xeomin in the treatment of arm and hand spasticity in the early rehabilitation phase of stroke].
Stroke
[Treatment and indication of botulinum toxin type A for limb spasticity - can we break the 6 months barrier?].
Stroke
[Treatment of focal upper limb spasticity with botulinum toxin after stroke. Interest of an individual approach.]
Subarachnoid Hemorrhage
Botulinum toxin a treatment of cricopharyngeal dysphagia after subarachnoid hemorrhage.
Sunburn
UV-B irradiation attenuates dermal effects of botulinum toxin A: a randomized, double-blind, placebo-controlled study.
Supranuclear Palsy, Progressive
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Supranuclear Palsy, Progressive
Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases.
Supranuclear Palsy, Progressive
Botulinum toxin-A improves the rigidity of progressive supranuclear palsy.
Supranuclear Palsy, Progressive
Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.
Sweating, Gustatory
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Sweating, Gustatory
Bilateral gustatory sweating in the submandibular region after bilateral neck dissection successfully treated with botulinum toxin.
Sweating, Gustatory
Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey's syndrome).
Sweating, Gustatory
Botulinum toxin for Frey's syndrome: a closer look at different treatment responses.
Sweating, Gustatory
Botulinum toxin therapy in Frey's syndrome: a retrospective study of 440 treatments in 100 patients.
Sweating, Gustatory
Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders.
Sweating, Gustatory
Botulinum toxin type A for Frey's syndrome: a preliminary prospective study.
Sweating, Gustatory
Botulinum toxin: 28 patients affected by Frey's syndrome treated with intradermal injections.
Sweating, Gustatory
Botulinum toxoid in the management of gustatory sweating (Frey's syndrome) after superficial parotidectomy.
Sweating, Gustatory
Clinical results in the management of Frey's syndrome with injections of Botulinum toxin.
Sweating, Gustatory
Congenital Frey's syndrome associated with nontraumatic bilateral trifid mandibular condyle.
Sweating, Gustatory
Control of Frey's syndrome in patients treated with botulinum toxin type A.
Sweating, Gustatory
Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.
Sweating, Gustatory
Frey's syndrome and botulinum toxin type A: duration of efficacy and patient satisfaction.
Sweating, Gustatory
Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A.
Sweating, Gustatory
Increased botulinum toxin type A dosage is more effective in patients with Frey's syndrome.
Sweating, Gustatory
Management of Frey's syndrome and hypersialorrhea with botulinum toxin.
Sweating, Gustatory
Management of parotid fistula and Frey's syndrome with Botulinum neurotoxin type A.
Sweating, Gustatory
Not only gustatory sweating and flushing: Signs and symptoms associated to the Frey syndrome and the role of botulinum toxin A therapy.
Sweating, Gustatory
Preliminary experience with botulinum toxin type A intracutaneous injection for Frey's syndrome.
Sweating, Gustatory
Re: Clark M, Koppel DA. Botulinum toxin in the treatment of Frey's syndrome (Letter). Br J Oral Maxillofac Surg 2001; 39: 483.
Sweating, Gustatory
Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome.
Sweating, Gustatory
Repeated botulinum toxin type A injections to treat patients with Frey syndrome.
Sweating, Gustatory
Role of medical thermography in treatment of Frey's syndrome with botulinum toxin A.
Sweating, Gustatory
The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A.
Sweating, Gustatory
The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes.
Sweating, Gustatory
Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin.
Sweating, Gustatory
Treatment of Frey's syndrome with topical ammonium alum: First report with twenty two cases.
Sweating, Gustatory
Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A.
Sweating, Gustatory
Treatment of gustatory sweating with low-dose botulinum toxin A: a case report.
Sweating, Gustatory
Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome).
Sweating, Gustatory
[Botulinum toxin for the treatment of secretory disorders of the head and neck area].
Sweating, Gustatory
[Botulinum toxin for treatment of gustatory sweating. A prospective randomized study]
Sweating, Gustatory
[Effectiveness of botulinum toxin A in the treatment of gustatory sweating]
Sweating, Gustatory
[Post-parotidectomy Frey's syndrome. Treatment with botulinum toxin type A]
Sweating, Gustatory
[Severe Frey syndrome after parotidectomy: treatment with botulinum neurotoxin type A]
Sweating, Gustatory
[Therapy of Frey syndrome with botulinum toxin A. Experiences with a new method of treatment]
Sweating, Gustatory
[Treatment of Frey syndrome with intracutaneous injections of botulinum toxin]
Synkinesis
An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire.
Synkinesis
Botulinum toxin in management of synkinesis in patients with unilateral and bilateral vocal fold paralysis.
Synkinesis
Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis.
Synkinesis
Buccinator synkinesis treated by botulinum toxin in facial palsy and hemifacial spasms.
Synkinesis
Complications of botulinum toxin application: differences between hemifacial spasm and post-facial palsy synkinesis.
Synkinesis
Congenital Oculonasal Synkinesis: Botulinum Toxin A in the Treatment of a Pure Facial Synkinesis.
Synkinesis
Cutaneous cooling to manage botulinum toxin injection-associated pain in patients with facial palsy: A randomised controlled trial.
Synkinesis
Diagnosis and management with botulinum toxin in 11 cases of laryngeal synkinesis.
Synkinesis
Discussion: quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type A.
Synkinesis
Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Synkinesis
Effect of botulinum toxin typeA in functionality, synkinesis and quality of life in peripheral facial palsy sequelae.
Synkinesis
Epidemiologic Overview of Synkinesis in 353 Patients with Longstanding Facial Paralysis under Treatment with Botulinum Toxin for 11 Years.
Synkinesis
Epidemiological overview of synkinesis in 353 patients with longstanding facial paralysis under treatment with botulinum toxin for 11 years.
Synkinesis
Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy.
Synkinesis
Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
Synkinesis
Long-Term Changes in the Treatment Pattern of Botulinum Toxin A Injections for Postfacial Paralysis Synkinesis Following Modified Selective Neurectomy.
Synkinesis
Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: a case-series study.
Synkinesis
Long-term therapy with botulinum toxin in facial synkinesis: Retrospective data analysis of data from 1998 to 2018.
Synkinesis
Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation.
Synkinesis
Management of Facial Synkinesis with a Combination of BTX-A and Biofeedback: A Randomized Trial.
Synkinesis
Masseteric-to-Facial Nerve Transfer and Selective Neurectomy for Rehabilitation of the Synkinetic Smile.
Synkinesis
Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis.
Synkinesis
Quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type A.
Synkinesis
Re: "Treating Buccinator with Botulinum Toxin in Patients with Facial Synkinesis: A Previously Overlooked Target".
Synkinesis
Reply re: "Treating Buccinator with Botulinum Toxin in Patients with Facial Synkinesis: A Previously Overlooked Target".
Synkinesis
Reply: Epidemiologic Overview of Synkinesis in 353 Patients with Longstanding Facial Paralysis under Treatment with Botulinum Toxin for 11 Years.
Synkinesis
Reply: Epidemiological overview of synkinesis in 353 patients with longstanding facial paralysis under treatment with botulinum toxin for 11 years.
Synkinesis
Subjective and objective outcome measures in the treatment of facial nerve synkinesis with onabotulinumtoxinA (Botox).
Synkinesis
Synkinesis in primary and postparalytic hemifacial spasm: Clinical features and therapeutic outcomes of botulinum toxin A treatment.
Synkinesis
Targeted chemodenervation of the posterior belly of the digastric muscle for the management of jaw discomfort in facial synkinesis.
Synkinesis
The use of botulinum toxin in head and face medicine: an interdisciplinary field.
Synkinesis
Treating Buccinator With Botulinum Toxin in Patients With Facial Synkinesis: A Previously Overlooked Target.
Synkinesis
Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy.
Synkinesis
Treatment Patterns and Outcomes in Botulinum Therapy for Patients With Facial Synkinesis.
Synkinesis
Validation of a new photogrammetric technique to monitor the treatment effect of Botulinum toxin in synkinesis.
Synkinesis
Variability in the development of synkinesis in a rabbit facial nerve axotomy model.
Synkinesis
[Botulinum toxin injection effective for post-peripheral facial nerve palsy synkinesis]
Synkinesis
[Rehabilitation of facial palsy and vertigo in patients with vestibular schwannoma].
Synkinesis
[Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A].
Synkinesis
[The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery].
Synovitis
Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study.
Syringoma
Carbon dioxide laser combined with botulinum toxin A for patients with periorbital syringomas.
Tachycardia
Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One-Year Follow-Up of a Randomized Pilot Study.
Talipes
Tibialis anterior tendinopathy in a dystonic talipes calcaneovarus foot: A case treated by botulinum toxin.
Talipes Cavus
Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A.
Tardive Dyskinesia
An open-label study of botulinum toxin A for treatment of tardive dystonia.
Tardive Dyskinesia
Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia.
Tardive Dyskinesia
Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia.
Tardive Dyskinesia
Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study.
Tardive Dyskinesia
Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
Tardive Dyskinesia
Improvement of both tardive dystonia and akathisia after botulinum toxin injection.
Tardive Dyskinesia
Refractory Open Jaw Oromandibular Tardive Dystonia with a Sensory Trick, Treated with Botulinum Toxin: A Case Report.
Tardive Dyskinesia
Successful treatment of intractable tardive dyskinesia with botulinum toxin.
Tardive Dyskinesia
Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin.
Tardive Dyskinesia
Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect.
Tardive Dyskinesia
Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia.
Tarsal Tunnel Syndrome
Efficacy of a single botulinum toxin A injection for distal tarsal tunnel syndrome: A protocol for a randomized, double-blinded trial.
Tauopathies
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Temporomandibular Joint Disorders
A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment.
Temporomandibular Joint Disorders
A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism.
Temporomandibular Joint Disorders
Application of botulinum toxin in maxillofacial field: Part II. Wrinkle, intraoral ulcer, and cranio-maxillofacial pain.
Temporomandibular Joint Disorders
Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin.
Temporomandibular Joint Disorders
Botulinum toxin in the management of temporomandibular disorders: a systematic review.
Temporomandibular Joint Disorders
Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials.
Temporomandibular Joint Disorders
Botulinum toxin type A and acupuncture for masticatory myofascial pain: a randomized clinical trial.
Temporomandibular Joint Disorders
Botulinum toxin type A for painful temporomandibular disorders: systematic review and meta-analysis.
Temporomandibular Joint Disorders
Botulinum toxin: new treatment for temporomandibular disorders.
Temporomandibular Joint Disorders
Clinical Aspects of the Use of Botulinum Toxin Type A in the Treatment of Dysfunction of the Masticatory System.
Temporomandibular Joint Disorders
Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain?
Temporomandibular Joint Disorders
Efficacy of botulinum toxin therapy in treatment of myofascial pain.
Temporomandibular Joint Disorders
Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study.
Temporomandibular Joint Disorders
Erratum: Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.
Temporomandibular Joint Disorders
Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.
Temporomandibular Joint Disorders
Evaluation of patient satisfaction after botulinum toxin A injection for the management of masticatory myofascial pain and dysfunction - A pilot study.
Temporomandibular Joint Disorders
Important uncertainty regarding the effects of botulinum toxin in patients with temporomandibular disorders or bruxism owing to serious limitations of a systematic review.
Temporomandibular Joint Disorders
Improvement in quality of life after botulinum toxin injection for temporomandibular disorder.
Temporomandibular Joint Disorders
IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder.
Temporomandibular Joint Disorders
Intramuscular botulinum toxin injection additional to arthrocentesis in the management of temporomandibular joint pain.
Temporomandibular Joint Disorders
Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?
Temporomandibular Joint Disorders
MR-guided navigation for botulinum toxin injection in the lateral pterygoid muscle. First results in the treatment of temporomandibular joint disorders.
Temporomandibular Joint Disorders
Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique.
Temporomandibular Joint Disorders
Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX - A)for treatment of temporomandibular disorder.
Temporomandibular Joint Disorders
RE: Botulinum toxin in the management of temporomandibular disorders: a systematic review.
Temporomandibular Joint Disorders
Temporomandibular Myofacial Pain Treated with Botulinum Toxin Injection.
Temporomandibular Joint Disorders
The effect of laser and botulinum toxin in the treatment of myofascial pain and mouth opening: A randomized clinical trial.
Temporomandibular Joint Disorders
The emerging role of botulinum toxin in the treatment of temporomandibular disorders.
Temporomandibular Joint Disorders
The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review.
Temporomandibular Joint Disorders
The therapeutic use of botulinum toxin in cervical and maxillofacial conditions.
Temporomandibular Joint Disorders
The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review.
Temporomandibular Joint Disorders
The use of botulinum toxin for the treatment of temporomandibular disorder.
Temporomandibular Joint Disorders
The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings.
Temporomandibular Joint Disorders
The use of botulinum toxin-a in the treatment of muscular temporomandibular joint disorders.
Temporomandibular Joint Disorders
Treatment of temporomandibular disorders with botulinum toxin.
Temporomandibular Joint Disorders
[Botulinum toxin A: Analgesic treatment for temporomandibular joint disorders].
Temporomandibular Joint Disorders
[Efficacy of semiconductor laser therapy combined with botulinum toxin A type injection in treatment of temporomandibular disorders].
Tendinopathy
Comparative Effectiveness of Injection Therapies in Rotator Cuff Tendinopathy: A Systematic Review, Pairwise and Network Meta-analysis of Randomized Controlled Trials.
Tendinopathy
Intramuscular injection of Botox causes tendon atrophy by induction of senescence of tendon-derived stem cells.
Tendinopathy
Number of botulinum toxin injections needed to stop requests for treatment for chronic lateral epicondylar tendinopathy. A 1-year follow-up study.
Tendinopathy
Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study.
Tendinopathy
Tibialis anterior tendinopathy in a dystonic talipes calcaneovarus foot: A case treated by botulinum toxin.
Tendinopathy
Treatment of iliopsoas tendinitis after a left total hip arthroplasty with botulinum toxin type A.
Tennis Elbow
A single botulinum toxin injection at a precise anatomic point on the forearm reduces pain at rest, compared to placebo injection in patients with chronic refractory lateral epicondylitis.
Tennis Elbow
Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study.
Tennis Elbow
Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study.
Tennis Elbow
Comparative effectiveness of botulinum toxin versus non-surgical treatments for treating lateral epicondylitis: a systematic review and meta-analysis.
Tennis Elbow
Comparison Between Botulinum Toxin and Corticosteroid Injection in the Treatment of Acute and Subacute Tennis Elbow: A Prospective, Randomized, Double-Blind, Active Drug-Controlled Pilot Study.
Tennis Elbow
Comparison Between Steroid and 2 Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized, Double-Blind, Active Drug-Controlled Pilot Study.
Tennis Elbow
Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis.
Tennis Elbow
Efficacy of Botulinum Toxin in Treating Lateral Epicondylitis, Does Injection Location Matter? A Systematic Review.
Tennis Elbow
Efficacy of Botulinum Toxin in Treating Lateral Epicondylitis-Does Injection Location Matter?: A Systematic Review.
Tennis Elbow
Improved intramuscular blood flow and normalized metabolism in lateral epicondylitis after botulinum toxin treatment.
Tennis Elbow
Injection of Botulinum Toxin for Treatment of Chronic Lateral Epicondylitis: Systematic Review and Meta-Analysis.
Tennis Elbow
Injection of botulinum toxin to the extensor carpi radialis brevis for tennis elbow.
Tennis Elbow
Re: Lim et al. injection of botulinum toxin to the extensor carpi radialis brevis for tennis elbow.
Tennis Elbow
The Effect of Botulinum Toxin Injection into the Common Extensor Tendon in Patients with Chronic Lateral Epicondylitis: A Randomized Trial.
Tennis Elbow
Treatment of chronic plantar fasciitis with Botulinum toxin A: preliminary clinical results.
Tennis Elbow
Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.
Tennis Elbow
Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial.
Tension-Type Headache
A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache.
Tension-Type Headache
Application of botulinum toxin in maxillofacial field: Part II. Wrinkle, intraoral ulcer, and cranio-maxillofacial pain.
Tension-Type Headache
Application of botulinum toxin to clinical therapy: advances and cautions.
Tension-Type Headache
Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.
Tension-Type Headache
Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
Tension-Type Headache
Botulinum toxin a in prostate disease: a venom from bench to bed-side.
Tension-Type Headache
Botulinum Toxin A in the Treatment of Chronic Tension-Type Headache With Cervical Myofascial Trigger Points: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Tension-Type Headache
Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache.
Tension-Type Headache
Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm.
Tension-Type Headache
Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension.
Tension-Type Headache
Botulinum toxin as a preventive treatment for migraine and chronic tension headache.
Tension-Type Headache
Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.
Tension-Type Headache
Botulinum toxin type A (Botox) in the treatment of migraine and other headaches.
Tension-Type Headache
Botulinum toxin type A and EMG: a key to the understanding of chronic tension-type headaches?
Tension-Type Headache
Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
Tension-Type Headache
Botulinum toxin type A therapy for chronic tension-type headache: fact versus fiction.
Tension-Type Headache
Botulinum toxin: could it be an effective treatment for chronic tension-type headache?
Tension-Type Headache
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
Tension-Type Headache
Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial.
Tension-Type Headache
Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature.
Tension-Type Headache
Evidence based medicine on the use of botulinum toxin for headache disorders.
Tension-Type Headache
Evidence to Use Botulinum Toxin Injections in Tension-Type Headache Management: A Systematic Review.
Tension-Type Headache
Evidence-based medicine: botulinum toxin A in migraine and tension-type headache.
Tension-Type Headache
Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections.
Tension-Type Headache
Incidental Treatment of a Subclinical Chronic Tension-Type Headache by Cosmetic Use of Botulinum Toxin A: A Case Report.
Tension-Type Headache
Intramuscular innervation patterns of the splenius capitis and splenius cervicis and their clinical implications for botulinum toxin injections.
Tension-Type Headache
Investigating prophylactic botulinum toxin type A for chronic headache disorders.
Tension-Type Headache
Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study.
Tension-Type Headache
Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
Tension-Type Headache
Procedures for administering botulinum toxin type A for migraine and tension-type headache.
Tension-Type Headache
Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A.
Tension-Type Headache
Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache.
Tension-Type Headache
Review: Prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults.
Tension-Type Headache
The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache.
Tension-Type Headache
The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache.
Tension-Type Headache
Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
Tension-Type Headache
Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial.
Tension-Type Headache
Treatment of tension-type headache with botox: a review of the literature.
Tension-Type Headache
Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study.
Tension-Type Headache
Treatment of tension-type headache with botulinum toxin: a pilot study.
Tension-Type Headache
[Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes]
Tension-Type Headache
[Botulinum toxin type A in headache treatment : Established and experimental indications].
Tetanus
A late phase of exocytosis from synaptosomes induced by elevated [Ca2+]i is not blocked by Clostridial neurotoxins.
Tetanus
A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.
Tetanus
Acrosomal Swelling and Membrane Docking Are Required for Hybrid Vesicle Formation During the Human Sperm Acrosome Reaction.
Tetanus
Affinity chromatography of tetanus toxin, tetanus toxoid, and botulinum A toxin on synaptosomes, and differentiation of their acceptors.
Tetanus
Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes.
Tetanus
Antibodies against rat brain vesicle-associated membrane protein (synaptobrevin) prevent inhibition of acetylcholine release by tetanus toxin or botulinum neurotoxin type B.
Tetanus
Application of NMR methods to identify detection reagents for use in development of robust nanosensors.
Tetanus
Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells.
Tetanus
Black widow spider toxin-induced calcium fluxes and transmitter release in a neurosecretory cell line.
Tetanus
BotR/A and TetR are alternative RNA polymerase sigma factors controlling the expression of the neurotoxin and associated protein genes in Clostridium botulinum type A and Clostridium tetani.
Tetanus
Botulinum A and the light chain of tetanus toxins inhibit distinct stages of Mg.ATP-dependent catecholamine exocytosis from permeabilised chromaffin cells.
Tetanus
Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease.
Tetanus
Botulinum and Tetanus Neurotoxin-Induced Blockade of Synaptic Transmission in Networked Cultures of Human and Rodent Neurons.
Tetanus
Botulinum E toxin light chain does not cleave SNAP-23 and only partially impairs insulin stimulation of GLUT4 translocation in 3T3-L1 cells.
Tetanus
Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal.
Tetanus
Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin.
Tetanus
Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin.
Tetanus
Botulinum neurotoxin type E fragmented with endoproteinase Lys-C reveals the site trypsin nicks and homology with tetanus neurotoxin.
Tetanus
Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2.
Tetanus
Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Tetanus
Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison?
Tetanus
Bradykinin-induced astrocyte\#8211;neuron signalling: glutamate release is mediated by ROS-activated volume-sensitive outwardly rectifying anion channels.
Tetanus
C. botulinum neurotoxin types A and E: isolated light chain breaks down into two fragments. Comparison of their amino acid sequences with tetanus neurotoxin.
Tetanus
Ca(2+) influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis.
Tetanus
Ca2+ or Sr2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin.
Tetanus
Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes.
Tetanus
Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin.
Tetanus
Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin.
Tetanus
Cleavage of SNAP-25 and VAMP-2 impairs store-operated Ca2+ entry in mouse pancreatic acinar cells.
Tetanus
Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release.
Tetanus
Clostridial neurotoxins compromise the stability of a low energy SNARE complex mediating NSF activation of synaptic vesicle fusion.
Tetanus
Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS.
Tetanus
Clostridium neurotoxins influence serotonin uptake and release differently in rat brain synaptosomes.
Tetanus
Comparative evaluation of mechanism of neuromuscular (n-m) blockade due to enhydrotoxin-A (EsNTx-a) and D-tubocurarine (d-TC).
Tetanus
Comparison of the intracellular effects of clostridial neurotoxins on exocytosis from streptolysin O-permeabilized rat pheochromocytoma (PC 12) and bovine adrenal chromaffin cells.
Tetanus
Comparison of the pH-induced conformational change of different clostridial neurotoxins.
Tetanus
Contributions of the European OMCL Network and Biological Standardisation Programme to Animal Welfare.
Tetanus
Cooperative action of the light chain of tetanus toxin and the heavy chain of botulinum toxin type A on the transmitter release of mammalian motor endplates.
Tetanus
Differences in the multiple step process of inhibition of neurotransmitter release induced by tetanus toxin and botulinum neurotoxins type A and B at Aplysia synapses.
Tetanus
Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments.
Tetanus
Different VAMP/synaptobrevin complexes for spontaneous and evoked transmitter release at the crayfish neuromuscular junction.
Tetanus
Direct evidence for the specific fixation of Cl. botulinum A neurotoxin to brain matter.
Tetanus
Distinct effects of clostridial toxins on activity-dependent modulation of autaptic responses in cultured hippocampal neurons.
Tetanus
Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals.
Tetanus
Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy.
Tetanus
Double anchorage to the membrane and intact interchain disulfide bond are required for the low pH induced entry of Tetanus and Botulinum Neurotoxins into neurons.
Tetanus
Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.
Tetanus
Escherichia coli hemolysin permeabilizes small unilamellar vesicles loaded with calcein by a single-hit mechanism.
Tetanus
Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
Tetanus
Evidence for a vesicle-mediated maintenance of store-operated calcium channels in a human embryonic kidney cell line.
Tetanus
Evidence for calcium-dependent vesicular transmitter release insensitive to tetanus toxin and botulinum toxin type F.
Tetanus
Evidence for different exocytosis pathways in dendritic and terminal dopamine release in vivo.
Tetanus
Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Tetanus
Exogenous mRNA encoding tetanus or botulinum neurotoxins expressed in Aplysia neurons.
Tetanus
Fragment C of tetanus toxin antagonizes the neuromuscular blocking properties of native tetanus toxin.
Tetanus
Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons.
Tetanus
Ganglioside GD3 enhances adherence of botulinum and tetanus neurotoxins to bovine brain synapsin I.
Tetanus
Genetic characterisation of the botulinum toxin complex of Clostridium botulinum strain NCTC 2916.
Tetanus
Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia.
Tetanus
Human sperm capacitation is necessary for SNARE assembly in neurotoxin-resistant complexes.
Tetanus
Human T-cell responses to botulinum neurotoxin Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
Tetanus
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
Tetanus
Identification of an ion channel-forming motif in the primary structure of tetanus and botulinum neurotoxins.
Tetanus
Identifying the principal protective antigenic determinants of type A botulinum neurotoxin.
Tetanus
Inhibitors of synaptic vesicle exocytosis reduce surface expression of postsynaptic glutamate receptors.
Tetanus
Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.
Tetanus
Intracellularly injected tetanus toxin inhibits exocytosis in bovine adrenal chromaffin cells.
Tetanus
Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin.
Tetanus
Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin.
Tetanus
Localization of putative receptors for tetanus toxin and botulinum neurotoxin type A in rat central nervous system.
Tetanus
Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A.
Tetanus
More than at the Neuromuscular Synapse: Actions of Botulinum Neurotoxin A in the Central Nervous System.
Tetanus
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Tetanus
Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins.
Tetanus
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Tetanus
Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity.
Tetanus
Quaternary structure of botulinum and tetanus neurotoxins as probed by chemical cross-linking and native gel electrophoresis.
Tetanus
Reductive cleavage of tetanus toxin and botulinum neurotoxin A by the thioredoxin system from brain. Evidence for two redox isomers of tetanus toxin.
Tetanus
Refining GAL4-driven transgene expression in Drosophila with a GAL80 enhancer-trap.
Tetanus
Regulation of gephyrin cluster size and inhibitory synaptic currents on Renshaw cells by motor axon excitatory inputs.
Tetanus
Restriction of secretory granule motion near the plasma membrane of chromaffin cells.
Tetanus
Role of protein kinase C in short-term transmission at the mammalian neuromuscular junction.
Tetanus
Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody.
Tetanus
Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
Tetanus
Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site.
Tetanus
Subcellular localization of tetanus neurotoxin-insensitive vesicle-associated membrane protein (VAMP)/VAMP7 in neuronal cells: evidence for a novel membrane compartment.
Tetanus
Tetanus and botulinum toxins block the release of acetylcholine from slices of rat striatum and from the isolated electric organ of Torpedo at different concentrations.
Tetanus
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.
Tetanus
Tetanus toxin and botulinum toxin A utilize unique mechanisms to enter neurons of the central nervous system.
Tetanus
Tetanus toxin and neuronal membranes: the relationship between binding and toxicity.
Tetanus
Tetanus toxin blocks the exocytosis of synaptic vesicles clustered at synapses but not of synaptic vesicles in isolated axons.
Tetanus
Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms.
Tetanus
The 25 kDa HCN Domain of Clostridial Neurotoxins Is Indispensable for Their Neurotoxicity.
Tetanus
The binding fragment from tetanus toxin antagonizes the neuromuscular blocking actions of botulinum toxin.
Tetanus
The C-terminal transmembrane region of synaptobrevin binds synaptophysin from adult synaptic vesicles.
Tetanus
The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins.
Tetanus
The in vitro detection of botulinum neurotoxin-cleaved endogenous VAMP is epitope-dependent.
Tetanus
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
Tetanus
The study of clostridial and related toxins. The search for unique mechanisms and common denominators.
Tetanus
Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins.
Tetanus
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Tetanus
[Tetanus and botulinum toxins are zinc metallopeptidases: molecular mechanisms and inhibition of their neurotoxicity]
Thoracic Outlet Syndrome
A review of thoracic outlet syndrome and the possible role of botulinum toxin in the treatment of this syndrome.
Thoracic Outlet Syndrome
Botulinum toxin injection for management of thoracic outlet syndrome: A double-blind, randomized, controlled trial.
Thoracic Outlet Syndrome
Botulinum toxin injection in neurogenic thoracic outlet syndrome: results and experience using a ultrasound-guided approach.
Thoracic Outlet Syndrome
Botulinum toxin type a improves blood flow in vascular thoracic outlet syndrome.
Thoracic Outlet Syndrome
Single CT-Guided Chemodenervation of the Anterior Scalene Muscle with Botulinum Toxin for Neurogenic Thoracic Outlet Syndrome.
Thoracic Outlet Syndrome
Sonographically guided botulinum toxin injections in patients with neurogenic thoracic outlet syndrome: correlation with surgical outcomes.
Thoracic Outlet Syndrome
Thoracic outlet syndrome secondary to localized scleroderma treated with botulinum toxin injection.
Thoracic Outlet Syndrome
Thoracic Outlet Syndrome Treated With Injecting Botulinum Toxin Into Middle Scalene Muscle and Pectoral Muscle Interfascial Planes: A Case Report.
Thrombosis
A case of thrombosis of subcutaneous anterior chest veins (Mondor's disease) as an unusual complication of botulinum type A injection.
Thrombosis
Analgesic injection of botulinum toxin in anal fissures is efficient and can be performed safely in patients actively receiving chemotherapy.
Thrombosis
Botulinum Toxin A and B Improve Perfusion, Increase Flap Survival, Cause Vasodilation, and Prevent Thrombosis: A Systematic Review and Meta-analysis of Controlled Animal Studies.
Thrombosis
Letter regarding "Prevention of anastomotic thrombosis by botulinum toxin B after acute injury in a rat model".
Thrombosis
Prevention of Anastomotic Thrombosis by Botulinum Toxin B After Acute Injury in a Rat Model.
Thrombosis
Preventive effect of botulinum toxin A in microanastomotic thrombosis: a rabbit model.
Thrombosis
The Use of Botulinum Toxin to Prevent Anastomotic Thrombosis and Promote Flap Survival: A Bridge to Developing Clinical Studies.
Thrombosis
Thrombosis Prevention with Botulinum Toxin A after Traumatic Crush Injury in a Rat Model.
Thrombosis
Upper Extremity Deep Vein Thrombosis After Botulinum Toxin Injection: A Case Report.
Thrombosis
[Therapy of anal fissure using botulinum toxin: perianal thrombosis as a complication]
Thymoma
CCN1 promotes tumorigenicity through Rac1/Akt/NF-?B signaling pathway in pancreatic cancer.
Thymoma
Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway 120:.
Thyroid Diseases
[Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease]
Thyroid Diseases
[Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]
Thyroiditis
Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens.
Tic Disorders
Botulinum toxin to control an incapacitating tic in a child with a clavicular fracture.
Tic Disorders
Progressive Cervical Spondylotic Myelopathy Caused by Tic Disorders in a Young Adult with Tourette Syndrome.
Tics
Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery.
Tics
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Tics
Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.
Tics
Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome.
Tics
Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects.
Tics
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Tics
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
Tics
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.
Tics
Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck.
Tics
Is botulinum toxin effective and safe for motor and phonic tics in patients affected by Tourette syndrome? A Cochrane Review summary with commentary.
Tics
Progress in Pharmacological and Surgical Management of Tourette Syndrome and Other Chronic Tic Disorders.
Tics
The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies.
Tics
Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A.
Tics
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]
Tinnitus
Botulinum toxin injection for objective tinnitus from palatal myoclonus: a case report.
Tinnitus
Botulinum toxin treatment for essential palatal tremors presenting with nasal clicks instead of pulsatile tinnitus: a case report.
Tinnitus
Botulinum Toxin Treatment of Objective Tinnitus Because of Essential Palatal Tremor: A Systematic Review.
Tinnitus
Palatal botulinum toxin as a novel therapy for objective tinnitus in forced eyelid closure syndrome.
Tinnitus
[Application status and prospect of botulinum toxin A in otorhinolaryngological treatment].
Toothache
OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients.
Tourette Syndrome
Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome.
Tourette Syndrome
Deep brain stimulation therapy for treatment-refractory Tourette's syndrome : A review.
Tourette Syndrome
Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck.
Tourette Syndrome
Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A.
Tourette Syndrome
Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections.
Toxemia
Antimicrobial susceptibility of 260 Clostridium botulinum types A, B, Ba and Bf strains and a neurotoxigenic Clostridium baratii type F strain isolated from California infant botulism patients.
Trauma, Nervous System
[Proposal for approach to selective tibial nerve block in spastic patient. A propos of a case].
Tremor
A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
Tremor
A new method for selective measurement of joint movement in hand tremor in Parkinson's disease patients.
Tremor
A Pilot Study of Botulinum Toxin for Jerky, Position-Specific, Upper Limb Action Tremor.
Tremor
A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.
Tremor
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
Tremor
A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor.
Tremor
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
Tremor
Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial.
Tremor
Benefits and risks of pharmacological and surgical treatments for essential tremor: disease mechanisms and current management.
Tremor
Bilateral Globus Pallidus Internus Deep Brain Stimulation in a Case of Progressive Dystonia in Mohr-Tranebjaerg Syndrome with Bilateral Cochlear Implants.
Tremor
Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease.
Tremor
Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
Tremor
Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach.
Tremor
Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
Tremor
Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
Tremor
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Tremor
Botulinum toxin is effective and safe for palatal tremor : A report of five cases and a review of the literature.
Tremor
Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor.
Tremor
Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.
Tremor
Botulinum toxin treatment for essential palatal tremors presenting with nasal clicks instead of pulsatile tinnitus: a case report.
Tremor
Botulinum Toxin Treatment of Objective Tinnitus Because of Essential Palatal Tremor: A Systematic Review.
Tremor
Botulinum toxin type A for hand tremor: a meta-analysis of randomised controlled trials.
Tremor
Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics.
Tremor
Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection.
Tremor
Changes in Cortical Excitability and Parkinson Tremor After Botulinum Toxin Therapy.
Tremor
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms.
Tremor
Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series.
Tremor
Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor.
Tremor
Comparison of botulinum toxin and propranolol for essential and dystonic vocal tremors.
Tremor
Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.
Tremor
Difference in outcome of botulinum toxin treatment of essential palatal tremor in children and adults.
Tremor
Differences in Botulinum Toxin Dosing Between Patients With Adductor Spasmodic Dysphonia and Essential Voice Tremor.
Tremor
Effect of ultrasonography-guided botulinum toxin type a injection in holmes' tremor secondary to pontine hemorrhage: case report.
Tremor
Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns.
Tremor
Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography.
Tremor
Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future.
Tremor
Holmes tremor in association with bilateral hypertrophic olivary degeneration and palatal tremor: chronological considerations. Case report.
Tremor
International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction.
Tremor
Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
Tremor
Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.
Tremor
Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment.
Tremor
OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas.
Tremor
Palatal Tremor - Pathophysiology, Clinical Features, Investigations, Management and Future Challenges.
Tremor
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Tremor
Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics.
Tremor
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Tremor
Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.
Tremor
Primary writing tremor: report of a case successfully treated with botulinum toxin A injections and discussion of underlying mechanism.
Tremor
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.
Tremor
Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic.
Tremor
Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis.
Tremor
Successful Treatment of Essential Palatal Tremor Lasting Over a Long Term with a Rare Application of Botulinum Toxin in a Child.
Tremor
The Prevalence of Dystonic Tremor and Tremor Associated with Dystonia in Patients with Cervical Dystonia.
Tremor
The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report.
Tremor
Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study.
Tremor
Transcranial Direct Current Stimulation Combined with Botulinum Neurotoxin Type A Injections for Treatment of Upper Limb Intention Tremor in Multiple Sclerosis: A Case Report.
Tremor
Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case Series.
Tremor
Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report.
Tremor
Treatment of primary writing tremor with botulinum toxin type a injections: report of a case series.
Tremor
Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor.
Tremor
Tremor in Idiopathic Cervical Dystonia - Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification.
Tremor
Yes/yes head tremor without appendicular tremor after bilateral cerebellar infarction.
Tremor
[Deep brain stimulation of the ventral intermediate thalamic nucleus in the treatment of essential tremor]
Trigeminal Autonomic Cephalalgias
Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.
Trigeminal Autonomic Cephalalgias
[Botulinum toxin type A in headache treatment : Established and experimental indications].
Trigeminal Nerve Diseases
Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction.
Trigeminal Nerve Diseases
Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy.
Trigeminal Nerve Diseases
Topical Review: Potential Use of Botulinum Toxin in the Management of Painful Posttraumatic Trigeminal Neuropathy.
Trigeminal Nerve Injuries
Use of Botulinum Toxin Type A Injection for Neuropathic Pain after Trigeminal Nerve Injury.
Trigeminal Neuralgia
A new target for the treatment of trigeminal neuralgia with botulinum toxin type A.
Trigeminal Neuralgia
A new treatment paradigm for trigeminal neuralgia using botulinum toxin type a.
Trigeminal Neuralgia
An update on the pharmacological management of pain in patients with multiple sclerosis.
Trigeminal Neuralgia
BoTN-A: The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Trigeminal Neuralgia
Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.
Trigeminal Neuralgia
Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial.
Trigeminal Neuralgia
Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations.
Trigeminal Neuralgia
Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials.
Trigeminal Neuralgia
Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up.
Trigeminal Neuralgia
Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?
Trigeminal Neuralgia
Botulinum toxin type A as an alternative way to treat trigeminal neuralgia: a systematic review.
Trigeminal Neuralgia
Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect.
Trigeminal Neuralgia
Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial.
Trigeminal Neuralgia
Botulinum toxin type A for trigeminal neuralgia - we have the prima facie evidence.
Trigeminal Neuralgia
Botulinum toxin type A reduces the expression of transient receptor potential melastatin 3 and transient receptor potential vanilloid type 4 in the trigeminal subnucleus caudalis of a rat model of trigeminal neuralgia.
Trigeminal Neuralgia
Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?
Trigeminal Neuralgia
Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia.
Trigeminal Neuralgia
CGRP Plasma Levels Decrease in Classical Trigeminal Neuralgia Patients Treated with Botulinum Toxin Type A: A Pilot Study.
Trigeminal Neuralgia
Current status of the application of botulinum toxin as a treatment option for trigeminal neuralgia.
Trigeminal Neuralgia
Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia.
Trigeminal Neuralgia
Efficacy of Botulinum Toxin Type A in Trigeminal Neuralgia in a South Asian Cohort.
Trigeminal Neuralgia
Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine.
Trigeminal Neuralgia
Factors affecting the therapeutic effect of botulinum toxin A on trigeminal neuralgia: A follow-up retrospective study of 152 patients.
Trigeminal Neuralgia
Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain.
Trigeminal Neuralgia
Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia.
Trigeminal Neuralgia
Neuromodulators for Atypical Facial Pain and Neuralgias: A Systematic Review and Meta-Analysis.
Trigeminal Neuralgia
Neuropathic Pain in Multiple Sclerosis Improved With Oral Famciclovir: A Case Report.
Trigeminal Neuralgia
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data.
Trigeminal Neuralgia
Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.
Trigeminal Neuralgia
Review: In trigeminal neuralgia, carbamazepine, botulinum toxin type A, or lidocaine improve response rate vs placebo.
Trigeminal Neuralgia
Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia.
Trigeminal Neuralgia
Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study.
Trigeminal Neuralgia
Sphenopalatine Ganglion Block with Botulinum Neurotoxin for Treating Trigeminal Neuralgia Using CAD/CAM-Derived Injection Guide.
Trigeminal Neuralgia
Subcutaneous and Perineural Botulinum Toxin Type A For Neuropathic Pain: A Descriptive Review.
Trigeminal Neuralgia
The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.
Trigeminal Neuralgia
The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Trigeminal Neuralgia
The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review.
Trigeminal Neuralgia
Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials.
Trigeminal Neuralgia
Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review.
Trigeminal Neuralgia
Trigeminal Neuralgia With Extraoral Trigger Zone Successfully Treated With Intraoral Injections of Botulinum Toxin: A Case Report.
Trigeminal Neuralgia
Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.
Trigeminal Neuralgia
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice.
Trigeminal Neuralgia
Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
Trigeminal Neuralgia
[Evaluation of therapeutic effectiveness and safety of botulinum toxin type A in the treatment of idiopathic trigeminal neuralgia in patients older than 70 years].
Trismus
A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer.
Trismus
Botulinum Toxin A for Spastic Trismus Due to Brain Stem Encephalitis in a Pediatric Intensive Care Setting: A Unique Case Report.
Trismus
Botulinum toxin A is effective in treating trismus associated with postradiation myokymia and muscle spasm.
Trismus
Botulinum toxin in masticatory muscles of the adult rat induces bone loss at the condyle and alveolar regions of the mandible associated with a bone proliferation at a muscle enthesis.
Trismus
Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin.
Trismus
Stroke-induced trismus in a pediatric patient: long-term resolution with botulinum toxin A.
Trismus
Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms.
Trismus
The value of physiatrists in pediatric intensive care unit: A case report of botulinum toxin injection into masseter muscle for the treatment of trismus.
Trochlear Nerve Diseases
Fourth nerve palsy unmasked by botulinum toxin therapy for cervical torticollis.
Tularemia
Current therapy and the development of therapeutic options for the treatment of diseases due to bacterial agents of potential biowarfare and bioterrorism.
Tularemia
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Tularemia
The threat of biological terrorism: a public health and infection control reality.
Upper Extremity Deep Vein Thrombosis
Upper Extremity Deep Vein Thrombosis After Botulinum Toxin Injection: A Case Report.
Urethral Obstruction
Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model.
Urethral Stricture
Botulinum toxin type A: a novel approach to the treatment of recurrent urethral strictures.
Urethral Stricture
[Local injection of BTX-A prevents iatrogenic anterior urethral stricture in rabbits].
Urinary Bladder Diseases
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.
Urinary Bladder Neck Obstruction
A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines.
Urinary Bladder Neck Obstruction
Botulinum toxin: An emerging therapy in female bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies.
Urinary Bladder Neck Obstruction
Effect of Botulinum Toxin on Expression of Nerve Growth Factor and Transient Receptor Potential Vanilloid 1 in Urothelium and Detrusor Muscle of Rats With Bladder Outlet Obstruction-induced Detrusor Overactivity.
Urinary Bladder Neck Obstruction
Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs.
Urinary Bladder Neck Obstruction
Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.
Urinary Bladder, Neurogenic
A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Urinary Bladder, Neurogenic
A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder.
Urinary Bladder, Neurogenic
A simplified technique for botulinum toxin injections in children with neurogenic bladder.
Urinary Bladder, Neurogenic
Applicability of botulinum toxin type A in paediatric neurogenic bladder management.
Urinary Bladder, Neurogenic
Beyond botulinum neurotoxin A for chemodenervation of the bladder.
Urinary Bladder, Neurogenic
Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies.
Urinary Bladder, Neurogenic
Botulinum toxin A improves neurogenic bladder fibrosis by suppressing transforming growth factor ?1 expression in rats.
Urinary Bladder, Neurogenic
Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review.
Urinary Bladder, Neurogenic
Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder.
Urinary Bladder, Neurogenic
Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction?
Urinary Bladder, Neurogenic
Changes in chemical coding of sympathetic chain ganglia (SChG) neurons supplying porcine urinary bladder after botulinum toxin (BTX) treatment.
Urinary Bladder, Neurogenic
Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A.
Urinary Bladder, Neurogenic
Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder.
Urinary Bladder, Neurogenic
Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.
Urinary Bladder, Neurogenic
Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
Urinary Bladder, Neurogenic
Evolution of the management of acquired neurogenic bladder in children using intradetrusor botulinum toxin type A injections: 5-year experience and perspectives.
Urinary Bladder, Neurogenic
Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Urinary Bladder, Neurogenic
Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience.
Urinary Bladder, Neurogenic
Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
Urinary Bladder, Neurogenic
Intravesical Injections of Botulinum Toxin Type A for Management of Neuropathic Bladder: A Comparison of Two Methods.
Urinary Bladder, Neurogenic
Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
Urinary Bladder, Neurogenic
Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Urinary Bladder, Neurogenic
Non-surgical urologic management of neurogenic bladder after spinal cord injury.
Urinary Bladder, Neurogenic
OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease.
Urinary Bladder, Neurogenic
Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.
Urinary Bladder, Neurogenic
Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease.
Urinary Bladder, Neurogenic
Prospective evaluation of antibiotic treatment for urological procedure in patients presenting with neurogenic bladder.
Urinary Bladder, Neurogenic
Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele.
Urinary Bladder, Neurogenic
Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder.
Urinary Bladder, Neurogenic
Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele.
Urinary Bladder, Neurogenic
Repeated injection of botulinum toxin a in patients with neurogenic bladder: our experience.
Urinary Bladder, Neurogenic
Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: Effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures.
Urinary Bladder, Neurogenic
Study of botulinum toxin A in neurogenic bladder due to spina bifida in children.
Urinary Bladder, Neurogenic
The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.
Urinary Bladder, Neurogenic
Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele.
Urinary Bladder, Neurogenic
Urodynamic Outcomes in Children after Single and Multiple Injections in Overactive and Low Compliance Neurogenic Bladder Treated with AboBotulinum Toxin-A.
Urinary Bladder, Neurogenic
Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
Urinary Bladder, Neurogenic
What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?
Urinary Bladder, Neurogenic
What is the optimum dose of type a botulinum toxin for treating neurogenic bladder overactivity?
Urinary Bladder, Neurogenic
[Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections].
Urinary Bladder, Neurogenic
[Botulinic toxin type A in the treatment of children with neurogenic bladder].
Urinary Bladder, Neurogenic
[Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction]
Urinary Bladder, Neurogenic
[Botulinum toxin injection for neurogenic and no neurogenic bladder dysfunction]
Urinary Bladder, Neurogenic
[Medico-economic evaluation of urological cares of spinal cord injured patients: A review].
Urinary Bladder, Neurogenic
[Neurogenic bladder: pathophysiology of the disorder of compliance]
Urinary Bladder, Neurogenic
[Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients]
Urinary Bladder, Overactive
A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder.
Urinary Bladder, Overactive
A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure.
Urinary Bladder, Overactive
A Patient-Centered Approach to Refractory Overactive Bladder and Barriers to Third-Line Therapy.
Urinary Bladder, Overactive
A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder.
Urinary Bladder, Overactive
A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome.
Urinary Bladder, Overactive
A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.
Urinary Bladder, Overactive
Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder.
Urinary Bladder, Overactive
Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome.
Urinary Bladder, Overactive
Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis-Different Mechanisms of Action of Botox on Bladder Dysfunction?
Urinary Bladder, Overactive
An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder.
Urinary Bladder, Overactive
An overview of treatment of overactive bladder syndrome in women.
Urinary Bladder, Overactive
An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders.
Urinary Bladder, Overactive
Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
Urinary Bladder, Overactive
Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.
Urinary Bladder, Overactive
Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial.
Urinary Bladder, Overactive
Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial.
Urinary Bladder, Overactive
Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
Urinary Bladder, Overactive
Beyond botulinum neurotoxin A for chemodenervation of the bladder.
Urinary Bladder, Overactive
Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Urinary Bladder, Overactive
Botulinum neurotoxin A for overactive bladder treatment: advantages and pitfalls.
Urinary Bladder, Overactive
Botulinum Neurotoxin Serotype A Suppresses Neurotransmitter Release from Afferent as Well as Efferent Nerves in the Urinary Bladder.
Urinary Bladder, Overactive
Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
Urinary Bladder, Overactive
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Urinary Bladder, Overactive
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Urinary Bladder, Overactive
Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICI-RS 2019?
Urinary Bladder, Overactive
Botulinum toxin A in the overactive bladder: current status and future directions.
Urinary Bladder, Overactive
Botulinum toxin a in the overactive bladder: current status and future directions.
Urinary Bladder, Overactive
Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Urinary Bladder, Overactive
Botulinum toxin A should not be first-line therapy for overactive bladder.
Urinary Bladder, Overactive
Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.
Urinary Bladder, Overactive
Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders.
Urinary Bladder, Overactive
Botulinum toxin and refractory non-neurogenic overactive detrusor.
Urinary Bladder, Overactive
Botulinum toxin as a treatment for refractory overactive bladder.
Urinary Bladder, Overactive
Botulinum toxin B is not an effective treatment of refractory overactive bladder.
Urinary Bladder, Overactive
Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Urinary Bladder, Overactive
Botulinum toxin for overactive bladder: reaching a happy median.
Urinary Bladder, Overactive
Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art.
Urinary Bladder, Overactive
Botulinum toxin for the treatment of lower urinary tract symptoms: a review.
Urinary Bladder, Overactive
Botulinum toxin in "refractory" detrusor overactivity. Re: Makovey I, et al. botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 2011;30:1538-1540.
Urinary Bladder, Overactive
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Urinary Bladder, Overactive
Botulinum toxin injections for adults with overactive bladder syndrome.
Urinary Bladder, Overactive
Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: Lack of anticholinergic efficacy versus intolerability.
Urinary Bladder, Overactive
Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI.
Urinary Bladder, Overactive
Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.
Urinary Bladder, Overactive
Botulinum toxin treatment for overactive bladder: risk of urinary retention.
Urinary Bladder, Overactive
Botulinum toxin type A (Botox) and idiopathic overactive bladder. For some severely affected patients.
Urinary Bladder, Overactive
Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
Urinary Bladder, Overactive
Botulinum toxin type a in patients with Parkinson's disease and refractory overactive bladder.
Urinary Bladder, Overactive
Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Urinary Bladder, Overactive
Botulinum toxin--a new therapeutic agent in girls with non-neurogenic overactive bladder--a case report and review of the literature.
Urinary Bladder, Overactive
Botulinum toxin-A (Botox((R))) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review.
Urinary Bladder, Overactive
Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
Urinary Bladder, Overactive
Can botox improve night-time overactive bladder symptoms in women?
Urinary Bladder, Overactive
Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
Urinary Bladder, Overactive
Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Urinary Bladder, Overactive
Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
Urinary Bladder, Overactive
Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Urinary Bladder, Overactive
Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
Urinary Bladder, Overactive
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Urinary Bladder, Overactive
Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation.
Urinary Bladder, Overactive
Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin - A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case-Control Study.
Urinary Bladder, Overactive
Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition).
Urinary Bladder, Overactive
Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
Urinary Bladder, Overactive
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
Urinary Bladder, Overactive
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
Urinary Bladder, Overactive
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Urinary Bladder, Overactive
Comparison of Short Term Outcomes of Sacral Nerve Stimulation and Intradetrusor Injection of OnabotulinumtoxinA (Botox) in Women With Refractory Overactive Bladder.
Urinary Bladder, Overactive
Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks.
Urinary Bladder, Overactive
Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.
Urinary Bladder, Overactive
Correction of overactive bladder with botulinum toxin type A (BTX-A).
Urinary Bladder, Overactive
Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder.
Urinary Bladder, Overactive
Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder.
Urinary Bladder, Overactive
Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre.
Urinary Bladder, Overactive
Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review.
Urinary Bladder, Overactive
Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
Urinary Bladder, Overactive
Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France.
Urinary Bladder, Overactive
Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
Urinary Bladder, Overactive
Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
Urinary Bladder, Overactive
Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.
Urinary Bladder, Overactive
Current and future pharmacological treatment for overactive bladder.
Urinary Bladder, Overactive
Current and potential urological applications of botulinum toxin A.
Urinary Bladder, Overactive
Current evidence and emerging drug therapies for overactive bladder.
Urinary Bladder, Overactive
Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Urinary Bladder, Overactive
Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study.
Urinary Bladder, Overactive
Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle strips.
Urinary Bladder, Overactive
Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Urinary Bladder, Overactive
Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?
Urinary Bladder, Overactive
Durable Efficacy and Safety of Long-term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5 Year Study.
Urinary Bladder, Overactive
Durable improvements in urinary incontinence and positive treatment response in patients with idiopathic overactive bladder syndrome following long-term onabotulinumtoxinA treatment: Final results of 3.5-year study.
Urinary Bladder, Overactive
Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
Urinary Bladder, Overactive
Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.
Urinary Bladder, Overactive
Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe.
Urinary Bladder, Overactive
Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Urinary Bladder, Overactive
Editorial Comment on: Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment.
Urinary Bladder, Overactive
Editorial Comment to OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Bladder, Overactive
Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder.
Urinary Bladder, Overactive
Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
Urinary Bladder, Overactive
Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial.
Urinary Bladder, Overactive
Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
Urinary Bladder, Overactive
Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study.
Urinary Bladder, Overactive
Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
Urinary Bladder, Overactive
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Urinary Bladder, Overactive
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
Urinary Bladder, Overactive
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial.
Urinary Bladder, Overactive
Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.
Urinary Bladder, Overactive
Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Urinary Bladder, Overactive
Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
Urinary Bladder, Overactive
Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.
Urinary Bladder, Overactive
Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
Urinary Bladder, Overactive
Emptying cystometry: A feasibility and validation pilot study on female patients.
Urinary Bladder, Overactive
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
Urinary Bladder, Overactive
Experience with injections of botulinum toxin type A into the detrusor muscle.
Urinary Bladder, Overactive
Expert consensus on scientific evidence available on the use of botulinum toxin in overactive bladder.
Urinary Bladder, Overactive
Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
Urinary Bladder, Overactive
Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity.
Urinary Bladder, Overactive
Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management: Translation of French recommendations.
Urinary Bladder, Overactive
Hematuria following Botox treatment for upper limb spasticity: a case report.
Urinary Bladder, Overactive
Higher Neural Correlates in Multiple Sclerosis Patients with Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
Urinary Bladder, Overactive
Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Urinary Bladder, Overactive
How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.
Urinary Bladder, Overactive
Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.
Urinary Bladder, Overactive
In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results.
Urinary Bladder, Overactive
Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Urinary Bladder, Overactive
Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice.
Urinary Bladder, Overactive
Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Urinary Bladder, Overactive
Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.
Urinary Bladder, Overactive
Intradetrusor Injection of Botulinum Toxin for the Management of Refractory Overactive Bladder Syndrome: An Update.
Urinary Bladder, Overactive
Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study.
Urinary Bladder, Overactive
Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Urinary Bladder, Overactive
Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection.
Urinary Bladder, Overactive
Intravesical injection of botulinum toxin A for treatment of overactive bladder in anticoagulated patients: Is it safe?
Urinary Bladder, Overactive
Intravesical injection of botulinum toxin for the treatment of overactive bladder.
Urinary Bladder, Overactive
Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Urinary Bladder, Overactive
Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.
Urinary Bladder, Overactive
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Urinary Bladder, Overactive
Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy.
Urinary Bladder, Overactive
Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?
Urinary Bladder, Overactive
Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
Urinary Bladder, Overactive
Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Urinary Bladder, Overactive
Long-term follow-up reveals a low persistence rate of abobotulinumtoxinA injections for idiopathic overactive bladder.
Urinary Bladder, Overactive
Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Urinary Bladder, Overactive
LONG-TERM OUTCOME OF THE USE OF INTRAVESICAL BOTULINUM TOXIN FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB).
Urinary Bladder, Overactive
Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
Urinary Bladder, Overactive
Low energy shock wave-delivered intravesical botulinum neurotoxin-A potentiates antioxidant genes and inhibits proinflammatory cytokines in rat model of overactive bladder.
Urinary Bladder, Overactive
Lower urinary tract dysfunction in patients with multiple sclerosis.
Urinary Bladder, Overactive
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Urinary Bladder, Overactive
Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
Urinary Bladder, Overactive
Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review.
Urinary Bladder, Overactive
Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Urinary Bladder, Overactive
Mechanisms of action of botulinum neurotoxins, ?(3) -adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders.
Urinary Bladder, Overactive
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.
Urinary Bladder, Overactive
Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder.
Urinary Bladder, Overactive
Mucosal modulation of contractility in bladder strips from normal and overactive rat models and the effect of botulinum toxin A on overactive bladder strips.
Urinary Bladder, Overactive
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA.
Urinary Bladder, Overactive
New agents to treat lower urinary tract and pelvic floor disorders.
Urinary Bladder, Overactive
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.
Urinary Bladder, Overactive
Nonantimuscarinic treatment for overactive bladder: a systematic review.
Urinary Bladder, Overactive
Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Urinary Bladder, Overactive
OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Bladder, Overactive
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Urinary Bladder, Overactive
OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
Urinary Bladder, Overactive
OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
Urinary Bladder, Overactive
OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions.
Urinary Bladder, Overactive
OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence.
Urinary Bladder, Overactive
OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use.
Urinary Bladder, Overactive
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Urinary Bladder, Overactive
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Urinary Bladder, Overactive
OnabotulinumtoxinA in overactive bladder: Evidence-based consensus recommendations.
Urinary Bladder, Overactive
OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
Urinary Bladder, Overactive
OnabotulinumtoxinA intravesical treatment in patients affected by overactive bladder syndrome: best practice in real-life management.
Urinary Bladder, Overactive
OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice.
Urinary Bladder, Overactive
OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Con.
Urinary Bladder, Overactive
OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Pro.
Urinary Bladder, Overactive
OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.
Urinary Bladder, Overactive
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Urinary Bladder, Overactive
Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms-A Prospective Study.
Urinary Bladder, Overactive
Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB).
Urinary Bladder, Overactive
Outcomes of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder Symptoms: A Systematic Review of the Literature.
Urinary Bladder, Overactive
Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
Urinary Bladder, Overactive
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.
Urinary Bladder, Overactive
Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome.
Urinary Bladder, Overactive
Pharmacotherapy for overactive bladder: minimally invasive treatment - botulinum toxins.
Urinary Bladder, Overactive
Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: Investigation of generalized spread using single-fiber EMG.
Urinary Bladder, Overactive
Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study.
Urinary Bladder, Overactive
Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.
Urinary Bladder, Overactive
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome.
Urinary Bladder, Overactive
Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Urinary Bladder, Overactive
Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review.
Urinary Bladder, Overactive
Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Urinary Bladder, Overactive
Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
Urinary Bladder, Overactive
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.
Urinary Bladder, Overactive
Promoting patient followup treatment with intra-detrusor onabotulinumtoxinA for overactive bladder.
Urinary Bladder, Overactive
Quality of Life Changes in Patients with Neurogenic versus Idiopathic Detrusor Overactivity after Intradetrusor Injections of Botulinum Neurotoxin Type A and Correlations with Lower Urinary Tract Symptoms and Urodynamic Changes.
Urinary Bladder, Overactive
Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Urinary Bladder, Overactive
Re: Comparison of Short Term Outcomes of Sacral Nerve Stimulation and Intradetrusor Injection of OnabotulinumtoxinA (Botox) in Women with Refractory Overactive Bladder.
Urinary Bladder, Overactive
Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder.
Urinary Bladder, Overactive
RE: Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.
Urinary Bladder, Overactive
Re: Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Urinary Bladder, Overactive
Re: Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder: D. A. Ginsberg, M. J. Drake, A. Kaufmann, S. Radomski, A. E. Gousse, C. J. Chermansky, A. Magyar, J. P. Nicandro and V. W. Nitti; 191622-096 Investigators J Urol 2017;198:897-904.
Urinary Bladder, Overactive
Re: OnabotulinumtoxinA Detrusor Injection Improves Female Sexual Function in Women with Overactive Bladder Wet Syndrome.
Urinary Bladder, Overactive
Re: OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Urinary Bladder, Overactive
Re: Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Urinary Bladder, Overactive
Re: Reduction of Urgency Severity is the Most Important Factor in the Subjective Therapeutic Outcome of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder.
Urinary Bladder, Overactive
Re: Urinary Retention Rates after Intravesical OnabotulinumtoxinA Injection for Idiopathic Overactive Bladder in Clinical Practice and Predictors of this Outcome.
Urinary Bladder, Overactive
Re: Women's Perspective of Botulinum Toxin Treatment for Overactive Bladder Symptoms.
Urinary Bladder, Overactive
Real World Performance of SNM and OnabotulinumtoxinA for OAB: Focus on Safety and Cost.
Urinary Bladder, Overactive
Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Urinary Bladder, Overactive
Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
Urinary Bladder, Overactive
Refractory idiopathic urge urinary incontinence and botulinum A injection.
Urinary Bladder, Overactive
Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Urinary Bladder, Overactive
Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?
Urinary Bladder, Overactive
Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
Urinary Bladder, Overactive
Reply from Authors re: Stephan Madersbacher OnabotulinumtoxinA for Idiopathic Overactive Bladder Symptoms: Many Answers but More Questions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.032: OnabotulinumtoxinA for Idiopathic Overactive Bladder Symptoms: Some Answers but Even More Questions.
Urinary Bladder, Overactive
Routine Office Assessment After OnabotulinumtoxinA Injection for Overactive Bladder Is Unnecessary to Detect Clinically Significant Voiding Dysfunction.
Urinary Bladder, Overactive
Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
Urinary Bladder, Overactive
Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Urinary Bladder, Overactive
Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Urinary Bladder, Overactive
Sacral Neuromodulation in Patients with Idiopathic Overactive Bladder after Initial Botulinum Toxin Therapy.
Urinary Bladder, Overactive
Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
Urinary Bladder, Overactive
Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con.
Urinary Bladder, Overactive
Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Pro.
Urinary Bladder, Overactive
Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
Urinary Bladder, Overactive
Side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings.
Urinary Bladder, Overactive
Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection.
Urinary Bladder, Overactive
Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment.
Urinary Bladder, Overactive
Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.
Urinary Bladder, Overactive
The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
Urinary Bladder, Overactive
The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
Urinary Bladder, Overactive
The Effect of Low-intensity Shockwave Therapy on Non-neurogenic Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Preclinical and Clinical Studies.
Urinary Bladder, Overactive
The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
Urinary Bladder, Overactive
The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections.
Urinary Bladder, Overactive
The effects of pelvic floor muscle therapy on symptoms, voiding, and pelvic floor muscle activity parameters in children with overactive bladder.
Urinary Bladder, Overactive
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Urinary Bladder, Overactive
The impact of frailty on treatment for overactive bladder in older adults.
Urinary Bladder, Overactive
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Urinary Bladder, Overactive
The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Urinary Bladder, Overactive
The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics.
Urinary Bladder, Overactive
The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.
Urinary Bladder, Overactive
The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
Urinary Bladder, Overactive
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.
Urinary Bladder, Overactive
The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.
Urinary Bladder, Overactive
The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty.
Urinary Bladder, Overactive
The use of botulinum toxin a in idiopathic overactive bladder syndrome.
Urinary Bladder, Overactive
The use of botulinum toxin for the treatment of overactive bladder syndrome.
Urinary Bladder, Overactive
The use of botulinum toxin in the treatment of refractory overactive bladder.
Urinary Bladder, Overactive
The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy.
Urinary Bladder, Overactive
Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
Urinary Bladder, Overactive
Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation.
Urinary Bladder, Overactive
Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA.
Urinary Bladder, Overactive
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials.
Urinary Bladder, Overactive
Treatment of overactive bladder with botulinum toxin type B: a pilot study.
Urinary Bladder, Overactive
Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with?
Urinary Bladder, Overactive
Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents.
Urinary Bladder, Overactive
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
Urinary Bladder, Overactive
Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder.
Urinary Bladder, Overactive
Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Urinary Bladder, Overactive
Urinary incontinence in children: botulinum toxin is a safe and effective treatment option.
Urinary Bladder, Overactive
Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
Urinary Bladder, Overactive
Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Urinary Bladder, Overactive
Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.
Urinary Bladder, Overactive
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
Urinary Bladder, Overactive
Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease.
Urinary Bladder, Overactive
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Urinary Bladder, Overactive
Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin.
Urinary Bladder, Overactive
von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder.
Urinary Bladder, Overactive
What is the Best Treatment Option for Coexisting Pelvic Floor Dysfunctions?
Urinary Bladder, Overactive
What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Urinary Bladder, Overactive
What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?
Urinary Bladder, Overactive
What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Urinary Bladder, Overactive
Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation.
Urinary Bladder, Overactive
Women's perspective of botulinum toxin treatment for overactive bladder symptoms.
Urinary Bladder, Overactive
[Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections].
Urinary Bladder, Overactive
[Botulinium toxin and idiopathic overactive bladder: Multicentric contempory management in Bourgogne].
Urinary Bladder, Overactive
[Botulinum toxin A in the treatment of the idiopathic overactive bladder. Expert letter Nr. 25 from 28 August 2007]]
Urinary Bladder, Overactive
[Botulinum toxin for the treatment of overactive bladder - an overview.]
Urinary Bladder, Overactive
[Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
Urinary Bladder, Overactive
[Does intravesical application of botulinum toxin lead to systemic muscle weakness? An approach to an uro-geriatric problem].
Urinary Bladder, Overactive
[Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder : A prospective analysis.]
Urinary Bladder, Overactive
[Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management].
Urinary Bladder, Overactive
[Gynecology: urinary incontinence - mini-review and case reports].
Urinary Bladder, Overactive
[How I do
the intra-detrusor injection of botulinum toxin for overactive bladder management].
Urinary Bladder, Overactive
[Idiopathic overactive bladder and BOTOX(®): Literature review.]
Urinary Bladder, Overactive
[INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
Urinary Bladder, Overactive
[Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome].
Urinary Bladder, Overactive
[Neuromodulation as a treatment for overactive bladder syndrome].
Urinary Bladder, Overactive
[Overactive bladder: prospects and limitations of botulinum toxin]
Urinary Bladder, Overactive
[Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients]
Urinary Bladder, Overactive
[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]
Urinary Bladder, Overactive
[Practical aspects of the use of botulinum toxin in the treatment of idiopathic overactive bladder].
Urinary Bladder, Overactive
[Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia]
Urinary Bladder, Overactive
[Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder]
Urinary Bladder, Overactive
[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
Urinary Bladder, Overactive
[The effect of botulinum toxin injection into the bladder for overactive bladder: two case]
Urinary Bladder, Overactive
[The quality of life of patients with overactive bladder after local injections of botulinum toxin A--a preliminary report]
Urinary Bladder, Overactive
[The treatment of overactive bladder syndrome with onabotulinumtoxinA therapy].
Urinary Bladder, Overactive
[Urinary incontinence and descensus genitalis--the silent sickness]
Urinary Bladder, Overactive
[Use and mechanism of botulinum toxin in overactive bladder treatment]
Urinary Bladder, Overactive
[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review].
Urinary Bladder, Overactive
[Use of botulinum toxin type A in non-neurogenic overactive bladder : Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women.]
Urinary Bladder, Overactive
[Value of nerve growth factor levels in overactive bladder syndrome : Alterations after botulinum toxin therapy].
Urinary Bladder, Underactive
Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
Urinary Bladder, Underactive
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Urinary Bladder, Underactive
Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction.
Urinary Bladder, Underactive
Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
Urinary Bladder, Underactive
Impact of bladder dysfunction in the management of post radical prostatectomy stress urinary incontinence-a review.
Urinary Bladder, Underactive
OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.
Urinary Bladder, Underactive
OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study.
Urinary Bladder, Underactive
The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.
Urinary Bladder, Underactive
Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.
Urinary Fistula
[French Association of Urology. COVID-19: Recommendations for functional urology].
Urinary Incontinence
A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients.
Urinary Incontinence
A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder.
Urinary Incontinence
A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders.
Urinary Incontinence
A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure.
Urinary Incontinence
An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder.
Urinary Incontinence
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.
Urinary Incontinence
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
Urinary Incontinence
Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
Urinary Incontinence
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Urinary Incontinence
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Urinary Incontinence
Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Urinary Incontinence
Botulinum toxin a in the treatment of neurogenic and idiopathic urinary incontinence.
Urinary Incontinence
Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
Urinary Incontinence
Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects.
Urinary Incontinence
Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
Urinary Incontinence
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Urinary Incontinence
Botulinum toxin type A (Botox) and idiopathic overactive bladder. For some severely affected patients.
Urinary Incontinence
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Urinary Incontinence
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Urinary Incontinence
Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
Urinary Incontinence
Botulinum toxin-A (Botox((R))) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review.
Urinary Incontinence
Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity.
Urinary Incontinence
Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence.
Urinary Incontinence
Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Urinary Incontinence
Combination therapy with botulinum toxin and bulking agent-An efficient, sustainable, and safe method to treat elderly women with mixed urinary incontinence.
Urinary Incontinence
Commentary on: Anticholinergic therapy vs onabotulinumtoxinA for urgency urinary incontinence.
Urinary Incontinence
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
Urinary Incontinence
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
Urinary Incontinence
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Urinary Incontinence
Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
Urinary Incontinence
Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial.
Urinary Incontinence
Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective.
Urinary Incontinence
Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France.
Urinary Incontinence
Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
Urinary Incontinence
Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study.
Urinary Incontinence
Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?
Urinary Incontinence
Durable improvements in urinary incontinence and positive treatment response in patients with idiopathic overactive bladder syndrome following long-term onabotulinumtoxinA treatment: Final results of 3.5-year study.
Urinary Incontinence
Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
Urinary Incontinence
Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe.
Urinary Incontinence
Editorial comment on: botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Urinary Incontinence
Editorial Comment to OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Incontinence
Editorial Comment: Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Urinary Incontinence
Effect of Intravesical Botulinum Neurotoxin-A Injection on Detrusor Hyperreflexia in Spinal Cord Injured Patients.
Urinary Incontinence
Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder.
Urinary Incontinence
Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
Urinary Incontinence
Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
Urinary Incontinence
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis.
Urinary Incontinence
Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study.
Urinary Incontinence
Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis.
Urinary Incontinence
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Urinary Incontinence
Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.
Urinary Incontinence
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial.
Urinary Incontinence
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials.
Urinary Incontinence
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.
Urinary Incontinence
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Urinary Incontinence
Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
Urinary Incontinence
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Urinary Incontinence
Efficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial.
Urinary Incontinence
Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice.
Urinary Incontinence
Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity.
Urinary Incontinence
Future Directions of Research and Care for Urinary Incontinence: Findings from the National Institute of Diabetes and Digestive and Kidney Diseases Summit on Urinary Incontinence Clinical Research in Women.
Urinary Incontinence
Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.
Urinary Incontinence
Inguinal hyperhidrosis misdiagnosed as urinary incontinence: treatment with botulinum toxin A.
Urinary Incontinence
Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up.
Urinary Incontinence
Intravesical Electromotive Botulinum Toxin Type A (Dysport) Administration in Children With Myelomeningocele.
Urinary Incontinence
Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
Urinary Incontinence
Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis.
Urinary Incontinence
Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
Urinary Incontinence
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Urinary Incontinence
Managing urinary incontinence in women - a review of new and emerging pharmacotherapy.
Urinary Incontinence
Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Urinary Incontinence
Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder.
Urinary Incontinence
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Urinary Incontinence
OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Incontinence
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Urinary Incontinence
OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
Urinary Incontinence
OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children.
Urinary Incontinence
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Urinary Incontinence
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Urinary Incontinence
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.
Urinary Incontinence
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Urinary Incontinence
OnabotulinumtoxinA in urinary incontinence: Prospective Study of a Case Series.
Urinary Incontinence
OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice.
Urinary Incontinence
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology.
Urinary Incontinence
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Urinary Incontinence
Outcomes of Intradetrusor OnabotulinumtoxinA Injection in Adults with Congenital Spinal Dysraphism in Tertiary Transitional Urology Clinic.
Urinary Incontinence
Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.
Urinary Incontinence
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Urinary Incontinence
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome.
Urinary Incontinence
Re: Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence.
Urinary Incontinence
Re: OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Urinary Incontinence
Re: OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Urinary Incontinence
Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Urinary Incontinence
Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Urinary Incontinence
Sacral Neuromodulation and OnabotulinumtoxinA for Refractory Urge Urinary Incontinence Offer Similar Success During 2-Year Follow-up.
Urinary Incontinence
Sacral Neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Urinary Incontinence
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Urinary Incontinence
Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury.
Urinary Incontinence
Six-Year Follow-Up of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity: Clinical and Urodynamic Results.
Urinary Incontinence
Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.
Urinary Incontinence
The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections.
Urinary Incontinence
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Urinary Incontinence
The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection.
Urinary Incontinence
The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
Urinary Incontinence
The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.
Urinary Incontinence
The Therapeutic Effects of Repeated Detrusor Injections Between 200 or 300 Units of OnabotulinumtoxinA in Chronic Spinal Cord Injured Patients.
Urinary Incontinence
Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.
Urinary Incontinence
Therapeutic efficacy of botulinum toxin in the treatment of urinary incontinence in female dogs.
Urinary Incontinence
Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Urinary Incontinence
Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Urinary Incontinence
Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Urinary Incontinence
Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder.
Urinary Incontinence
Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Urinary Incontinence
Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Urinary Incontinence
Urinary incontinence in children: botulinum toxin is a safe and effective treatment option.
Urinary Incontinence
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Urinary Incontinence
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Urinary Incontinence
Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.
Urinary Incontinence
Virtual trainer for intra-detrusor injection of botulinum toxin to treat urinary incontinence.
Urinary Incontinence
Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
Urinary Incontinence
[Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia]
Urinary Incontinence
[Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A]
Urinary Incontinence
[Incontinence--a common issue for people with Parkinson's disease. A systematic literature review].
Urinary Incontinence
[Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome].
Urinary Incontinence
[Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
Urinary Incontinence
[The quality of life of patients with overactive bladder after local injections of botulinum toxin A--a preliminary report]
Urinary Incontinence, Urge
Botulinum toxin injections for adults with overactive bladder syndrome.
Urinary Incontinence, Urge
Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
Urinary Incontinence, Urge
Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Urinary Incontinence, Urge
Cost-Effectiveness of Sacral Neuromodulation Versus Intravesical Botulinum A Toxin for Treatment of Refractory Urge Incontinence.
Urinary Incontinence, Urge
Efficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial.
Urinary Incontinence, Urge
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Urinary Incontinence, Urge
Management of Postoperative Lower Urinary Tract Symptoms (LUTS) After Pelvic Organ Prolapse (POP) Repair.
Urinary Incontinence, Urge
Nonantimuscarinic treatment for overactive bladder: a systematic review.
Urinary Incontinence, Urge
OnabotulinumtoxinA in overactive bladder: Evidence-based consensus recommendations.
Urinary Incontinence, Urge
PAW26 Are the beneficial effects of Botulinum toxin for refractory detrusor overactivity in multiple sclerosis sustained with repeat injections?
Urinary Incontinence, Urge
Refractory idiopathic urge urinary incontinence and botulinum A injection.
Urinary Incontinence, Urge
The use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinoma.
Urinary Incontinence, Urge
The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
Urinary Incontinence, Urge
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
Urinary Incontinence, Urge
Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
Urinary Incontinence, Urge
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Urinary Retention
Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
Urinary Retention
Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Urinary Retention
Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
Urinary Retention
Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICI-RS 2019?
Urinary Retention
Botulinum Toxin A Injection in the Bladder Neck: A Promising Treatment for Urinary Retention.
Urinary Retention
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Urinary Retention
Botulinum toxin treatment for overactive bladder: risk of urinary retention.
Urinary Retention
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Urinary Retention
Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
Urinary Retention
Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation.
Urinary Retention
Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity.
Urinary Retention
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Urinary Retention
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial.
Urinary Retention
Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
Urinary Retention
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Urinary Retention
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Urinary Retention
OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Retention
OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.
Urinary Retention
Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome).
Urinary Retention
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome.
Urinary Retention
Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
Urinary Retention
Re: Urinary Retention Rates after Intravesical OnabotulinumtoxinA Injection for Idiopathic Overactive Bladder in Clinical Practice and Predictors of this Outcome.
Urinary Retention
Real World Performance of SNM and OnabotulinumtoxinA for OAB: Focus on Safety and Cost.
Urinary Retention
Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Urinary Retention
Routine Office Assessment After OnabotulinumtoxinA Injection for Overactive Bladder Is Unnecessary to Detect Clinically Significant Voiding Dysfunction.
Urinary Retention
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Urinary Retention
The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
Urinary Retention
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Urinary Retention
The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection.
Urinary Retention
The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.
Urinary Retention
Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Urinary Retention
Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events.
Urinary Retention
Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Urinary Retention
Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia.
Urinary Retention
What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Urinary Retention
[Efficacy and safety of botulinum toxin in external urethral sphincter by transperineal way guided transrectal ultrasound and electromyography on chronic urinary retention due to spinal cord injury.]
Urinary Tract Infections
Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.
Urinary Tract Infections
Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
Urinary Tract Infections
Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Urinary Tract Infections
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Urinary Tract Infections
Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.
Urinary Tract Infections
Botulinum toxin type A (Botox) and idiopathic overactive bladder. For some severely affected patients.
Urinary Tract Infections
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Urinary Tract Infections
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Urinary Tract Infections
Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial.
Urinary Tract Infections
Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury.
Urinary Tract Infections
Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity.
Urinary Tract Infections
Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Urinary Tract Infections
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
Urinary Tract Infections
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial.
Urinary Tract Infections
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?
Urinary Tract Infections
Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Urinary Tract Infections
Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
Urinary Tract Infections
Is there a direct antimicrobial effect of botulinum neurotoxin type A?
Urinary Tract Infections
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Urinary Tract Infections
OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.
Urinary Tract Infections
OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
Urinary Tract Infections
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review.
Urinary Tract Infections
OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.
Urinary Tract Infections
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Urinary Tract Infections
Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study.
Urinary Tract Infections
Real World Performance of SNM and OnabotulinumtoxinA for OAB: Focus on Safety and Cost.
Urinary Tract Infections
Refractory idiopathic urge urinary incontinence and botulinum A injection.
Urinary Tract Infections
Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Urinary Tract Infections
Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Urinary Tract Infections
Risk of urinary tract infection after detrusor botulinum toxin a injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Urinary Tract Infections
Safety issues associated with using medication to treat overactive bladder.
Urinary Tract Infections
The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Urinary Tract Infections
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.
Urinary Tract Infections
The role of suprapubic catheter insertion in preventing urinary tract infections following intravesical Botulinum toxin A.
Urinary Tract Infections
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials.
Urinary Tract Infections
Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
Urologic Diseases
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Urologic Diseases
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA).
Urologic Diseases
Evaluation of Therapeutic Effect of Intratrigonal Injection of AbobotulinumtoxinA(Dysport) and Hydrodistention in Refractory Interstitial Cystitis /Bladder Pain Syndrome.
Urologic Diseases
[TEST FOR NEUTRALIZING ANTIBODIES IN UROLOGIC PATIENTS WITH NO RESPONSE TO INTRAVESICAL BOTULINUM TOXIN INJECTIONS].
Urticaria
Cholinergic Urticaria Responding to Botulinum Toxin injection for Axillary Hyperhidrosis.
Uterine Cervical Neoplasms
Effect of Rac1 downregulation mediated by shRNA on the biological behaviour of human cervical cancer cells.
Uveitis
Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
Uveitis, Anterior
Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
Uveitis, Anterior
Ocular adverse effects after facial cosmetic procedures: a review of case reports.
Vaccinia
Combination of biobarcode assay with on-chip capillary electrophoresis for ultrasensitive and multiplex biological agent detection.
Vaginismus
Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome.
Vaginismus
Comparing the effectiveness of functional electrical stimulation via sexual cognitive/behavioral therapy of pelvic floor muscles versus local injection of botulinum toxin on the sexual functioning of patients with primary vaginismus: a randomized clinical trial.
Vaginismus
Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.
Vaginismus
Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia.
Vasculitis
Vasculitis with panniculitis following botulinum toxin A injection for cosmetic use.
Venous Thrombosis
Preventive effect of botulinum toxin A in microanastomotic thrombosis: a rabbit model.
Venous Thrombosis
Upper Extremity Deep Vein Thrombosis After Botulinum Toxin Injection: A Case Report.
Ventilator-Induced Lung Injury
[Study on Rac1/MAPK/ERK pathway mediated mechanism and role in rats with ventilator induced lung injury].
Vesico-Ureteral Reflux
Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Vesico-Ureteral Reflux
Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity.
Vesico-Ureteral Reflux
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?
Vesico-Ureteral Reflux
Intravesical Electromotive Botulinum Toxin Type A Administration-Part II: Clinical Application.
Vesico-Ureteral Reflux
The Effects of Intradetrusor BoNT-A Injections on Vesicoureteral Reflux in Children With Myelodysplasia.
Virus Diseases
Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulinum toxin and denervation.
Vitreous Hemorrhage
Inadvertent Globe Penetration and Subretinal injection of Botulinum Toxin in an Oculocutaneous Albinism Patient.
Vitreous Hemorrhage
Vitreous hemorrhage and Rhegmatogenous retinal detachment that developed after botulinum toxin injection to the extraocular muscle: case report.
Vitreous Hemorrhage
Vitreous hemorrhage following inadvertent intra-ocular injection of botulinum toxin.
Vocal Cord Dysfunction
Office-based laryngeal injection of botulinum toxin for paradoxical vocal fold motion in a child.
Vocal Cord Dysfunction
Periodic botulinum toxin injections for paradoxical vocal fold motion in a child with cerebral palsy: a case study.
Vocal Cord Dysfunction
Vocal fold botulinum toxin injection for refractory paradoxical vocal fold motion disorder.
Vocal Cord Paralysis
Botulinum toxin for relief of bilateral abductor paralysis of the larynx: histologic study in an animal model.
Vocal Cord Paralysis
Injection of botulinum toxin into external laryngeal muscles in pediatric laryngeal paralysis.
Vocal Cord Paralysis
Use of botulinum toxin to lateralize true vocal cords: a biochemical method to relieve bilateral abductor vocal cord paralysis.
Vocal Cord Paralysis
[Botulinum toxin type A-induced "rebalancing" in bilateral vocal cord paralysis?]
Voice Disorders
Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
Voice Disorders
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Voice Disorders
Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
Voice Disorders
Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Voice Disorders
Voice disorders in the workplace: Productivity in spasmodic dysphonia and the impact of botulinum toxin.
Vulvar Diseases
Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia.
Vulvar Vestibulitis
Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome.
Vulvodynia
Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial.
Vulvodynia
Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study.
Vulvodynia
Botulinum toxin-treatment of localized provoked vulvodynia refractory to conventional treatment.
Vulvodynia
Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia.
Vulvodynia
Intralevator injection of botulinum toxin for the treatment of hypertonic pelvic floor muscle dysfunction and vestibulodynia.
Vulvodynia
Long-term assessment of effectiveness and quality of life of OnabotulinumtoxinA injections in provoked vestibulodynia.
Vulvodynia
Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis.
Vulvodynia
Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.
Vulvodynia
The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain-a new answer to old problems?
Warts
Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures.
Whooping Cough
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.
Whooping Cough
Inhibitory effect of fluvastatin on lysophosphatidylcholine-induced nonselective cation current in Guinea pig ventricular myocytes.
Whooping Cough
Intracellular dynamics of alkaline phosphatase-containing granules in electropermeabilized human neutrophils.
Whooping Cough
Regulation by bradykinin of phosphoinositide metabolism in the endothelial cells of the pulmonary artery.
Whooping Cough
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Wiskott-Aldrich Syndrome
Deleted in colorectal cancer binding netrin-1 mediates cell substrate adhesion and recruits Cdc42, Rac1, Pak1, and N-WASP into an intracellular signaling complex that promotes growth cone expansion.
Xerophthalmia
Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report.
Xerostomia
Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia.
Zenker Diverticulum
Botulinum toxin type A (Dysport) for the treatment of Zenker's diverticulum.
Zenker Diverticulum
Management of upper esophageal sphincter disorders: indications and complications of myotomy.
Zika Virus Infection
Botulinum Toxin Type A in the Spasticity of Cerebral Palsy Related to Congenital Zika Syndrome: An Observational Study.
Zika Virus Infection
The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
gene bont/F; proteolytic and nonproteolytic strains, bivalent strains, including Bf and Af, gene bont/A
UniProt
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
genes bont, 6 subtypes, DNA and amino acid sequence determination and analysis. The genes from proteolytic, group I, strains form subtypes F1 through F5, while the genes from nonproteolytic, group II, strains form subtype F6, phylogenetic analysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Raphael, B.H.; Choudoir, M.J.; Luquez, C.; Fernandez, R.; Maslanka, S.E.
Sequence diversity of genes encoding botulinum neurotoxin type F
Appl. Environ. Microbiol.
76
4805-4812
2010
Clostridium botulinum (C5IWN7), Clostridium botulinum (D2KCK3), Clostridium botulinum (P30996), Clostridium botulinum (Q58GH1), Clostridium botulinum, Clostridium baratii (Q45851), Clostridium baratii
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.24.69)
Transporter Classification Database (TCDB): 1.C.8.1.3
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
